"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] I would now like to Lisa DeFrancesco. You may",44,"Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] I would now like to Lisa DeFrancesco. You may begin."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The",367,"Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.actavis.com. 
We're conducting a live webcast of this call a, replay of which will be available on our website after its conclusion. Please note that today's call is a copyrighted material of Actavis and cannot be rebroadcast without the company's express written consent. 
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make suggestions or other forward-looking remarks regarding future events or the future financial performance of the company. It is important to note that such statements and events are forward-looking statements and reflects our current perspective of the business trends and information as of today's date. Actual results may differ materially from our current expectations and projections depending on a number of factors affecting the Actavis business. These factors are detailed in our periodic filings with the Securities and Exchange Commission. Actavis disclaims any intent or obligation to update these forward-looking statements except as expressly required by law. 
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our first quarter financial and business highlights, progress on our innovation of Allergan and provide an update to our 2015 forecast. Tessa Hilado, our Chief Financial Officer, will then discuss the Actavis' first quarter results in more detail and the assumptions surrounding our 2015 forecast; and David Nicholson, Senior Vice President of Global Brands, Research and Development, will provide an update on our brands, R&D progress in the quarter and upcoming developments milestones. Also, on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Paul Navarro, President of International Brands; Philippe, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer. 
With that, I'll turn the call over to Brent."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we're on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GAA",1778,"Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we're on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GAAP revenue growth versus the prior year, double-digit growth from key North American Brands, double-digit growth from global generics and double-digit growth from ANDA, our Distribution business, 3 rock-solid pillars to which we are adding the Allergan business. 
While keeping focused on customers and driving robust growth, we also achieved a long list of accomplishments during the quarter, including completion of a largest deal in health care over the last 10 years, expanding the reach of our International portfolio, executing deals that increase our focus on profitable generic markets such as Auden Mackenzie in the U.K. while completing divestitures that sharpened our brand therapy focus such as our respiratory and Doryx and Pharma Tech deal, ramping up productivity of our branded generics R&D teams with 4 new brand product approvals and about 20 new generic launches in the United States and completing the largest financing ever in health care, not to mention kicking off one of the most thoughtful and rapid integrations I have ever seen. I am so proud of each of the people in our combined global team. 
One thing is clear. This combined team rallies quickly around surprising opportunities, focuses on the key objectives and executes flawlessly. When it comes to execution, we are like a finely tuned, high-performance engine. 
Even though we just closed the Allergan acquisition on March 17, we have already made significant progress on the integration, and we're doing exceptionally well on our cost synergies capture. How did we do it? We quickly named a new management team with skilled and experienced leaders from both companies, but we didn't stop there. 
In the vast majority of countries, we designed our entire organization all the way to the frontline preclose so we could rapidly inform our colleagues about their future, give them certainty and move quickly to the new go-forward team. 
For example, our global sales force of approximately 7,500 representatives has already been realigned in all but a handful of countries with the intent to minimize customer disruption. We also stood up our new International model with one Country Manager per country, allowing us to operate as one company while taking full advantage of our global brand and generic capabilities. 
Being bold, nimble and focused during the integration is how we are staying on track with our aggressive synergy targets and more importantly, how we will keep our sales momentum going. After just 6 weeks, we are making great progress on our integration milestones and are on track to deliver about 80% of our synergies by the end of the first quarter of 2016. 
And in a moment, David Nicholson will give an overview of the tremendous progress in the pipeline and will make a few comments about the R&D portfolio prioritization, which is nearly complete. Tessa will also join us to describe our financial performance in detail, but from a high-level perspective, you can see the impact of our transformation over the past 12 to 18 months. 
Non-GAAP net revenue was $4.2 billion, a 65% increase largely driven by the Forest acquisition with only 2 weeks of Allergan in the results; $4.30 of non-GAAP EPS even with the impact of the Allergan financing; $1.8 billion in adjusted EBITDA; and $525 million in cash flow from operations, more than $800 million if you add back the onetime cash charges for severances, restructuring and integration. 
Turning to the business performance. On a pro forma basis, total U.S. branded sales increased 5% if you exclude Allergan and increased 17% if you exclude Namenda IR. 8 of the top 10 Actavis brands are growing double digits versus prior year not just growing, thriving. 
In fact, many of our key products are hitting new highs in volume and market share, including Linzess, which is now approaching a run rate of $400 million annually. Bystolic had a strong performance, running towards $650 million annually. And Lo Loestrin, Estrace and Minastrin are really soaring with a focus we are putting on Women's Health. will likely be a beneficiary of that focus. 
Meanwhile, Namenda XR sales are up sharply as we continue to drive the conversion rate and have resolved last year supply constraints. Physicians and caregivers continue to convert more patients to Namenda XR with its more convenient and cost-effective profile. Over 70,000 physicians have prescribed Namenda XR, which is a testament to its usefulness and treatment with patients with Alzheimer's disease. 
Our patient awareness campaign, focused on caregivers and their loved ones with Alzheimer's disease, has been well received and is helping with conversion. We are currently at about 50% and climbing towards 60% by the end of the second quarter, and we expect to exceed that figure with the launch of Namzaric, which opens up the market segment worth about $2 billion. 
The primary source of business for Namzaric will be the plus Namenda IR market. The main point here is that the market for Namzaric is bigger than the market for Namenda XR. Namzaric will give patients all the benefits of combination therapy for Alzheimer's disease in one pill, once a day. We intend to support Namzaric with formulary access and direct-to-consumer marketing. Shipping begins this week and full promotional launch later this month. Given the broad use of combination and therapy, we think there is a great opportunity for Namzaric to expand the once a day branded market. 
Turning to the Allergan business. Here again, we come back to our theme of double-digit growth. In the midst of planning for the integration, legacy Allergan delivered double-digit pro forma sales growth of 13% in constant currency to $1.75 billion for its final quarter. Allergan drove this performance while maintaining inventories in the customary, well-managed range. The performance was broad-based, driven by continued strong performance across the company's Eye Care, Botox and Aesthetic businesses. Eye care was up 14% in constant currency, driven by Restasis and. Botox, up 16% in constant currency, driven by growth in therapeutics. Skincare, breast aesthetics and facial aesthetics, up a combined 12% in constant currency. International Allergan sales were also up double digits in constant currency with all 3 units, eye care, medical aesthetics and specialty care achieving double-digit growth. 
We are capitalizing on the exceptional sustaining performance of Actavis and Allergan to create an impressive leader in growth pharma. So the bottom line on our combined company brand performance is strong performance for our key brands, including Namenda XR, Linzess, Botox, Restasis, Bystolic and. Meanwhile, we only have to look at the performance of Lo Loestrin, Saphris, Minastrin and the GI products to see that our team has firmly established a core competency in relaunching products that we acquired. This ability to invigorate acquired products is a differentiator for us. 
We acquire assets to grow them, and we succeed. That opens up more possibilities for us than is appreciated, more growth, more leverage and more credibility for other bolt-on deals. While this early, we're off to a very good start with our new launches,and we are now poised to be a significant player in the increasingly important antibiotics space with Dalvance and AVYCAZ. This is where our model of development prowess, life cycle investment and smart business development is creating enduring competitive advantage. 
Turning to the North American Generics and International business. Sales were up 20% this quarter in constant currency versus prior year. North American sales were $1.2 billion and continue to benefit from the contribution from key products like generic Concerta, Lidoderm and Intuniv. Special capabilities and being First-to-File again and again combined to make our Generics business a best-in-class competitor. 
This year, we have launched 20 generic products in the U.S. including our most recent launch of generic following our court win last week. We also launched generic OxyContin, Temovate and generic ophthalmic products as well. 
This quarter, we also launched our generic injectable business after we regained the rights to about 20 injectables from Saygent at the end of 2014, giving us added strength with hospital purchasers. 
On the R&D side, our generic business continues to fire on all cylinders with the 7 confirmed first-to-files out of the total 18 total filings posted on the FDA website this quarter. 
On the International side, non-GAAP sales were $527 million, growing 20%, excluding foreign exchange. We launched close to 100 products during this quarter. 
International revenue growth was driven by multiple markets, including Russia, up 41% on a constant-currency basis driven by our strong sales organization and OTC performance; and the U.K., up 22% on a constant-currency basis driven by new product launches. 
Our strategy in International generics is to continue allocating resources to markets that deliver high-growth potential and where we can be among the leaders. That is why we divested generic products in Australia and invested in Auden Mackenzie acquisition in the U.K., which is expected to close in the second quarter. 
Let me close with a few comments in our preliminary view of the 2015 financials. We are certainly off to a terrific start. We previously planned to provide guidance at the end of Q2, but given the strong performance this quarter, the progress we're making on integration synergies and the impact of foreign exchange and divestitures, we felt it would be good to give you our preliminary view of 2015 today. 
First, since we acquired Allergan on March 17 as-reported revenue is projected to be in a range of $20.5 billion to $21 billion. On a pro forma basis, full year sales are projected at $22 billion to $22.5 billion, which was consistent with or slightly ahead of our prior comments of $23 billion if you exclude the impact of foreign exchange and the multiple divestitures such as respiratory and Pharma Tech. 
Our current view on 2014 (sic) (2015) non-GAAP earnings per share on an as-reported basis, including Allergan as of March 17, is in the range of $17 to $18.15 -- I'm sorry, $18.50. We will narrow the range over time. 
With this view, you can see that we have put together a terrific company with a very compelling outlook for 2015, and we are executing like a high-performance engine driving towards our aspirational target of $25 per share in EPS in 2017. We look forward to giving you more refined guidance on our second quarter call. 
With that, I'll now turn the call over to Tessa, who will provide you with an overview of our financial performance during the quarter. Tessa?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on",972,"Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on March 17. The Allergan business contributed $258 million in net revenue and $113 million in adjusted EBITDA in the quarter. 
Turning to our results for the first quarter on Slide 15. In Q1, we delivered strong performance with top line growth across key franchises, both year-over-year and quarter-over-quarter despite negative foreign currency impact. The year-over-year increase was also driven by the Forest and Allergan acquisition. 
On a non-GAAP basis, consolidated net revenue for the first quarter was $4.2 billion, an increase of 65% versus the prior year quarter. Non-GAAP R&D investments for the quarter was $284 million compared to $175 million in the prior year period. 
Non-GAAP R&D spending was $110 million for generics, $125 million for brands, $15 million for biosimilars and $34 million for Allergan. Non-GAAP SG&A as a percentage of revenue was 20.9%, an increase of 1.7 percentage points over the prior year quarter as a result of the Forest branded products that have higher SG&A spend. Non-GAAP adjusted EBITDA for the quarter was $1.78 billion, an increase of 107% versus the prior year, driven by strong revenues and higher gross margins across the business. 
Non-GAAP earnings per diluted share for the quarter increased 23% to $4.30 compared to $3.49 per diluted share in the first quarter of 2014. Excluding the impact of Allergan and its related financing, Actavis' non-GAAP EPS was $4.59 for the first quarter 2015, representing a 17% sequential increase from $3.91 in the fourth quarter. This highlights our continued strong performance on top of integration activities. 
Our non-GAAP tax rate improved from 16.4% in the year-ago period to 14.3% in the current year quarter mainly due to geographic mix. Cash flow from operations for the first quarter was $525 million. Our cash flow from operations would have been more than $800 million if cash charges for severance, restructuring and integration are added back. 
Turning now to our business segments. North American Brands business delivered strong performance year-over-year, powered by the acquired Forest Products and growth in our Women's Health franchise. North American Brands revenue was $1.74 billion for the quarter, up 192% versus the prior year period, driven by the addition of the Forest business, including strong double-digit year-over-year growth from 8 out of our top 10 products. 
Compared to the prior quarter, sales were down slightly, driven by normal decline in prescription fill rates from fourth quarter to first quarter but typically recover in the second quarter and wholesaler buying patterns. 
Adjusted gross margin within North America Brands decreased to 86.6% largely due to partner products within the Forest portfolio, including Namenda and Linzess. Sequentially, adjusted gross margin improved due to lower Namenda IR sales, which carry a lower margin. 
Non-GAAP SG&A as a percent of revenue increased to 27.8% driven by expenses related to the acquired Forest products. 
Our North America Generics and International business continues to perform strongly with non-GAAP revenues of $1.7 billion for the quarter, up 12% versus the prior year period. Growth was driven by strong sales of key products and new product launches, including generic versions of Concerta, Lidoderm, Intuniv and OxyContin. 
Internationally, our Generics business was negatively impacted by the strength in U.S. dollar but at constant currency rates, this business grew 20% versus prior year quarter. 
On a non-GAAP basis, adjusted gross margins increased 3.2 percentage points compared to the year-ago quarter due to continued strong performance within our International business. Non-GAAP SG&A as a percentage of adjusted net revenue for the segment declined to 14.8% due to the divestiture of our Western European assets and elimination of the supportive infrastructure of that business. 
Turning to our Anda business. Revenues increased to $462 million, up from $300 million in the prior year, an increase of 18% driven by a higher mix of chain drugstore sales. Gross margin for the Anda business decreased 2.6 percentage points to 12.5% as a result of the higher product mix of chain drugstore sales. 
Slide 19 details our debt capitalization following the close of the Allergan acquisition. We ended the first quarter 2015 with total debt of approximately $44 billion and equity of $71 billion related to the Allergan acquisition and previous financing. 
Currently, our leverage ratio stands at 4.1x debt to pro forma adjusted EBITDA. Over the next 12 months, we are committed to using our anticipated strong free cash flows from our business segments to accelerate debt repayment. We expect to achieve a pro forma leverage ratio of 3.5x debt to adjusted EBITDA by the end of the first quarter of 2016, in line with our prior guidance. 
Finally, I would like to provide an overview of our key assumptions for the 2015 combined forecast Brent provided earlier in this call. Our non-GAAP EPS of $17 to $18.50 includes key near- and longer-term drivers that we expect over the next few months that will impact our business, including in U.S. brands, we assume the Namenda XR conversion trending to 60% by the end of Q2, Namenda IR generic enters the market in mid-July, Namzaric launch this week. 
In our GX business, we assumed launch of generic Pulmicort, continued current market conditions for Concerta, additional competition on Lidoderm, Auden Mackenzie acquisition close late in Q2, a tax rate of approximately 15%, 2015 fully diluted average shares of approximately 386 million, and year-end 2015 fully diluted shares outstanding of 415 million. Foreign exchange rates are based on average forward consensus for Q2 to Q4. 
I'd now like to turn the call over to David Nicholson, who will provide an update on our brands R&D progress in the quarter. Dave?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines. Turning",962,"Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines. 
Turning to Slide 22. We have achieved tremendous progress, and I would applaud the combined efforts of our commercial and R&D teams. We have nearly completed the rationalization of our combined pipeline. Our teams have identified and confirmed 70 projects that will move forward as part of the combined development program with more than 50 projects in either late stage or registration stages of development. 
Whilst we have made very significant progress on the rationalization of our pipeline, we are still evaluating certain projects. We continue to drive these projects forward, the key milestones to allow us to make cost-effective but also data-driven decisions. We will present our combined rationalized pipeline as part of an up-and-coming R&D day. 
We have achieved significant progress across key programs from both the legacy Actavis and the legacy Allergan R&D pipelines. 
Turning to Slide 23. You get an insight into the extent of our progress to strengthen our key franchises. In the quarter, we achieved milestones across core franchises, including Women's Health, infectious disease, CNS and Gastroenterology. 
Key FDA and European approvals included Liletta. This was FDA approved in February as a long-acting progestin-only intrauterine system or IUS to prevent pregnancy for up to 3 years and was launched in the U.S. in April. To support the use of Liletta for up to 7 years, we are continuing the ACCESS study. The initial results of this study were published online in April in Contraception. The study found Liletta to be more than 99% effective for the prevention of pregnancy for up to 3 years of use in women aged 16 to 35 regardless of their race, history of previous births or BMI. 
AVYCAZ, our combination of ceftazidime and the inhibitor avibactam was FDA approved in March as a treatment for adult patients with complicated intra-abdominal and urinary tract infections. The AVYCAZ launch is in progress. 
As you have heard, Namzaric is being launched, and we are in discussions with the FDA about extending the range of doses that we can make available to maximize convenience for patients. 
Dalbavancin was approved in Europe in February as Xydalba for the treatment of acute bacterial skin and skin structure infections, ABSSSI. We are developing a single-dose regimen of Dalvance, and in April, we announced positive top line results for a Phase III study comparing a single 1.5 gram dose of Dalvance with the same total dose event as 2 doses 1 week apart for the treatment of ABSSSI infections caused by susceptible gram-positive bacteria, including MERSA. The top line data demonstrated that the single dose of Dalvance achieved its primary endpoint for control of infection at 72 hours after initiation of therapy. The study was also positive at end of treatment, the endpoint required by the European Medicines Agency. 
I will return to Botox later. 
We also announced the initiation of a Phase IIb study for relamorelin, our investigational treatment for gastroparesis in patients with type 1 and type 2 diabetes. We are very pleased with this collaboration with our partner, Rhythm Health. 
Turning to Slide 24. We achieved sNDA approvals for a lower dose of 20 milligrams Viibryd, expanding dosing options for clinicians and for Saphris monotherapy for the acute treatment of manic or mixed episodes associated with bipolar 1 disorder in pediatric patients. FDA have accepted our sNDA to expand the Teflaro label to ABSSSI with concurrent bacteremia. 
We received FDA approval for the expanded label of Botox for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose for adults within 3 months treated for one or more indications. We remain very committed to extending our Botox franchise. 
Looking ahead, and moving on to Slide 25, we have a significant number of regulatory milestones in the next few months. We have upcoming PDUFA dates for Eluxadoline in the second quarter and for cariprazine in June. For eluxadoline, we do not expect an FDA Advisory Committee hearing on our submission, and DEA scheduling begins once approval is achieved. 
We are continuing to build out our Linzess franchise, and we expect to submit an sNDA for a low dosage form of the drug to treat Chronic Idiopathic Constipation in 2016. 
For DARPin, our Phase II programs for AND and DME in the U.S. and Japan are ongoing, and we will begin enrollment in our Phase III program in the U.S. later this quarter or early in the third quarter. This on-time start of Phase III is just one of many examples that our strong combined R&D team is maintaining momentum during the integration of our 2 companies. 
Restasis is on track to submit the dossier for multi-dose, preservative-free formulations by the end of the year. 
I'm excited about Bimatoprost SR. The Phase III trials are continuing in the U.S., and we'll be starting Phase III in Europe later this year. 
SER 120, a low-dose nasal formulation for the treatment of nocturia, is nearing completion in Phase III, and we are looking forward to seeing the data. 
I also wanted to mention our dermal fillers. We are continuing to roll out additional HA formulations. We anticipate extending our Volite line in Europe and our Juvederm line in Asia during the course of the year. 
In conclusion, the first quarter of 2015 has been very productive for the R&D team, and we will continue to see momentum in the second quarter and beyond from our industry-leading pipeline. 
With that, I will now turn the call back over to Brent, who will provide closing remarks. Brent?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving",87,"Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving our key aspirations: double-digit branded revenue growth, about $8 billion in free cash flow in 2016 and our aspirational EPS target of $25 per share in 2017.
With that, I'll turn the call back to Lisa, and we'll take your questions."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions.",11,"Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank.",15,"[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial cents?",47,"My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial cents?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, Greg. Obviously, -- history is a proof point of that with the Allergan acquisition, which was not part of our strategy but as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies",118,"Yes, Greg. Obviously, -- history is a proof point of that with the Allergan acquisition, which was not part of our strategy but as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies. I think as you look forward obviously, our commitment to maintain our investment-grade rating is of critical importance to us. We will continue to look at bolt-on deals as a matter of course. I think with respect to transformational deals, we would be limited by cash constraints, obviously. So it would have to be something truly compelling for us to want to use our equity to do something like that."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And Brent, just another question for you. How are you thinking about your generic business given that obviously there someone out there right now, who is willing to pay a very high multiple for it? And is there a way to sell the generic business in a tax-",49,"And Brent, just another question for you. How are you thinking about your generic business given that obviously there someone out there right now, who is willing to pay a very high multiple for it? And is there a way to sell the generic business in a tax-efficient manner?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, it's a great question, Jami, and obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industries in a bit of turmoil right now with 2 hostile situations going on, and my views on hostile s",202,"Yes, it's a great question, Jami, and obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industries in a bit of turmoil right now with 2 hostile situations going on, and my views on hostile situations of going concern, full companies. It tends to destroy value and cause lots of distractions. When you look at our business up almost 20% on top line this year, firing on all cylinders and R&D pipeline that's the envy of the industry, continuing to just be on First-to-Files in the U.S. time and time again, launching 100 brands outside or products outside the United States and our way we manage it, which is so different than anybody else, I think it's something that we've take a lot of pride, and we see a lot of connectivity to generics and our branded business. That being said, I think if you look at trying to sell it, I'm not sure there's a tax-efficient way. We do have reasonably high basis in it, but it'd still be a very difficult thing to do, but I think the bigger calculation would be strategically we value that business."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","You talked about the $25 in 2017 is the target. Maybe you can just give us a the sense of the push and pulls on that number relative to where you were when you first put that number out? And I know you said we can't do a second, but just on the implant, c",74,"You talked about the $25 in 2017 is the target. Maybe you can just give us a the sense of the push and pulls on that number relative to where you were when you first put that number out? And I know you said we can't do a second, but just on the implant, can you just give us a sense of how long that product is lasting relative to the daily eye drop?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So I think, Marc, it's a great question. Really to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with a $25 aspiration, we're pretty much on course. There are obviously some",127,"Yes. So I think, Marc, it's a great question. Really to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with a $25 aspiration, we're pretty much on course. There are obviously some minor puts and takes that occurred in the model, but overall, we're exactly where we kind of thought we would be. Obviously, currency has moved against us, but stronger performance has compensated for some of that. I think we're seeing good productivity out of the R&D pipeline. David has to finish and tie up the pipeline review, which we expect to happen this quarter. But overall, I'd say we're pretty much where we thought we would be."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Are the synergies coming through as fast as you thought when you originally set it out?",16,"Are the synergies coming through as fast as you thought when you originally set it out?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I think I would say we're probably a little ahead, and that's what you saw it quite a large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for few countries. We're substantially ahead of where we though",103,"Yes, I think I would say we're probably a little ahead, and that's what you saw it quite a large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for few countries. We're substantially ahead of where we thought we would be and the severances and the charges associated with that came through in a large way this quarter. You should expect that to dissipate over time, and so I think we're feeling good by the bold and aggressive actions we've taken to combine these companies, get the distraction behind us and focus on top line growth."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And the Namenda sales piece of it hasn't changed much?",11,"And the Namenda sales piece of it hasn't changed much?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, I think I'll ask Bill to chime in here, but when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We'll see",88,"No, I think I'll ask Bill to chime in here, but when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We'll see what happens, but when you look at what our team has done and by pulling off the shelf a plan B 24 hours after that court ruling, it's nothing short of extraordinary. I'll ask Bill to just comment on it."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric it, which I think will be a sales accelerator, we should achieve our target. And all the research that we've done if we can provide for formulary coverage that we believe we're g",124,"Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric it, which I think will be a sales accelerator, we should achieve our target. And all the research that we've done if we can provide for formulary coverage that we believe we're going to be able to move more and more patients either from IR to XR or patients who Namzaric, which is frankly, a stronger selling proposition than even XR, fewer pills, fewer administrations, no increase in side effects better efficacy, and we've made sure that it's economical for health plan and caregivers, and so we've taken a lot of effort and a lot of investment, a lot of energy. So I think we're going to reach the target."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Plus it opens up the market, which is bigger than the market.",12,"Plus it opens up the market, which is bigger than the market."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","That's right.",3,"That's right."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Liav Abraham with Citi.",12,"Our next question comes from the line of Liav Abraham with Citi."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick question on and your decision moving forward here. Just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than it is now?",66,"Just a quick question on and your decision moving forward here. Just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than it is now? Or are you progressing forward with this in order to potentially bring a combination DARPin PDGF to market?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, let me -- I'll start, and let me ask David to come in, and just one backup on for Marc. I think in the studies we're seeing, it lasted about 3 to 4 months, something in that range versus the drops, which compliance and persistence is a huge issue and",337,"Yes, let me -- I'll start, and let me ask David to come in, and just one backup on for Marc. I think in the studies we're seeing, it lasted about 3 to 4 months, something in that range versus the drops, which compliance and persistence is a huge issue and glaucoma, and if you talk to glaucoma specialist they're dying for an effective treatment that would increase compliance and persistence for disease that typically asymptomatic. It's doing a lot of damage to the back of the eye. In terms of DARPin, Liav, I think you're right on both tracks. I think the way we're thinking about DARPin is that it should achieve the 3 to 4x a year dosing regimen to make it really differentiator. Obviously, people don't like getting an injection in the back of the eye. If you look at even EYLEA, they're dosing it more frequently than the label suggests, and so doctors are really looking for something that -- and patients probably even more so looking for something to minimize injection. So we're really trying to design the experiment or the Phase III to hit the 12-week dosing regimen. The other thing I would put out there is remember, we put nothing in our deal model in DARPin, and so outside the cost of the Phase III study, it's essentially a free call option. And so given where we are, we think after all the modeling and everything we looked at, it was worth going for, but you're right. It's a high hurdle to get there, and to the extent we can, it should provide a very compelling, large opportunity for us in the future, but we've got to get there. I think the second thing it does is sets us up for dual DARPin, and that could be a very exciting place to be, but it's early. And so we've got a lot of work to do there as well. I don't know, David, if you want to add any color."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Brent, I think you said it. We're very excited by our partnership with Molecular Partners. The DARPin and combining proteins are a novel class of therapeutic active agents, and our lead DARPin has globally high affinity for VEGF, which opens up the possib",142,"Brent, I think you said it. We're very excited by our partnership with Molecular Partners. The DARPin and combining proteins are a novel class of therapeutic active agents, and our lead DARPin has globally high affinity for VEGF, which opens up the possibility for administration every 12 weeks. We're going to evaluate that in Phase III. And as Brent mentioned coming along behind it, we have a number of other binding proteins, other constructs. Those projects are early. So it's too early to talk about. Those the dual DARPin is just in preclinical development. It's very exciting. It's a combination of PDGF and VEGF, which should have advantages in AMD, but it's very early. It's still in preclinical development. We need to work our way through and generate more data just to see how exciting that project is really going to be."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And you feel comfortable with the implementation at this point?",10,"And you feel comfortable with the implementation at this point?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","We know, I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of LUCENTIS development. So we very carefully watc",78,"We know, I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of LUCENTIS development. So we very carefully watching ocular inflammation as we progress into Phase III. We've got a Data Safety Monitoring Board in place, and we are confident that we're going to -- that we're in control of the situation."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ronny Gal with Bernstein.",12,"Our next question comes from the line of Ronny Gal with Bernstein."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question is for David Nicholson. David, you keep on saying clinical trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they expect to reach the ma",47,"My question is for David Nicholson. David, you keep on saying clinical trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they expect to reach the market?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, so Ronny, I know you wanted David. I'll turn it over to him in a second, but to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think we have some",118,"Yes, so Ronny, I know you wanted David. I'll turn it over to him in a second, but to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think we have some real interesting ones and ones that maybe perhaps will fall out. We'll go through that over the course of the next month or so, but dry eye is something that we're also very committed to, and we're looking at a variety of external innovations as well as our internal programs, and you'll see us very committed to the space for the long term."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, basically that covers it, Ronny. Obviously, always happy to discuss this with you. And as you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclosporine i",74,"Yes, I mean, basically that covers it, Ronny. Obviously, always happy to discuss this with you. And as you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclosporine in early stages of development, which we think could be a real advance over Restasis itself. And as Brent said, we really believe we can maintain our leadership in this franchise, yes."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And the product which you just discussed submitting before the end of the year, that's Restasis X?",17,"And the product which you just discussed submitting before the end of the year, that's Restasis X?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean I'm not sure at the question Ronny. Ask me again.",13,"Yes, I mean I'm not sure at the question Ronny. Ask me again."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So the product that you just mentioned, the preservative free multi-dose product, is that what used to be called Restatis X?",21,"So the product that you just mentioned, the preservative free multi-dose product, is that what used to be called Restatis X?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Absolutely not. That is not Restasis X. That's just the preservative free, which doctors have been asking for.",18,"Absolutely not. That is not Restasis X. That's just the preservative free, which doctors have been asking for."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, multi-dosing formulation.",3,"Yes, multi-dosing formulation."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Chris Schott with JPMorgan.",12,"Your next question comes from the line of Chris Schott with JPMorgan."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Great. Can you just talk a little bit about your expectations for the Legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses. Should we think about this as a double-digit growth business f",125,"Great. Can you just talk a little bit about your expectations for the Legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses. Should we think about this as a double-digit growth business for the remainder of 2015 on a constant-currency basis? And if I can just do a quick follow-up to I think Jami's question earlier, if shares remain at current valuations, does that change your view at all about a potential separation of your brand and generic franchise you've got a great generic business but does valuation play a factor here at all if can work 6 or 9 months away and you're still trading at a fairly low multiple in forward earnings?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, as you think about the legacy Allergan business, our expectation is that double-digit branded growth in constant-currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We have comple",292,"Yes, I mean, as you think about the legacy Allergan business, our expectation is that double-digit branded growth in constant-currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We have completely solidified our sales and marketing colleagues around the world with perhaps a few countries as an exception only. The team is absolutely committed. They've been driving lots of growth in the first quarter, and we expect that to continue throughout the year and beyond, and that is part of the firm basis of which we believe we'll have double-digit branded growth along with the North American Forest legacy brands. I think to respect to your second question, Chris, in terms of the stock being perhaps at lower levels than we all would expect, I don't think it's a question of selling the Genetics business. I think it's a question of digesting this integration, helping shareholders understand the value proposition here by the compelling growth opportunity that we've created in growth pharma the enduring, sustainable bottom line growth continuing to prove out our aspiration of $25 of EPS, 25 and then showing how the business is support each other and add additional turbo boosting growth to one another. And so it's still early. We only closed Allergan a few weeks ago I think 5, 6 weeks ago, and so I think no one wants to have a trigger finger and overreact to 5 weeks of weakness, if you will, in the midst of closing, rebasing your shareholders, having a lot of people sorting through differing moving parts. Let's let things settle down and let us tell our story and prove our points as we continue to execute on all cylinders here."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Our next question comes from the line of Ken Cacciatore with Cowen and Company."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Brent, just wanted to flesh out a little bit of your earlier comments for possible versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together especially to get used to your c",94,"Brent, just wanted to flesh out a little bit of your earlier comments for possible versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together especially to get used to your currency but just wondering if you saw clearly down the road a reason to approach a larger player? When we would you become more encouraging, I think you used the word hostile versus remaining passive is there any time that you would that of alter the philosophy that you have?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, you never say number I mean, I just think that doing a hostile deal against a large, growing concern like we've seen in the industry over the last 12 months is value destroying. We are quite experienced in integrations. We do them quite well,",325,"Yes, I mean, you never say number I mean, I just think that doing a hostile deal against a large, growing concern like we've seen in the industry over the last 12 months is value destroying. We are quite experienced in integrations. We do them quite well, and one of the largest reasons we do them well is because we treat people with dignity and respect. We have information exchange freely, of course, following all the rules and regulations around jumping, and that allows us to get a jump on things like you saw in this quarter with the integration of Actavis Allergan, but it also shows how you restore momentum by keeping people's morale high, and that is certainly the case for the most part in our combined company. I think there are opportunities to do hostile deals. I think you have to do them when you're buying a single product perhaps or just a research program or a file where people aren't the key driver. But in most of these businesses, people are such a large part of the equation. I think hostile in virtually every instance is a mistake. There could always be an exception to that. I think the second thing is there are other large players that we believe are inefficient that would benefit from our operating model, our management philosophy, the way we approach customers in a more efficient manner, and so over time, there may be some targets that could be surprising to folks, but we have to de-lever, and we have to contain our investment-grade rating. And so those are all the factors that go into everything we look at. And obviously, I think by now we've earned some trust that if there's something opportunistic that creates a shareholder value, this isn't a team that sits back and watches it pass us by. We react very quickly and do things in a very creative but value-creating way."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My actually is for Tessa not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in headwinds",71,"My actually is for Tessa not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in headwinds from accounts receivable as well as $200 million in inventory. So I just wanted to understand that better if you had any color in that."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million, about $400 million in receivables change was really largely due to 2 things. One, a change in payment terms with a",148,"Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million, about $400 million in receivables change was really largely due to 2 things. One, a change in payment terms with a couple of customers; and two, with higher sales obviously, you have higher AR. And then on the inventory side, that was purposefully done to ensure that we don't have any outages in terms of supply, but what you'll find is towards the next couple of quarters sequentially, our cash flow will improve in a manner such that by 2016, we will be at roughly $8 billion of cash flow. So there's a couple of puts and takes in Q1 that are, I would say, abnormal in nature largely due to restructuring, but you will see that improve sequentially through the next couple of quarters."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Michael Faerm with Wells Fargo.",13,"Your next question comes from the line of Michael Faerm with Wells Fargo."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question's on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?",31,"My question's on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, maybe I'll turn it to David. Maybe you want to?",11,"Yes, maybe I'll turn it to David. Maybe you want to?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So as I've said, we've got an upcoming PDUFA date for eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the div",92,"Yes. So as I've said, we've got an upcoming PDUFA date for eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the division, then the scheduling goes to the DEA for finalization. The timeline for scheduling is it varies from company to company. So it's not possible for us to say when we'll get the scheduling -- the finalized schedule decision. The PDUFA date, as I mentioned earlier, is in second quarter."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would just add that our current model has us launching likely at the end of this calendar year, but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinki",51,"I would just add that our current model has us launching likely at the end of this calendar year, but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinking about it."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth target in some detail? Could you define that, the timing, what it includes, what it excludes just so we have a better sense for how you're thinking about that 10%",47,"Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth target in some detail? Could you define that, the timing, what it includes, what it excludes just so we have a better sense for how you're thinking about that 10% goal?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces",165,"Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces to that, and I think if you look at it in constant currency, and it's hard to hold management out in the field and in the countries accountable for currency. Obviously, you can hold us accountable for it here at the center but not a lot we can do about it that we see that growth. When you look at how we've kind of baselined it, it's really starting in this quarter with generic IR and then everything else is it. And so that's how we think about it as a CAGR on a go-forward basis, and we expect that as we look at it, we should do better than 10% branded revenue growth throughout our planning period."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Got it. So that excludes the impact of IR?",9,"Got it. So that excludes the impact of IR?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","It excludes currency and IR. That would be the only 2 exclusions that I'm aware of, and of course, -- yes, we did have respiratory Doryx, Pharma Tech, Australia, we've had some divestitures. We baselined it again to those divestitures as well.",42,"It excludes currency and IR. That would be the only 2 exclusions that I'm aware of, and of course, -- yes, we did have respiratory Doryx, Pharma Tech, Australia, we've had some divestitures. We baselined it again to those divestitures as well."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Louise Chen with Guggenheim.",12,"Your next question comes from the line of Louise Chen with Guggenheim."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So just a more macro question here. Curious how you think about branded generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here.",36,"So just a more macro question here. Curious how you think about branded generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So let me tackle generic pricing maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products tha",114,"Yes. So let me tackle generic pricing maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products that go up, but the battle for generics is price increases as more competitors come into the market. That's just the way the business works, and overall we still model a mid-single-digit price decrease in our business. That being said, the environment has remained pretty stable and favorable. So we don't expect that to change short term either. I don't know, Paul, if you have other thoughts."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that pr",68,"I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that product line, and we're obviously taking advantage of the situation as they present -- as situations present themselves."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob, anything you want to add?",6,"Bob, anything you want to add?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, I think that exactly covers it.",7,"No, I think that exactly covers it."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Okay. In terms of the branded side, our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associated with the i",70,"Okay. In terms of the branded side, our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associated with the innovation. But in the short term when you look at our current portfolio, we're reasonably well positioned, and Bill, you want to expand on that?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I don't think when our look our sales expectations over the next several years we're overly dependent on price as a driver. A lot of the gross trends that you're seeing are volume based. I would also point out that generally speaking, our pricing str",132,"Yes, I don't think when our look our sales expectations over the next several years we're overly dependent on price as a driver. A lot of the gross trends that you're seeing are volume based. I would also point out that generally speaking, our pricing strategy is tied to our IP, and most of the assets that we have on the market right now have long exclusivity periods. And so our primary objective, generally speaking, in a market is market share. And as it relates to price increases, we're very realistic about what they can look like. We're predictable and reasonable, and I think payers know that. I think that's a right way to be over the next several years, and I don't anticipate any surprises to our plan because of price."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And I would add, Philippe, you want to make a comment about aesthetics?",13,"And I would add, Philippe, you want to make a comment about aesthetics?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, on the cash base side, we have increased our price by 3% this year, and we can see double-digit growth, strong double-digit growth in our business. So we're pretty confident about the future of this business.",37,"Yes, on the cash base side, we have increased our price by 3% this year, and we can see double-digit growth, strong double-digit growth in our business. So we're pretty confident about the future of this business."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Great.",1,"Great."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of David Amsellem with Piper Jaffray.",13,"Our next question comes from the line of David Amsellem with Piper Jaffray."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","I want to stay on the bolt-ons, M&A. i wanted to ask about the generic business and is the addition of additional businesses either x U.S. or small businesses in the U.S. a priority, and also maybe talk about what kind of formulations and dosage forms mig",60,"I want to stay on the bolt-ons, M&A. i wanted to ask about the generic business and is the addition of additional businesses either x U.S. or small businesses in the U.S. a priority, and also maybe talk about what kind of formulations and dosage forms might be a high priority in terms of bolstering the business by M&A."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I'll turn it over to Bob Stewart to comment on that.",12,"I'll turn it over to Bob Stewart to comment on that."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the",223,"Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the full range of dosage forms that we need to be able to compete globally. We'll always look at opportunistic M&A in the U.S. I think we've got the scale that we need. I don't necessarily think that another acquisition in the U.S. is really going to give us anything because I think again we've got the size the portfolio, we've got a best-in-class commercial team, perhaps maybe looking at some portfolios of products in injectables and things like that. That would be the only thing that I would see that would be of interest in the U.S. Outside the U.S., we're always looking at different geographies that where we're already strong, you saw us do it with Auden Mackenzie in the U.K. We may look in certain markets that where there might be some tuck-in type acquisitions to adjust increase our overall strength there, more portfolio based, more small company type of transactions. But outside of that, I don't necessarily think that we need a large-scale transaction within the Generics business to remain viable or competitive."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would say best-in-class.",5,"I would say best-in-class."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",14,"Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick one on methylphenidate. I think you said and your guidance reflects current market conditions, but shares been ramping obviously very going to get an update here imminently. We don't know what the 2 other competitors are going to do and there",83,"Just a quick one on methylphenidate. I think you said and your guidance reflects current market conditions, but shares been ramping obviously very going to get an update here imminently. We don't know what the 2 other competitors are going to do and there's obviously very good case for you where they leave the market, and that leaves you with some pricing opportunity as well. So if you could maybe just comment on how you're thinking about that situation that would be great."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob?",1,"Bob?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, so Randall, I guess the way we've guided is exactly how you illustrate it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at to",121,"Yes, so Randall, I guess the way we've guided is exactly how you illustrate it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at today, but we see both competitors in the BX kind of situation. Now obviously, if FDA does take action and/or if the manufacturers or further the retailers do the responsible thing by continuing -- by not dispensing the BX product, that would provide upside to us, both in terms of volume as well as just overall, I guess, stability within the marketplace. So we would see that as an upside compared to."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we could guide.",4,"And we could guide."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that the competitors do come out of the marketplace, that we would be able to ensure that",53,"And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that the competitors do come out of the marketplace, that we would be able to ensure that all customers are served."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our last question comes from the line of David Maris with BMO Capital Markets.",14,"Our last question comes from the line of David Maris with BMO Capital Markets."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you or potentially is that something you spend a lot of time",139,"Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you or potentially is that something you spend a lot of time wringing your hands about? Or do you see that as something you're pretty happy about maybe 2 competitors will distracted for a year or 2 and in an integration, is that more of an opportunity? And separately in aesthetics, we've heard from a number of cosmetics terms that they've seen several of your peers being distracted lately, but they've seen no change in their Allergan sales coverage. So what have you done to minimize the disruption to customers? And how do you think you've done holding on to share during this transition period?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should cre",252,"Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should create some opportunity for us. It certainly doesn't distract us. It keeps us laser focused on our competitors. And just anecdotally, I'll give you one example. I was down at DNA CBS with Paul and Bob Stuart and our branded colleagues, and our other competitors were either there in a very light presence or not at all because they were on the road trying to convince shareholders that their plan or their defense was on track. And so you can already see them despite what they say saying it doesn't impact them, impacting them, and so hopefully we're already in the pole position with respect to R&D, but this will hopefully continue to allow us to continue to be in a pole position with respect to customer service. On the aesthetics aside, maybe Philippe will chime in and Paul perhaps internationally. I think our goal was to really do no harm, right? And so we approach this integration very, very carefully in that there was really no change to the facial aesthetics teams around the world or virtually no change around the world with the key focus on maintaining customer focus and connectivity in the U.S. and key International markets. Philippe, anything you'd add to that?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and is becoming the #1 filler. It has grown 30% during the first quarter, and despite Galderma, which is stronger than Valean",57,"Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and is becoming the #1 filler. It has grown 30% during the first quarter, and despite Galderma, which is stronger than Valeant, we're still getting market share. So overall, I'm very confident and very positive about that business."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And Paul Navarro, who runs International brands, you want to chime in?",12,"And Paul Navarro, who runs International brands, you want to chime in?"
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent the sales first were actually not affected by integration. So we maintained exactly the same level of service with customers.",38,"So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent the sales first were actually not affected by integration. So we maintained exactly the same level of service with customers."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely, and so that's why again I underscore in most si",175,"Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely, and so that's why again I underscore in most situations hostile deals are value destroying, and you have to look to do things on a friendly basis obviously, with a few exceptions to that rule.
Yes, thank you, David. So I think that was our last question. I would just again close with saying that this team has continued to take bold and decisive action to create value. We are absolutely well on our way to achieving our key aspirations of double-digit branded growth, $8 billion of free cash flow in '16 and remain committed to our aspirational target of $25 per share in 2017. We thank you for joining us today and taking the time to go through a quarter with lots of moving parts, and we look forward to the simpler quarters in the future. Thank you."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thanks, everybody.",2,"Thanks, everybody."
36478,291601714,810470,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Thank you. This concludes today's conference call. You may now disconnect.",11,"Thank you. This concludes today's conference call. You may now disconnect."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] Thank you.I would now like to turn the call",51,"Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] Thank you.
I would now like to turn the call over to Lisa DeFrancesco. You may begin."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The",368,"Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.actavis.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Actavis and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It is important to note that such statements and events are forward-looking statements and reflect our current perspective of the business trends and information as of today's date. Actual results may differ materially from our current expectations and projections depending on a number of factors affecting the Actavis business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Actavis disclaims any intent or obligation to update these forward-looking statements except as expressly required by law.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our first quarter financial and business highlights, progress on our innovation of Allergan and provide an update to our 2015 forecast; Tessa Hilado, our Chief Financial Officer, will then discuss the Actavis first quarter results in more detail and the assumptions surrounding our 2015 forecast; and David Nicholson, Senior Vice President of Global Brands, Research and Development, will provide an update on our brands, R&D progress in the quarter and upcoming development milestones. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I'll turn the call over to Brent."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we are on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GA",1788,"Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we are on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GAAP revenue growth versus the prior year, double-digit growth from key North American Brands, double-digit growth from Global Generics and double-digit growth from Anda, our distribution business, 3 rock-solid pillars to which we are adding the Allergan business.
While keeping focused on customers and driving robust growth, we also achieved a long list of accomplishments during the quarter, including completion of a largest deal in health care over the last 10 years, expanding the reach of our International portfolio, executing deals that increased our focus on profitable generic markets such as Auden Mckenzie in the U.K. while completing divestitures that sharpened our brand therapy focus such as our respiratory and Doryx deals and Pharmatech deal, ramping up productivity of our branded generic R&D teams with 4 new brand product approvals and about 20 new generic launches in the United States, and completing the largest financing ever in health care, not to mention kicking off one of the most thoughtful and rapid integrations I've ever seen. I am so proud of each of the people in our combined global team.
One thing is clear. This combined team rallies quickly around surprising opportunities, focuses on the key objectives and executes flawlessly. When it comes to execution, we are like a finely tuned, high-performance engine.
Even though we just closed the Allergan acquisition on March 17, we have already made significant progress on the integration, and we're doing exceptionally well on our cost synergy capture. How did we do it? We quickly named a new management team with skilled and experienced leaders from both companies, but we didn't stop there. In the vast majority of countries, we designed our entire organization all the way to the frontline preclose so we could rapidly inform our colleagues about their future, give them certainty and move quickly to the new go-forward team.
For example, our global sales force of approximately 7,500 representatives has already been realigned in all but a handful of countries with the intent to minimize customer disruption. We also stood up our new International model with one Country Manager per country, allowing us to operate as one company while taking full advantage of our global brand and generic capabilities.
Being bold, nimble and focused during the integration is how we are staying on track with our aggressive synergy targets and more importantly, how we will keep our sales momentum going. After just 6 weeks, we are making great progress on our integration milestones and are on track to deliver about 80% of our synergies by the end of the first quarter of 2016.
And in a moment, David Nicholson will give an overview of the tremendous progress in the pipeline and will make a few comments about the R&D portfolio prioritization, which is nearly complete. Tessa will also join us to describe our financial performance in detail, but from a high-level perspective, you can see the impact of our transformation over the past 12 to 18 months.
Non-GAAP net revenue was $4.2 billion, a 65% increase largely driven by the Forest acquisition, with only 2 weeks of Allergan in the results; $4.30 of non-GAAP EPS even with the impact of the Allergan financing; $1.8 billion in adjusted EBITDA; and $525 million in cash flow from operations, more than $800 million if you add back the onetime cash charges for severances, restructuring and integration.
Turning to the business performance. On a pro forma basis, total U.S. branded sales increased 5% if you exclude Allergan and increased 17% if you exclude Namenda IR. 8 of the top 10 Actavis brands are growing double digits versus prior year; not just growing, thriving.
In fact, many of our key products are hitting new highs in volume and market share, including Linzess, which is now approaching a run rate of $400 million annually. Bystolic had a strong performance, running towards $650 million annually. And Lo Loestrin, Estrace and Minastrin are really soaring with the focus we are putting on Women's Health. Lialda will likely be a beneficiary of that focus.
Meanwhile, Namenda XR sales are up sharply as we continue to drive the conversion rate and have resolved last year's supply constraints. Physicians and caregivers continue to convert more patients to Namenda XR with its more convenient and cost-effective profile. Over 70,000 physicians have prescribed Namenda XR, which is a testament to its usefulness and treatment with patients with Alzheimer's disease.
Our patient awareness campaign focused on caregivers and their loved ones with Alzheimer's disease has been well received and is helping with conversion. We are currently at about 50% and climbing towards 60% by the end of the second quarter, and we expect to exceed that figure with the launch of Namzaric, which opens up the donepezil market segment worth about $2 billion.
The primary source of business for Namzaric will be the donepezil or donepezil plus Namenda IR market. The main point here is that the market for Namzaric is bigger than the market for Namenda XR. Namzaric will give patients all the benefits of combination therapy for Alzheimer's disease in one pill, once a day. We intend to support Namzaric with formulary access and direct-to-consumer marketing. Shipping begins this week and full promotional launch later this month. Given the broad use of combination donepezil and memantine therapy, we think there is a great opportunity for Namzaric to expand the once-a-day branded market.
Turning to the Allergan business. Here again, we come back to our theme of double-digit growth. In the midst of planning for the integration, legacy Allergan delivered double-digit pro forma sales growth of 13% in constant currency to $1.75 billion for its final quarter. Allergan drove this performance while maintaining inventories in the customary, well-managed range. The performance was broad-based, driven by continued strong performance across the company's Eye Care, Botox and Aesthetic businesses. Eye care was up 14% in constant currency, driven by Restasis and Ozurdex; Botox, up 16% in constant currency, driven by growth in therapeutics; skin care, breast aesthetics and facial aesthetics, up a combined 12% in constant currency. International Allergan sales were also up double digits in constant currency, with all 3 units, eye care, medical aesthetics and specialty care, achieving double-digit growth.
We are capitalizing on the exceptional sustaining performance of Actavis and Allergan to create an impressive leader in growth pharma. So the bottom line on our combined company brand performance is strong performance for our key brands, including Namenda XR, Linzess, Botox, Restasis, Bystolic and Ozurdex. Meanwhile, you only have to look at the performance of Lo Loestrin, Saphris, Minastrin and the GI products to see that our team has firmly established a core competency in relaunching products that we acquired. This ability to invigorate acquired products is a differentiator for us. We acquire assets to grow them, and we succeed. That opens up more possibilities for us than is appreciated, more growth, more leverage and more credibility for other bolt-on deals.
While this early, we're off to a very good start with our new launches, and we are now poised to be a significant player in the increasingly important antibiotics space with Dalvance and AVYCAZ. This is where our model of development prowess, life cycle investment and smart business development is creating enduring competitive advantage.
Turning to the North American Generics and International business. Sales were up 20% this quarter in constant currency versus prior year. North American sales were $1.2 billion and continue to benefit from the contribution from key products like generic Concerta, Lidoderm and Intuniv. Special capabilities and being first to file again and again combined to make our generics business a best-in-class competitor.
This year, we have launched 20 generic products in the U.S., including our most recent launch of generic Pulmicort following our court win last week. We also launched generic OxyContin, Temovate and generic ophthalmic products as well.
This quarter, we also launched our generic injectable business after we regained the rights to about 20 injectables from Sagent at the end of 2014, giving us added strength with hospital purchasers.
On the R&D side, our generic business continues to fire on all cylinders with 7 confirmed first-to-files out of the total 18 total filings posted on the FDA website this quarter.
On the International side, non-GAAP sales were $527 million, growing 20%, excluding foreign exchange. We launched close to 100 products during this quarter.
International revenue growth was driven by multiple markets, including Russia, up 41% on a constant-currency basis, driven by our strong sales organization and OTC performance; and the U.K., up 22% on a constant-currency basis, driven by new product launches.
Our strategy in international generics is to continue allocating resources to markets that deliver high-growth potential and where we can be among the leaders. That is why we divested generic products in Australia and invested in Auden Mckenzie acquisition in the U.K., which is expected to close in the second quarter.
Let me close with a few comments on our preliminary view of the 2015 financials. We are certainly off to a terrific start. We previously planned to provide guidance at the end of Q2, but given the strong performance this quarter, the progress we're making on integration synergies and the impact of foreign exchange and divestitures, we felt it would be good to give you our preliminary view of 2015 today.
First, since we acquired Allergan on March 17, as-reported revenue is projected to be in the range of $20.5 billion to $21 billion. On a pro forma basis, full year sales are projected at $22 billion to $22.5 billion, which was consistent with or slightly ahead of our prior comments of $23 billion if you exclude the impact of foreign exchange and the multiple divestitures such as respiratory and Pharmatech.
Our current view on 2014 (sic) (2015) non-GAAP earnings per share on an as-reported basis, including Allergan as of March 17, is in the range of $17 to $18.15 -- I'm sorry, $18.50. We will narrow the range over time.
With this view, you can see that we have put together a terrific company with a very compelling outlook for 2015, and we are executing like a high-performance engine driving towards our aspirational target of $25 per share in EPS in 2017. We look forward to giving you more refined guidance on our second quarter call.
With that, I'll now turn the call over to Tessa, who will provide you with an overview of our financial performance during the quarter. Tessa?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on",970,"Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on March 17. The Allergan business contributed $258 million in net revenue and $113 million in adjusted EBITDA in the quarter.
Turning to our results for the first quarter on Slide 15. In Q1, we delivered strong performance with top line growth across key franchises, both year-over-year and quarter-over-quarter despite negative foreign currency impact. The year-over-year increase was also driven by the Forest and Allergan acquisition.
On a non-GAAP basis, consolidated net revenue for the first quarter was $4.2 billion, an increase of 65% versus the prior year quarter. Non-GAAP R&D investment for the quarter was $284 million compared to $175 million in the prior year period. Non-GAAP R&D spending was $110 million for generics, $125 million for brands, $15 million for biosimilars and $34 million for Allergan.
Non-GAAP SG&A as a percentage of revenue was 20.9%, an increase of 1.7 percentage points over the prior year quarter as a result of the Forest branded products that have higher SG&A spend.
Non-GAAP adjusted EBITDA for the quarter was $1.78 billion, an increase of 107% versus the prior year, driven by strong revenues and higher gross margins across the business.
Non-GAAP earnings per diluted share for the quarter increased 23% to $4.30 compared to $3.49 per diluted share in the first quarter of 2014. Excluding the impact of Allergan and its related financing, Actavis non-GAAP EPS was $4.59 for the first quarter 2015, representing a 17% sequential increase from $3.91 in the fourth quarter. This highlights our continued strong performance on top of integration activities.
Our non-GAAP tax rate improved from 16.4% in the year-ago period to 14.3% in the current-year quarter mainly due to geographic mix.
Cash flow from operations for the first quarter was $525 million. Our cash flow from operations would have been more than $800 million if cash charges for severance, restructuring and integration are added back.
Turning now to our business segments. North American Brands business delivered strong performance year-over-year, powered by the acquired Forest products and growth in our Women's Health franchise. North American Brands revenue was $1.74 billion for the quarter, up 192% versus the prior year period, driven by the addition of the Forest business, including strong double-digit year-over-year growth from 8 out of our top 10 products.
Compared to the prior quarter, sales were down slightly, driven by normal decline in prescription fill rates from fourth quarter to first quarter but typically recover in the second quarter and wholesaler buying patterns.
Adjusted gross margin within North America Brands decreased to 86.6% largely due to partner products within the Forest portfolio, including Namenda and Linzess. Sequentially, adjusted gross margin improved due to lower Namenda IR sales, which carry a lower margin.
Non-GAAP SG&A as a percent of revenue increased to 27.8%, driven by expenses related to the acquired Forest products.
Our North America Generics and International business continues to perform strongly with non-GAAP revenues of $1.7 billion for the quarter, up 12% versus the prior year period. Growth was driven by strong sales of key products and new product launches, including generic versions of Concerta, Lidoderm, Intuniv and OxyContin.
Internationally, our generics business was negatively impacted by the strengthened U.S. dollar, but at constant currency rates, this business grew 20% versus prior year quarter.
On a non-GAAP basis, adjusted gross margins increased 3.2 percentage points compared to the year-ago quarter due to continued strong performance within our International business.
Non-GAAP SG&A as a percentage of adjusted net revenue for the segment declined to 14.8% due to the divestiture of our Western European assets and elimination of the supportive infrastructure of that business.
Turning to our Anda business. Revenues increased to $462 million, up from $300 million in the prior year, an increase of 18% driven by a higher mix of chain drugstore sales. Gross margin for the Anda business decreased 2.6 percentage points to 12.5% as a result of the higher product mix of chain drugstore sales.
Slide 19 details our debt capitalization following the close of the Allergan acquisition. We ended the first quarter 2015 with total debt of approximately $44 billion and equity of $71 billion related to the Allergan acquisition and previous financing.
Currently, our leverage ratio stands at 4.1x debt to pro forma adjusted EBITDA. Over the next 12 months, we are committed to using our anticipated strong free cash flows from our business segments to accelerate debt repayment. We expect to achieve a pro forma leverage ratio of 3.5x debt to adjusted EBITDA by the end of the first quarter of 2016, in line with our prior guidance.
Finally, I would like to provide an overview of our key assumptions for the 2015 combined forecast Brent provided earlier in this call. Our non-GAAP EPS of $17 to $18.50 includes key near- and longer-term drivers that we expect over the next few months that will impact our business, including: In U.S. brands, we assumed the Namenda XR conversion trending to 60% by the end of Q2, Namenda IR generic enters the market in mid-July, Namzaric launch this week. In our GX business, we assumed launch of generic Pulmicort, continued current market conditions for Concerta, additional competition on Lidoderm, Auden Mckenzie acquisition close late in Q2. A tax rate of approximately 15%, 2015 fully diluted average shares of approximately 386 million, and year-end 2015 fully diluted shares outstanding of 415 million. Foreign exchange rates are based on average forward consensus for Q2 to Q4.
I'd now like to turn the call over to David Nicholson, who will provide an update on our brands R&D progress in the quarter. David?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines.Turning",964,"Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines.
Turning to Slide 22. We have achieved tremendous progress, and I would applaud the combined efforts of our commercial and R&D teams. We have nearly completed the rationalization of our combined pipeline. Our teams have identified and confirmed 70 projects that will move forward as part of the combined development program with more than 50 projects in either late stage or registration stages of development.
Whilst we have made very significant progress on the rationalization of our pipeline, we are still evaluating certain projects. We continue to drive these projects forward, the key milestones, to allow us to make cost-effective but also data-driven decisions. We will present our combined rationalized pipeline as part of an up-and-coming R&D day.
We have achieved significant progress across key programs from both the legacy Actavis and the legacy Allergan R&D pipelines.
Turning to Slide 23. You get an insight into the extent of our progress to strengthen our key franchises. In the quarter, we achieved milestones across core franchises, including women's health, infectious disease, CNS and gastroenterology.
Key FDA and European approvals included Liletta. This was FDA-approved in February as a long-acting progestin-only intrauterine system, or IUS, to prevent pregnancy for up to 3 years and was launched in the U.S. in April. To support the use of Liletta for up to 7 years, we are continuing the ACCESS study. The initial results of this study were published online in April in Contraception. The study found Liletta to be more than 99% effective for the prevention of pregnancy for up to 3 years of use in women aged 16 to 35 regardless of their race, history of previous births or BMI.
AVYCAZ, our combination of ceftazidime and the novel beta lactamase inhibitor, avibactam, was FDA-approved in March as a treatment for adult patients with complicated intra-abdominal and urinary tract infections. The AVYCAZ launch is in progress.
As you have heard, Namzaric is being launched, and we are in discussions with the FDA about extending the range of doses that we can make available to maximize convenience for patients.
Dalbavancin was approved in Europe in February as Xydalba for the treatment of acute bacterial skin and skin structure infections, ABSSSI. We are developing a single-dose regimen of Dalvance. And in April, we announced positive top line results for a Phase III study comparing a single 1.5 gram dose of Dalvance with the same total dose given as 2 doses 1 week apart for the treatment of ABSSSI infections caused by susceptible gram-positive bacteria, including MRSA. The top line data demonstrated that the single dose of Dalvance achieved its primary endpoint for control of infection at 72 hours after initiation of therapy. The study was also positive at end of treatment, the endpoint required by the European Medicines Agency.
I will return to Botox later.
We also announced the initiation of a Phase IIb study for relamorelin, our investigational treatment for gastroparesis in patients with type 1 and type 2 diabetes. We are very pleased with this collaboration with our partner, Rhythm Health.
Turning to Slide 24. We achieved sNDA approvals for a lower dose of 20 milligrams Viibryd, expanding dosing options for clinicians; and for Saphris monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients. FDA has accepted our sNDA to expand the Teflaro label to ABSSSI with concurrent bacteremia.
We received FDA approval for the expanded label of Botox for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose for adults within 3 months treated for one or more indications. We remain very committed to extending our Botox franchise.
Looking ahead, and moving on to Slide 25, we have a significant number of regulatory milestones in the next few months. We have upcoming PDUFA dates for Eluxadoline in the second quarter and for Cariprazine in June. For Eluxadoline, we do not expect an FDA Advisory Committee hearing on our submission, and DEA scheduling begins once approval is achieved.
We are continuing to build out our Linzess franchise, and we expect to submit an sNDA for a low dosage form of the drug to treat chronic idiopathic constipation in 2016.
For DARPin, our Phase II programs for AMD and DME in the U.S. and Japan are ongoing, and we will begin enrollment in our Phase III program in the U.S. later this quarter or early in the third quarter. This on-time start of Phase III is just one of many examples that our strong combined R&D team is maintaining momentum during the integration of our 2 companies.
Restasis is on track to submit the dossier for multi-dose, preservative-free formulations by the end of the year.
I'm excited about Bimataprost SR. The Phase III trials are continuing in the U.S., and we will be starting Phase III in Europe later this year.
SER 120, a low-dose nasal formulation for the treatment of Nocturia, is nearing completion of Phase III, and we are looking forward to seeing the data.
I also wanted to mention our dermal fillers. We are continuing to roll out additional HA formulations. We anticipate extending our Volite line in Europe and our Juvederm line in Asia during the course of this year.
In conclusion, the first quarter of 2015 has been very productive for the R&D team, and we will continue to see momentum in the second quarter and beyond from our industry-leading pipeline.
With that, I will now turn the call back over to Brent, who will provide closing remarks. Brent?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving",87,"Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving our key aspirations: double-digit branded revenue growth, about $8 billion in free cash flow in 2016 and our aspirational EPS target of $25 per share in 2017.
With that, I'll turn the call back to Lisa, and we'll take your questions."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions.",11,"Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank.",15,"[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial sense?",47,"My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial sense?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, Greg. Obviously, history is a proof point of that with the Allergan acquisition, which was not part of our strategy but, as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies.",117,"Yes, Greg. Obviously, history is a proof point of that with the Allergan acquisition, which was not part of our strategy but, as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies. I think as you look forward, obviously, our commitment to maintain our investment-grade rating is of critical importance to us. We will continue to look at bolt-on deals as a matter of course. I think with respect to transformational deals, we would be limited by cash constraints, obviously. So it would have to be something truly compelling for us to want to use our equity to do something like that."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And Brent, just another question for you. How are you thinking about your generics business given that, obviously, there's someone out there right now who is willing to pay a very high multiple for it? And is there a way to sell the generics business in a",49,"And Brent, just another question for you. How are you thinking about your generics business given that, obviously, there's someone out there right now who is willing to pay a very high multiple for it? And is there a way to sell the generics business in a tax-efficient manner?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, it's a great question, Jami. And obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industry is in a bit of turmoil right now with too hostile situations going on. And my views on hostil",205,"Yes, it's a great question, Jami. And obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industry is in a bit of turmoil right now with too hostile situations going on. And my views on hostile situations of going concern, full companies, it tends to destroy value and cause lots of distractions. When you look at our business, up almost 20% on top line this year, firing on all cylinders, and R&D pipeline that's the envy of the industry, continuing to just be on First-to-Files in the U.S. time and time again, launching 100 brands outside -- or products outside the United States and our way we manage it, which is so different than anybody else, I think it's something that we take a lot of pride in, and we see a lot of connectivity to generics and our branded business. That being said, I think if you look at trying to sell it, I'm not sure there's a tax-efficient way. We do have reasonably high basis in it, but it'd still be a very difficult thing to do. But I think the bigger takeaway should be strategically, we value that business."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","You talked about the $25 in 2017 is the target. Maybe you can just give us a sense of the push and pulls on that number relative to where you were when you first put that number out. And I know you said we can't do a second, but just on the LUMIGAN implan",74,"You talked about the $25 in 2017 is the target. Maybe you can just give us a sense of the push and pulls on that number relative to where you were when you first put that number out. And I know you said we can't do a second, but just on the LUMIGAN implant, can you just give us a sense of how long that product is lasting relative to the daily eye drop?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So I think, Marc, it's a great question. Really, to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with the $25 aspiration, we're pretty much on course. There are obviously s",127,"Yes. So I think, Marc, it's a great question. Really, to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with the $25 aspiration, we're pretty much on course. There are obviously some minor puts and takes that occurred in the model, but overall, we're exactly where we kind of thought we would be. Obviously, currency has moved against us, but stronger performance has compensated for some of that. I think we're seeing good productivity out of the R&D pipeline. David has to finish and tie up the pipeline review, which we expect to happen this quarter. But overall, I'd say we're pretty much where we thought we would be."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Are the synergies coming through as fast as you thought when you originally set it out?",16,"Are the synergies coming through as fast as you thought when you originally set it out?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I think I would say we're probably a little ahead, and that's why you saw a quite large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for a few countries. We're substantially ahead of where we thought",103,"Yes, I think I would say we're probably a little ahead, and that's why you saw a quite large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for a few countries. We're substantially ahead of where we thought we would be. And the severances and the charges associated with that came through in a large way this quarter. You should expect that to dissipate over time. And so I think we're feeling good by the bold and aggressive actions we've taken to combine these companies, get the distraction behind us and focus on top line growth."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And the Namenda sales piece of it hasn't changed much?",11,"And the Namenda sales piece of it hasn't changed much?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No. I think I'll ask Bill to chime in here, but I think when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We",90,"No. I think I'll ask Bill to chime in here, but I think when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We'll see what happens. But when you look at what our team has done and by pulling off the shelf a plan B 24 hours after that court ruling, it's nothing short of extraordinary. I'll ask Bill to just comment on it."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric to it, which I think will be a sales accelerator, we should achieve our target. And in all the research that we've done, if we can provide for formulary coverage, then we believe",126,"Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric to it, which I think will be a sales accelerator, we should achieve our target. And in all the research that we've done, if we can provide for formulary coverage, then we believe we're going to be able to move more and more patients either from IR to XR or patients to Namzaric, which is, frankly, a stronger selling proposition than even XR. Fewer pills, fewer administrations, no increase in side effects, better efficacy, and we've made sure that it's economical for health plan and caregivers. And so we've taken a lot of effort and a lot of investment, a lot of energy. But I think we're going to reach the target."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Plus it opens up the donepezil market, which is much bigger than the memantine market.",15,"Plus it opens up the donepezil market, which is much bigger than the memantine market."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","That's right.",3,"That's right."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Liav Abraham with Citi.",12,"Our next question comes from the line of Liav Abraham with Citi."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick question on DARPin and your decision to move forward here. Just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than it",68,"Just a quick question on DARPin and your decision to move forward here. Just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than it is now? Or are you progressing forward with this in order to potentially bring a combination DARPin PDGF to market?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, let me -- I'll start, and let me ask David to comment. And just one backup on LUMIGAN for Marc. I mean, I think in the studies, we're seeing it lasted about 3 to 4 months, something in that range, versus the drops, which compliance and persistence is",342,"Yes, let me -- I'll start, and let me ask David to comment. And just one backup on LUMIGAN for Marc. I mean, I think in the studies, we're seeing it lasted about 3 to 4 months, something in that range, versus the drops, which compliance and persistence is a huge issue and glaucoma. And if you talk to glaucoma specialists, they're dying for an effective treatment that would increase compliance and persistence for a disease that's typically asymptomatic. It's doing a lot of damage to the back of the eye. In terms of DARPin, Liav, I think you're right on both tracks. I think the way we're thinking about DARPin is that it should achieve the 3 to 4x a year dosing regimen to make it really a differentiator. Obviously, people don't like getting an injection at the back of the eye. If you look at even EYLEA, they're dosing it more frequently than the label suggests, and so doctors are really looking for something that -- and patients probably even more so looking for something to minimize injection. So we're really trying to design the experiment or the Phase III to hit the 12-week dosing regimen. The other thing I would put out there is remember, we put nothing in our deal model in DARPin, and so outside of the cost of the Phase III study, it's essentially a free call option. And so given where we are, we think after all the modeling and everything we looked at, it was worth going for. But you're right, it's a high hurdle to get there, and to the extent we can, it should provide a very compelling, large opportunity for us in the future, but we've got to get there. I think the second thing it does, it sets us up for dual DARPin, and that could be a very exciting place to be, but it's early. And so we've got a lot of work to do there as well. I don't know, David, if you want to add any color."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Brent, I think you said it. We are very excited by our partnership with Molecular Partners. The DARPin Ankyrin-binding proteins are a novel class of therapeutically active agents. Our lead DARPin has an incredibly high affinity for VEGF, which opens up th",142,"Brent, I think you said it. We are very excited by our partnership with Molecular Partners. The DARPin Ankyrin-binding proteins are a novel class of therapeutically active agents. Our lead DARPin has an incredibly high affinity for VEGF, which opens up the possibility for administration every 12 weeks. We're going to evaluate that in Phase III. And as Brent mentioned, coming along behind it, we have a number of other Ankyrin-binding proteins, other constructs. Those projects are early, so it's too early to talk about those. The dual DARPin is just in preclinical development. It's very exciting. It's a combination of PDGF and VEGF, which should have advantages in AMD, but it's very early. It's still in preclinical development. We need to work our way through and generate more data just to see how exciting that project is really going to be."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And you feel comfortable with the inflammation at this point?",10,"And you feel comfortable with the inflammation at this point?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","We know that -- I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of Lucentis development. So we're very care",81,"We know that -- I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of Lucentis development. So we're very carefully watching ocular inflammation as we progress into Phase III. We've got a Data Safety Monitoring Board in place. And we are confident that we are going to -- that we're in control of the situation."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ronny Gal with Bernstein.",12,"Our next question comes from the line of Ronny Gal with Bernstein."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question is for David Nicholson. David, can -- you keep on seeing on ClinicalTrials.gov trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they ex",50,"My question is for David Nicholson. David, can -- you keep on seeing on ClinicalTrials.gov trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they expect to reach the market?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, so Ronny, it's Brent. I know you wanted David. I'll turn it over to him in a second. But to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think w",120,"Yes, so Ronny, it's Brent. I know you wanted David. I'll turn it over to him in a second. But to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think we have some real interesting ones and ones that maybe perhaps will fall out. We'll go through that over the course of the next month or so. But dry eye is something that we're also very committed to. And we're looking at a variety of external innovations as well as our internal programs, and you'll see us very committed to the space for the long term."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I think, basically, that covers it, Ronny. Obviously, always happy to discuss this with you. As you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclospo",75,"Yes, I mean, I think, basically, that covers it, Ronny. Obviously, always happy to discuss this with you. As you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclosporine in early stages of development, which we think could be a real advance over Restasis itself. And as Brent said, we really believe we can maintain our leadership in this franchise, yes."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Okay. And the product which you just discussed submitting before the end of the year, that's Restasis X?",18,"Okay. And the product which you just discussed submitting before the end of the year, that's Restasis X?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I'm not sure of the question, Ronny. Ask again.",12,"Yes, I mean, I'm not sure of the question, Ronny. Ask again."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So the product that you just mentioned, the preservative-free, multi-dose product, is that what used to be called Restatis X?",20,"So the product that you just mentioned, the preservative-free, multi-dose product, is that what used to be called Restatis X?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, yes, I'm sorry. Absolutely not. That is not Restasis X. That's just the preservative-free, which doctors have been asking for.",21,"No, yes, I'm sorry. Absolutely not. That is not Restasis X. That's just the preservative-free, which doctors have been asking for."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, multi-dose formulation.",3,"Yes, multi-dose formulation."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Chris Schott with JPMorgan.",12,"Your next question comes from the line of Chris Schott with JPMorgan."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Great. Can you just talk a little bit about your expectations for the legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses? I guess should we think about this as a double-digit growth bu",131,"Great. Can you just talk a little bit about your expectations for the legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses? I guess should we think about this as a double-digit growth business for the remainder of 2015 on a constant currency basis? And if I can just do a quick follow-up to, I think, Jami's question earlier, if shares remain at current valuations, does that change your view at all about a potential separation of your brand and generic franchise as technology? You've got a great generic business, but does valuation play a factor here at all if you can work 6 or 9 months away and you're still trading at a fairly low multiple in forward earnings?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I think as you think about the legacy Allergan business, our expectation is the double-digit branded growth in a constant currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We ha",295,"Yes, I mean, I think as you think about the legacy Allergan business, our expectation is the double-digit branded growth in a constant currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We have completely solidified our sales and marketing colleagues around the world with perhaps a few countries as an exception only. The team is absolutely committed. They've been driving lots of growth in the first quarter, and we expect that to continue throughout the year and beyond, and that is part of the firm basis of which we believe we'll have double-digit branded growth along with the North American Forest legacy brands. I think to respect to your second question, Chris, in terms of the stock being perhaps at lower levels than we all would expect, I don't think it's a question of selling the generics business. I think it's a question of digesting this integration, helping shareholders understand the value proposition here, the compelling growth opportunity that we've created in growth pharma, the enduring, sustainable bottom line growth, continuing to prove out our aspiration of $25 of EPS, some $25, and then showing how the businesses support each other and add additional turbo boosting growth to one another. And so it's still early. We only closed Allergan a few weeks ago, I think 5, 6 weeks ago. And so I think no one wants to have a trigger finger and overreact to 5 weeks of weakness, if you will, in the midst of closing, rebasing your shareholders, having a lot of people sorting through different moving parts. Let's let things settle down, and let us tell our story and prove our points as we continue to execute on all cylinders here."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Our next question comes from the line of Ken Cacciatore with Cowen and Company."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Brent, just wanted to flesh out a little bit of your earlier comment for a possible versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together, especially to get used to your",94,"Brent, just wanted to flesh out a little bit of your earlier comment for a possible versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together, especially to get used to your currency. But just wondering if you saw clearly down the road a reason to approach a larger player. When would you become more encouraging, I think you used the word hostile, versus remaining passive? Is there any time that you would kind of alter the philosophy that you have?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, you never say never. I just think that doing a hostile deal against a large, going concern, like we've seen in the industry over the last 12 months, is value destroying. We are quite experienced in integrations. We do them quite well. And one",323,"Yes, I mean, you never say never. I just think that doing a hostile deal against a large, going concern, like we've seen in the industry over the last 12 months, is value destroying. We are quite experienced in integrations. We do them quite well. And one of the largest reasons we do them well is because we treat people with dignity and respect. We have information exchange freely, of course, following all the rules and regulations around jumping, and that allows us to get a jump on things like you saw in this quarter with the integration of Actavis Allergan, but it also shows how you restore momentum by keeping people's morale high, and that is certainly the case for the most part in our combined company. I think there are opportunities to do hostile deals. I think you have to do them when you're buying a single product perhaps or just a research program or a file where people aren't the key driver. But in most of these businesses, people are such a large part of the equation. I think going hostile in virtually every instance is a mistake. There could always be an exception to that. I think the second thing is there are other large players that we believe are inefficient that would benefit from our operating model, our management philosophy, the way we approach customers in a more efficient manner. And so over time, there may be some targets that could be surprising to folks, but we have to delever, and we have to maintain our investment-grade rating. And so those are all the factors that go into everything we look at. And obviously, I think by now, we've earned some trust that if there's something opportunistic that creates shareholder value, this isn't a team that sits back and watches it pass us by. We react very quickly and do things in a very creative but value-creating way."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question actually is for Tessa, not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in",72,"My question actually is for Tessa, not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in headwinds from accounts receivable as well as $200 million in inventory. So I just wanted to understand that better, if you had any color on that."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million. About $400 million in receivables change was really largely due to 2 things: one, a change in payment terms with a",148,"Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million. About $400 million in receivables change was really largely due to 2 things: one, a change in payment terms with a couple of customers; and two, with higher sales, obviously, you have higher AR. And then on the inventory side, that was purposefully done to ensure that we don't have any outages in terms of supply. But what you'll find is towards the next couple of quarters sequentially, our cash flow will improve in a manner such that by 2016, we will be at roughly $8 billion of cash flow. So there's a couple of puts and takes in Q1 that are, I would say, abnormal in nature largely due to restructuring, but you will see that improve sequentially through the next couple of quarters."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Michael Faerm with Wells Fargo.",13,"Your next question comes from the line of Michael Faerm with Wells Fargo."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question is on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?",31,"My question is on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, maybe I'll turn it to David. Do you want to...",11,"Yes, maybe I'll turn it to David. Do you want to..."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So as I've said, we've got an upcoming PDUFA date for Eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the div",93,"Yes. So as I've said, we've got an upcoming PDUFA date for Eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the division, then the scheduling goes to the DEA for finalization. The timeline for scheduling is -- it varies from company to company. So it's not possible for us to say when we'll get the scheduling -- the finalized schedule decision. The PDUFA date, as I mentioned earlier, is in second quarter."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would just add that our current model has us launching likely at the end of this calendar year but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinkin",51,"I would just add that our current model has us launching likely at the end of this calendar year but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinking about it."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth for target in some detail? Could you define that, the timing, what it includes, what it excludes, just so we have a better sense for how you're thinking about tha",48,"Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth for target in some detail? Could you define that, the timing, what it includes, what it excludes, just so we have a better sense for how you're thinking about that 10% goal?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces",166,"Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces to that, and I think if you look at it in constant currency -- and it's hard to hold management out in the field and in the countries accountable for currency. Obviously, you can hold us accountable for it here at the center, but not a lot we can do about it that -- we see that growth. When you look at how we've kind of baselined it, it's really starting in this quarter with generic IR, then everything else is in. And so that's how we think about it as a CAGR on a go-forward basis. And we expect that as we look at it, we should do better than 10% branded revenue growth throughout our planning period."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Got it. So that excludes the impact of IR?",9,"Got it. So that excludes the impact of IR?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","It excludes currency and IR. That would be the only 2 exclusions that I'm aware of. And of course -- yes, we did have respiratory, Doryx, Pharmatech, Australia, we've had some divestitures. We baselined it against those divestitures as well.",40,"It excludes currency and IR. That would be the only 2 exclusions that I'm aware of. And of course -- yes, we did have respiratory, Doryx, Pharmatech, Australia, we've had some divestitures. We baselined it against those divestitures as well."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Louise Chen with Guggenheim.",12,"Your next question comes from the line of Louise Chen with Guggenheim."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So just a more macro question here. Curious how you think about brand and generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here.",37,"So just a more macro question here. Curious how you think about brand and generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So let me tackle generic pricing. Maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products th",114,"Yes. So let me tackle generic pricing. Maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products that go up, but the battle for generics is price decreases as more competitors come into the market. That's just the way the business works. And overall, we still model a mid-single-digit price decrease in our business. That being said, the environment has remained pretty stable and favorable. So we don't expect that to change short term either. I don't know, Paul, if you have other thoughts."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that pr",68,"I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that product line, and we're obviously taking advantage of the situation as they present -- as situations present themselves."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob, anything you'd want to add?",6,"Bob, anything you'd want to add?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, I think that exactly covers it.",7,"No, I think that exactly covers it."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Okay. In terms of the branded side, again, I think our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associ",75,"Okay. In terms of the branded side, again, I think our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associated with the innovation. But in the short term, when you look at our current price portfolio, we're reasonably well positioned. And Bill, do you want to expand on that?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I don't think when we look at our sales expectations over the next several years, we're overly dependent on price as a driver. A lot of the growth trends that you're seeing are volume-based. I would also point out that generally speaking, our pricing",132,"Yes, I don't think when we look at our sales expectations over the next several years, we're overly dependent on price as a driver. A lot of the growth trends that you're seeing are volume-based. I would also point out that generally speaking, our pricing strategy is tied to our IP, and most of the assets that we have on the market right now have long exclusivity periods. And so our primary objective, generally speaking, in a market is market share. And as it relates to price increases, we're very realistic about what they can look like. We're predictable and reasonable, and I think payers know that. I think that's the right way to be over the next several years, and I don't anticipate any surprises to our plan because of price."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And I would add, Philippe, you want to make a comment about aesthetics?",13,"And I would add, Philippe, you want to make a comment about aesthetics?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. On the cash base side, we have increased our price by 3% this year, and we can see double-digit growth -- strong double-digit growth in our business. So we're pretty confident about the future of this business.",38,"Yes. On the cash base side, we have increased our price by 3% this year, and we can see double-digit growth -- strong double-digit growth in our business. So we're pretty confident about the future of this business."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of David Amsellem with Piper Jaffray.",13,"Our next question comes from the line of David Amsellem with Piper Jaffray."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So I want to stay on the bolt-on M&A. I wanted to ask about the generics business. And is the addition of additional businesses, either x U.S. or small businesses in the U.S. a priority? And also maybe talk about what kind of formulations and dosage forms",61,"So I want to stay on the bolt-on M&A. I wanted to ask about the generics business. And is the addition of additional businesses, either x U.S. or small businesses in the U.S. a priority? And also maybe talk about what kind of formulations and dosage forms might be a high priority in terms of bolstering the business by M&A."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I'll turn it over to Bob Stewart to comment on that.",12,"Yes, I'll turn it over to Bob Stewart to comment on that."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the",225,"Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the full range of dosage forms that we need to be able to compete globally. We'll always look at opportunistic M&A in the U.S. I think we've got the scale that we need. I don't necessarily think that another acquisition in the U.S. is really going to give us anything because I think, again, we've got the size of the portfolio, we've got a best-in-class commercial team, perhaps maybe looking at some portfolios of products in injectables and things like that. That would be the only thing I would see that would be of interest in the U.S. Outside the U.S., we're always looking at different geographies that -- where we're already strong. You saw us do it with Auden Mckenzie in the U.K. We may look in certain markets that -- where there might be some tuck-in type acquisitions to just increase our overall strength there, more portfolio based, more small company type of transactions. But outside of that, I don't necessarily think that we need a large-scale transaction within the generics business to remain viable or competitive."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would say best in class.",6,"I would say best in class."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",14,"Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick one on methylphenidate. I think you said your guidance reflects current market conditions, but share has been ramping. Obviously, we're going to get an update here imminently. We don't know what the 2 other competitors are going to do, and th",84,"Just a quick one on methylphenidate. I think you said your guidance reflects current market conditions, but share has been ramping. Obviously, we're going to get an update here imminently. We don't know what the 2 other competitors are going to do, and there's obviously a very good case for you where they leave the market, and that leaves you with some pricing opportunity as well. So if you could maybe just comment on how you're thinking about that situation, that would be great."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob?",1,"Bob?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So Randall, I guess the way we've guided is exactly how you illustrated it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at t",125,"Yes. So Randall, I guess the way we've guided is exactly how you illustrated it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at today. But we see both competitors in the BX kind of situation. Now obviously, if FDA does take action and/or if the manufacturers or further the retailers do the responsible thing by continuing -- by not dispensing the BX product, that would provide upside to us, both in terms of volume as well as just overall, I guess, stability within the marketplace. So we would see that as an upside compared to what we have guided."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we could guide.",4,"And we could guide."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that -- the competitors do come out of the marketplace, that we would be able to ensure th",54,"And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that -- the competitors do come out of the marketplace, that we would be able to ensure that all customers are served."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our last question comes from the line of David Maris with BMO Capital Markets.",14,"Our last question comes from the line of David Maris with BMO Capital Markets."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you -- or potentially coming together, is that something you",145,"Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you -- or potentially coming together, is that something you spend a lot of time wringing your hands about? Or do you see that as something you're pretty happy about that maybe 2 competitors will be distracted for a year or 2 and -- in an integration? Is that more of an opportunity? And separately, in aesthetics, we've heard from a number of cosmetics terms that they've seen several of your peers being distracted lately, but they've seen no change in their Allergan sales coverage. So what have you done to minimize the disruption to customers? And how do you think you've done holding on to share during this transition period?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should cre",253,"Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should create some opportunity for us. It certainly doesn't distract us. It keeps us laser focused on our competitors. And just anecdotally, I'll give you one example. I was down at the NACDS with Paul and Bob Stewart and our branded colleagues, and our other competitors were either there in a very light presence or not at all because they were on the road trying to convince shareholders that their plan or their defense was on track. And so you can already see them despite what they say, saying it doesn't impact them -- impacting them, and so hopefully, we're already in the pole position with respect to R&D, but this will hopefully continue to allow us to continue to be in a pole position with respect to customer service. On the aesthetics side, maybe Philippe will chime in, and Paul perhaps internationally. I think our goal was to really do no harm, right? And so we approach this integration very, very carefully in that there was really no change to the facial aesthetics teams around the world or virtually no change around the world with the key focus on maintaining customer focus and connectivity in the U.S. and key international markets. Philippe, anything you'd add to that?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and VOLUMA. VOLUMA is becoming the #1 filler. It has grown 30% during the first quarter. And despite Galderma, that is -- whi",62,"Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and VOLUMA. VOLUMA is becoming the #1 filler. It has grown 30% during the first quarter. And despite Galderma, that is -- which is stronger than Valeant, we're still getting market share. So overall, I'm very confident and very positive about that business."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. And Paul Navarre, who runs International brands, would you want to chime in?",14,"Yes. And Paul Navarre, who runs International brands, would you want to chime in?"
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent, the sales force were actually not affected by the integrations. So we maintained exactly the same level of service with customers.",39,"So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent, the sales force were actually not affected by the integrations. So we maintained exactly the same level of service with customers."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely. And so that's why, again, I underscore in most",174,"Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely. And so that's why, again, I underscore in most situations, hostile deals are value destroying, and you have to look to do things on a friendly basis, obviously, with a few exceptions to that rule.
Yes, thank you, David. So I think that was our last question. I would just again close with saying that this team has continued to take bold and decisive action to create value. We are absolutely well on our way to achieving our key aspirations of double-digit branded growth, $8 billion of free cash flow in '16 and remain committed to our aspirational target of $25 per share in 2017. We thank you for joining us today and taking the time to go through a quarter with lots of moving parts, and we look forward to simpler quarters in the future. Thank you."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thanks, everybody.",2,"Thanks, everybody."
36478,291601714,810773,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Thank you. This concludes today's conference call. You may now disconnect.",11,"Thank you. This concludes today's conference call. You may now disconnect."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] Thank you.I would now like to turn the call",51,"Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Actavis First Quarter 2015 Earnings Conference Call. [Operator Instructions] Thank you.
I would now like to turn the call over to Lisa DeFrancesco. You may begin."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The",368,"Thank you, Jackie, and good morning, everyone. I'd like to welcome you to the Actavis First Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Actavis' earnings for the first quarter ended March 31, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.actavis.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Actavis and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It is important to note that such statements and events are forward-looking statements and reflect our current perspective of the business trends and information as of today's date. Actual results may differ materially from our current expectations and projections depending on a number of factors affecting the Actavis business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Actavis disclaims any intent or obligation to update these forward-looking statements except as expressly required by law.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our first quarter financial and business highlights, progress on our innovation of Allergan and provide an update to our 2015 forecast; Tessa Hilado, our Chief Financial Officer, will then discuss the Actavis first quarter results in more detail and the assumptions surrounding our 2015 forecast; and David Nicholson, Senior Vice President of Global Brands, Research and Development, will provide an update on our brands, R&D progress in the quarter and upcoming development milestones. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I'll turn the call over to Brent."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we are on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GA",1790,"Thank you, Lisa, and good morning, everyone. Let me start with the obvious. We had a terrific quarter on all key measures, and we are on an excellent trajectory for 2015 and beyond. Actavis' first quarter performance was highlighted by double-digit non-GAAP revenue growth versus the prior year, double-digit growth from key North American Brands, double-digit growth from Global Generics and double-digit growth from Anda, our distribution business, 3 rock-solid pillars to which we are adding the Allergan business.
While keeping focused on customers and driving robust growth, we also achieved a long list of accomplishments during the quarter, including completion of a largest deal in health care over the last 10 years, expanding the reach of our International portfolio, executing deals that increased our focus on profitable generic markets such as Auden Mckenzie in the U.K. while completing divestitures that sharpened our brand therapy focus such as our respiratory and Doryx deals and Pharmatech deal, ramping up productivity of our branded generic R&D teams with 4 new brand product approvals and about 20 new generic launches in the United States, and completing the largest financing ever in health care, not to mention kicking off one of the most thoughtful and rapid integrations I've ever seen. I am so proud of each of the people in our combined global team.
One thing is clear. This combined team rallies quickly around surprising opportunities, focuses on the key objectives and executes flawlessly. When it comes to execution, we are like a finely tuned, high-performance engine.
Even though we just closed the Allergan acquisition on March 17, we have already made significant progress on the integration, and we're doing exceptionally well on our cost synergy capture. How did we do it? We quickly named a new management team with skilled and experienced leaders from both companies, but we didn't stop there. In the vast majority of countries, we designed our entire organization all the way to the frontline pre-close so we could rapidly inform our colleagues about their future, give them certainty and move quickly to the new go-forward team.
For example, our global sales force of approximately 7,500 representatives has already been realigned in all but a handful of countries with the intent to minimize customer disruption. We also stood up our new International model with one Country Manager per country, allowing us to operate as one company while taking full advantage of our global brand and generic capabilities.
Being bold, nimble and focused during the integration is how we are staying on track with our aggressive synergy targets and more importantly, how we will keep our sales momentum going. After just 6 weeks, we are making great progress on our integration milestones and are on track to deliver about 80% of our synergies by the end of the first quarter of 2016.
And in a moment, David Nicholson will give an overview of the tremendous progress in the pipeline and will make a few comments about the R&D portfolio prioritization, which is nearly complete. Tessa will also join us to describe our financial performance in detail, but from a high-level perspective, you can see the impact of our transformation over the past 12 to 18 months.
Non-GAAP net revenue was $4.2 billion, a 65% increase largely driven by the Forest acquisition, with only 2 weeks of Allergan in the results; $4.30 of non-GAAP EPS even with the impact of the Allergan financing; $1.8 billion in adjusted EBITDA; and $525 million in cash flow from operations, more than $800 million if you add back the onetime cash charges for severances, restructuring and integration.
Turning to the business performance. On a pro forma basis, total U.S. branded sales increased 5% if you exclude Allergan and increased 17% if you exclude Namenda IR. 8 of the top 10 Actavis brands are growing double digits versus prior year; not just growing, thriving.
In fact, many of our key products are hitting new highs in volume and market share, including Linzess, which is now approaching a run rate of $400 million annually. Bystolic had a strong performance, running towards $650 million annually. And Lo Loestrin, Estrace and Minastrin are really soaring with the focus we are putting on Women's Health. Liletta will likely be a beneficiary of that focus.
Meanwhile, Namenda XR sales are up sharply as we continue to drive the conversion rate and have resolved last year's supply constraints. Physicians and caregivers continue to convert more patients to Namenda XR with its more convenient and cost-effective profile. Over 70,000 physicians have prescribed Namenda XR, which is a testament to its usefulness and treatment with patients with Alzheimer's disease.
Our patient awareness campaign focused on caregivers and their loved ones with Alzheimer's disease has been well received and is helping with conversion. We are currently at about 50% and climbing towards 60% by the end of the second quarter, and we expect to exceed that figure with the launch of Namzaric, which opens up the donepezil market segment worth about $2 billion.
The primary source of business for Namzaric will be the donepezil or donepezil plus Namenda IR market. The main point here is that the market for Namzaric is bigger than the market for Namenda XR. Namzaric will give patients all the benefits of combination therapy for Alzheimer's disease in one pill, once a day. We intend to support Namzaric with formulary access and direct-to-consumer marketing. Shipping begins this week and full promotional launch later this month. Given the broad use of combination donepezil and Memantine therapy, we think there is a great opportunity for Namzaric to expand the once-a-day branded market.
Turning to the Allergan business. Here again, we come back to our theme of double-digit growth. In the midst of planning for the integration, legacy Allergan delivered double-digit pro forma sales growth of 13% in constant currency to $1.75 billion for its final quarter. Allergan drove this performance while maintaining inventories in the customary, well-managed range. The performance was broad-based, driven by continued strong performance across the company's Eye Care, Botox and Aesthetic businesses. Eye care was up 14% in constant currency, driven by Restasis and Ozurdex; Botox, up 16% in constant currency, driven by growth in therapeutics; skin care, breast aesthetics and facial aesthetics, up a combined 12% in constant currency. International Allergan sales were also up double digits in constant currency, with all 3 units, eye care, medical aesthetics and specialty care, achieving double-digit growth.
We are capitalizing on the exceptional sustained performance of Actavis and Allergan to create an impressive leader in growth pharma. So the bottom line on our combined company brand performance is strong performance for our key brands, including Namenda XR, Linzess, Botox, Restasis, Bystolic and Ozurdex. Meanwhile, you only have to look at the performance of Lo Loestrin, Saphris, Minastrin and the GI products to see that our team has firmly established a core competency in relaunching products that we acquired. This ability to invigorate acquired products is a differentiator for us. We acquire assets to grow them, and we succeed. That opens up more possibilities for us than is appreciated, more growth, more leverage and more credibility for other bolt-on deals.
While this early, we're off to a very good start with our new launches, and we are now poised to be a significant player in the increasingly important antibiotics space with Dalvance and AVYCAZ. This is where our model of development prowess, life cycle investment and smart business development is creating enduring competitive advantage.
Turning to the North American Generics and International business. Sales were up 20% this quarter in constant currency versus prior year. North American sales were $1.2 billion and continue to benefit from the contribution from key products like generic Concerta, Lidoderm and Intuniv. Special capabilities and being first to file again and again combined to make our generics business a best-in-class competitor.
This year, we have launched 20 generic products in the U.S., including our most recent launch of generic Pulmicort following our court win last week. We also launched generic OxyContin, Temovate and generic ophthalmic products as well.
This quarter, we also launched our generic injectable business after we regained the rights to about 20 injectables from Sagent at the end of 2014, giving us added strength with hospital purchasers.
On the R&D side, our generic business continues to fire on all cylinders with 7 confirmed first-to-files out of the total 18 total filings posted on the FDA website this quarter.
On the International side, non-GAAP sales were $527 million, growing 20%, excluding foreign exchange. We launched close to 100 products during this quarter.
International revenue growth was driven by multiple markets, including Russia, up 41% on a constant-currency basis, driven by our strong sales organization and OTC performance; and the U.K., up 22% on a constant-currency basis, driven by new product launches.
Our strategy in international generics is to continue allocating resources to markets that deliver high-growth potential and where we can be among the leaders. That is why we divested generic products in Australia and invested in Auden Mckenzie acquisition in the U.K., which is expected to close in the second quarter.
Let me close with a few comments on our preliminary view of the 2015 financials. We are certainly off to a terrific start. We previously planned to provide guidance at the end of Q2, but given the strong performance this quarter, the progress we're making on integration synergies and the impact of foreign exchange and divestitures, we felt it would be good to give you our preliminary view of 2015 today.
First, since we acquired Allergan on March 17, as-reported revenue is projected to be in the range of $20.5 billion to $21 billion. On a pro forma basis, full year sales are projected at $22 billion to $22.5 billion, which was consistent with or slightly ahead of our prior comments of $23 billion if you exclude the impact of foreign exchange and the multiple divestitures such as respiratory and Pharmatech.
Our current view on 2014 (sic) [ 2015 ] non-GAAP earnings per share on an as-reported basis, including Allergan as of March 17, is in the range of $17 to $18.15 -- I'm sorry, $18.50. We will narrow the range over time.
With this view, you can see that we have put together a terrific company with a very compelling outlook for 2015, and we are executing like a high-performance engine driving towards our aspirational target of $25 per share in EPS in 2017. We look forward to giving you more refined guidance on our second quarter call.
With that, I'll now turn the call over to Tessa, who will provide you with an overview of our financial performance during the quarter. Tessa?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on",970,"Thank you, Brent. Good morning, everyone. Before I turn to our results, I would like to remind you that the current quarter results, which I will discuss, now include 15 days of financial contribution from the Allergan acquisition, which was completed on March 17. The Allergan business contributed $258 million in net revenue and $113 million in adjusted EBITDA in the quarter.
Turning to our results for the first quarter on Slide 15. In Q1, we delivered strong performance with top line growth across key franchises, both year-over-year and quarter-over-quarter despite negative foreign currency impact. The year-over-year increase was also driven by the Forest and Allergan acquisition.
On a non-GAAP basis, consolidated net revenue for the first quarter was $4.2 billion, an increase of 65% versus the prior year quarter. Non-GAAP R&D investment for the quarter was $284 million compared to $175 million in the prior year period. Non-GAAP R&D spending was $110 million for generics, $125 million for brands, $15 million for biosimilars and $34 million for Allergan.
Non-GAAP SG&A as a percentage of revenue was 20.9%, an increase of 1.7 percentage points over the prior year quarter as a result of the Forest branded products that have higher SG&A spend.
Non-GAAP adjusted EBITDA for the quarter was $1.78 billion, an increase of 107% versus the prior year, driven by strong revenues and higher gross margins across the business.
Non-GAAP earnings per diluted share for the quarter increased 23% to $4.30 compared to $3.49 per diluted share in the first quarter of 2014. Excluding the impact of Allergan and its related financing, Actavis non-GAAP EPS was $4.59 for the first quarter 2015, representing a 17% sequential increase from $3.91 in the fourth quarter. This highlights our continued strong performance on top of integration activities.
Our non-GAAP tax rate improved from 16.4% in the year-ago period to 14.3% in the current-year quarter mainly due to geographic mix.
Cash flow from operations for the first quarter was $525 million. Our cash flow from operations would have been more than $800 million if cash charges for severance, restructuring and integration are added back.
Turning now to our business segments. North American Brands business delivered strong performance year-over-year, powered by the acquired Forest products and growth in our Women's Health franchise. North American Brands revenue was $1.74 billion for the quarter, up 192% versus the prior year period, driven by the addition of the Forest business, including strong double-digit year-over-year growth from 8 out of our top 10 products.
Compared to the prior quarter, sales were down slightly, driven by normal decline in prescription fill rates from fourth quarter to first quarter but typically recover in the second quarter and wholesaler buying patterns.
Adjusted gross margin within North America Brands decreased to 86.6% largely due to partner products within the Forest portfolio, including Namenda and Linzess. Sequentially, adjusted gross margin improved due to lower Namenda IR sales, which carry a lower margin.
Non-GAAP SG&A as a percent of revenue increased to 27.8%, driven by expenses related to the acquired Forest products.
Our North America Generics and International business continues to perform strongly with non-GAAP revenues of $1.7 billion for the quarter, up 12% versus the prior year period. Growth was driven by strong sales of key products and new product launches, including generic versions of Concerta, Lidoderm, Intuniv and OxyContin.
Internationally, our generics business was negatively impacted by the strengthened U.S. dollar, but at constant currency rates, this business grew 20% versus prior year quarter.
On a non-GAAP basis, adjusted gross margins increased 3.2 percentage points compared to the year-ago quarter due to continued strong performance within our International business.
Non-GAAP SG&A as a percentage of adjusted net revenue for the segment declined to 14.8% due to the divestiture of our Western European assets and elimination of the supportive infrastructure of that business.
Turning to our Anda business. Revenues increased to $462 million, up from $300 million in the prior year, an increase of 18% driven by a higher mix of chain drugstore sales. Gross margin for the Anda business decreased 2.6 percentage points to 12.5% as a result of the higher product mix of chain drugstore sales.
Slide 19 details our debt capitalization following the close of the Allergan acquisition. We ended the first quarter 2015 with total debt of approximately $44 billion and equity of $71 billion related to the Allergan acquisition and previous financing.
Currently, our leverage ratio stands at 4.1x debt to pro forma adjusted EBITDA. Over the next 12 months, we are committed to using our anticipated strong free cash flows from our business segments to accelerate debt repayment. We expect to achieve a pro forma leverage ratio of 3.5x debt to adjusted EBITDA by the end of the first quarter of 2016, in line with our prior guidance.
Finally, I would like to provide an overview of our key assumptions for the 2015 combined forecast Brent provided earlier in this call. Our non-GAAP EPS of $17 to $18.50 includes key near- and longer-term drivers that we expect over the next few months that will impact our business, including: In U.S. brands, we assumed the Namenda XR conversion trending to 60% by the end of Q2, Namenda IR generic enters the market in mid-July, Namzaric launched this week. In our GX business, we assumed launch of generic Pulmicort, continued current market conditions for Concerta, additional competition on Lidoderm, Auden Mckenzie acquisition close late in Q2, a tax rate of approximately 15%, 2015 fully diluted average shares of approximately 386 million, and year-end 2015 fully diluted shares outstanding of 415 million. Foreign exchange rates are based on average forward consensus for Q2 to Q4.
I'd now like to turn the call over to David Nicholson, who will provide an update on our brands R&D progress in the quarter. David?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines.Turning",964,"Thank you, Tessa, and good morning, everyone. During the first quarter 2015, our R&D teams focused on advancing our near-term development programs whilst also looking towards the future, and the integration of the Actavis and Allergan pipelines.
Turning to Slide 22. We have achieved tremendous progress, and I would applaud the combined efforts of our commercial and R&D teams. We have nearly completed the rationalization of our combined pipeline. Our teams have identified and confirmed 70 projects that will move forward as part of the combined development program with more than 50 projects in either late stage or registration stages of development.
Whilst we have made very significant progress on the rationalization of our pipeline, we are still evaluating certain projects. We continue to drive these projects forward, the key milestones, to allow us to make cost-effective but also data-driven decisions. We will present our combined rationalized pipeline as part of an up-and-coming R&D day.
We have achieved significant progress across key programs from both the legacy Actavis and the legacy Allergan R&D pipelines.
Turning to Slide 23. You get an insight into the extent of our progress to strengthen our key franchises. In the quarter, we achieved milestones across core franchises, including women's health, infectious disease, CNS and gastroenterology.
Key FDA and European approvals included Liletta. This was FDA-approved in February as a long-acting progestin-only intrauterine system, or IUS, to prevent pregnancy for up to 3 years and was launched in the U.S. in April. To support the use of Liletta for up to 7 years, we are continuing the ACCESS study. The initial results of this study were published online in April in Contraception. The study found Liletta to be more than 99% effective for the prevention of pregnancy for up to 3 years of use in women aged 16 to 35 regardless of their race, history of previous births or BMI.
AVYCAZ, our combination of ceftazidime and the novel beta lactamase inhibitor, avibactam, was FDA-approved in March as a treatment for adult patients with complicated intra-abdominal and urinary tract infections. The AVYCAZ launch is in progress.
As you have heard, Namzaric is being launched, and we are in discussions with the FDA about extending the range of doses that we can make available to maximize convenience for patients.
Dalbavancin was approved in Europe in February as Xydalba for the treatment of acute bacterial skin and skin structure infections, ABSSSI. We are developing a single-dose regimen of Dalvance. And in April, we announced positive top line results for a Phase III study comparing a single 1.5 gram dose of Dalvance with the same total dose given as 2 doses 1 week apart for the treatment of ABSSSI infections caused by susceptible gram-positive bacteria, including MRSA. The top line data demonstrated that the single dose of Dalvance achieved its primary endpoint for control of infection at 72 hours after initiation of therapy. The study was also positive at end of treatment, the endpoint required by the European Medicines Agency.
I will return to Botox later.
We also announced the initiation of a Phase IIb study for relamorelin, our investigational treatment for gastroparesis in patients with type 1 and type 2 diabetes. We are very pleased with this collaboration with our partner, Rhythm Health.
Turning to Slide 24. We achieved sNDA approvals for a lower dose of 20 milligrams Viibryd, expanding dosing options for clinicians; and for Saphris monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients. FDA has accepted our sNDA to expand the Teflaro label to ABSSSI with concurrent bacteremia.
We received FDA approval for the expanded label of Botox for the treatment of upper limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose for adults within 3 months treated for one or more indications. We remain very committed to extending our Botox franchise.
Looking ahead, and moving on to Slide 25, we have a significant number of regulatory milestones in the next few months. We have upcoming PDUFA dates for Eluxadoline in the second quarter and for Cariprazine in June. For Eluxadoline, we do not expect an FDA Advisory Committee hearing on our submission, and DEA scheduling begins once approval is achieved.
We are continuing to build out our Linzess franchise, and we expect to submit an sNDA for a low dosage form of the drug to treat chronic idiopathic constipation in 2016.
For DARPin, our Phase II programs for AMD and DME in the U.S. and Japan are ongoing, and we will begin enrollment in our Phase III program in the U.S. later this quarter or early in the third quarter. This on-time start of Phase III is just one of many examples that our strong combined R&D team is maintaining momentum during the integration of our 2 companies.
Restasis is on track to submit the dossier for multi-dose, preservative-free formulations by the end of the year.
I'm excited about Bimataprost SR. The Phase III trials are continuing in the U.S., and we will be starting Phase III in Europe later this year.
SER 120, a low-dose nasal formulation for the treatment of Nocturia, is nearing completion of Phase III, and we are looking forward to seeing the data.
I also wanted to mention our dermal fillers. We are continuing to roll out additional HA formulations. We anticipate extending our Volite line in Europe and our Juvederm line in Asia during the course of this year.
In conclusion, the first quarter of 2015 has been very productive for the R&D team, and we will continue to see momentum in the second quarter and beyond from our industry-leading pipeline.
With that, I will now turn the call back over to Brent, who will provide closing remarks. Brent?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving",87,"Thank you, David. As you have seen, we're off to a great start. We are taking bold actions, firing on all cylinders and establishing a very strong trajectory while creating the most dynamic company in growth pharma. And we are well on our way to achieving our key aspirations: double-digit branded revenue growth, about $8 billion in free cash flow in 2016 and our aspirational EPS target of $25 per share in 2017.
With that, I'll turn the call back to Lisa, and we'll take your questions."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions.",11,"Thank you, Brent. [Operator Instructions] Jackie, we're ready to take questions."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank.",15,"[Operator Instructions] Our first question comes from the line of Greg Gilbert with Deutsche Bank."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial sense?",47,"My one question is for Brent. Sometimes the best things in life come along when you're least ready for them. Can you speak to your readiness and desire to move on a large acquisition in the near term if it were to make strategic and financial sense?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, Greg. Obviously, history is a proof point of that with the Allergan acquisition, which was not part of our strategy but, as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies.",117,"Yes, Greg. Obviously, history is a proof point of that with the Allergan acquisition, which was not part of our strategy but, as you know, was put in play, and we were able to be opportunistic as a white knight and really combine these 2 great companies. I think as you look forward, obviously, our commitment to maintain our investment-grade rating is of critical importance to us. We will continue to look at bolt-on deals as a matter of course. I think with respect to transformational deals, we would be limited by cash constraints, obviously. So it would have to be something truly compelling for us to want to use our equity to do something like that."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Our next question comes from the line of Jami Rubin with Goldman Sachs."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And Brent, just another question for you. How are you thinking about your generics business given that, obviously, there's someone out there right now who is willing to pay a very high multiple for it? And is there a way to sell the generics business in a",49,"And Brent, just another question for you. How are you thinking about your generics business given that, obviously, there's someone out there right now who is willing to pay a very high multiple for it? And is there a way to sell the generics business in a tax-efficient manner?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, it's a great question, Jami. And obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industry is in a bit of turmoil right now with 2 hostile situations going on. And my views on hostile",206,"Yes, it's a great question, Jami. And obviously, that is something we get from a few folks from time to time, and no surprise. Look, I think the generic industry is in a bit of turmoil right now with 2 hostile situations going on. And my views on hostile situations of going concern, full companies, it tends to destroy value and cause lots of distractions. When you look at our business, up almost 20% on top line this year, firing on all cylinders, an R&D pipeline that's the envy of the industry, continuing to just be on First-to-Files in the U.S. time and time again, launching 100 brands outside -- or products outside the United States and our way we manage it, which is so different than anybody else, I think it's something that we take a lot of pride in, and we see a lot of connectivity to generics and our branded business. That being said, I think if you look at trying to sell it, I'm not sure there's a tax-efficient way. We do have a reasonably high basis in it, but it'd still be a very difficult thing to do. But I think the bigger takeaway should be strategically, we value that business."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Marc Goodman with UBS.",12,"Our next question comes from the line of Marc Goodman with UBS."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","You talked about the $25 in 2017 is the target. Maybe you can just give us a sense of the push and pulls on that number relative to where you were when you first put that number out. And I know you said we can't do a second, but just on the LUMIGAN implan",74,"You talked about the $25 in 2017 is the target. Maybe you can just give us a sense of the push and pulls on that number relative to where you were when you first put that number out. And I know you said we can't do a second, but just on the LUMIGAN implant, can you just give us a sense of how long that product is lasting relative to the daily eye drop?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So I think, Marc, it's a great question. Really, to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with the $25 aspiration, we're pretty much on course. There are obviously s",127,"Yes. So I think, Marc, it's a great question. Really, to be fair, not a lot has changed. The good news is as we sit here several months from when we announced the deal and came up with the $25 aspiration, we're pretty much on course. There are obviously some minor puts and takes that occurred in the model, but overall, we're exactly where we kind of thought we would be. Obviously, currency has moved against us, but stronger performance has compensated for some of that. I think we're seeing good productivity out of the R&D pipeline. David has to finish and tie up the pipeline review, which we expect to happen this quarter. But overall, I'd say we're pretty much where we thought we would be."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Are the synergies coming through as fast as you thought when you originally set it out?",16,"Are the synergies coming through as fast as you thought when you originally set it out?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I think I would say we're probably a little ahead, and that's why you saw a quite large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for a few countries. We're substantially ahead of where we thought",103,"Yes, I think I would say we're probably a little ahead, and that's why you saw a quite large cash charge this quarter. We're making great progress, for example, on headcount. We're up but for a few countries. We're substantially ahead of where we thought we would be. And the severances and the charges associated with that came through in a large way this quarter. You should expect that to dissipate over time. And so I think we're feeling good by the bold and aggressive actions we've taken to combine these companies, get the distraction behind us and focus on top line growth."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And the Namenda sales piece of it hasn't changed much?",11,"And the Namenda sales piece of it hasn't changed much?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No. I think I'll ask Bill to chime in here, but I think when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We",90,"No. I think I'll ask Bill to chime in here, but I think when you look at XR, it is an amazing performance. Obviously, the legal setback is what it is, and perhaps we'll get a ruling from the court. Perhaps they'll delay until it doesn't matter anymore. We'll see what happens. But when you look at what our team has done and by pulling off the shelf a plan B 24 hours after that court ruling, it's nothing short of extraordinary. I'll ask Bill to just comment on it."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric to it, which I think will be a sales accelerator, we should achieve our target. And in all the research that we've done, if we can provide for formulary coverage, then we believe",126,"Yes. I mean, listen, I think we're trending towards 60%. If you add Namzaric to it, which I think will be a sales accelerator, we should achieve our target. And in all the research that we've done, if we can provide for formulary coverage, then we believe we're going to be able to move more and more patients either from IR to XR or patients to Namzaric, which is, frankly, a stronger selling proposition than even XR. Fewer pills, fewer administrations, no increase in side effects, better efficacy, and we've made sure that it's economical for health plan and caregivers. And so we've taken a lot of effort and a lot of investment, a lot of energy. But I think we're going to reach the target."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Plus it opens up the donepezil market, which is much bigger than the Memantine market.",15,"Plus it opens up the donepezil market, which is much bigger than the Memantine market."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","That's right.",3,"That's right."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Liav Abraham with Citi.",12,"Our next question comes from the line of Liav Abraham with Citi."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick question on DARPin and your decision to move forward here. 'm just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than",69,"Just a quick question on DARPin and your decision to move forward here. 'm just curious as to what your objective is with the assets. Do you view this as a highly differentiated compound in a wet AMD market that will be even more competitive in 2019 than it is now? Or are you progressing forward with this in order to potentially bring a combination DARPin PDGF to market?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, let me -- I'll start, and let me ask David to comment. And just one backup on LUMIGAN for Marc. I mean, I think in the studies, we're seeing it lasted about 3 to 4 months, something in that range, versus the drops, which compliance and persistence is",341,"Yes, let me -- I'll start, and let me ask David to comment. And just one backup on LUMIGAN for Marc. I mean, I think in the studies, we're seeing it lasted about 3 to 4 months, something in that range, versus the drops, which compliance and persistence is a huge issue and glaucoma. And if you talk to glaucoma specialists, they're dying for an effective treatment that would increase compliance and persistence for a disease that's typically asymptomatic. It's doing a lot of damage to the back of the eye. 
In terms of DARPin, Liav, I think you're right on both tracks. I think the way we're thinking about DARPin is that it should achieve the 3x to 4x a year dosing regimen to make it really a differentiator. Obviously, people don't like getting an injection at the back of the eye. If you look at even EYLEA, they're dosing it more frequently than the label suggests, and so doctors are really looking for something that, and patients probably even more so looking, for something to minimize injection. So we're really trying to design the experiment or the Phase III to hit the 12-week dosing regimen. The other thing I would put out there is remember, we put nothing in our deal model in DARPin, and so outside of the cost of the Phase III study, it's essentially a free call option. And so given where we are, we think after all the modeling and everything we looked at, it was worth going for. But you're right, it's a high hurdle to get there, and to the extent we can, it should provide a very compelling, large opportunity for us in the future, but we've got to get there. I think the second thing it does, it sets us up for dual DARPin, and that could be a very exciting place to be, but it's early. And so we've got a lot of work to do there as well. I don't know, David, if you want to add any color."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Brent, I think you said it. We are very excited by our partnership with Molecular Partners. The DARPin Ankyrin-binding proteins are a novel class of therapeutically active agents. Our lead DARPin has an incredibly high affinity for VEGF, which opens up th",142,"Brent, I think you said it. We are very excited by our partnership with Molecular Partners. The DARPin Ankyrin-binding proteins are a novel class of therapeutically active agents. Our lead DARPin has an incredibly high affinity for VEGF, which opens up the possibility for administration every 12 weeks. We're going to evaluate that in Phase III. And as Brent mentioned, coming along behind it, we have a number of other Ankyrin-binding proteins, other constructs. Those projects are early, so it's too early to talk about those. The dual DARPin is just in preclinical development. It's very exciting. It's a combination of PDGF and VEGF, which should have advantages in AMD, but it's very early. It's still in preclinical development. We need to work our way through and generate more data just to see how exciting that project is really going to be."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","And you feel comfortable with the inflammation at this point?",10,"And you feel comfortable with the inflammation at this point?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","We know that -- I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of Lucentis development. So we're very care",81,"We know that -- I'm sure you do as well, that all VEGF inhibitors cause ocular inflammation. It was kind of interesting for me to see the change in rate of ocular inflammation that was observed during the course of Lucentis development. So we're very carefully watching ocular inflammation as we progress into Phase III. We've got a Data Safety Monitoring Board in place. And we are confident that we are going to -- that we're in control of the situation."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ronny Gal with Bernstein.",12,"Our next question comes from the line of Ronny Gal with Bernstein."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question is for David Nicholson. David, can -- you keep on seeing on ClinicalTrials.gov trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they ex",50,"My question is for David Nicholson. David, can -- you keep on seeing on ClinicalTrials.gov trials that you guys are doing in dry eye. Can you just organize this pipeline for us? What are the various programs? Where are they in development? When do they expect to reach the market?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, so Ronny, it's Brent. I know you wanted David. I'll turn it over to him in a second. But to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think w",120,"Yes, so Ronny, it's Brent. I know you wanted David. I'll turn it over to him in a second. But to be fair, we're not ready to go into great detail on the pipeline. We will do that soon. I will tell you that we have roughly 4 programs in dry eye. We think we have some real interesting ones and ones that maybe perhaps will fall out. We'll go through that over the course of the next month or so. But dry eye is something that we're also very committed to. And we're looking at a variety of external innovations as well as our internal programs, and you'll see us very committed to the space for the long term."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I think, basically, that covers it, Ronny. Obviously, always happy to discuss this with you. As you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclospo",75,"Yes, I mean, I think, basically, that covers it, Ronny. Obviously, always happy to discuss this with you. As you know, we continue to be very excited about Restasis and expanding the Restasis geographies. And we've also got a novel formulation of cyclosporine in early stages of development, which we think could be a real advance over Restasis itself. And as Brent said, we really believe we can maintain our leadership in this franchise, yes."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Okay. And the product which you just discussed submitting before the end of the year, that's Restasis X?",18,"Okay. And the product which you just discussed submitting before the end of the year, that's Restasis X?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I'm not sure of the question, Ronny. Ask again.",12,"Yes, I mean, I'm not sure of the question, Ronny. Ask again."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So the product that you just mentioned, the preservative-free, multi-dose product, is that what used to be called Restatis X?",20,"So the product that you just mentioned, the preservative-free, multi-dose product, is that what used to be called Restatis X?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, yes, I'm sorry. Absolutely not. That is not Restasis X. That's just the preservative-free, which doctors have been asking for.",21,"No, yes, I'm sorry. Absolutely not. That is not Restasis X. That's just the preservative-free, which doctors have been asking for."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, multi-dose formulation.",3,"Yes, multi-dose formulation."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Chris Schott with JPMorgan.",12,"Your next question comes from the line of Chris Schott with JPMorgan."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Great. Can you just talk a little bit about your expectations for the legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses? I guess should we think about this as a double-digit growth bu",130,"Great. Can you just talk a little bit about your expectations for the legacy Allergan products for the remainder of this year, particularly as we had some tougher comps as the year progresses? I guess should we think about this as a double-digit growth business for the remainder of 2015 on a constant currency basis? And if I can just do a quick follow-up to, I think, Jami's question earlier, if shares remain at current valuations, does that change your view at all about a potential separation of your brand and generic franchise as technology? You've got a great generic business, but does valuation play a factor here at all if, again, we're 6 or 9 months away and you're still trading at a fairly low multiple in forward earnings?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I think as you think about the legacy Allergan business, our expectation is the double-digit branded growth in a constant currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We ha",299,"Yes, I mean, I think as you think about the legacy Allergan business, our expectation is the double-digit branded growth in a constant currency basis. I think the -- there's nothing to suggest otherwise. The business has a lot of momentum behind it. We have completely solidified our sales and marketing colleagues around the world with perhaps a few countries as an exception only. The team is absolutely committed. They've been driving lots of growth in the first quarter, and we expect that to continue throughout the year and beyond, and that is part of the firm basis of which we believe we'll have double-digit branded growth along with the North American Forest legacy brands. 
I think to respect to your second question, Chris, in terms of the stock being perhaps at lower levels than we all would expect, I don't think it's a question of selling the generics business. I think it's a question of digesting this integration, helping shareholders understand the value proposition here, the compelling growth opportunity that we've created in growth pharma, the enduring, sustainable bottom line growth, continuing to prove out our aspiration of $25 of EPS in '25 (sic) [ 2017 ], and then showing how the businesses support each other and add additional turbo boosting growth to one another. And so it's still early. We only closed Allergan a few weeks ago, I think 5, 6 weeks ago. And so I think no one wants to have a trigger finger and overreact to 5 weeks of weakness, if you will, in the midst of closing, rebasing your shareholders, having a lot of people sorting through different moving parts. Let's let things settle down, and let us tell our story and prove our points as we continue to execute on all cylinders here."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of Ken Cacciatore with Cowen and Company.",14,"Our next question comes from the line of Ken Cacciatore with Cowen and Company."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Brent, just wanted to flesh out a little bit of your earlier comment for -- of hostile versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together, especially to get you to us",99,"Brent, just wanted to flesh out a little bit of your earlier comment for -- of hostile versus not combined with your discussion about potentially a large deal, and you indicated there's always a lot would have to come together, especially to get you to use your currency. But just wondering if you saw, and this is clearly down the road, a reason to approach a larger player. When would you become more encouraging, I think you used the word hostile, versus remaining passive? Is there any time that you would kind of alter the philosophy that you have?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I mean, you never say never. I just think that doing a hostile deal against a large, going concern, like we've seen in the industry over the last 12 months, is value destroying. We are quite experienced in integrations. We do them quite well. And one",323,"Yes, I mean, you never say never. I just think that doing a hostile deal against a large, going concern, like we've seen in the industry over the last 12 months, is value destroying. We are quite experienced in integrations. We do them quite well. And one of the largest reasons we do them well is because we treat people with dignity and respect. We have information exchange freely, of course, following all the rules and regulations gun jumping, and that allows us to get a jump on things like you saw in this quarter with the integration of Actavis Allergan, but it also shows how you restore momentum by keeping people's morale high, and that is certainly the case for the most part in our combined company. 
I think there are opportunities to do hostile deals. I think you have to do them when you're buying a single product perhaps or just a research program or a file where people aren't the key driver. But in most of these businesses, people are such a large part of the equation. I think going hostile in virtually every instance is a mistake. There could always be an exception to that. I think the second thing is there are other large players that we believe are inefficient that would benefit from our operating model, our management philosophy, the way we approach customers in a more efficient manner. And so over time, there may be some targets that could be surprising to folks, but we have to delever, and we have to maintain our investment-grade rating. And so those are all the factors that go into everything we look at. And obviously, I think by now, we've earned some trust that if there's something opportunistic that creates shareholder value, this isn't a team that sits back and watches it pass us by. We react very quickly and do things in a very creative, but value-creating, way."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question actually is for Tessa, not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in",72,"My question actually is for Tessa, not for Brent today. Tessa, I noticed $525 million in cash flow from operations based on the results today versus $1.3 billion in non-GAAP net income. And I also noticed on the cash flow statement you had $700 million in headwinds from accounts receivable as well as $200 million in inventory. So I just wanted to understand that better, if you had any color on that."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million. About $400 million in receivables change was really largely due to 2 things: one, a change in payment terms with a",148,"Yes. So good question. First, if you add back restructuring and integration charges back into cash flow, you'll get to roughly $800 million. About $400 million in receivables change was really largely due to 2 things: one, a change in payment terms with a couple of customers; and two, with higher sales, obviously, you have higher AR. And then on the inventory side, that was purposefully done to ensure that we don't have any outages in terms of supply. But what you'll find is towards the next couple of quarters sequentially, our cash flow will improve in a manner such that by 2016, we will be at roughly $8 billion of cash flow. So there's a couple of puts and takes in Q1 that are, I would say, abnormal in nature largely due to restructuring, but you will see that improve sequentially through the next couple of quarters."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Michael Faerm with Wells Fargo.",13,"Your next question comes from the line of Michael Faerm with Wells Fargo."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","My question is on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?",31,"My question is on Eluxadoline. Do you have a specific PDUFA date for that? And what sort of a time frame are you anticipating for launch along for the DEA scheduling?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, maybe I'll turn it to David. Do you want to...",11,"Yes, maybe I'll turn it to David. Do you want to..."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So as I've said, we've got an upcoming PDUFA date for Eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the div",93,"Yes. So as I've said, we've got an upcoming PDUFA date for Eluxadoline. We're in the middle of labeling discussions at the moment with the agency for this potential product. Labeling discussions are going well. Once we have finalized approval from the division, then the scheduling goes to the DEA for finalization. The timeline for scheduling is -- it varies from company to company. So it's not possible for us to say when we'll get the scheduling -- the finalized schedule decision. The PDUFA date, as I mentioned earlier, is in second quarter."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would just add that our current model has us launching likely at the end of this calendar year but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinkin",51,"I would just add that our current model has us launching likely at the end of this calendar year but most likely in the first quarter of next year. And so that's how we've been anticipating it, and we think that that's still a very accurate way of thinking about it."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Risinger with Morgan Stanley.",13,"Your next question comes from the line of David Risinger with Morgan Stanley."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth for target in some detail? Could you define that, the timing, what it includes, what it excludes, just so we have a better sense for how you're thinking about tha",48,"Yes. My question is for Brent. Brent, could you just explain your 10% branded revenue growth for target in some detail? Could you define that, the timing, what it includes, what it excludes, just so we have a better sense for how you're thinking about that 10% goal?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces",166,"Yes. So the 10% branded growth is a long-term goal. We expect that over our planning period, which is a few years, that our branded business will achieve 10% growth on the top line into the future or better. Obviously, currency is one of the moving pieces to that, and I think if you look at it in constant currency -- and it's hard to hold management out in the field and in the countries accountable for currency. Obviously, you can hold us accountable for it here at the center, but not a lot we can do about it. That -- we see that growth. When you look at how we've kind of baselined it, it's really starting in this quarter with generic IR, then everything else is in. And so that's how we think about it as a CAGR on a go-forward basis. And we expect that as we look at it, we should do better than 10% branded revenue growth throughout our planning period."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Got it. So that excludes the impact of IR?",9,"Got it. So that excludes the impact of IR?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","It excludes currency and IR. That would be the only 2 exclusions that I'm aware of. And of course -- yes, we did have respiratory, Doryx, Pharmatech, Australia, we've had some divestitures. We re-baselined it against those divestitures as well.",40,"It excludes currency and IR. That would be the only 2 exclusions that I'm aware of. And of course -- yes, we did have respiratory, Doryx, Pharmatech, Australia, we've had some divestitures. We re-baselined it against those divestitures as well."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Louise Chen with Guggenheim.",12,"Your next question comes from the line of Louise Chen with Guggenheim."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So just a more macro question here. Curious how you think about brand and generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here.",37,"So just a more macro question here. Curious how you think about brand and generic drug pricing, given that there have been concerns that it may not be as favorable going forward. Just curious your thoughts here."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So let me tackle generic pricing. Maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products th",114,"Yes. So let me tackle generic pricing. Maybe Paul will want to weigh in as well since he has a deep history here. We haven't seen much of a change despite all the fanfare and publicity around drug pricing in generics. There are obviously a few products that go up, but the model for generics is price decreases as more competitors come into the market. That's just the way the business works. And overall, we still model a mid-single-digit price decrease in our business. That being said, the environment has remained pretty stable and favorable. So we don't expect that to change short term either. I don't know, Paul, if you have other thoughts."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that pr",68,"I think the only thing I would say is our pipeline and product line give us a bit of an advantage because of the uniqueness of it. It allows us to be somewhat insulated from the general reduction of prices. As you know, we work very hard to create that product line, and we're obviously taking advantage of the situation as they present -- as situations present themselves."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob, anything you'd want to add?",6,"Bob, anything you'd want to add?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","No, I think that exactly covers it.",7,"No, I think that exactly covers it."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Okay. In terms of the branded side, again, I think our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associ",75,"Okay. In terms of the branded side, again, I think our goal over the medium and long term is to continue to climb the innovation curve with novel drugs like Eluxadoline or Esmya or relamorelin, where we believe we can continue to command the prices associated with the innovation. But in the short term, when you look at our current price portfolio, we're reasonably well positioned. And Bill, do you want to expand on that?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I don't think when we look at our sales expectations over the next several years, we're overly dependent on price as a driver. A lot of the growth trends that you're seeing are volume-based. I would also point out that generally speaking, our pricing",132,"Yes, I don't think when we look at our sales expectations over the next several years, we're overly dependent on price as a driver. A lot of the growth trends that you're seeing are volume-based. I would also point out that generally speaking, our pricing strategy is tied to our IP, and most of the assets that we have on the market right now have long exclusivity periods. And so our primary objective, generally speaking, in a market is market share. And as it relates to price increases, we're very realistic about what they can look like. We're predictable and reasonable, and I think payers know that. I think that's the right way to be over the next several years, and I don't anticipate any surprises to our plan because of price."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And I would add, Philippe, you want to make a comment about aesthetics?",13,"And I would add, Philippe, you want to make a comment about aesthetics?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. On the cash base side, we have increased our price by 3% this year, and we can see double-digit growth -- strong double-digit growth in our business. So we're pretty confident about the future of this business.",38,"Yes. On the cash base side, we have increased our price by 3% this year, and we can see double-digit growth -- strong double-digit growth in our business. So we're pretty confident about the future of this business."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our next question comes from the line of David Amsellem with Piper Jaffray.",13,"Our next question comes from the line of David Amsellem with Piper Jaffray."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","So I want to stay on the bolt-on M&A. I wanted to ask about the generics business. And is the addition of additional businesses, either x U.S. or small businesses in the U.S. a priority? And also maybe talk about what kind of formulations and dosage forms",61,"So I want to stay on the bolt-on M&A. I wanted to ask about the generics business. And is the addition of additional businesses, either x U.S. or small businesses in the U.S. a priority? And also maybe talk about what kind of formulations and dosage forms might be a high priority in terms of bolstering the business by M&A."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, I'll turn it over to Bob Stewart to comment on that.",12,"Yes, I'll turn it over to Bob Stewart to comment on that."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the",225,"Yes, David, looking at our business, I'm pretty comfortable that we've got pretty much all the technology platforms that we need. When you look at what Forest brought to us as well as what Allergan brings to us in terms of technology base, we have now the full range of dosage forms that we need to be able to compete globally. We'll always look at opportunistic M&A in the U.S. I think we've got the scale that we need. I don't necessarily think that another acquisition in the U.S. is really going to give us anything because I think, again, we've got the size of the portfolio, we've got a best-in-class commercial team. Perhaps maybe looking at some portfolios of products in injectables and things like that, that would be the only thing I would see that would be of interest in the U.S. Outside the U.S., we're always looking at different geographies that -- where we're already strong. You saw us do it with Auden Mckenzie in the U.K. We may look in certain markets that -- where there might be some tuck-in type acquisitions to just increase our overall strength there, more portfolio based, more small company type of transactions. But outside of that, I don't necessarily think that we need a large-scale transaction within the generics business to remain viable or competitive."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","I would say best in class.",6,"I would say best in class."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",14,"Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Just a quick one on methylphenidate. I think you said your guidance reflects current market conditions, but share has been ramping. Obviously, we're going to get an update here imminently. We don't know what the 2 other competitors are going to do, and th",84,"Just a quick one on methylphenidate. I think you said your guidance reflects current market conditions, but share has been ramping. Obviously, we're going to get an update here imminently. We don't know what the 2 other competitors are going to do, and there's obviously a very good case for you where they leave the market, and that leaves you with some pricing opportunity as well. So if you could maybe just comment on how you're thinking about that situation, that would be great."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Bob?",1,"Bob?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. So Randall, I guess the way we've guided is exactly how you illustrated it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at t",125,"Yes. So Randall, I guess the way we've guided is exactly how you illustrated it there. So we are modeling it as if both the manufacturers remain in the marketplace and that we continue to hold on to or maybe slightly tick up in share from where we're at today. But we see both competitors in the BX kind of situation. Now obviously, if FDA does take action and/or if the manufacturers or further the retailers do the responsible thing by continuing -- by not dispensing the BX product, that would provide upside to us, both in terms of volume as well as just overall, I guess, stability within the marketplace. So we would see that as an upside compared to what we have guided."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we could supply.",4,"And we could supply."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that -- the competitors do come out of the marketplace, that we would be able to ensure th",54,"And we have 100% of the volume, and we've notified FDA of that, that we have 100% of the volume or inventory needed to supply the marketplace. So in the event that, that -- the competitors do come out of the marketplace, that we would be able to ensure that all customers are served."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Our last question comes from the line of David Maris with BMO Capital Markets.",14,"Our last question comes from the line of David Maris with BMO Capital Markets."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Analysts","Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you -- or potentially coming together, is that something you",145,"Wanted to talk to you a little bit about distractions, so both in the generics and then the aesthetics business. When you see 2 of your major competitors coming together, is that something that you -- or potentially coming together, is that something you spend a lot of time wringing your hands about? Or do you see that as something you're pretty happy about that maybe 2 competitors will be distracted for a year or 2 and -- in an integration? Is that more of an opportunity? 
And separately, in aesthetics, we've heard from a number of cosmetics derms that they've seen several of your peers being distracted lately, but they've seen no change in their Allergan sales coverage. So what have you done to minimize the disruption to customers? And how do you think you've done holding on to share during this transition period?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should cre",253,"Yes, great questions, David. Thanks. I think as you think about the generic industry right now, I kind of alluded to this earlier. Having 2 out of your 3 major competitors kind of tied up in knots, fighting each other in a hostile way certainly should create some opportunity for us. It certainly doesn't distract us. It keeps us laser focused on our competitors. And just anecdotally, I'll give you one example. I was down at the NACDS with Paul and Bob Stewart and our branded colleagues, and our other competitors were either there in a very light presence or not at all because they were on the road trying to convince shareholders that their plan or their defense was on track. And so you can already see them despite what they say, saying it doesn't impact them -- impacting them, and so hopefully, we're already in the pole position with respect to R&D, but this will hopefully continue to allow us to continue to be in a pole position with respect to customer service. On the aesthetics side, maybe Philippe will chime in, and Paul perhaps internationally. I think our goal was to really do no harm, right? And so we approach this integration very, very carefully in that there was really no change to the facial aesthetics teams around the world or virtually no change around the world with the key focus on maintaining customer focus and connectivity in the U.S. and key international markets. Philippe, anything you'd add to that?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and VOLUMA. VOLUMA is becoming the #1 filler. It has grown 30% during the first quarter. And despite Galderma, that is -- whi",62,"Listen, we're growing by 13% during Q1. We are investing heavily in direct-to-consumer advertising. You've seen that behind Botox and VOLUMA. VOLUMA is becoming the #1 filler. It has grown 30% during the first quarter. And despite Galderma, that is -- which is stronger than Valeant, we're still getting market share. So overall, I'm very confident and very positive about that business."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Yes. And Paul Navarre, who runs International brands, would you want to chime in?",14,"Yes. And Paul Navarre, who runs International brands, would you want to chime in?"
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent, the sales force were actually not affected by the integrations. So we maintained exactly the same level of service with customers.",39,"So very briefly, Q1 for medical specific was great. We grew by 15.9%. And as you say, Brent, the sales force were actually not affected by the integrations. So we maintained exactly the same level of service with customers."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely. And so that's why, again, I underscore in most",173,"Just to conclude, you couldn't do that if this was a hostile deal. These sales reps would have been taken out by competitors. They would have been -- the marketing teams would have been distracted immensely. And so that's why, again, I underscore in most situations, hostile deals are value-destroying, and you have to look to do things on a friendly basis, obviously, with a few exceptions to that rule.
Yes, thank you, David. So I think that was our last question. I would just again close with saying that this team has continued to take bold and decisive action to create value. We are absolutely well on our way to achieving our key aspirations of double-digit branded growth, $8 billion of free cash flow in '16 and remain committed to our aspirational target of $25 per share in 2017. We thank you for joining us today and taking the time to go through a quarter with lots of moving parts, and we look forward to simpler quarters in the future. Thank you."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Executives","Thanks, everybody.",2,"Thanks, everybody."
36478,291601714,810904,"Actavis plc, Q1 2015 Earnings Call, May 11, 2015",2015-05-11,"Earnings Calls","Allergan plc","Operator","Thank you. This concludes today's conference call. You may now disconnect.",11,"Thank you. This concludes today's conference call. You may now disconnect."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Holly, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] I'll now turn the conference over to Lisa DeFran",50,"Good morning. My name is Holly, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] I'll now turn the conference over to Lisa DeFrancesco, Vice President, Global Investor Relations. Please go ahead."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015",346,"Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.
Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Allergan and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements that reflects our current perspective of the business trends and information as of today's date.
Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Allergan business. These factors are detailed in our public periodic filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements except as expressly required by law.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our second quarter business highlights; Tessa Hilado, our Chief Financial Officer, will the then discuss the Allergan second quarter results in more detail; and David Nicholson, Executive Vice President and President of Global Brands and R&D, will provide an update on our brand's R&D progress in the quarter and upcoming development milestones. 
Also on the call are available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of the environment; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I will turn the call over to Brent."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we have last quarter. This was also our first full quarter of a combined operations following th",1364,"Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we have last quarter. This was also our first full quarter of a combined operations following the close of the Allergan acquisition on March 17. And I'm very proud of what our team has accomplished, especially the momentum they have created to propel our future growth.
Turning to Slide 5. Allergan's second quarter performance highlights our ability to execute on our 4 pillars of our long-term growth strategy. First, operational excellence is yielding exceptional financial performance and result in all key business segments, key products and key geographies. Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive innovative R&D engine has produced more than 100 branded product approvals globally and 56 branded regulatory submissions year-to-date. And fourth, and forth, we're executing on strategic business deals to support our growth in the therapy areas and charge-off our pipeline for the future.
We also changed our name to Allergan in the quarter to symbolize our transformation into a leader in growth pharma or brands now contribute more than 2/3 of our company's revenues. Whereas our focus in growth pharma, we are encouraging our employees around the world to be bold and smart in the way we think and act. 
Turning to Slide 6. The announcement of our plans to combine our Global Generics business with Teva in a $40.5 billion deal is the latest bold move by our company to continue our transformation towards being a leader in branded Growth Pharma. For years, we've been lessening up the innovation curve towards especially pharma products. This agreement clearly our transformation. This deal allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapy areas and reload our capital structure to continue our transformation. There are certainly more to come on this story.
We are confident that we're creating the most dynamic company in growth pharma, while adding our impressive generic commercial, generic R&D and operating capabilities to Teva. 
Now let's turn to Slide 7 and talk about the business performance in the second quarter.
Our second quarter revenue more than doubled on a year-over-year basis to $5.7 billion as a result of the acquisitions of Allergan and Forest. On a pro forma basis, sales were up 12%, excluding the impact of foreign currency, Namenda IR and divestitures, with double the growth in Brand and Global Generics segments. The strong sales increase introduced from the integration of Allergan and Forest were the primary drivers of the 29% increase in earnings per share to $4.41. 
Meanwhile, non-GAAP EBITDA rose to $2.6 billion and cash flow from operations was about $1.7 billion, excluding one-time cash payments for severance, acquisitions and integration. Tessa will talk more about the financials shortly.
On Slide 8. Our Global Generics business is doing very well and the units that comprise it are firing at all cylinders as we prepare for the combination with Teva. Generics sales are up 17%, excluding the impact of foreign currency. Generic profitability is up and our exceptional generic R&D capabilities are evident, with 12 new first-to-file drugs this year. This brings the total number of ANDAs under review to approximately 220 with 76 confirmed first-to-files.
U.S. Generics revenues were $1.1 billion in the quarter and continue to benefit from new product introductions and contribution from high barrier and semiexclusive products like generic Concerta. Meanwhile, our International Generics team continues to drive excellent performance in key markets, excluding the impact of foreign currency such as the U.K., which was up 85%, including the effect of the Auden Mckenzie transaction that closed in May, and Russia, which was up 32%.
Turning to Slide 9. Our brand business continues to thrive impressive performance with 12 of the top 15 Global Brands growing, many with double-digit pro forma year-over-year growth. Sales increased 11%, excluding Namenda IR, the divestitures and the impact of foreign exchange. And the success is broad-based, excluding the impact of foreign currency, we drove double-digit growth in eye care, GI and key woman health products and cardiovascular. Double-digit growth from our latest largest leading brands like Botox, Restasis, Namenda XR and our Fillers, including Juvederm. Double-digit growth from well-established brands like Bystolic, LoLoestrin and Estrace and double-digit growth from Linzess, Aciphex and other large brands, which puts us in excellent position to our growth will into the future.
It is a terrific lineup of brands with long exclusivity and is backed by a great team on the ground and our leading pipeline with multiple shops in each of our 7 priority therapeutic areas.
Turning to Slide 10. We continue to drive conversion of patients to Namenda XR right up to the end of the Namenda IR exclusivity, reaching about 53% before generic entry. With continued promotion and the launch of Namzaric, we believe the penetration rate goes even higher, towards our target of 60%, 65% as the year progresses. And with once a day dosing, formulary access at every 1 of the top 8 plans and focused sales team, we maintain relatively stable volumes on Namenda XR even as the Namenda IR prescriptions dropped.
We are now doing the blocking and tackling to build the demand and access for Namzaric. With full promotion just getting underway, our DTC campaign beginning in September and an anticipated 7 out of the top 10 plans having coverage by the beginning of 2016, we think we are well-prepared to drive market expansion in 2016. 
Given the broad use of combination to therapy, the efficacy of Namzaric and the patient caregiver and system benefits of 1 pill, once a day, we think there's a great opportunity for the innovation of Namzaric to become the cornerstone of once a day branded market in Alzheimer's treatment.
Turning to Slide 11. In a few moments, David will give an update on the pipeline, but I want to point out that our pipeline remains one of the best kept secrets of our company. With 70 projects in mid to late development, we are in an enviable position of having multiple programs in each of our therapeutic areas to help a sustain leadership in the areas we chose to compete. And we built this pipeline step-by-step, not by investing big dollars on discovery, but by investing in smart development projects.
Even with ESN breadth and depth of our current pipeline, we're always on the look out for R&D assets that can extend our leadership by bringing novel approaches to existing therapy areas. And then last 2 months alone, we've announced agreements for 4 planned acquisitions in Aesthetics, eye care and CNS, each will bring novelty to existing areas and will add to our ability to lead in these therapeutic areas. And each of these deals to bring games and their potential ideas to our pipeline.
ABL is off to to a strong start in aesthetics, with sales already surpassing $1 million and a recent approval in Canada. We are making great progress towards closing the transaction mode that we've cleared antitrust review in the U.S. And as announced yesterday, we no longer intend to issue our shares to complete this acquisition. The Oculeve acquisition has also cleared HSR in the U.S. and we'll work toward extending our try opportunities with our novel nasal neurostimulation device. 
In CNS, we're working to close deals to extend our migraine offering with Merck's first in oral -- first-in-class oral CGRP antagonist and the Naurex novel approach to treating new disorders including severe depression, which remains aleading cause of suicidal.
In closing, our team continues to focus on execution and the results indicate that we are exceptionally skilled at delivering strong operating results, while also doing surprising things that make our company the most dynamic in all of health care.
I'm so proud of our team for their performance and I'm looking forward to what we can do with the strength and focus on branded pharmaceuticals and a significantly reduced operating structure and reloaded capital structure. 
With that, I'll now turn the call over to Tessa."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter in Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second q",941,"Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter in Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second quarter was $5.7 billion, an increase of 36% versus Q1 2015. 
Non-GAAP R&D investment for the quarter was $406 million compared to $185 million in the prior year period. Non-GAAP SG&A as a percentage of revenue was 21.7%, an increase of 3 percentage points over the prior year quarter, as a result of the Forest branded products and business, which we have higher SG&A spend.
Adjusted EBITDA for the quarter was $2.6 billion, an increase of 203% versus the prior year, driven by strong revenues and higher gross margins across our segments. Non-GAAP earnings per diluted share for the quarter increased 29% to $4.41 compared to $3.42 per diluted share in the second quarter of 2014.
Our non-GAAP tax rate improved from 17.1% in the year-ago period to 14.5% in the current-year quarter, mainly due to the geographic mix of our businesses. Cash flow from operations for the second quarter was $1.4 billion, an increase of 198% versus the year-ago quarter. Excluding acquisition-related restructuring and integration payments, our second quarter free cash flow would be $1.7 billion.
Before turning to our business segment results, I would like to take a moment to review our new segment reporting for the second quarter. In this quarter, we are reporting results in 5 segments. The U.S. brand segment represents sales and expenses related to branded products within the United States, including Botox therapeutics. 
The U.S. Medical Aesthetics segment represents sales and expenses related to aesthetics and dermatology products within the United States, including Botox cosmetics. The International Brands segment represents revenues and operating expenses in countries that have the majority of their businesses represented by branded sales and revenues and expenses related to product sales in Canada, Switzerland and Austria. 
The Global Generics segment represents revenues in operating expenses in countries that have the majority of their business represented by generic product sales, a third-party Medis business and revenues and expenses related to product sales in the U.S., Canada, Switzerland and Austria. 
The Anda distribution segment results represents sales and expenses related to distribution of generic and brand pharmaceutical products manufactured by third parties. Also, as a result of Teva's acquisition of Allergan's generic business, Allergan will report its generics business as discontinued operations beginning in the third quarter of 2015. Since the divested business spans both Global Generics and international brand segments, it will be difficult today to model the remaining Allergan business. We will provide some guidance in September.
Turning now to our U.S. brand results on Slide 15. The business has strong performance year-over-year and quarter-over-quarter. U.S. brands revenue was $2.44 billion for the quarter, up 331% versus the prior year period and 35% in the prior quarter, driven by the addition of the Forest and Allergan businesses and strong growth across key products, including Linzess and Namenda XR.
Adjusted gross margin within the U.S. brands remains steady at 87.4%. SG&A as a percentage of revenue increased to 20.8% versus 17.8% in the year-ago quarter, driven by expenses related to the Forest and Allergan acquisitions.
Turning to Slide 16 in our U.S. Medical Aesthetics business. The second quarter revenues were $487 million, an increase of 510% versus first quarter 2015 results. Second quarter gross margin of 93% and segment margin of 70.6% were largely in line with expectations. SG&A in the quarter remains steady. 
Turning to Slide 17 in our International Brands results. Second quarter revenues were $717 million versus $169 million in the prior year period, an increase of 324%. Gross margins increased 21.7 percentage points to 77.8% in the second quarter, due largely to the inclusion of higher margin legacy Allergan products. 
Segment SG&A improved 7.2 percentage points to 32% versus Q1 2015 due largely to synergy capture related to the Allergan acquisition.
On Slide 18, Global Generics revenues in the quarter were $1.6 billion, up 10% versus the prior year period. Growth was driven by strong sales in the base business, including generic Concerta, offset in part additional competition on certain products, including generic Lidoderm. Adjusted gross margins increased 1 percentage points compared to the year-ago quarter due to continued strong performance within our international business.
Lower gross margin versus the prior year quarter was mainly due to lower contribution of ER and oxycodone in the second quarter the first quarter of 2015. SG&A as a percentage of adjusted net revenue decreased slightly to 15% from 15.8% in the year-ago quarter.
Turning to our Anda business on Slide 19. Revenues increased $462 million, up from $427 million in the prior year, an increase of 8%, driven by trends in our base business and a higher mix of chain drugstore sales. 
Slide 20 details our debt capitalization following the completion of our first full quarter following the close of the Allergan acquisition. We ended the second quarter 2015 with total debt of approximately $42.9 billion and equity of $72.1 billion related to the Allergan acquisition and previous financing. In the second quarter, we paid down approximately $1.4 billion of our debt. Currently, our leverage ratio stands at 3.9x debt to pro forma adjusted EBITDA versus 4.1x in the prior quarter. We remain committed to using strong free cash flows from our business segments to accelerate debt repayment, and we continue to remain committed to investment-grade ratings.
I'd now like to turn the call over to David Nicholson, who will provide an update on our brand's R&D progress in the quarter. David?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our brand's R&D team continues to be tremendously productive. Year-to-date, worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approvals",1253,"Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our brand's R&D team continues to be tremendously productive. Year-to-date, worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approvals and 56 regulatory submissions. 
I will highlight some of the most significant of this in my overview. Following the first round of integration prioritization, we now have more than 7 the mid- to late-stage development projects, with approximately 45 projects in either late-stage development or registration. The productivity of the legacy Allergan R&D organizations is demonstrated by the industry-leading figure of 14 MME approval in the United States over the last 6.5 years. Going forward, we'll continue to make data-driven prioritization positions in all of our programs.
In addition to rationalizing and driving productivity from our existing pipeline, we are committed to identifying and executing acquisitions and licensing agreements that further strengthen our long-term leadership position in key therapeutic areas. This is exemplified by ap ending acquisitions of Kythera, Oculeve and Naurex and licensing of Merck's oral CGRP programs during the quarter. 
The next 2 slides summarize some highlights and describe the progress in our late-stage pipeline. Slide 23 shows late-stage game-changing opportunities across our therapeutic areas. 
In aesthetics, we are adding ABLF from to our pipeline. Our aesthetics pipeline already includes by for hair growth, and so for acne, as well as many line extensions to our dealers. 
In eye care, we are adding the intranasal dry eye device from Oculeve to our dry eye franchise, further enhancing our leading position in our therapeutic area. My colleagues and I have reviewed our restated data and again, find our efficacy and tolerability data very compelling in comparison to the recently published data from other compounds in development and registration. 
In Phase III, we are developing dark and have a sustained-release formulation of bimatoprost. 
In CNS, we are adding generics, an modulator to our pipeline. These compounds of the first novel mechanism for mood disorders for more than 2 decades. We're also adding oral CGRP antagonist. These compounds in-license from Merck are designed both for the acute treatment as well as for the prophylaxis of migraine. We also have Cariprazine in development and Namzaric, which combines 2 complementary therapeutic agents, Namenda and Aricept. 
Recently, much attention has turned to prevention of Alzheimer's and like all of us, I had hoped that effective preventive therapy will be discovered. Namzaric was recently presented in the 2015 Alzheimer's Association International Conference. The efficacy of Namzaric in patients with Alzheimer's is least similar magnitude to that reported with the present preventative agents in development. 
In GI disorders, together with our partner [ph], we continue to develop dosage and formulations of our IBS and the to offer a very complete package to physician and patients. Also, we complete the deal initial development of Alex and by YSP. 
In Urology, together with our partner Serenity, we have intranasal completing Phase III from Nocturia. 
In our anti-infectives franchise, we continue to develop and AVYCAZ. In biologics, Phase III will be completed this year for bevacizumab, a biosimilar of of Avastin, which is part of our partnership with Amgen.
Last, but certainly not least, is Botox. We continue to further develop and launch these agents across our Aesthetics, C&S and Urology franchises. 
Turning to Slide 24, I'm going to update you on progress with regulatory authorities to key late-stage products.
In Aesthetics, naturally inspirer, tested breast implants received FDA approval for women undergoing breast reconstruction, augmentation or revision surgery, and we are on track for FDA submission of our Filler in the third quarter 2015. Yesterday, we received FDA approval to market 28 additional styles of NATRELLE 410 breast implants. 
In Asia, we received licensing rights for commercial sales of Juvederm in China and submitted an NDA to Botox [indiscernible] in Japan. In eye care, Botox received approval in Japan for the treatment of strabismus. We're on track for FDA submission as a multi-dose preservative-free formulations of Restasis in September. We've currently enrolling patients in Phase III trials for bimatoprost in the U.S., and we've initiated pivotal Phase III trials of our lead Darphin in age-related macular degeneration on target in June this year. 
In CNS, we have a PDUFA date in September for Cariprazine as a treatment for schizophrenia and bipolar mania. In this quarter, we launched Namzaric and we'll be filing additional dose combinations of this agent later this year.
In GI, our strong pipeline does continue to develop new opportunities. We expect to complete the Phase III study for a low-dosage form of Linzess to treat chronic idiopathic constipation in the second half of the year, and we expect to submit an sNDA for this indication next year. 
Meanwhile, has been approved by the FDA as a twice-daily oral treatment for IBSD. We're awaiting DEA scheduling of prior to  launch of this product in the United States, and we submitted the dosage eluxadoline in Europe in May.
In women's health, enrollment in our Phase III trial of Esmya for the treatment of bleeding disorders caused by uterine fibroids is on track. We're committed to completing trial enrollment this year.
In Urology, we completed our Phase III trials of SER 120 in Nocturia. The date is on our review prior submission to the agency. In anti-infectives, our development of a single-dose formulation of Dalvance remains on track. We've made regulatory submissions for approval in both the United States in Europe. We're also anticipating approval for Teflaro in bacteremia during the course of this year.
On Slide 25, we outlined some of our most recent business development opportunities. Obviously, these this helps us to further solidify our leadership position in our core therapeutic areas. 
With Kythera, we add a first-in-class agent, Kybella, for the treatment of submental fat or double chin to our product line. The product is launched in the States and was recently approved in Canada. 
In addition, Kythera has an interesting and genetically validated here growth problem in early development. Oculeve will strengthen our leading position in dry eye, with the ODO 1 development program, an intranasal neurostimulation device that increases tear production in patients with dry eye. 
Our licensing agreement with Merck built in our commitment to the development of treatment to migraine. We're adding oral formulations of CGRP antagonist of our product line. The use of both small molecules as well as antibodies has clearly shown that CGRP antagonism is effective in treating migraine. 
There are 4 injectable antibodies in development whilst, we will have the only oral CGRP antagonist. 
Finally, Naurex. The acquisition of NRx add innovative development programs in depression to our pipeline. Depression is an area of medicine that has seen minimal progress for the last 20 years. The Naurex compounds are MMDA modulators, a unique approach to the treatment of depression. These agents have the potential to be fast onset antidepressant and hence, may be beneficial in the alleviation of suicidality, which is so often a terrible feature of this disorder. 
In early-stage development, the Naurex team showed their compound in [indiscernible] and also to be effective in treating depression, which fail to respond to traditional antidepressants.
In closing, the second quarter of 2015 was another period of continuous strong productivity for the Allergan R&D team. We look forward to continue to deliver on the promise of many of our development programs in our pipeline for the remainder of 2015 and beyond. With that, I'd like to turn it over to brand for closing remarks.
Brand?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you've heard, we'd have a lot going on a look forward to giving updates on our browsers over the next few months. In mid to late September, we will provide updated guidance for continuing operations for the remainder of 2015. This wil",124,"Thank you, David. As you've heard, we'd have a lot going on a look forward to giving updates on our browsers over the next few months. In mid to late September, we will provide updated guidance for continuing operations for the remainder of 2015. This will reflect our Global Generics business as discontinued operations as we wait for the close of the transaction with Teva next year.
In conjunction with our third quarter earnings result, we also plan to host an R&D update meeting on November 4 in Irvine, California at our campus. It will be our opportunity for R&D team to sign a spotlight on the post prioritization R&D portfolio.
With that, I'd like to turn the call back to Lisa for Q&A."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, brands. We'll now take questions. [Operator Instructions]",9,"Thank you, brands. We'll now take questions. [Operator Instructions]"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question will come from that line of Chris Schott with JPMorgan.",15,"[Operator Instructions] Your first question will come from that line of Chris Schott with JPMorgan."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","One of the question we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the Te",99,"One of the question we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the Teva deal closes if the right transaction are available, I guess both from an operational and financial standpoint? And just a very quick second one, on that guidance in September, is that just 2015 or could we think about the preliminary view or either '16 or update on the $25 2017 outlook at that time as well?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, thanks, Chris. With respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible pr",184,"Yes, thanks, Chris. With respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible prior to that and we have always been bold in thinking about how to execute things if the timing was right. But I think in fairness, given to our commitment to our investment-grade rating our ability to the play cash after the deal is closed versus prior or perhaps, our flexibility to deploy cash after the deal closes is better than prior. I think that's probably how you should think about it. Now that doesn't mean he couldn't engage in analysis or discussions or other things like that with someone who is interested in doing a deal with us or we were interested in doing a deal with them. But I would say that it's most likely after the close of the Teva transaction. With respect to the guidance, maybe I'll ask Tessa to talk about that for a second."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so in September, what we will be providing you is what the remaining business we look like since Teva will be discontinued operations. That's not exactly a very easy separation to do and also just to manage expectations, so we provide that given the",117,"Yes, so in September, what we will be providing you is what the remaining business we look like since Teva will be discontinued operations. That's not exactly a very easy separation to do and also just to manage expectations, so we provide that given the account growth, it will be very difficult at this point in time for you to model what the remaining 2015 will look like. As an example, for instance, depth will continue to remain with the Allergan branded business and not go to discontinued operations. There's no such thing as non-GAAP discontinued operations. So we'll provide a little bit more clarity come September, but it's really largely focused on the remainder of 2015."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Jamie Rubin with Goldman Sachs.",14,"Your next question will come from the line of Jamie Rubin with Goldman Sachs."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just a follow-up on that earlier question, Brent or Tessa. So when you give continued or rather when you give pro forma earnings going forward, which presumably only includes the branded business. Will that branded business also include all the interest e",154,"Just a follow-up on that earlier question, Brent or Tessa. So when you give continued or rather when you give pro forma earnings going forward, which presumably only includes the branded business. Will that branded business also include all the interest expense that you're carrying in your books? In other words, I would assume that some of that $40.5 billion is going to reduce debt. So how do we think about that when we think about the base business going forward? And then secondly, just to follow up on that $25 number, that $25 obviously includes about $5 or $2.4 billion in EBIT from the generic business. Brent, at what point can we expect you to update us on that guidance? And I think the last call you didn't withdraw that $25. So any, again, any color on how we should think about the company's ability to replace that $2.4 billion in EBIT?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So Tessa, you want to take the first one?",9,"So Tessa, you want to take the first one?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","You definitely touched on some of the nuances related to discontinued operations as it pertains to that as an example, for instance. So on a go-forward basis, in the September earnings what you will see is that, debt will reside in the remaining company a",135,"You definitely touched on some of the nuances related to discontinued operations as it pertains to that as an example, for instance. So on a go-forward basis, in the September earnings what you will see is that, debt will reside in the remaining company and not a look at it though discontinued ops. Obviously, as you think about that on a go-forward basis, it would really largely depend on what we do with the capital on a go-forward basis. What we have been indicated in our coin related whatever that we would use a portion of the proceeds to pay down debt. But again, it's largely dependent on how much we use for capital deployment. Having said that, though, we are committed to our investment-grade ratings we will ensure that the debt is paid down."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think the net-net, Jamie, on guidance and now this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually closed the transaction that will be very",273,"Yes, I think the net-net, Jamie, on guidance and now this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually closed the transaction that will be very difficult for you guys to run models and do clean comparisons. We are, as always, committed to as much transparency around product sales like we were in this press release and we will do the best we can given their rules that we have to I'll leave with. But it will make for some tough modeling work on your guys part over the next 2 or 3 quarters. And we apologize in advance for that and we'll do everything we can to help facilitate that. With respect to the $25 aspiration, what I said I think in -- I think you asked this question on the deal call if I recall correctly, Jamie, is that we actually remain steadfast in our aspiration to increase our earnings per share to as high as possible, including the $25 target. What has change obviously, is by selling the generics business and the $2.4 billion of EBITDA to Teva, the timing of that aspiration. And so we need to continue to look at how we will deploy the capital and how the timing of the deployment of that capital will pull-through to give a more precise view of it. So again, we're not withdrawing the $25 but we will come back and have to add some variables to it like capital deployment and timing of capital deployment to get there."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Liav Abraham from Citi.",13,"Your next question will come from the line of Liav Abraham from Citi."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, another question on the topic of business development. I want to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in potentially transformational transaction and interested in moving up the",126,"Brent, another question on the topic of business development. I want to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in potentially transformational transaction and interested in moving up the value chain. You've also said you're not necessarily in favor of early-stage research. I'm trying to reconcile these comments or can you engage in a larger pharma transaction and move up the value chain without a greater commitment to early-stage research going forward? And this necessary to at least in certain extent secure longer-term organic growth? And then very quickly for a deal, can you comment on how much you will be giving away increment that in terms riveting order to secure formula one status for Namzaric next year?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure, I think the answer to the first part of your question is yes, with an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or something th",191,"Sure, I think the answer to the first part of your question is yes, with an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or something that isn't widely available in external research like venture backed companies or researcher academia that's companies or smaller biotechs. And so I think if you look at the what David and his team did with Allergan, we kept the research capabilities where they had unique strength and proven track records like in Aesthetics and Eye Care. And we have -- and we will continue to fund that as appropriate. What we won't to do is waste our money on R&D that is widely available elsewhere. And so I think have to really consider us as very practical when it comes to research basic research. But also virtual as to a company when it comes to research as demonstrated by some of the deals we just did like Naurex and even the licensing of the oral CGRPs from Merck. David, any comments on research?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Look, one of the question I would like to make is how impressed I am with the biotech industry these days. And I've seen the biotech industry today with founded by so many brilliant academic scientists, coupled with more and more people with pharmaceutica",115,"Look, one of the question I would like to make is how impressed I am with the biotech industry these days. And I've seen the biotech industry today with founded by so many brilliant academic scientists, coupled with more and more people with pharmaceutical executive experience, excellent in generating early-stage molecules, which we can pick up and further developed through to the market. There are plenty of opportunities out there. Also, when you look at what's going on in the academic world, you are increasingly see academic institutions setting themselves up to generate more spinoff opportunities. And we are very keen on interacting with the external world. We think that where research should be performed.."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And to be fair, you heard me say this before, we have. I don't think different in our other great innovators in the industry and really not doing discover themselves, but licensing-in compounds. And there's some fantastic companies that have sold some hug",101,"And to be fair, you heard me say this before, we have. I don't think different in our other great innovators in the industry and really not doing discover themselves, but licensing-in compounds. And there's some fantastic companies that have sold some huge unmet them medical needs without discovery labs and I won't go through naming them. They could divide that moniker that the but didn't have discovered but rather smart business development and in-licensing and that's essentially our approach. We just come out with a very practical approach and a real for not wasting money. You want to about Namzaric?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","On Namzaric we've got a product to market with the Alzheimer's community has wanted for over 10 years since we launched Namenda. In 2004, we think it should be the standard of care for patients with moderate to severe disease and we're at the very early s",132,"On Namzaric we've got a product to market with the Alzheimer's community has wanted for over 10 years since we launched Namenda. In 2004, we think it should be the standard of care for patients with moderate to severe disease and we're at the very early stages of the exclusivity period and so our primary aim is going to be market share in volume and giving access to physicians in caregivers. As it relate to the discount rate, it's going to be consistent with what we had for in 2015 and for x, I think will be consistent in 2016. No dramatic changes, we manage the price volume relationship on that business very, very carefully and we're at a price point that is attractive to health plans and acceptable to us."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question comes from that line of Sumant Kulkarni from Bank of America.",14,"Your next question comes from that line of Sumant Kulkarni from Bank of America."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of products offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relativ",51,"On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of products offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relatively significant contributor in terms of sales?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, maybe David, you want to talk about our dry eye pipeline for any gaps?",15,"Yes, maybe David, you want to talk about our dry eye pipeline for any gaps?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure, dry eye is underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actually re",138,"Sure, dry eye is underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actually receive treatment at the moment. And I think with Restasis, obviously, we have the leading product. And Oculeve is a very interesting device. I used it myself recently, I can assure you it works. And it's really adding to our products line. In addition to the anti-inflammatory agents like Restasis, there are some other opportunities in the biotech pipeline with different mechanisms of action. So I think in the future, we are going to see either opportunities out there, which are going to be effective by other approaches in dry eye. Brent, anything to add?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll just say, by now, we have the large waterfront covered we have all busy or artificial tear. Oculeve is essentially a natural tear option and Restasis is an anti-inflammatory. And so we offer more complete product line for the eye care community",70,"Yes, I'll just say, by now, we have the large waterfront covered we have all busy or artificial tear. Oculeve is essentially a natural tear option and Restasis is an anti-inflammatory. And so we offer more complete product line for the eye care community than any company in the sector and I agree with David there are a few opportunities out there but we have most of the market coverage."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I think also people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its single dos",189,"I think also people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its single dose applicator is dosage and compliance because it's very hard to get that single dose in the eye. And so for patient convenience, and patient compliance and those income other multidose applicator ease-of-use innovation and something that we're very excited about bringing to market next year. And then keep in mind, we also have 4 other development programs of both Restasis and mechanisms earlier in our pipeline. On Bystolic and card to come I mean, I think the way I think about Dan Bill certainly chiming is Bystolic while certainly a Cargill drug nice to be more like a primary care drug about 80% of its volume comes from our primary care field force. We do have a partnership with trivia for an earlier stage products we are not completely walking away from cardio, but it's not 1 of our core focus therapeutic areas. Paul or David, anything to add?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, that's absolutely right. The exclusivity period of the Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific fi",48,"Yes, that's absolutely right. The exclusivity period of the Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific filing cardiology and primary care."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I always here anecdotal, but I hear from doctors doctors all the time about it being their favorite beta blocker to prescribe. so the us they can get it through managed care.",32,"I always here anecdotal, but I hear from doctors doctors all the time about it being their favorite beta blocker to prescribe. so the us they can get it through managed care."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Marc Goodman with UBS.",13,"Your next question will come from the line of Marc Goodman with UBS."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","May be built at the about some of the products in the the product in the portfolio just the dynamics in the quarter Restasis seem to be very, very strong in the quarter, much bigger than what we thought Process that is much weaker than we thought in both",87,"May be built at the about some of the products in the the product in the portfolio just the dynamics in the quarter Restasis seem to be very, very strong in the quarter, much bigger than what we thought Process that is much weaker than we thought in both of us. Some of the key product suggested dynamics in the U.S. versus international, what's going on? Did not maybe Alaska field to talk about that maybe you can time you read the other of kinesthetic product suite."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on",283,"Yes, I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on that. We think the trends in the second quarter look terrific, and I think the outlook for the rest of the year is the same. I don't see anything that would disrupt the reliability of that sales frame. As it relates to Restasis, we're focused on a large OTC artificial tear market. There are millions of patients overusing artificial tears. We have an effort where to increase the diagnosis rate through in office screenings for dry eye, which have been linked to blurred vision, adverse post outcomes. And so it is an educational effort. And finally, we have launched a primary care effort for Restasis. And the formulary coverage on the drug is rocksolid. And then I probably just add Linzess in there. We have our foot on the gas. The response to our second wave of direct-to-consumer advertising is exceeding industry norms. We just launched a effort into long-term care for the first time since Linzess was approved and that's about 25% of the market. Our relationship with Ironwood is excellent, and we're waiting for launch low-dose version of Linzess. And so I feel very good about our top products and as Brent mentioned in his opening remarks, 12 of our 15 products are increasing. If you look at the U.S. business, 12 of the 15 products are increasing at a double-digit rate. And we've had virtually in my opinion the disruption due to the integration and the total folks and customers."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Really, you have some thoughts?",5,"Really, you have some thoughts?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, sure. On business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also in Botox, which grew by 12.5%. All those growth are mostly linked to our strong BBC campaign and you might have seen our",81,"Yes, sure. On business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also in Botox, which grew by 12.5%. All those growth are mostly linked to our strong BBC campaign and you might have seen our bottles advance our volume on and on volume, you can see that increased by 42% from 27% in Q1. So very strong business and linked to their store advertising during the second quarter."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Ronny Gal with Bernstein.",13,"Your next question will come from the line of Ronny Gal with Bernstein."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just a quick housekeeping one. Would you able to provide us the constant currency growth rate for the Aesthetics product release that we have. And then second regarding the optical franchise, I notice that you were excluded from both CVS and express formu",75,"Just a quick housekeeping one. Would you able to provide us the constant currency growth rate for the Aesthetics product release that we have. And then second regarding the optical franchise, I notice that you were excluded from both CVS and express formularies starting in 2016. How should we think about is franchises there? Another taste of this franchise be or franchise Biarritz is something that we will generally think about as flat to declining?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, So Tessa, you want to take the first one?",10,"Yes, So Tessa, you want to take the first one?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, on an overall basis x-currency we grew about 11% to think about it weak correct most of our Aesthetics products are mostly U.S. products. So we've there are product sold internationally but it's not significant as it relates to the overall portfolio.",52,"Yes, on an overall basis x-currency we grew about 11% to think about it weak correct most of our Aesthetics products are mostly U.S. products. So we've there are product sold internationally but it's not significant as it relates to the overall portfolio. So doesn't have any currency but given their U.S.-based."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, and as it relates to the Masonic product line, as you all know, Ronnie, you win some and lose some. We had a big win with Linzess on that same formulary at the expense of AMITIZA but it through the mesalamine product line, the excluded it. We view it",90,"Yes, and as it relates to the Masonic product line, as you all know, Ronnie, you win some and lose some. We had a big win with Linzess on that same formulary at the expense of AMITIZA but it through the mesalamine product line, the excluded it. We view it as a mature business. It is promoted behind Linzess. We have a core group of users. We're managing volume. And, of course, taking price increases when and where appropriate, that's how I would think about it as an established business."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Elliot Wilbur from Raymond James.",14,"Your next question will come from the line of Elliot Wilbur from Raymond James."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And just for the segment data, it looks like the generics business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess going forward also of trying to figure out how much the proceeds from your business will be app",114,"And just for the segment data, it looks like the generics business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess going forward also of trying to figure out how much the proceeds from your business will be applied to a immediate debt reduction versus potentially using internal now cash flow generation to pay down debt and target external opportunities. But is that sort of right percentage to think about and kind of just sort of a ballpark number when thinking about your prior indications that the combined business would generate around $8 billion in free cash flow. Would the generic business account for roughly 20%, 25% of that?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Add my 2 cents. Eli, it's not that simple and I think we're trying to highlight with the earlier comments are on the there to guys apologize advance for the next couple of quarters because what's in that is, as we reported today, unnecessarily what's bein",148,"Add my 2 cents. Eli, it's not that simple and I think we're trying to highlight with the earlier comments are on the there to guys apologize advance for the next couple of quarters because what's in that is, as we reported today, unnecessarily what's being sold due to have fun than a straight line. Also, as you to GAAP reporting and reporting around discontinued operations, what gets assigned to each business is also not intuitive and not necessarily straightforward to reality either. So it's going to make for some difficult quarters ahead. Again, we are committed to as much transparency as we can possibly provide around product sales and perhaps, cash flow may be a good way to look at the business. But it's not as straightforward or as intuitive as you would hope or want it to be, just interested in oh, Tessa, I don't know..."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes to add to that is to give a little bit of context is to remember we are really managing the business on a consolidated basis. We weren't managing the business separately, as a solely business or a branded business we didn't have the holding company ap",149,"Yes to add to that is to give a little bit of context is to remember we are really managing the business on a consolidated basis. We weren't managing the business separately, as a solely business or a branded business we didn't have the holding company approach. We were actually managing the business on a consolidated basis and from a segment reporting basis, even the and International Brands or generic products and in Global Generics, also branded products. The other thing to note, which you also highlighted is from a balance sheet perspective. It's really all intermingled as it relates to gap in the tax rate, some of the things that are not necessarily operational your related to I guess the want to give context as to why it's not that difficult to circulate strip out into the percentage of cash flow and say that's what attributable to generics."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from that line of Randall Stanicky with RBC capital.",14,"Your next question will come from that line of Randall Stanicky with RBC capital."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, just a question for you. A lot of people are watching the legacy Allergan waiting for some moderation. That hasn't happened. In fact, they were really strong. So the question that I have is just given a difference in spending spurt in sales and mar",99,"Brent, just a question for you. A lot of people are watching the legacy Allergan waiting for some moderation. That hasn't happened. In fact, they were really strong. So the question that I have is just given a difference in spending spurt in sales and marketing between the legacy Allergan and where you're at today. And I'm just looking at Slide 15, number 1, do you feel like that infrastructure is rightsized? And then secondly, just your confidence level in some of the key products in being able to continue to sustain that growth Botox and were very strong?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think, Rondeau, that's a great question. I think we are -- we have rationalized our sales force for acquisitions and for the market as we see it over the next few years. And so we don't anticipate any additional cuts in the field. And in fact, we w",216,"Yes, I think, Rondeau, that's a great question. I think we are -- we have rationalized our sales force for acquisitions and for the market as we see it over the next few years. And so we don't anticipate any additional cuts in the field. And in fact, we would selectively add if we thought the opportunity payback. So as an example, we've the acquisition of a, we will increase our facial aesthetics sales force by roughly 75 physicians, making us the strongest field force in Aesthetics by a large margin. And so I think you will see us continue to look for ways as long as we're increasing our line that strategy of product flow come either through our R&D aero-engine or through licensing and acquisition of building and making sure we maintain leadership, strong leadership positions, commercially in each of our therapeutic areas. With respect to spending on DTC and otherwise, we always look on the return on investment. And so to the extent we think we can add more money to Botox or Restasis or Linzess or even Namzaric, which will kickoff in the fall DTC. We're always monitoring the situation looking at both response and return in those investments. And have no issue making terms of loss we see a strong ROI."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","The other thing that we heard legacy Allergan talk a lot about is the international emerging market in Asian geographies is a big opportunity perks that something that we should still think about for you guys that is in front of you?",42,"The other thing that we heard legacy Allergan talk a lot about is the international emerging market in Asian geographies is a big opportunity perks that something that we should still think about for you guys that is in front of you?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think it is. It's a slower build but big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next week with",115,"Yes, I think it is. It's a slower build but big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next week with our team looking at how we can put it the leverage our infrastructure in Latin America and grow. So clearly, the divestiture of the tablet business has some drawbacks in mid-markets like Eastern Europe and Russia and that their livers still the old legacy activities infrastructure in those markets but thinking that we can compensate for those and continued to grow and build in emerging markets."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from that line of Umer Raffat of Evercore ISI.",14,"Your next question will come from that line of Umer Raffat of Evercore ISI."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Maybe the first one for David, David, what's the status of the Darphin Japanese tried is ongoing? Should we expect benefit to them? And what would that look like? And the second one for Brent, if I may. The transformation of M&A the us we could get from i",92,"Maybe the first one for David, David, what's the status of the Darphin Japanese tried is ongoing? Should we expect benefit to them? And what would that look like? And the second one for Brent, if I may. The transformation of M&A the us we could get from investors, so how do you think about companies with growth profile that might be lower than with your 10% or companies with potential by a similar headwinds were even as U.S. companies for that matter, just wanted to understand how you think about this."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. David, you want to take I'll come to the transformational M&A question.",13,"Sure. David, you want to take I'll come to the transformational M&A question."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So dark been in Japan, we as we want at the joint in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional smaller study in the United States. We are in the process of finalizing th",77,"So dark been in Japan, we as we want at the joint in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional smaller study in the United States. We are in the process of finalizing those studies prior to including Japanese sites in the Phase III trials sometime next year. So yes, there will be some updates on that going forward."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think to your second point around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth rate b",338,"Yes, I think to your second point around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth rate because I think based on at least of today's measure with high-growth rate so that would really limit the universe. That being said, I think that the issue for us is we want to be in growth pharma. We'd be willing to go from, let's say, roughly 10% to a 9% top line growth rate of the highly accretive bottom line deal? The answer is absolutely. We'd be willing to go from 10% to 3% or 4% top line growth to do a highly accretive deal, I would say highly unlikely. And so we want to go out and make sure that we can acquire something that we believe has a growth orientation to it that has longer duration assets. And I think it should also keep in mind, we're pretty, as I use the word, bold in our thinking. So yes, I think think a lot of people look at the universe of transformational deals and say you can't touch this because it's got this particular product track over this particular issue. We've been known to be very creative consulting for those things in the past and I'll be at a very deal, I would pointed clearly excess just an illustration. They had 2 assets, they had the NDA for [ph] and they had royalty stream from Tekada. We divested the royalties stream Tekada to Royalty Pharma at the time we announced the deal. We had that repeat wired. And so we kept what we wanted and we sold something that was available to somebody else to help pay for the deal. And so to the extent we look at companies or opportunities things we like, and some things perhaps we don't like, there are always potential for solving for those issues."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And you're next question will come from the line of Gregg Gilbert the Deutsche Bank.",16,"And you're next question will come from the line of Gregg Gilbert the Deutsche Bank."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, if another party were to boldly approach you us an inversion targets, other than doing what's best for shareholders, which I think you have a reputation of doing along with Paul on the Board. Are very certain elements of the model and its specialne",65,"Brent, if another party were to boldly approach you us an inversion targets, other than doing what's best for shareholders, which I think you have a reputation of doing along with Paul on the Board. Are very certain elements of the model and its specialness in growth profile that you might be concerned about that might into your thinking about longer term shareholder value creation?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, Greg. I think you're right, it would have to be a bold offer. Second, I think Paul and I would always debate and talk to our board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so spec",193,"Yes, Greg. I think you're right, it would have to be a bold offer. Second, I think Paul and I would always debate and talk to our board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so special about this company, a lot of it goes to the depth and quality of our management team. And so to the extent someone would be open to thinking about cultural change and change and balance to leadership and talent and management, I think that would be more helpful for us. I think clearly, our commitment to R&D and the way we think about R&D is also very special. And I think our ability to be nimble and move quickly and do what we believe is always in the shareholders best interest is also a beginning. And so those are the types of discussions that we would have to get that thing to do that but that would be I think at least top of mind for debate and I see Paul is shaking his head so I know he's in agreement."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","You're next question will come from the line of David Maris with BMO Capital.",15,"You're next question will come from the line of David Maris with BMO Capital."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On the Naurex, this looks to be like a potential billion-dollar-plus drug and I know will cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this, how it's different shifted the market but also, most",58,"On the Naurex, this looks to be like a potential billion-dollar-plus drug and I know will cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this, how it's different shifted the market but also, most importantly, what's the next steps toward the path to approval?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll ask David to comment. I'll just give you my quick take of why I'm so excited to the deal with Naurex is that this is an area, a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, the minor",168,"Yes, I'll ask David to comment. I'll just give you my quick take of why I'm so excited to the deal with Naurex is that this is an area, a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, the minority of patients are adequately served by SSIR or SNRI and then may have to leave with in some cases a very difficult side effects from those medicines as well. It's a long onset of action for those with acute issues that need to be dealt with more quickly. And I think David, you mentioned this in your earlier remarks, there's been no real novel breakthrough in depression in about 20 years. And so for us to be able to be at the forefront of potentially revolutionizing the very large and horrific disease is something that I think is a very exciting for us, given our commitment to leading in CNS and particularly psychiatry. David, your 2 cents?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I've only got time for 2 cents so I have to be quick. And so I've got to be quick or so working for psychiatry in 20 years and pick and components of the market, buildout is the mass commercialized some of the biggest antidepressants. So I think. So I thi",87,"I've only got time for 2 cents so I have to be quick. And so I've got to be quick or so working for psychiatry in 20 years and pick and components of the market, buildout is the mass commercialized some of the biggest antidepressants. So I think. So I think the thing we got her, no depression in the area over the last 20 decades. So in an opportunity like Naurex comes along with a novel mechanism of action over the last 2 decades, yes."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","There at the colleague.",4,"There at the colleague."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Just feels [indiscernible] for 20 seconds.",6,"Just feels [indiscernible] for 20 seconds."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Loss of Botox. So when an new opportunity comes along with mechanism of action I think that's team here can see it pretty quickly excepting go but the novel mechanism of action and showing a strong satisfaction in depression, not only in depression but in",105,"Loss of Botox. So when an new opportunity comes along with mechanism of action I think that's team here can see it pretty quickly excepting go but the novel mechanism of action and showing a strong satisfaction in depression, not only in depression but in depression where the patient fail to respond to SSRIs. So that's an exciting opportunity. And the next steps for us as we get into Phase III as quickly as possible with extruded, the lead molecule and to get into Phase IIb with the second compound in Rx 1074 and we're going to do that as early as possible next year."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","We'd like to close the deal but then we'll move pretty aggressively to doing that.",16,"We'd like to close the deal but then we'll move pretty aggressively to doing that."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And our final question for the day will come from the line of David Risinger with Morgan Stanley.",18,"And our final question for the day will come from the line of David Risinger with Morgan Stanley."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Sorry about that. Thanks for your patience. I apologize. I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slide",71,"Sorry about that. Thanks for your patience. I apologize. I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slides. Could you just tell us what the organic growth was in the second quarter of the generics business that you're selling? And then I have a follow-up."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","David, if I understand the question, I think the differences are between what we have and what Teva have on their slide deck and it will be very difficult for us to comment on the differences between what we have and what another company has.",45,"David, if I understand the question, I think the differences are between what we have and what Teva have on their slide deck and it will be very difficult for us to comment on the differences between what we have and what another company has."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the artistic, obviously, we can't comment on that did not that to be fair, their number for '16, not our number for '16. Just to be clear.",48,"So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the artistic, obviously, we can't comment on that did not that to be fair, their number for '16, not our number for '16. Just to be clear."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences and the revenue reported on. . .",28,"Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences and the revenue reported on. . ."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","We can address that.",4,"We can address that."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","It's Lisa. SO in the top brand slide, the x U.S. branded products from Forest, Warner Chilcott and Actavis are not counter generic product, they count in the brand products. Did in the Brad Delco. When you look at our global generics segment, our Global G",65,"It's Lisa. SO in the top brand slide, the x U.S. branded products from Forest, Warner Chilcott and Actavis are not counter generic product, they count in the brand products. Did in the Brad Delco. When you look at our global generics segment, our Global Generics segment still counts those as for accounting rules as part of the global generics business. That's the difference."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And in terms of the organic growth of the generics business, what was that in the second quarter?",18,"And in terms of the organic growth of the generics business, what was that in the second quarter?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's what we gave you -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter.",21,"That's what we gave you -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's not a clean. That's the point by was trying to make earlier about way too difficult to model. That's not apples-to-apples of what's being sold and what's staying. There's puts and takes in from the segments versus what was actually being sold. And",49,"That's not a clean. That's the point by was trying to make earlier about way too difficult to model. That's not apples-to-apples of what's being sold and what's staying. There's puts and takes in from the segments versus what was actually being sold. And that's what makes [indiscernible]."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Yes, got it. Yes, I can follow-up on that. And then separately, with Namenda switch here, obviously, take you look longer-than-expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surprised if you're lea",78,"Yes, got it. Yes, I can follow-up on that. And then separately, with Namenda switch here, obviously, take you look longer-than-expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surprised if you're leaving that unchanged. When you talk about 60% to 65%, is that a percentage of the total prescriptions, including the generics? Or is that just the branded Allergan franchise that you are now forecasting?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That would be the total Namenda business, including brands and generics and the way we think about it is we launched Namzaric only 2.5 weeks ago. A DPC campaign starts in September. We expect exceptional formulary coverage by January 1, and incremental sa",126,"That would be the total Namenda business, including brands and generics and the way we think about it is we launched Namzaric only 2.5 weeks ago. A DPC campaign starts in September. We expect exceptional formulary coverage by January 1, and incremental sales from Namzaric by essentially taking advantage of an untapped apped combination market, especially in moderate Alzheimer's disease effectively is going to get us to our target conversion rate, as I said, earlier, if the formulary coverage have not developed like it has, they might have a different situation right here. But as it relates relates to 2016, Namzaric is going to be highly economical. XR is and I think the majority of the patients are going to have an opportunity to get the."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Okay, thanks, everybody. Breant, would you like to make some closing remarks?",12,"Okay, thanks, everybody. Breant, would you like to make some closing remarks?"
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize, I think we have a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our gr",114,"Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize, I think we have a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our growth agenda and the were focus on our key therapeutic categories and establishing long duration leadership in those categories. I think our leading pipeline, our reload capital structure and our know focused focused on branded pharmaceuticals and willingness to date bold and decisive actions may cause the most dynamic company in growth pharma. I'd thank you for your time and look forward to updating you later again in September."
36478,305435704,850606,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, everyone. And I know we didn't get quite a few people in the Q&A so we'll follow up with you shortly. Thanks.",23,"Thanks, everyone. And I know we didn't get quite a few people in the Q&A so we'll follow up with you shortly. Thanks."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Holly, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] I'll now turn the conference over to Lisa DeFran",49,"Good morning. My name is Holly, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] 
I'll now turn the conference over to Lisa DeFrancesco, Vice President, Global Investor Relations. Please go ahead."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015",343,"Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.
Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Allergan and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflects our current perspective of the business trends and information as of today's date. Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Allergan business. These factors are detailed in our public periodic filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our second quarter business highlights; Tessa Hilado, our Chief Financial Officer, will then discuss the Allergan second quarter results in more detail; and David Nicholson, Executive Vice President and President of Global Brands R&D, will provide an update on our Brands R&D progress in the quarter and upcoming development milestones. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I'll turn the call over to Brent."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we had last quarter. This was also our first full quarter of a combined operations following the",1369,"Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we had last quarter. This was also our first full quarter of a combined operations following the close of the Allergan acquisition on March 17. And I'm very proud of what our team has accomplished, especially the momentum they have created to propel our future growth.
Turning to Slide 5. Allergan's second quarter performance highlights our ability to execute on our 4 pillars of our long-term growth strategy. First, operational excellence is yielding exceptional financial performance and results in all key business segments, key products and key geographies. Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive and innovative R&D engine has produced more than 100 branded product approvals globally and 56 branded regulatory submissions year-to-date. And fourth, we're executing on strategic business deals to support our growth in key therapy areas and charge up our pipeline for the future.
We also changed our name to Allergan in the quarter to symbolize our transformation into a leader in Growth Pharma, where brands now contribute more than 2/3 of our company's revenues. With our focus in Growth Pharma, we are encouraging our employees around the world to be bold and smart in the way we think and act. 
Turning to Slide 6. The announcement of our plans to combine our Global Generics business with Teva in a $40.5 billion deal is the latest bold move by our company to continue our transformation towards being a leader in branded Growth Pharma. For years, we've been moving up the innovation curve towards specialty pharma products. This agreement clearly accelerates our transformation. This deal allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapy areas and reload our capital structure to continue our transformation. There's certainly more to come on this story.
We are confident that we are creating the most dynamic company in Growth Pharma, while adding our impressive global generic commercial, generic R&D and operating capabilities to Teva. 
Now let's turn to Slide 7 and talk about the business performance in the second quarter. Our second quarter revenue more than doubled on a year-over-year basis to $5.7 billion as a result of the acquisitions of Allergan and Forest. On a pro forma basis, sales were up 12%, excluding the impact of foreign currency, Namenda IR and divestitures, with double-digit growth in brand and Global Generics segments. The strong sales increase introduced from the integration of Allergan and Forest were the primary drivers of the 29% increase in earnings per share to $4.41. Meanwhile, non-GAAP EBITDA rose to $2.6 billion and cash flow from operations was about $1.7 billion, excluding onetime cash payments for severance, acquisitions and integration. Tessa will talk more about the financials shortly.
On Slide 8. Our Global Generics business is doing very well and the units that comprise it are firing on all cylinders as we prepare for the combination with Teva. Generics sales are up 17%, excluding the impact of foreign currency. Generic profitability is up and our exceptional generic R&D capabilities are evident, with 12 new first-to-file drugs this year. This brings the total number of ANDAs under review to approximately 220 with 76 confirmed first-to-files.
U.S. Generic revenues were $1.1 billion in the quarter and continued to benefit from new product introductions and contribution from high-barrier and semi-exclusive products, like generic Concerta. Meanwhile, our International Generics team continues to drive excellent performance in key markets, excluding the impact of foreign currency such as the U.K., which was up 85%, including the effect of the Auden Mckenzie transaction that closed in May; and Russia, which was up 32%.
Turning to Slide 9. Our brands business continues to thrive impressive performance with 12 of the top 15 global brands growing, many with double-digit pro forma year-over-year growth. Sales increased 11%, excluding Namenda IR, the divestitures and the impact of foreign exchange. And the success is broad-based. Excluding the impact of foreign currency, we drove double-digit growth in eye care, GI and key woman health products and cardiovascular; double-digit growth from our latest largest leading brands like Botox, Restasis, Namenda XR and our fillers, including Juvederm; double-digit growth from well-established brands like Bystolic, LoLoestrin and Estrace; and double-digit growth from Linzess, Ozurdex and other launch brands, which puts us in excellent position to power growth well into the future. It is a terrific lineup of brands with long exclusivity and is backed by a great team on the ground and our leading pipeline, with multiple shots on each of our 7 priority therapeutic areas.
Turning to Slide 10. We continue to drive conversion of patients to Namenda XR right up to the end of the Namenda IR exclusivity, reaching about 53% before generic entry. With continued promotion and the launch of Namzaric, we believe the penetration rate goes even higher, towards our target of 60% to 65% as the year progresses. And with once a day dosing, formulary access at every 1 of the top 8 plans and a focused sales team, we maintain relatively stable volumes on Namenda XR even as the Namenda IR prescriptions dropped. We are now doing the blocking and tackling to build the demand and access for Namzaric. With full promotion just getting underway, our DTC campaign beginning in September and an anticipated 7 out of the top 10 plans having coverage by the beginning of 2016, we think we are well prepared to drive market expansion in 2016. Given the broad use of combination donepezil and memantine therapy, the efficacy of Namzaric and the patient caregiver and system benefits of one pill, once a day, we think there's a great opportunity for the innovation of Namzaric to become the cornerstone of once-a-day branded market in Alzheimer's treatment.
Turning to Slide 11. In a few moments, David Nicholson will give an update on the pipeline, but I want to point out that our pipeline remains one of the best-kept secrets of our company. With 70 projects in mid to late development, we are in an enviable position of having multiple programs in each of our therapeutic areas to help us sustain leadership in the areas we choose to compete. And we built this pipeline step-by-step, not by investing big dollars on discovery, but by investing in smart development projects.
Even with the excellent breadth and depth of our current pipeline, we are always on the lookout for R&D assets that can extend our leadership by bringing novel approaches to existing therapy areas. And in last 2 months alone, we've announced agreements for 4 planned acquisitions in aesthetics, eye care and CNS. Each will bring novelty to existing areas and will add to our ability to lead in these therapeutic areas. And each of these deals bible game-changer potential ideas to our pipeline.
Kybella is off to a strong start in aesthetics, with sales already surpassing $1 million and a recent approval in Canada. We are making great progress towards closing the transaction now that we have cleared antitrust review in the U.S. And as we announced yesterday, we no longer intend to issue our shares to complete this acquisition. The Oculeve acquisition has also cleared HSR in the U.S. and we'll look forward to extending our dry ey opportunities with our novel nasal neurostimulation device. In CNS, we're working to close deals to extend our migraine offering with Merck's first in oral -- first-in-class oral CGRP antagonist and the Naurex novel approach to treating mood disorders, including severe depression, which remains a leading cause of suicide.
In closing, our team continues to focus on execution and the results indicate that we are exceptionally skilled at delivering strong operating results, while also doing surprising things that make our company the most dynamic in all of health care. I'm so proud of our team for their performance and I'm looking forward to what we can do with a strength and focus on branded pharmaceuticals and a significantly reduced operating structure and reloaded capital structure. 
With that, I'll now turn the call over to Tessa."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter on Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second q",945,"Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter on Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second quarter was $5.7 billion, an increase of 36% versus Q1 2015. 
Non-GAAP R&D investment for the quarter was $406 million compared to $185 million in the prior year period. Non-GAAP SG&A as a percentage of revenue was 21.7%, an increase of 3 percentage points over the prior year quarter, as a result of the Forest branded products and Allergan business, which we have higher SG&A spend.
Adjusted EBITDA for the quarter was $2.6 billion, an increase of 203% versus the prior year, driven by strong revenues and higher gross margins across our segments. Non-GAAP earnings per diluted share for the quarter increased 29% to $4.41 compared to $3.42 per diluted share in the second quarter of 2014.
Our non-GAAP tax rate improved from 17.1% in the year-ago period to 14.5% in the current-year quarter, mainly due to the geographic mix of our businesses. Cash flow from operations for the second quarter was $1.4 billion, an increase of 198% versus the year-ago quarter. Excluding acquisition-related restructuring and integration payments, our second quarter free cash flow would be $1.7 billion.
Before turning to our business segment results, I would like to take a moment to review our new segment reporting for the second quarter. In this quarter, we are reporting results in 5 segments: The U.S. Brands segment represents sales and expenses related to branded products within the United States, including Botox therapeutics. The U.S. Medical Aesthetics segment represents sales and expenses related to aesthetics and dermatology products within the United States, including Botox cosmetics. The International Brands segment represents revenues and operating expenses in countries that have the majority of their businesses represented by branded sales and revenues and expenses related to product sales in Canada, Switzerland and Austria. The Global Generics segment represents revenues and operating expenses in countries that have the majority of their business represented by generic product sales, our third-party Medis business and revenues and expenses related to product sales in the U.S., Canada, Switzerland and Austria. The Anda Distribution segment results represents sales and expenses related to distribution of generic and brand pharmaceutical products manufactured by third parties. Also, as a result of Teva's acquisition of Allergan's generic business, Allergan will report its generics business as discontinued operations beginning in the third quarter of 2015. Since the divested business spans both Global Generics and International Brand segments, it will be difficult today to model the remaining Allergan business. We will provide some guidance in September.
Turning now to our U.S. Brand results on Slide 15. The business delivered strong performance year-over-year and quarter-over-quarter. U.S. Brands revenue was $2.44 billion for the quarter, up 331% versus the prior year period and 35% in the prior quarter, driven by the addition of the Forest and Allergan businesses and strong growth across key products, including Linzess and Namenda XR. Adjusted gross margin within U.S. Brands remained steady at 87.4%. SG&A as a percentage of revenue increased to 20.8% versus 17.8% in the year-ago quarter, driven by expenses related to the Forest and Allergan acquisitions.
Turning to Slide 16 and our U.S. Medical Aesthetics business. The second quarter revenues were $487 million, an increase of 510% versus first quarter 2015 results. Second quarter gross margin of 93% and segment margin of 70.6% were largely in line with expectations. SG&A in the quarter remained steady. 
Turning to Slide 17 and our International Brands results. Second quarter revenues were $717 million versus $169 million in the prior year period, an increase of 324%. Gross margins increased 21.7 percentage points to 77.8% in the second quarter, due largely to the inclusion of higher margin legacy Allergan products. Segment SG&A improved 7.2 percentage points to 32% versus Q1 2015 due largely to synergy capture related to the Allergan acquisition.
On Slide 18, Global Generics revenues in the quarter were $1.6 billion, up 10% versus the prior year period. Growth was driven by strong sales in the base business, including generic Concerta, offset in part by additional competition on certain products, including generic Lidoderm. Adjusted gross margins increased 1 percentage points compared to the year-ago quarter due to continued strong performance within our international business. Lower gross margin versus the prior year quarter was mainly due to lower contribution of Guanfacine ER and oxycodone in the second quarter versus the first quarter of 2015. SG&A as a percentage of adjusted net revenue decreased slightly to 15% from 15.8% in the year-ago quarter.
Turning to our Anda business on Slide 19. Revenues increased to $462 million, up from $427 million in the prior year, an increase of 8%, driven by trends in our base business and a higher mix of chain drugstore sales. 
Slide 20 details our debt capitalization following the completion of our first full quarter following the close of the Allergan acquisition. We ended the second quarter 2015 with total debt of approximately $42.9 billion and equity of $72.1 billion related to the Allergan acquisition and previous financing. In the second quarter, we paid down approximately $1.4 billion of our debt. Currently, our leverage ratio stands at 3.9x debt to pro forma adjusted EBITDA versus 4.1x in the prior quarter. We remain committed to using strong free cash flows from our business segments to accelerate debt repayment, and we continue to remain committed to investment-grade ratings.
I'd now like to turn the call over to David Nicholson, who will provide an update on our Brands R&D progress in the quarter. David?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our Brands R&D team continues to be tremendously productive. Year-to-date and worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approval",1270,"Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our Brands R&D team continues to be tremendously productive. Year-to-date and worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approvals and 56 regulatory submissions. I will highlight some of the most significant of these in my overview. 
Following the first round of integration prioritization, we now have more than 70 mid- to late-stage development projects, with approximately 45 projects in either late-stage development or registration. The productivity of the legacy Allergan R&D organizations is demonstrated by the industry-leading figure of 14 NME approvals in the United States over the last 6.5 years. Going forward, we'll continue to make data-driven prioritization decision on all of our programs.
In addition to rationalizing and driving productivity from our existing pipeline, we are committed to identifying and executing acquisitions and licensing agreements that further strengthen our long-term leadership position in key therapeutic areas. This is exemplified by our pending acquisitions of Kythera, Oculeve and Naurex and licensing of Merck's oral CGRP programs during the quarter. 
The next 2 slides summarize some highlights and describe the progress in our late-stage pipeline. Slide 23 shows late-stage game-changing opportunities across our therapeutic areas. 
In aesthetics, we are adding Kybella from Kythera to our pipeline. Our aesthetics pipeline already includes bimatoprost for hair growth, Aczone and sarecycline for acne as well as many line extensions to our fillers. In eye care, we are adding the intranasal dry eye device from Oculeve to our dry eye franchise, further enhancing our leading position in this therapeutic area. 
My colleagues and I have reviewed our restated data and again, find our efficacy and tolerability data very compelling in comparison to the recently published data from other compounds in development and registration. In Phase III, we are developing DARPin and have a sustained-release formulation of bimatoprost. In CNS, we are adding the Naurex NMDA modulator to our pipeline. These compounds have the first novel mechanism for mood disorders for more than 2 decades. We're also adding oral CGRP antagonists. These compounds, in license from Merck, are designed both for the acute treatment as well as for the prophylaxis of migraine. We also have cariprazine in development and Namzaric, which combines 2 complementary therapeutic agents, Namenda and Aricept. 
Recently, much attention has turned to prevention of Alzheimer's and like all of us, I hope that effective preventive therapy will be discovered. Data on Namzaric was recently presented at the 2015 Alzheimer's Association International Conference. The efficacy of Namzaric in patients with Alzheimer's is at least a similar magnitude to that reported with the present preventative agents in development. 
In GI disorders, together with our partner, Ironwood, we continue to develop dosage and formulations of our IBS-C agent, Linzess, to offer a very complete package to physician and patients. Also, we're completing the initial development of eluxadoline, Viberzi, for IBS-D. 
In urology, together with our partner Serenity, we have intranasal desmopressin completing Phase III for nocturia. In our anti-infective franchise, we continue to develop Dalvance and Avycaz. In biologics, Phase III will be completed this year for bevacizumab, a biosimilar of Avastin, which is part of our partnership with Amgen. Last, but certainly not least, is Botox. We continue to further develop and launch these agent across our aesthetics, CNS and urology franchises. 
Turning to Slide 24. I'm going to update you on progress with regulatory authorities to key late-stage products.
In aesthetics, Natrelle Inspira textured breast implants received FDA approval for women undergoing breast reconstruction, augmentation or revision surgery, and we are on track for FDA submission of our Volbella filler in the third quarter 2015. Yesterday, we received FDA approval to market 28 additional styles of Natrelle 410 breast implants. 
In Asia, we received licensing rights for commercial sales of Juvederm in China and submitted an NDA for Botox for crow's feet lines in Japan. In eye care, Botox received approval in Japan for the treatment of strabismus. We're on track for FDA submission of a multidose, preservative-free formulation of Restasis in September. We've currently enrolling patients in Phase III trials for bimatoprost in the U.S., and we've initiated pivotal Phase III trials of our lead DARPin in age-related macular degeneration, on target in June this year. 
In CNS, we have a PDUFA date in September for cariprazine as a treatment for schizophrenia and bipolar mania. And this quarter, we launched Namzaric and we'll be filing additional dose combinations of this agent later this year.
In GI, our strong pipeline does continue to develop new opportunities. We expect to complete the Phase III study for a low-dosage form of Linzess to treat chronic idiopathic constipation in the second half of the year, and we expect to submit an sNDA for this indication next year. 
Meanwhile, Viberzi, eluxadoline, has been approved by the FDA as a twice-daily oral treatment for IBS-D. We're awaiting DEA scheduling of Viberzi prior to launch of this product in the United States. And we submitted the dossier of eluxadoline in Europe in May.
In women's health, enrollment in our Phase III trial of Esmya for the treatment of bleeding disorders caused by uterine fibroids is on track. We're committed to completing trial enrollment this year.
In urology, we completed our Phase III trials of SER 120 in nocturia. The data is under our review prior to submission to the agency. In anti-infectives, our development of a single-dose formulation of Dalvance remains on track. We've made regulatory submissions for approval in both the United States and Europe. We're also anticipating approval for Teflaro in bacteremia during the course of this year.
On Slide 25, we outline some of our most recent business development opportunities. Obviously, these help us to further solidify our leadership position in our core therapeutic areas. 
With Kythera, we add a first-in-class agent, Kybella, for the treatment of submental fat, or double chin, to our product line. The product is launched in the States and was recently approved in Canada. In addition, Kythera has an interesting and genetically validated hair growth product in early development. 
Oculeve will strengthen our leading position in dry eye with the OD-01 development program, an intranasal neurostimulatory device that increases tear production in patients with dry eye. 
Our licensing agreement with Merck builds on our commitment to the development of treatments for migraine. We're adding oral formulations of CGRP antagonists to our product line. The use of both small molecules as well as antibodies has clearly shown that CGRP antagonism is effective in treating migraine. There are 4 injectable antibodies in development, whilst we will have the only oral CGRP antagonist. 
Finally, Naurex. The acquisition of Naurex adds innovative development programs in depression to our pipeline. Depression is an area of medicine that has seen minimal progress for the last 20 years. The Naurex compounds are NMDA modulators, a unique approach to the treatment of depression. These agents have the potential to be fast-onset antidepressants and, hence, may be beneficial in the alleviation of suicidality, which is so often a terrible feature of this disorder. In early-stage development, the Naurex team showed their compound indeed to be fast in onset and also to be effective in treating depression, which fail to respond to traditional antidepressants.
In closing, the second quarter of 2015 was another period of continuous strong productivity for the Allergan R&D team. We look forward to continue to deliver on the promise of many of our development programs in our pipeline for the remainder of 2015 and beyond. 
With that, I'd like to turn it over to Brent for closing remarks.
Brent?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you've heard, we have a lot going on and look forward to giving you updates on our progress over the next few months. In mid- to late September, we will provide updated guidance for our continuing operations for the remainder of 2015.",126,"Thank you, David. As you've heard, we have a lot going on and look forward to giving you updates on our progress over the next few months. In mid- to late September, we will provide updated guidance for our continuing operations for the remainder of 2015. This will reflect our Global Generics business as discontinued operations as we wait for the close of the transaction with Teva next year.
In conjunction with our third quarter earnings result, we also plan to host an R&D update meeting on November 4 in Irvine, California at our campus. It will be our opportunity for to R&D team to shine a spotlight on the post-prioritization R&D portfolio.
With that, I'd like to turn the call back to Lisa for Q&A."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. We'll now take questions. [Operator Instructions]",9,"Thank you, Brent. We'll now take questions. [Operator Instructions]"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question will come from the line of Chris Schott with JPMorgan.",15,"[Operator Instructions] Your first question will come from the line of Chris Schott with JPMorgan."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","One of the questions we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the T",100,"One of the questions we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the Teva deal closes if the right transaction were available, I guess, both from an operational and financial standpoint? And just a very quick second one on that guidance in September, is that just 2015? Or can we think about a preliminary view on either '16 or an update on the $25 2017 outlook at that time as well?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, thanks, Chris. So with respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible",185,"Yes, thanks, Chris. So with respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible prior to that and we have always been bold in thinking about how to execute things if the timing was right. But I think in fairness, given the commitment to our investment-grade rating and our ability to deploy cash after the deal has closed versus prior -- or perhaps, our flexibility to deploy cash after the deal closes is better than prior. I think that's probably how you should think about it. Now that doesn't mean we couldn't engage in analysis or discussions or other things like that with someone who is interested in doing a deal with us or we were interested in doing a deal with them. But I would say that it's most likely after the close of the Teva transaction. 
With respect to the guidance, maybe I'll ask Tessa to talk about that for a second."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so in September, what we will be providing you is what the remaining will -- business will look like since Teva will be discontinued operations. That's not exactly a very easy separation to do. And also just to manage expectations, so we provide that",118,"Yes, so in September, what we will be providing you is what the remaining will -- business will look like since Teva will be discontinued operations. That's not exactly a very easy separation to do. And also just to manage expectations, so we provide that given the account rules, it will be very difficult at this point in time for you to model what the remaining 2015 will look like. As an example, for instance, debt will continue to remain with the Allergan-branded business and not go to discontinued operations. There's no such thing as non-GAAP discontinued operations. So we'll provide a little bit more clarity come September, but it's really largely focused on the remainder of 2015."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Jami Rubin with Goldman Sachs.",14,"Your next question will come from the line of Jami Rubin with Goldman Sachs."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just to follow up on that earlier question, Brent or Tessa. So when you give discontinued -- or rather, when you give pro forma earnings going forward, which presumably only includes the branded business, will that branded business also include all the in",156,"Just to follow up on that earlier question, Brent or Tessa. So when you give discontinued -- or rather, when you give pro forma earnings going forward, which presumably only includes the branded business, will that branded business also include all the interest expense that you're carrying on your books? In other words, I would assume that some of that $40.5 billion is going to reduce debt. So how do we think about that when we think about the base business going forward? And then secondly, just to follow up on that $25 number, that $25 obviously includes about $5 or $2.4 billion in EBIT from the generic business. Brent, at what point can we expect you to update us on that guidance? And I think on the last call, you didn't withdraw that $25. So any, again, any color on how we should think about the company's ability to replace that $2.4 billion in EBIT?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So Tessa, you want to take the first one?",9,"So Tessa, you want to take the first one?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So you definitely touched on some of the nuances related to discontinued operations as it pertains to debt as an example, for instance. So on a go-forward basis, in the September earnings, what you will see is that, debt will reside in the remaining compa",137,"So you definitely touched on some of the nuances related to discontinued operations as it pertains to debt as an example, for instance. So on a go-forward basis, in the September earnings, what you will see is that, debt will reside in the remaining company and not allocated to discontinued ops. Obviously, as you think about that on a go-forward basis, it would really largely depend on what we do with the capital on a go-forward basis. What we had indicated in our call related to Teva that we would use a portion of the proceeds to pay down debt. But again, it's largely dependent on how much we used for capital deployment. Having said that, though, we are committed to our investment-grade rating so we will ensure that the appropriate amount of debt is paid down."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think the net-net, Jami, on guidance and knowing this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually close the transaction, it will be ver",271,"Yes, I think the net-net, Jami, on guidance and knowing this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually close the transaction, it will be very difficult for you guys to run models and do clean comparisons. We are, as always, committed to as much transparency around product sales, like we were in this press release. And we will do the best we can given the rules that we have to all live with. But it will make for some tough modeling work on your guys' part over the next 2 or 3 quarters. And we apologize in advance for that and we'll do everything we can to help facilitate that. 
With respect to the $25 aspiration, what I said -- I think you asked this question on the deal call, if I recall correctly, Jami, was that we absolutely remain steadfast in our aspiration to increase our earnings per share to as high as possible, including the $25 target. What has changed, obviously, is by selling the generics business and the $2.4 billion of EBITDA to Teva, the timing of that aspiration. And so we need to continue to look at how we will deploy that capital and how the timing of the deployment of that capital will pull through to give a more precise view of it. So again, we're not withdrawing the $25 but we will come back and have to add some variables to it, like capital deployment and timing of capital deployment to get there."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Liav Abraham with Citi.",13,"Your next question will come from the line of Liav Abraham with Citi."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, another question on the topic of business development. I wanted to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in a potentially transformational transaction and interested in moving up",130,"Brent, another question on the topic of business development. I wanted to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in a potentially transformational transaction and interested in moving up the value chain. You've also said that you're not necessarily in favor of early-stage research. I'm trying to reconcile these comments. Can you engage in a larger pharma transaction and move up the value chain without a greater commitment to early-stage research going forward? And isn't this route necessary to at least -- to a certain extent, to secure longer-term organic growth? And then very quickly for Bill, can you comment on how much you'll be giving away incrementally in terms of rebates in order to secure formulary status for Namzaric next year?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. So Liav, I think the answer to the first part of your question is yes, with an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or som",189,"Sure. So Liav, I think the answer to the first part of your question is yes, with an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or something that isn't widely available in external research like venture-backed companies or researcher academia-backed companies or smaller biotechs. And so I think if you look at what David and his team did with Allergan, we kept the research capabilities where they had unique strength and proven track records like in aesthetics and eye care. And we have -- and we will continue to fund that as appropriate. What we won't to do is waste our money on R&D that is widely available elsewhere. And so I think you have to really consider us as very practical when it comes to research, basic research. But also virtual-like company when it comes to research as demonstrated by some of the deals we just did, like Naurex and even the licensing of the oral CGRPs from Merck. 
David, any other comments on research?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Look, one of the points that I always like to make is how impressed I am with the biotech industry these days. I've seen the biotech industry today with -- founded by so many brilliant academic scientists, coupled with more and more people with pharmaceut",115,"Look, one of the points that I always like to make is how impressed I am with the biotech industry these days. I've seen the biotech industry today with -- founded by so many brilliant academic scientists, coupled with more and more people with pharmaceutical executive experience, excellent in generating early-stage molecules, which we can pick up and further develop through to the market. There are plenty of opportunities out there. Also, when you look at what's going on in the academic world, you increasingly see academic institutions setting themselves up to generate more spinoff opportunities. And we are very keen on interacting with the external world. We think that's where research should be performed.."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And to be fair -- and you've heard me say this before, Liav. I don't think what we do is any different than the great other innovators in our industry and really not doing discoveries themselves, but licensing in compounds. And there's some fantastic comp",111,"And to be fair -- and you've heard me say this before, Liav. I don't think what we do is any different than the great other innovators in our industry and really not doing discoveries themselves, but licensing in compounds. And there's some fantastic companies that have solved for huge unmet medical need without discovery labs. And I won't go through naming them but they get the biotech moniker but really have no discovery but rather, smart business development and licensing. And that's essentially our approach. We just come at it with a very practical approach and a real bent for not wasting money. 
Bill, you want to talk about Namzaric?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, Liav, listen, on Namzaric working with Adamas, we got a product to market that the Alzheimer's community has wanted for over 10 years since we launched Namenda in 2004. We think it should be the standard of care for patients with moderate to severe d",138,"Yes, Liav, listen, on Namzaric working with Adamas, we got a product to market that the Alzheimer's community has wanted for over 10 years since we launched Namenda in 2004. We think it should be the standard of care for patients with moderate to severe disease and we're at the very early stages of the exclusivity period. And so our primary aim is going to be market share and volume and getting access to physicians and caregivers. As it relates to the discount rate, it's going to be consistent with what we had for XR in 2015. And for XR, I think it'll be consistent in 2016. No dramatic changes. We manage the price volume relationship on that business very, very carefully and we're at a price point that is attractive to health plans and acceptable to us."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Sumant Kulkarni with Bank of America.",14,"Your next question comes from the line of Sumant Kulkarni with Bank of America."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of product offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relative",51,"On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of product offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relatively significant contributor in terms of sales?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so maybe, David, you want to talk about our dry eye pipeline for a second or any gaps.",19,"Yes, so maybe, David, you want to talk about our dry eye pipeline for a second or any gaps."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure, look dry eye is a underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actu",135,"Sure, look dry eye is a underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actually receive treatment at the moment. And I think with Restasis, obviously, we have the leading product. Oculeve is a very interesting device. I used it myself recently. I can assure you it works and it's really adding to our product line. In addition to the anti-inflammatory agents, like Restasis, there are some other opportunities in the biotech pipeline with different mechanisms of action. So I think in the future, we are going to see either opportunities out there, which are going to be effective via other approaches in dry eye."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Bill, anything to add?",4,"Bill, anything to add?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll just say, right now, we have the waterfront largely covered: We have an OTC, our artificial tear. Oculeve, essentially, is a natural tear option and then Restasis is an anti-inflammatory. And so we offer more complete product line for the eye ca",72,"Yes, I'll just say, right now, we have the waterfront largely covered: We have an OTC, our artificial tear. Oculeve, essentially, is a natural tear option and then Restasis is an anti-inflammatory. And so we offer more complete product line for the eye care community than any company in the sector. And I agree with David that there are a few opportunities out there but we have most of the market covered."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And I think also, people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its singl",193,"And I think also, people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its single-dose applicator, is dosage and compliance because it's very hard to get that little single dose in the eye. And so for patient convenience, and patient compliance and dosing, the multidose applicator is a huge something and something that we're very excited about bringing to market next year. And then keep in mind, we also have 4 other development programs of both Restasis and novel mechanisms earlier in our pipeline. On Bystolic in cardio, I mean, I think the way I think about it -- and Bill, certainly chime in, is Bystolic, while certainly a cardio drug, is managed a bit more like a primary care drug and about 80% of its volume comes from our primary care field force. We do have a partnership with Trevena for an earlier-stage products, so we're not completely walking away from cardio. But it's not one of our core focus therapeutic areas. Bill or David, anything you'd add?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, that's absolutely right. The exclusivity period of Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific follow",48,"Yes, that's absolutely right. The exclusivity period of Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific following in cardiology and primary care."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And I always hear anecdotal, but I hear from doctors all the time about it being their favorite beta blocker to prescribe, so long as they can get it through managed care.",32,"And I always hear anecdotal, but I hear from doctors all the time about it being their favorite beta blocker to prescribe, so long as they can get it through managed care."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Marc Goodman with UBS.",13,"Your next question will come from the line of Marc Goodman with UBS."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent or maybe Bill, can you talk about some of the key products in the product in the portfolio and just the dynamics in the quarter? Restasis seemed to be very, very strong in the quarter, much bigger than what we thought. Breast aesthetics is much weak",68,"Brent or maybe Bill, can you talk about some of the key products in the product in the portfolio and just the dynamics in the quarter? Restasis seemed to be very, very strong in the quarter, much bigger than what we thought. Breast aesthetics is much weaker than we thought and Botox. Just some of the key products and just the dynamics, U.S. versus international, what's going on."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So maybe I'll ask Bill to talk about his and then, Philippe, maybe you can chime in on a few of the key aesthetic products.",26,"So maybe I'll ask Bill to talk about his and then, Philippe, maybe you can chime in on a few of the key aesthetic products."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on that.",285,"I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on that. We think the trends in the second quarter look terrific, and I think the outlook for the rest of the year is the same. I don't see anything that would disrupt the reliability of that sales frame. As it relates to Restasis, we're focused on a large OTC artificial tear market. There are millions of patients overusing artificial tears. We have an effort where -- to increase the diagnosis rate through in-office screenings for dry eye, which have been linked to blurred vision, adverse post-op outcomes, and so there's an educational effort there. And then finally, we launched a primary care effort for Restasis, and the formulary coverage on the drug is rock solid. And then I'd just probably add Linzess in there. We have our foot on the gas. The response to our second wave of direct-to-consumer advertising is exceeding industry norms. We just launched a effort into long-term care for the first time since Linzess was approved and that's about 25% of the market. Our relationship with Ironwood is excellent, and we're waiting to launch a low-dose version of Linzess. And so I feel very good about our top products, and as Brent mentioned in his opening remarks, 12 of our 15 products are increasing. If you look at the U.S. business, 12 of the 15 products are increasing at a double-digit rate. And we've had virtually, in my opinion, no disruption due to the integration and there's total focus on customers."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Philippe, you have some thoughts?",5,"Philippe, you have some thoughts?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. On -- facial business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also on Botox, which grew by 12.5%. All those growth is mostly linked to our strong DTC campaign. And you might have see",85,"Sure. On -- facial business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also on Botox, which grew by 12.5%. All those growth is mostly linked to our strong DTC campaign. And you might have seen our Botox ad and Voluma ad. And on Voluma, you can see that the brand awareness increased by 42% from 27% in Q1. So very strong business and linked to very strong advertising during the second quarter."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Ronny Gal with Bernstein.",13,"Your next question will come from the line of Ronny Gal with Bernstein."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just a quick housekeeping one. Would you be able to provide us the constant-currency growth rate for the aesthetics products. This is, I guess, the way we're tracking this market. It will be very useful to have though. And then second, regarding the [indi",90,"Just a quick housekeeping one. Would you be able to provide us the constant-currency growth rate for the aesthetics products. This is, I guess, the way we're tracking this market. It will be very useful to have though. And then second, regarding the [indiscernible] mesalamine franchise, I noticed that you were excluded on both CVS and Express formularies starting in 2016. How should we think about this franchises there? Another phase to this franchise or is this something that will generally -- we should think about as flat to declining"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes. So Tessa, you want to take the first one?",10,"Yes. So Tessa, you want to take the first one?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so on an overall basis, ex currency, we grew about 11%. Think about it this way, most of our aesthetics products are mostly U.S. products. So with -- there are products sold internationally but it's not significant as it relates to the product portfo",60,"Yes, so on an overall basis, ex currency, we grew about 11%. Think about it this way, most of our aesthetics products are mostly U.S. products. So with -- there are products sold internationally but it's not significant as it relates to the product portfolio. So a good amount of them does not have any currency impact, given they're U.S.-based."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, and as it relates to the mesalamine product line, as you all know, Ronnie, you win some and lose some. We got a big win with Linzess on that same formulary at the expense of Amitiza. But as it related to the mesalamine product line, they excluded it.",93,"Yes, and as it relates to the mesalamine product line, as you all know, Ronnie, you win some and lose some. We got a big win with Linzess on that same formulary at the expense of Amitiza. But as it related to the mesalamine product line, they excluded it. We view it as a mature business. It is promoted behind Linzess. We have a core group of users. We're managing volume and of course, taking price increases when and where appropriate. And that's how I would think about it, as an established business."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Elliot Wilbur with Raymond James.",14,"Your next question will come from the line of Elliot Wilbur with Raymond James."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And just running the segment data, it looks like the generic business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess, going forward, we're all sort of tasked with trying to figure out how much of the proceeds",118,"And just running the segment data, it looks like the generic business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess, going forward, we're all sort of tasked with trying to figure out how much of the proceeds from the generic business will be applied to immediate debt reduction versus potentially using internal cash flow generation to pay down debt and target external opportunities. But is that sort of right percentage to think about and kind of just sort of a ballpark number when thinking about your prior indications that the combined business would generate around $8 billion in free cash flow? Would the generic business account for roughly 20%, 25% of that?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","It's at -- and Tessa can certainly add her two cents. Elliot, I think it's not that simple and that's the issue I think we're trying to highlight with the earlier comments around it being tough for you guys. And our apologize in advance for that for the n",170,"It's at -- and Tessa can certainly add her two cents. Elliot, I think it's not that simple and that's the issue I think we're trying to highlight with the earlier comments around it being tough for you guys. And our apologize in advance for that for the next couple of quarters because what's in that business is, as we reported today, isn't necessarily what's being sold to Teva down a straight line. Also, as you do GAAP reporting and reporting around discontinued operations, what gets assigned to what part of each business is also not intuitive and not necessarily straightforward to reality either. So it's going to make for some difficult quarters ahead. Again, we are committed to as much transparency as we can possibly provide around product sales and perhaps, cash flow may be a good way to look at the business. But it's not as straightforward or as intuitive as you would hope or want it to be, just in fairness. I don't know, Tessa, you're..."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I mean, if I may just add to that, just to give a little bit of context is to remember that we were really managing the business on a consolidated basis. We weren't managing the business separately, as solely a generic business and a branded business",160,"Yes, I mean, if I may just add to that, just to give a little bit of context is to remember that we were really managing the business on a consolidated basis. We weren't managing the business separately, as solely a generic business and a branded business. We didn't have the holding company approach. We actually were managing the business on a consolidated basis and from a segment reporting basis, even today in International Brands or generic products in there. And in Global Generics, there's also branded products. The other thing to note, which you also highlighted is, from a balance sheet perspective, it's really all intermingled as it relates to debt and the tax rate, some of the things that are not necessarily operationally related. So I just wanted to give context as to why it's not as difficult to sort of like strip out and do a percentage of cash flow and say that's what's attributable to generics."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Randall Stanicky with RBC Capital.",14,"Your next question will come from the line of Randall Stanicky with RBC Capital."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, just a question for you. A lot of people have been watching the legacy Allergan products, waiting for some moderation. That hasn't happened. In fact, they were really strong. And so the question that I have is, just given the difference in spending",107,"Brent, just a question for you. A lot of people have been watching the legacy Allergan products, waiting for some moderation. That hasn't happened. In fact, they were really strong. And so the question that I have is, just given the difference in spending support levels on sales and marketing between the legacy Allergan and where you're at today -- and I'm just looking at Slide 15, number one, do you feel like that infrastructure is rightsized? And then secondly, just your confidence level on some of the key products in being able to continue to sustain that growth. I mean, Botox and Restasis were very strong."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think -- Randall, that's a great question. I think we are -- we have rationalized our sales force for our acquisitions and for the market as we see it over the next few years, and so we don't anticipate any additional cuts in the field. And in fact",220,"Yes, I think -- Randall, that's a great question. I think we are -- we have rationalized our sales force for our acquisitions and for the market as we see it over the next few years, and so we don't anticipate any additional cuts in the field. And in fact, we would selectively add if we thought the opportunity paid back. So as an example, with the acquisition of Kythera, we will increase our facial aesthetic sales force by roughly 75 positions, making us the strongest field force in aesthetics by a large margin. And so I think you'll see us continue to look for ways so long as we're increasing our line cloth-type strategy of product flow come, either through our R&D engine or through licensing and acquisition, of building and making sure we maintain leadership, strong leadership positions, commercially in each of our therapeutic areas. 
With respect to spending on DTC and otherwise, we always look at the return on investment. And so to the extent we think we can add more money to Botox or Restasis or Linzess or even Namzaric, which will kick off in the fall DTC, we're always monitoring the situation looking at both response and return on those investments and have no issue making them so long as we see a strong ROI."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","The other thing that we heard legacy Allergan talk a lot about was the international emerging market in Asian geographies as a big opportunity. Is that something that we should still think about for you guys that is in front of you?",42,"The other thing that we heard legacy Allergan talk a lot about was the international emerging market in Asian geographies as a big opportunity. Is that something that we should still think about for you guys that is in front of you?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think it is. It's a slower build but big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next week with",113,"Yes, I think it is. It's a slower build but big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next week with our team looking at how we can continue to leverage our infrastructure in Latin America and grow. So clearly, the divestiture of the Teva business has some drawbacks in mid-markets, like Eastern Europe and Russia, and that we leveraged the old legacy activist infrastructure in those markets. But I think we can compensate for those and continue to grow and build in emerging markets."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Umer Raffat with Evercore ISI.",14,"Your next question will come from the line of Umer Raffat with Evercore ISI."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Maybe the first one for David. David, what's the status of the DARPin Japanese trial that's ongoing? Should we be expecting an update soon? And what will that look like? And then second one for Brent, if I may. On transformational M&A, the question that w",92,"Maybe the first one for David. David, what's the status of the DARPin Japanese trial that's ongoing? Should we be expecting an update soon? And what will that look like? And then second one for Brent, if I may. On transformational M&A, the question that we all keep getting from investors, so how do you think about companies with growth profiles that might be lower than with your 10% or companies with potential biosimilar headwinds or even ex U.S. companies for that matter? Just wanted to understand how you think about this."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. David, you want to take DARPin? I'll come to the transformational M&A question.",14,"Sure. David, you want to take DARPin? I'll come to the transformational M&A question."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so sure, yes. So DARPin in Japan, we actually want Japan to join in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional smaller study in the United States. We're in the proce",78,"Yes, so sure, yes. So DARPin in Japan, we actually want Japan to join in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional smaller study in the United States. We're in the process of finalizing those studies prior to including Japanese sites in the Phase III trials sometime next year. So yes, there will be some updates on that going forward."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think to your second point, Umer, around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth",352,"Yes, I think to your second point, Umer, around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth rate because I think based on at least today's measure, the only one with a higher growth rate is Celgene. So that would really limit the universe. That being said, I think that the issue for us is, look, we want to be in Growth Pharma. Would we be willing to go from, let's say, roughly 10% to a 9% top line growth rate to do a highly accretive bottom line deal? The answer is absolutely. Would we be willing to go from 10% to 3% or 4% top line growth to do a highly accretive deal? I would say highly unlikely. And so we want to go out and make sure that we can acquire something that we believe has a growth orientation to it, that has longer-duration assets. And I think you should also keep in mind, we're pretty, as I use the word, bold in our thinking. So I think a lot of people look at the universe of transformational deals and say, ""Well, you can't touch this because it's got this particular product drag"" or this particular issue. We've been known to be very creative in solving for those things in the past and albeit a very deal, I would point to Furiex as just an illustration, where they had 2 assets. They had the NDA for eluxadoline and they had a royalty stream from Takeda. We divested the royalties stream of Takeda to Royalty Pharma at the time we announced the deal. We had that prewired. And so we kept what we wanted and we sold something that was valuable to somebody else to help pay for the deal. And so to the extent we look at companies or opportunities that have things we like, and some things, perhaps, we don't like, there are always potential solutions for solving for those issues."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And your next question will come from the line of Gregg Gilbert with Deutsche Bank.",15,"And your next question will come from the line of Gregg Gilbert with Deutsche Bank."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, if another party were to boldly approach you as an inversion target, other than doing what's best for shareholders, which I think you have a reputation of doing, along with Paul and the board, are there certain elements of the model and its special",64,"Brent, if another party were to boldly approach you as an inversion target, other than doing what's best for shareholders, which I think you have a reputation of doing, along with Paul and the board, are there certain elements of the model and its specialness and growth profile that you'd be concerned about that might play into your thinking about longer-term shareholder value creation?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, Gregg, I think you're right. It would have to be a bold offer. Second, I think Paul and I always would debate and talk to our board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so spe",192,"Yes, Gregg, I think you're right. It would have to be a bold offer. Second, I think Paul and I always would debate and talk to our board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so special about this company, a lot of it goes to the depth and quality of our management team. And so to the extent someone would be open to thinking about cultural change and change and balance to leadership and talent and management, I think that would be more helpful for us. I think clearly, our commitment to R&D and the way we think about R&D is also very special. And I think our ability to be nimble and move quickly and do what we believe is always in the shareholders' best interest is also a bit unique. And so those are the types of discussions that we would have. It's not limited to that but that would be, I think, at least top of mind, for debate and I see Paul his shaking his head so I know he's in agreement."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of David Maris with BMO Capital.",14,"Your next question will come from the line of David Maris with BMO Capital."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On Naurex, this looks to be like a potential billion-dollar-plus drug and I know we'll cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this. How it's differentiated the market? But also, most impor",57,"On Naurex, this looks to be like a potential billion-dollar-plus drug and I know we'll cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this. How it's differentiated the market? But also, most importantly, what are the next steps toward the path to approval?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll ask David to comment. I'll just give you my quick take of why I was so excited to do the deal with Naurex is that, this is an area -- a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, t",170,"Yes, I'll ask David to comment. I'll just give you my quick take of why I was so excited to do the deal with Naurex is that, this is an area -- a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, the minority of patients are adequately served by SSRI or SNRI. And then, they have to live with, in some cases, very difficult side effects from those medicines as well. It's a long onset of action for those with acute issues that need to be dealt with more quickly. And I think, David, you mentioned this in your earlier remarks. There's been no real novel breakthrough in depression in about 20 years. And so for us to be able to be at the forefront of potentially revolutionizing this very large and horrific disease is something that I think that's very exciting for us, given our commitment to leading in CNS and in particular, psychiatry. David, your two cents?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I've only got time for two cents apparently, so I have to be quick. So I've been working in psychiatry in 20 years. I've taken compounds through to the market. Bill and his team have commercialized some of the biggest selling antidepressants. So I think t",193,"I've only got time for two cents apparently, so I have to be quick. So I've been working in psychiatry in 20 years. I've taken compounds through to the market. Bill and his team have commercialized some of the biggest selling antidepressants. So I think the team that we got here knows depression and the area over the last 20 decades. So when an opportunity like Naurex comes along with a novel mechanism of action over the last 2 decades, yes...
So when an new opportunity comes along with a new mechanism of action I think the team here can recognize it and seize it pretty quickly. These things are exciting: completely novel mechanism of action, showing a fast onset of action in depression, in -- and not only in depression but in depression where the patients failed to respond to SSRIs. So that's an exciting opportunity. And the next steps for us are to get into Phase III as quickly as possible with GLYX-13, the lead molecule, and to get into Phase IIb with the second compound in NRX-1074. And we aim to do that as early as possible next year."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Certainly, we'd like to close a deal, but then we'll move pretty aggressively to doing it.",16,"Certainly, we'd like to close a deal, but then we'll move pretty aggressively to doing it."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And our final question for the day will come from the line of David Risinger with Morgan Stanley.",18,"And our final question for the day will come from the line of David Risinger with Morgan Stanley."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","David, are you there?",4,"David, are you there?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Sorry about that. I apologize. I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slides. Could you just tell us",67,"Sorry about that. I apologize. I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slides. Could you just tell us what the organic growth was in the second quarter of the generics business that you're selling? And then I have a follow-up."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, David, if I understand the question, I think the differences are between what we have and what Teva had on their slide deck and it will be very difficult for us to comment on the differences between what we have and what another company has.",46,"Yes, David, if I understand the question, I think the differences are between what we have and what Teva had on their slide deck and it will be very difficult for us to comment on the differences between what we have and what another company has."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the difference and, obviously, we can't comment on their 2016...",31,"So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the difference and, obviously, we can't comment on their 2016..."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And just to be fair, it's their number for '16, not our number for '16. Just to be clear.",19,"And just to be fair, it's their number for '16, not our number for '16. Just to be clear."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences. And the revenue reported on your [indiscernible] slide...",29,"Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences. And the revenue reported on your [indiscernible] slide..."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","We can address that, yes.",5,"We can address that, yes."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","David, it's Lisa. So in the Top Global Branded Product Highlight slide, the ex U.S.-branded products from Forest, Warner Chilcott and Aptalis are not counted as generic products. They're counted in the brand total. When you look at our Global Generics seg",63,"David, it's Lisa. So in the Top Global Branded Product Highlight slide, the ex U.S.-branded products from Forest, Warner Chilcott and Aptalis are not counted as generic products. They're counted in the brand total. When you look at our Global Generics segment, our Global Generics segment still counts those as per accounting rules as part of the Global Generics business. That's the difference."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And in terms of the organic growth of the generics business, what was that in the second quarter?",18,"And in terms of the organic growth of the generics business, what was that in the second quarter?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's what we gave you as -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter.",22,"That's what we gave you as -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's not a clean -- that's the point I was trying to make earlier about why it's so difficult to model. That's not apples-to-apples of what's being sold and what's staying. There are puts and takes in -- from the segments versus what was actually being",55,"That's not a clean -- that's the point I was trying to make earlier about why it's so difficult to model. That's not apples-to-apples of what's being sold and what's staying. There are puts and takes in -- from the segments versus what was actually being sold. And that's what makes things so complicated."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Got it. Okay. Yes, I can follow up on that. And then separately, with respect to the Namenda switch here, obviously, it's taking you longer than expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surpr",83,"Got it. Okay. Yes, I can follow up on that. And then separately, with respect to the Namenda switch here, obviously, it's taking you longer than expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surprised that you're leaving that unchanged. When you talk about 60% to 65%, is that a percentage of the total prescriptions, including the generics? Or is that just the branded Allergan franchise that you're now forecasting?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That would be the total Namenda business, including brands and generics. And the way we think about it is we launched Namzaric only 2.5 weeks ago. A DTC campaign starts in September. We expect exceptional formulary coverage by January 1. And the increment",124,"That would be the total Namenda business, including brands and generics. And the way we think about it is we launched Namzaric only 2.5 weeks ago. A DTC campaign starts in September. We expect exceptional formulary coverage by January 1. And the incremental sales from Namzaric, by essentially taking advantage of an untapped combination market, especially in moderate Alzheimer's disease, effectively is going to get us to our target conversion rate. As I said earlier, if the formulary coverage had not developed like it has, we might have a different situation right here. But as it relates to 2016, Namzaric's going to be highly economical. XR already is and I think the majority of patients are going to have an opportunity to get it."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Okay, thanks, everybody. Brent, would you like to make some closing remarks?",12,"Okay, thanks, everybody. Brent, would you like to make some closing remarks?"
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize, I think we had a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our gro",111,"Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize, I think we had a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our growth agenda and are focused on our key therapeutic categories and establishing long-duration leadership in those categories. I think our leading pipeline, our reloaded capital structure and our now focused on branded pharmaceuticals and willingness to take bold and decisive actions make us the most dynamic company in Growth Pharma. I thank you for your time and look forward to updating you later again in September."
36478,305435704,851152,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, everyone. And I know we didn't get to quite a few people in the Q&A, so we'll follow up with you shortly. Thanks.",24,"Thanks, everyone. And I know we didn't get to quite a few people in the Q&A, so we'll follow up with you shortly. Thanks."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Holly, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] I'll now turn the conference over to Lisa DeFran",49,"Good morning. My name is Holly, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Allergan 2015 Second Quarter Earnings Conference Call. [Operator Instructions] 
I'll now turn the conference over to Lisa DeFrancesco, Vice President, Global Investor Relations. Please go ahead."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015",343,"Thank you, Holly, and good morning, everyone. I'd like to welcome you to the Allergan Second Quarter 2015 Earnings Conference Call.
Earlier this morning, we issued a press release reporting Allergans earnings for the second quarter ended June 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyrighted material of Allergan and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflects our current perspective of the business trends and information as of today's date. Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Allergan business. These factors are detailed in our public periodic filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our second quarter business highlights; Tessa Hilado, our Chief Financial Officer, will then discuss the Allergan second quarter results in more detail; and David Nicholson, Executive Vice President and President of Global Brands R&D, will provide an update on our Brands R&D progress in the quarter and upcoming development milestones. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I'll turn the call over to Brent."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we had last quarter. This was also our first full quarter of a combined operations following the",1372,"Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the second quarter of 2015, which builds on the terrific results we had last quarter. This was also our first full quarter of a combined operations following the close of the Allergan acquisition on March 17. And I'm very proud of what our team has accomplished, especially the momentum they have created to propel our future growth.
Turning to Slide 5. Allergan's second quarter performance highlights our ability to execute on our 4 pillars of our long-term growth strategy. First, operational excellence is yielding exceptional financial performance and results in all key business segments, key products and key geographies. Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive and innovative R&D engine has produced more than 100 branded product approvals globally and 56 branded regulatory submissions year-to-date. And fourth, we're executing on strategic business deals to support our growth in key therapy areas and charge up our pipeline for the future.
We also changed our name to Allergan in the quarter to symbolize our transformation into a leader in Growth Pharma, where brands now contribute more than 2/3 of our company's revenues. With our focus in Growth Pharma, we are encouraging our employees around the world to be bold and smart in the way we think and act. 
Turning to Slide 6. The announcement of our plans to combine our Global Generics business with Teva in a $40.5 billion deal is the latest bold move by our company to continue our transformation towards being a leader in branded Growth Pharma. For years, we've been moving up the innovation curve towards specialty pharma products. This agreement clearly accelerates our transformation. This deal allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapy areas and reload our capital structure to continue our transformation. There's certainly more to come on this story.
We are confident that we are creating the most dynamic company in Growth Pharma, while adding our impressive global generic commercial, generic R&D and operating capabilities to Teva. 
Now let's turn to Slide 7 and talk about the business performance in the second quarter. Our second quarter revenue more than doubled on a year-over-year basis to $5.7 billion as a result of the acquisitions of Allergan and Forest. On a pro forma basis, sales were up 12%, excluding the impact of foreign currency, Namenda IR and divestitures, with double-digit growth in our brand and Global Generics segments. The strong sales increase introduced from the integration of Allergan and Forest were the primary drivers of the 29% increase in earnings per share to $4.41. Meanwhile, non-GAAP EBITDA rose to $2.6 billion and cash flow from operations was about $1.7 billion, excluding onetime cash payments for severance, acquisitions and integration. Tessa will talk more about the financials shortly.
On Slide 8. Our Global Generics business is doing very well and the units that comprise it are firing on all cylinders as we prepare for the combination with Teva. Generics sales are up 17%, excluding the impact of foreign currency. Generic profitability is up and our exceptional generic R&D capabilities are evident, with 12 new first-to-file drugs this year. This brings the total number of ANDAs under review to approximately 220 with 76 confirmed first-to-files.
U.S. Generic revenues were $1.1 billion in the quarter and continued to benefit from new product introductions and contribution from high-barrier and semi-exclusive products, like generic Concerta. Meanwhile, our International Generics team continues to drive excellent performance in key markets, excluding the impact of foreign currency such as the U.K., which was up 85%, including the effect of the Auden Mckenzie transaction that closed in May; and Russia, which was up 32%.
Turning to Slide 9. Our brands business continues to thrive impressive performance with 12 of the top 15 global brands growing, many with double-digit pro forma year-over-year growth. Sales increased 11%, excluding Namenda IR, the divestitures and the impact of foreign exchange. And the success is broad-based. Excluding the impact of foreign currency, we drove double-digit growth in eye care, GI and key woman health products and cardiovascular; double-digit growth from our latest largest leading brands like Botox, Restasis, Namenda XR and our fillers, including Juvederm; double-digit growth from well-established brands like Bystolic, LoLoestrin and Estrace; and double-digit growth from Linzess, Ozurdex and other launch brands, which puts us in excellent position to power growth well into the future. It is a terrific lineup of brands with long exclusivity and is backed by a great team on the ground and our leading pipeline, with multiple shots on each of our 7 priority therapeutic areas.
Turning to Slide 10. We continue to drive conversion of patients to Namenda XR right up to the end of the Namenda IR exclusivity, reaching about 53% before generic entry. With continued promotion and the launch of Namzaric, we believe the penetration rate goes even higher, towards our target of 60% to 65% as the year progresses. And with once a day dosing, formulary access at every 1 of the top 8 plans and a focused sales team, we maintain relatively stable volumes on Namenda XR even as the Namenda IR prescriptions drop. We are now doing the blocking and tackling to build the demand and access for Namzaric. With full promotion just getting underway, our DTC campaign beginning in September and an anticipated 7 out of the top 10 plans having coverage by the beginning of 2016, we think we are well prepared to drive market expansion in 2016. Given the broad use of combination donepezil and memantine therapy, the efficacy of Namzaric and the patient, caregiver and system benefits of one pill, once a day, we think there's a great opportunity for the innovation of Namzaric to become the cornerstone of once-a-day branded market in Alzheimer's treatment.
Turning to Slide 11. In a few moments, David Nicholson will give an update on the pipeline, but I want to point out that our pipeline remains one of the best-kept secrets of our company. With 70 projects in mid to late development, we are in an enviable position of having multiple programs in each of our therapeutic areas to help us sustain leadership in the areas we choose to compete. And we have built this pipeline step-by-step, not by investing big dollars on discovery, but by investing in smart development projects.
Even with the excellent breadth and depth of our current pipeline, we are always on the lookout for R&D assets that can extend our leadership by bringing novel approaches to existing therapy areas. And in the last 2 months alone, we've announced agreements for 4 planned acquisitions in aesthetic eye care and CNS. Each will bring novelty to existing areas and will add to our ability to lead in these therapeutic areas. And each of these deals brings game-changer potential ideas to our pipeline.
Kybella is off to a strong start in aesthetics, with sales already surpassing $1 million and a recent approval in Canada. We are making great progress towards closing the transaction now that we have cleared antitrust review in the U.S. And as we announced yesterday, we no longer intend to issue our shares to complete this acquisition. The Oculeve acquisition has also cleared HSR in the U.S. and we'll look forward to extending our dry eye opportunities with our novel nasal neurostimulation device. In CNS, we're working to close deals to extend our migraine offering with Merck's first in oral -- first-in-class oral CGRP antagonist and the Naurex novel approach to treating mood disorders, including severe depression, which remains a leading cause of suicide.
In closing, our team continues to focus on execution and the results indicate that we are exceptionally skilled at delivering strong operating results, while also doing surprising things that make our company the most dynamic in all of health care. I'm so proud of our team for their performance and I'm looking forward to what we can do with a strength and focus on branded pharmaceuticals and a significantly reduced operating structure and reloaded capital structure. 
With that, I'll now turn the call over to Tessa."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter on Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second q",945,"Thank you, Brent. Good morning, everyone. Turning to our overall results for the second quarter on Slide 13. In Q2, we delivered strong performance, both year-over-year and quarter-to-quarter. On a non-GAAP basis, consolidated net revenue for the second quarter was $5.7 billion, an increase of 36% versus Q1 2015. 
Non-GAAP R&D investment for the quarter was $406 million compared to $185 million in the prior year period. Non-GAAP SG&A as a percentage of revenue was 21.7%, an increase of 3 percentage points over the prior year quarter, as a result of the Forest branded products and Allergan business, which we have higher SG&A spend.
Adjusted EBITDA for the quarter was $2.6 billion, an increase of 203% versus the prior year, driven by strong revenues and higher gross margins across our segments. Non-GAAP earnings per diluted share for the quarter increased 29% to $4.41 compared to $3.42 per diluted share in the second quarter of 2014.
Our non-GAAP tax rate improved from 17.1% in the year-ago period to 14.5% in the current-year quarter, mainly due to the geographic mix of our businesses. Cash flow from operations for the second quarter was $1.4 billion, an increase of 198% versus the year-ago quarter. Excluding acquisition-related restructuring and integration payments, our second quarter free cash flow would be $1.7 billion.
Before turning to our business segment results, I would like to take a moment to review our new segment reporting for the second quarter. In this quarter, we are reporting results in 5 segments: The U.S. Brands segment represents sales and expenses related to branded products within the United States, including Botox therapeutics. The U.S. Medical Aesthetics segment represents sales and expenses related to aesthetics and dermatology products within the United States, including Botox cosmetics. The International Brands segment represents revenues and operating expenses in countries that have the majority of their businesses represented by branded sales and revenues and expenses related to product sales in Canada, Switzerland and Austria. The Global Generics segment represents revenues and operating expenses in countries that have the majority of their business represented by generic product sales, our third-party Medis business and revenues and expenses related to product sales in the U.S., Canada, Switzerland and Austria. The Anda Distribution segment results represents sales and expenses related to distribution of generic and brand pharmaceutical products manufactured by third parties. Also, as a result of Teva's acquisition of Allergan's generic business, Allergan will report its generics business as discontinued operations beginning in the third quarter of 2015. Since the divested business spans both Global Generics and International Brand segments, it will be difficult today to model the remaining Allergan business. We will provide some guidance in September.
Turning now to our U.S. Brand results on Slide 15. The business delivered strong performance year-over-year and quarter-over-quarter. U.S. Brands revenue was $2.44 billion for the quarter, up 331% versus the prior year period and 35% in the prior quarter, driven by the addition of the Forest and Allergan businesses and strong growth across key products, including Linzess and Namenda XR. Adjusted gross margin within U.S. Brands remained steady at 87.4%. SG&A as a percentage of revenue increased to 20.8% versus 17.8% in the year-ago quarter, driven by expenses related to the Forest and Allergan acquisitions.
Turning to Slide 16 and our U.S. Medical Aesthetics business. The second quarter revenues were $487 million, an increase of 510% versus first quarter 2015 results. Second quarter gross margin of 93% and segment margin of 70.6% were largely in line with expectations. SG&A in the quarter remained steady. 
Turning to Slide 17 and our International Brands results. Second quarter revenues were $717 million versus $169 million in the prior year period, an increase of 324%. Gross margins increased 21.7 percentage points to 77.8% in the second quarter, due largely to the inclusion of higher margin legacy Allergan products. Segment SG&A improved 7.2 percentage points to 32% versus Q1 2015 due largely to synergy capture related to the Allergan acquisition.
On Slide 18, Global Generics revenues in the quarter were $1.6 billion, up 10% versus the prior year period. Growth was driven by strong sales in the base business, including generic Concerta, offset in part by additional competition on certain products, including generic Lidoderm. Adjusted gross margins increased 1 percentage points compared to the year-ago quarter due to continued strong performance within our international business. Lower gross margin versus the prior year quarter was mainly due to lower contribution of Guanfacine ER and oxycodone in the second quarter versus the first quarter of 2015. SG&A as a percentage of adjusted net revenue decreased slightly to 15% from 15.8% in the year-ago quarter.
Turning to our Anda business on Slide 19. Revenues increased to $462 million, up from $427 million in the prior year, an increase of 8%, driven by trends in our base business and a higher mix of chain drugstore sales. 
Slide 20 details our debt capitalization following the completion of our first full quarter, following the close of the Allergan acquisition. We ended the second quarter 2015 with total debt of approximately $42.9 billion and equity of $72.1 billion related to the Allergan acquisition and previous financing. In the second quarter, we paid down approximately $1.4 billion of our debt. Currently, our leverage ratio stands at 3.9x debt to pro forma adjusted EBITDA versus 4.1x in the prior quarter. We remain committed to using strong free cash flows from our business segments to accelerate debt repayment, and we continue to remain committed to investment-grade ratings.
I'd now like to turn the call over to David Nicholson, who will provide an update on our Brands R&D progress in the quarter. David?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our Brands R&D team continues to be tremendously productive. Year-to-date and worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approval",1268,"Thanks, Tessa, and good morning, everyone. Let's go to Slide 22. Our Brands R&D team continues to be tremendously productive. Year-to-date and worldwide, our strong late-stage pipeline has delivered more than 100 pharmaceutical and medical device approvals and 56 regulatory submissions. I will highlight some of the most significant of these in my overview. 
Following the first round of integration prioritization, we now have more than 70 mid- to late-stage development projects, with approximately 45 projects in either late-stage development or registration. The productivity of the legacy Allergan R&D organizations is demonstrated by the industry-leading figure of 14 NME approvals in the United States over the last 6.5 years. Going forward, we'll continue to make data-driven prioritization decisions on all of our programs.
In addition to rationalizing and driving productivity from our existing pipeline, we are committed to identifying and executing acquisitions and licensing agreements that further strengthen our long-term leadership position in key therapeutic areas. This is exemplified by our pending acquisitions of Kythera, Oculeve and Naurex and licensing of Merck's oral CGRP programs during the quarter. 
The next 2 slides summarize some highlights and describe the progress in our late-stage pipeline. Slide 23 shows late-stage game-changing opportunities across our therapeutic areas. 
In aesthetics, we are adding Kybella from Kythera to our pipeline. Our aesthetics pipeline already includes bimatoprost for hair growth, Aczone and sarecycline for acne as well as many line extensions to our fillers. In eye care, we are adding the intranasal dry eye device from Oculeve to our dry eye franchise, further enhancing our leading position in this therapeutic area. 
My colleagues and I have reviewed our restated data and again, find our efficacy and tolerability data very compelling in comparison to recently published data from other compounds in development and registration. In Phase III, we are developing DARPin and have a sustained-release formulation of bimatoprost. In CNS, we are adding the Naurex NMDA modulators to our pipeline. These compounds have the first novel mechanism for mood disorders for more than 2 decades. We're also adding oral CGRP antagonists. These compounds, in license from Merck, are designed both for the acute treatment as well as for the prophylaxis of migraine. We also have cariprazine in development and Namzaric, which combines 2 complementary therapeutic agents, Namenda and Aricept. 
Recently, much attention has turned to prevention of Alzheimer's and like all of us, I hope that effective preventive therapy will be discovered. Data on Namzaric was recently presented at the 2015 Alzheimer's Association International Conference. The efficacy of Namzaric in patients with Alzheimer's is at least a similar magnitude to that reported with the present preventative agents in development. 
In GI disorders, together with our partner, Ironwood, we continue to develop dosage and formulations of our IBS-C agent, Linzess, to offer a very complete package to physician and patients. Also, we're completing the initial development of eluxadoline, Viberzi, for IBS-D. 
In urology, together with our partner Serenity, we have intranasal desmopressin completing Phase III for nocturia. In our anti-infective franchise, we continue to develop Dalvance and Avycaz. In biologics, Phase III will be completed this year for bevacizumab, a biosimilar of Avastin, which is part of our partnership with Amgen. Last, but certainly not least, is Botox. We continue to further develop and launch these agent across our aesthetics, CNS and urology franchises. 
Turning to Slide 24. I'm going to update you on progress with regulatory authorities to key late-stage products.
In aesthetics, Natrelle Inspira textured breast implants received FDA approval for women undergoing breast reconstruction, augmentation or revision surgery, and we are on track for FDA submission of our Volbella filler in third quarter 2015. Yesterday, we received FDA approval to market 28 additional styles of Natrelle 410 breast implants. 
In Asia, we received licensing rights for commercial sales of Juvederm in China and submitted an NDA for Botox for crow's feet lines in Japan. In eye care, Botox received approval in Japan for the treatment of strabismus. We're on track for FDA submission of a multidose, preservative-free formulation of Restasis in September. We've currently enrolling patients in Phase III trials for bimatoprost in the U.S., and we've initiated pivotal Phase III trials of our lead DARPin in age-related macular degeneration, on target in June this year. 
In CNS, we have a PDUFA date in September for cariprazine as a treatment for schizophrenia and bipolar mania. And this quarter, we launched Namzaric and we'll be filing additional dose combinations of this agent later this year.
In GI, our strong pipeline does continue to develop new opportunities. We expect to complete the Phase III study for a low-dosage form of Linzess to treat chronic idiopathic constipation in the second half of the year, and we expect to submit an sNDA for this indication next year. 
Meanwhile, Viberzi, eluxadoline, has been approved by the FDA as a twice-daily oral treatment for IBS-D. We're awaiting DEA scheduling of Viberzi prior to launch of this product in the United States. And we submitted the dossier of eluxadoline in Europe in May.
In women's health, enrollment in our Phase III trial of Esmya for the treatment of bleeding disorders caused by uterine fibroids is on track. We're committed to completing trial enrollment this year.
In urology, we completed our Phase III trials of SER 120 in nocturia. The data is under our review prior to submission to the agency. In anti-infectives, our development of a single-dose formulation of Dalvance remains on track. We've made regulatory submissions for approval in both the United States and Europe. We're also anticipating approval for Teflaro in bacteremia during the course of this year.
On Slide 25, we outline some of our most recent business development opportunities. Obviously, these help us to further solidify our leadership position in our core therapeutic areas. 
With Kythera, we add a first-in-class agent, Kybella, for the treatment of submental fat, or double chin, to our product line. The product is launched in the States and was recently approved in Canada. In addition, Kythera has an interesting and genetically validated hair growth product in early development. 
Oculeve will strengthen our leading position in dry eye with the OD-01 development program, an intranasal neurostimulatory device that increases tear production in patients with dry eye. 
Our licensing agreement with Merck builds on our commitment to the development of treatments for migraine. We're adding oral formulations of CGRP antagonists to our product line. The use of both small molecules as well as antibodies has clearly shown that CGRP antagonism is effective in treating migraine. There are 4 injectable antibodies in development, whilst we will have the only oral CGRP antagonist. 
Finally, Naurex. The acquisition of Naurex adds innovative development programs in depression to our pipeline. Depression is an area of medicine that has seen minimal progress for the last 20 years. The Naurex compounds are NMDA modulators, a unique approach to the treatment of depression. These agents have the potential to be fast-onset antidepressants and, hence, may be beneficial in the alleviation of suicidality, which is so often a terrible feature of this disorder. In early-stage development, the Naurex team showed their compound indeed to be fast in onset and also to be effective in treating depression, which fail to respond to traditional antidepressants.
In closing, the second quarter of 2015 was another period of continuous strong productivity for the Allergan R&D team. We look forward to continue to deliver on the promise of many of our development programs in our pipeline for the remainder of 2015 and beyond. 
With that, I'd like to turn it over to Brent for closing remarks.
Brent?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, David. As you've heard, we have a lot going on and look forward to giving you updates on our progress over the next few months. In mid- to late September, we will provide updated guidance for continuing operations for the remainder of 2015. Thi",125,"Thank you, David. As you've heard, we have a lot going on and look forward to giving you updates on our progress over the next few months. In mid- to late September, we will provide updated guidance for continuing operations for the remainder of 2015. This will reflect our Global Generics business as discontinued operations as we wait for the close of the transaction with Teva next year.
In conjunction with our third quarter earnings result, we also plan to host an R&D update meeting on November 4 in Irvine, California at our campus. It will be our opportunity for the R&D team to shine a spotlight on the post-prioritization R&D portfolio.
With that, I'd like to turn the call back to Lisa for Q&A."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. We'll now take questions. [Operator Instructions]",9,"Thank you, Brent. We'll now take questions. [Operator Instructions]"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question will come from the line of Chris Schott with JPMorgan.",15,"[Operator Instructions] Your first question will come from the line of Chris Schott with JPMorgan."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","One of the questions we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the T",100,"One of the questions we've been getting post the Teva divestiture is, as you guys are considering transformational acquisitions, it's obviously a very fluid market out there right now. Is it possible for Allergan to pursue a large transaction before the Teva deal closes if the right transaction were available, I guess, both from an operational and financial standpoint? And just a very quick second one on that guidance in September, is that just 2015? Or can we think about a preliminary view on either '16 or an update on the $25 2017 outlook at that time as well?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, thanks, Chris. So with respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible",185,"Yes, thanks, Chris. So with respect to potential for transformational M&A, I think that the way to think about it is the most likely scenario would be after the close of Teva, if in fact, we were to do transformational M&A. Certainly, anything is possible prior to that and we have always been bold in thinking about how to execute things if the timing was right. But I think in fairness, given the commitment to our investment-grade rating and our ability to deploy cash after the deal has closed versus prior -- or perhaps, our flexibility to deploy cash after the deal closes is better than prior. I think that's probably how you should think about it. Now that doesn't mean we couldn't engage in analysis or discussions or other things like that with someone who is interested in doing a deal with us, or we were interested in doing a deal with them. But I would say that it's most likely after the close of the Teva transaction. 
With respect to the guidance, maybe I'll ask Tessa to talk about that for a second."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so in September, what we will be providing you is what the remaining will -- business will look like since Teva will be discontinued operations. That's not exactly a very easy separation to do. And also just to manage expectations, so we provide that",118,"Yes, so in September, what we will be providing you is what the remaining will -- business will look like since Teva will be discontinued operations. That's not exactly a very easy separation to do. And also just to manage expectations, so we provide that given the account rules, it will be very difficult at this point in time for you to model what the remaining 2015 will look like. As an example, for instance, debt will continue to remain with the Allergan-branded business and not go to discontinued operations. There's no such thing as non-GAAP discontinued operations. So we'll provide a little bit more clarity come September, but it's really largely focused on the remainder of 2015."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Jami Rubin with Goldman Sachs.",14,"Your next question will come from the line of Jami Rubin with Goldman Sachs."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just to follow up on that earlier question, Brent or Tessa. So when you give discontinued -- or rather, when you give pro forma earnings going forward, which presumably only includes the branded business, will that branded business also include all the in",156,"Just to follow up on that earlier question, Brent or Tessa. So when you give discontinued -- or rather, when you give pro forma earnings going forward, which presumably only includes the branded business, will that branded business also include all the interest expense that you're carrying on your books? In other words, I would assume that some of that $40.5 billion is going to reduce debt. So how do we think about that when we think about the base business going forward? And then secondly, just to follow up on that $25 number, that $25 obviously includes about $5 or $2.4 billion in EBIT from the generic business. Brent, at what point can we expect you to update us on that guidance? And I think on the last call, you didn't withdraw that $25. So any, again, any color on how we should think about the company's ability to replace that $2.4 billion in EBIT?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So Tessa, you want to take the first one?",9,"So Tessa, you want to take the first one?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So you definitely touched on some of the nuances related to discontinued operations as it pertains to debt as an example, for instance. So on a go-forward basis, in the September earnings, what you will see is that, debt will reside in the remaining compa",137,"So you definitely touched on some of the nuances related to discontinued operations as it pertains to debt as an example, for instance. So on a go-forward basis, in the September earnings, what you will see is that, debt will reside in the remaining company and not allocated to discontinued ops. Obviously, as you think about that on a go-forward basis, it would really largely depend on what we do with the capital on a go-forward basis. What we had indicated in our call related to Teva that we would use a portion of the proceeds to pay down debt. But again, it's largely dependent on how much we used for capital deployment. Having said that, though, we are committed to our investment-grade rating. So we will ensure that the appropriate amount of debt is paid down."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think the net-net, Jami, on guidance and knowing this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually close the transaction, it will be ver",271,"Yes, I think the net-net, Jami, on guidance and knowing this will drive your teams nuts and many on the phone nuts. The rules are the rules. It's the accounting policy. So the next couple of quarters until we actually close the transaction, it will be very difficult for you guys to run models and do clean comparisons. We are, as always, committed to as much transparency around product sales, like we were in this press release. And we will do the best we can, given the rules that we have to all live with. But it will make for some tough modeling work on your guys' part over the next 2 or 3 quarters. And we apologize in advance for that and we'll do everything we can to help facilitate that. 
With respect to the $25 aspiration, what I said -- I think you asked this question on the deal call, if I recall correctly, Jami, was that we absolutely remain steadfast in our aspiration to increase our earnings per share to as high as possible, including the $25 target. What has changed, obviously, is by selling the generics business and the $2.4 billion of EBITDA to Teva, the timing of that aspiration. And so we need to continue to look at how we will deploy that capital and how the timing of the deployment of that capital will pull through to give a more precise view of it. So again, we're not withdrawing the $25 but we will come back and have to add some variables to it, like capital deployment and timing of capital deployment to get there."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Liav Abraham with Citi.",13,"Your next question will come from the line of Liav Abraham with Citi."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, another question on the topic of business development. I wanted to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in a potentially transformational transaction and interested in moving up",130,"Brent, another question on the topic of business development. I wanted to get a better understanding of your appetite for earlier-stage research. You've said that you're interested in a potentially transformational transaction and interested in moving up the value chain. You've also said that you're not necessarily in favor of early-stage research. I'm trying to reconcile these comments. Can you engage in a larger pharma transaction and move up the value chain without a greater commitment to early-stage research going forward? And isn't this route necessary to at least -- to a certain extent, to secure longer-term organic growth? And then very quickly for Bill, can you comment on how much you'll be giving away incrementally in terms of rebates in order to secure formulary status for Namzaric next year?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. So Liav, I think the answer to the first part of your question is yes! With an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or som",192,"Sure. So Liav, I think the answer to the first part of your question is yes! With an exclamation point on it. I think we love research and we have no issue with research. We just don't like to do it ourselves unless, of course, it's unique research or something that isn't wildly -- widely available in external research like venture-backed companies or researcher academia-backed companies or smaller biotechs. And so I think if you look at what David and his team did with Allergan, we kept the research capabilities where they had unique strength and proven track records like in aesthetics and eye care. And we have -- and we will continue to fund that as appropriate. What we won't to do is waste our money on R&D that is widely available elsewhere. And so I think you have to really consider us as very practical when it comes to research, basic research. But also a virtual-like company when it comes to research as demonstrated by some of the deals we just did, like Naurex, or even the licensing of the oral CGRPs from Merck. 
David, any other comments on research?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Look, one of the points that I always like to make is how impressed I am with the biotech industry these days. I've seen the biotech industry today with -- founded by so many brilliant academic scientists, coupled with more and more people with pharmaceut",115,"Look, one of the points that I always like to make is how impressed I am with the biotech industry these days. I've seen the biotech industry today with -- founded by so many brilliant academic scientists, coupled with more and more people with pharmaceutical executive experience; excellent in generating early-stage molecules, which we can pick up and further develop through to the market. There are plenty of opportunities out there. Also, when you look at what's going on in the academic world, you increasingly see academic institutions setting themselves up to generate more spinoff opportunities. And we are very keen on interacting with the external world. We think that's where research should be performed.."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And to be fair -- and you've heard me say this before, Liav. I don't think what we do is any different than the great other innovators in our industry and really not doing discoveries themselves, but licensing in compounds. And there's some fantastic comp",111,"And to be fair -- and you've heard me say this before, Liav. I don't think what we do is any different than the great other innovators in our industry and really not doing discoveries themselves, but licensing in compounds. And there's some fantastic companies that have solved for huge unmet medical need without discovery labs. And I won't go through naming them but they get the biotech moniker, but really have no discovery but rather, smart business development and licensing. And that's essentially our approach. We just come at it with a very practical approach and a real bent for not wasting money. 
Bill, you want to talk about Namzaric?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, Liav, listen, on Namzaric working with Adamas, we got a product to market that the Alzheimer's community has wanted for over 10 years since we launched Namenda in 2004. We think it should be the standard of care for patients with moderate to severe d",138,"Yes, Liav, listen, on Namzaric working with Adamas, we got a product to market that the Alzheimer's community has wanted for over 10 years since we launched Namenda in 2004. We think it should be the standard of care for patients with moderate to severe disease and we're at the very early stages of the exclusivity period. And so our primary aim is going to be market share and volume and getting access to physicians and caregivers. As it relates to the discount rate, it's going to be consistent with what we had for XR in 2015. And for XR, I think it'll be consistent in 2016. No dramatic changes. We manage the price volume relationship on that business very, very carefully and we're at a price point that is attractive to health plans and acceptable to us."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Sumant Kulkarni with Bank of America.",14,"Your next question comes from the line of Sumant Kulkarni with Bank of America."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of product offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relative",51,"On your dry eye programs after the purchase of Oculeve, do you see any gaps in the types of product offering that you have in that portfolio? And very quickly, how should we think about your cardiovascular franchise given that Bystolic is still a relatively significant contributor in terms of sales?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so maybe, David, you want to talk about our dry eye pipeline for a second or any gaps.",19,"Yes, so maybe, David, you want to talk about our dry eye pipeline for a second or any gaps."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure, look dry eye is a underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actu",135,"Sure, look dry eye is a underserved market at the moment. There's Restasis out there and a couple of other things in development, but there are not many product offerings for dry eye. And a relatively low proportion of patients suffering from dry eye actually receive treatment at the moment. And I think with Restasis, obviously, we have the leading product. Oculeve is a very interesting device. I used it myself recently. I can assure you it works and it's really adding to our product line. In addition to the anti-inflammatory agents, like Restasis, there are some other opportunities in the biotech pipeline with different mechanisms of action. So I think in the future, we are going to see either opportunities out there, which are going to be effective via other approaches in dry eye."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Bill, anything to add?",4,"Bill, anything to add?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll just say, right now, we have the waterfront largely covered: We have an OTC, our artificial tear: Oculeve, essentially, is a natural tear option and then Restasis is an anti-inflammatory. And so we offer more complete product line for the eye ca",72,"Yes, I'll just say, right now, we have the waterfront largely covered: We have an OTC, our artificial tear: Oculeve, essentially, is a natural tear option and then Restasis is an anti-inflammatory. And so we offer more complete product line for the eye care community than any company in the sector. And I agree with David that there are a few opportunities out there but we have most of the market covered."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And I think also, people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its singl",193,"And I think also, people underestimate the importance of the multidose preservative-free, which we intend to file in September. Having worked in this space before, one of the biggest issues with chronic eyedrops, particularly Restasis because of its single-dose applicator, is dosage and compliance. Because it's very hard to get that little single dose in the eye. And so for patient convenience, and patient compliance and dosing, the multidose applicator is a huge innovation and something that we're very excited about bringing to market next year. And then keep in mind, we also have 4 other development programs of both Restasis and novel mechanisms earlier in our pipeline. On Bystolic in cardio, I mean, I think the way I think about it -- and Bill, certainly chime in, is Bystolic, while certainly a cardio drug, is managed a bit more like a primary care drug and about 80% of its volume comes from our primary care field force. We do have a partnership with Trevena for an earlier-stage products, so we're not completely walking away from cardio. But it's not one of our core focus therapeutic areas. Bill or David, anything you'd add?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, that's absolutely right. The exclusivity period of Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific follow",48,"Yes, that's absolutely right. The exclusivity period of Bystolic extends out for many years. It's a big primary care product. We're going to increase detailing in the second half of the year. We have great formulary coverage and it's got a terrific following in cardiology and primary care."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And I always hear -- anecdotal -- but I hear from doctors all the time about it being their favorite beta blocker to prescribe, so long as they can get it through managed care.",34,"And I always hear -- anecdotal -- but I hear from doctors all the time about it being their favorite beta blocker to prescribe, so long as they can get it through managed care."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Marc Goodman with UBS.",13,"Your next question will come from the line of Marc Goodman with UBS."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent or maybe Bill, can you talk about some of the key products in the product in the portfolio and just the dynamics in the quarter? Restasis seemed to be very, very strong in the quarter, much bigger than what we thought. Breast aesthetics is much weak",68,"Brent or maybe Bill, can you talk about some of the key products in the product in the portfolio and just the dynamics in the quarter? Restasis seemed to be very, very strong in the quarter, much bigger than what we thought. Breast aesthetics is much weaker than we thought and Botox. Just some of the key products and just the dynamics, U.S. versus international, what's going on."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So maybe I'll ask Bill to talk about his and then, Philippe, maybe you can chime in on a few of the key aesthetic products.",26,"So maybe I'll ask Bill to talk about his and then, Philippe, maybe you can chime in on a few of the key aesthetic products."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on that.",285,"I'll start with Botox. Botox therapeutic, we're focused on 2 high-growth areas, which is migraine and overactive bladder. Our priorities right now are to increase injector productivity and expand our injector user base. And we have complete focus on that. We think the trends in the second quarter look terrific, and I think the outlook for the rest of the year is the same. I don't see anything that would disrupt the reliability of that sales frame. As it relates to Restasis, we're focused on a large OTC artificial tear market. There are millions of patients overusing artificial tears. We have an effort where -- to increase the diagnosis rate through in-office screenings for dry eye, which have been linked to blurred vision, adverse post-op outcomes, and so there's an educational effort there. And then finally, we launched a primary care effort for Restasis, and the formulary coverage on the drug is rock solid. And then I'd just probably add Linzess in there. We have our foot on the gas. The response to our second wave of direct-to-consumer advertising is exceeding industry norms. We just launched a effort into long-term care for the first time since Linzess was approved and that's about 25% of the market. Our relationship with Ironwood is excellent, and we're waiting to launch a low-dose version of Linzess. And so I feel very good about our top products, and as Brent mentioned in his opening remarks, 12 of our 15 products are increasing. If you look at the U.S. business, 12 of the 15 products are increasing at a double-digit rate. And we've had virtually, in my opinion, no disruption due to the integration. And there's total focus on customers."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Philippe, you have some thoughts?",5,"Philippe, you have some thoughts?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. On -- facial business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also on Botox, which grew by 12.5%. All those growth is mostly linked to our strong DTC campaign. And you might have see",86,"Sure. On -- facial business grew by 13.5% versus the prior year for the quarter and year-to-date, we grew by 13%. A very strong growth also on Botox, which grew by 12.5%. All those growth is mostly linked to our strong DTC campaign. And you might have seen our Botox ad and our Voluma ad. And on Voluma, you can see that the brand awareness increased by 42% from 27% in Q1. So very strong business and linked to very strong advertising during the second quarter."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Ronny Gal with Bernstein.",13,"Your next question will come from the line of Ronny Gal with Bernstein."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Just a quick housekeeping one. Would you be able to provide us the constant-currency growth rate for the aesthetics products? This is, I guess, the way we're tracking this market. It will be very useful to have though. And then second, regarding the [indi",91,"Just a quick housekeeping one. Would you be able to provide us the constant-currency growth rate for the aesthetics products? This is, I guess, the way we're tracking this market. It will be very useful to have though. And then second, regarding the [indiscernible] mesalamine franchise, I noticed that you were excluded on both CVS and Express formularies starting in 2016. How should we think about this franchise. Is there another phase to this franchise or is this something that will generally -- we should think about as flat to declining?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes. So Tessa, you want to take the first one?",10,"Yes. So Tessa, you want to take the first one?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so on an overall basis, ex currency, we grew about 11%. Think about it this way, most of our aesthetics products are mostly U.S. products. So with -- there are products sold internationally but it's not significant as it relates to the product portfo",60,"Yes, so on an overall basis, ex currency, we grew about 11%. Think about it this way, most of our aesthetics products are mostly U.S. products. So with -- there are products sold internationally but it's not significant as it relates to the product portfolio. So a good amount of them do not have any currency impact, given they're U.S.-based."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, and as it relates to the mesalamine product line, as you all know, Ronny, you win some and you lose some. We got a big win with Linzess on that same formulary at the expense of Amitiza. But as it related to the mesalamine product line, they excluded",94,"Yes, and as it relates to the mesalamine product line, as you all know, Ronny, you win some and you lose some. We got a big win with Linzess on that same formulary at the expense of Amitiza. But as it related to the mesalamine product line, they excluded it. We view it as a mature business. It is promoted behind Linzess. We have a core group of users. We're managing volume and of course, taking price increases when and where appropriate. And that's how I would think about it, as an established business."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Elliot Wilbur with Raymond James.",14,"Your next question will come from the line of Elliot Wilbur with Raymond James."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And just running through the segment data, it looks like the generic business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess, going forward, we're all sort of tasked with trying to figure out how much of the p",120,"And just running through the segment data, it looks like the generic business contributed about 23% of the segment profitability, inclusive of R&D allocation. And I guess, going forward, we're all sort of tasked with trying to figure out how much of the proceeds from the generic business will be applied to immediate debt reduction versus potentially using internal cash flow generation to pay down debt and target external opportunities. But is that sort of the right percentage to think about and kind of just sort of a ballpark number when thinking about your prior indications that the combined business would generate around $8 billion in free cash flow? Would the generic business account for roughly 20%, 25% of that?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","It's at -- and Tessa can certainly add her two cents. Elliot, I think it's not that simple and that's the issue I think we were trying to highlight with the earlier comments around it being tough for you guys. And our apologize in advance for that, for th",171,"It's at -- and Tessa can certainly add her two cents. Elliot, I think it's not that simple and that's the issue I think we were trying to highlight with the earlier comments around it being tough for you guys. And our apologize in advance for that, for the next couple of quarters. Because what's in that business is, as we reported today, isn't necessarily what's being sold to Teva down a straight line. Also, as you do GAAP reporting and reporting around discontinued operations, what gets assigned to what part of each business is also not intuitive and not necessarily straightforward to reality either. So it's going to make for some difficult quarters ahead. Again, we are committed to as much transparency as we can possibly provide around product sales and perhaps, cash flow may be a good way to look at the business. But it's not as straightforward or as intuitive as you would hope or want it to be, just in fairness. I don't know, Tessa, you're..."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I mean, if I may just add to that, just to give a little bit of context is to remember that we were really managing the business on a consolidated basis. We weren't managing the business separately, as solely a generic business and a branded business",160,"Yes, I mean, if I may just add to that, just to give a little bit of context is to remember that we were really managing the business on a consolidated basis. We weren't managing the business separately, as solely a generic business and a branded business. We didn't have the holding company approach. We actually were managing the business on a consolidated basis and from a segment reporting basis, even today in International Brands or generic products in there, and in Global Generics, there's also branded products. The other thing to note, which you also highlighted is, from a balance sheet perspective, it's really all intermingled as it relates to debt and the tax rate. Some of the things that are not necessarily operationally related. So I just wanted to give context as to why it's not as difficult to sort of like strip out and do a percentage of cash flow and say that's what's attributable to generics."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Randall Stanicky with RBC Capital.",14,"Your next question will come from the line of Randall Stanicky with RBC Capital."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, just a question for you. A lot of people have been watching the legacy Allergan products, waiting for some moderation. That hasn't happened. In fact, they were really strong. And so the question that I have is, just given the difference in spending",106,"Brent, just a question for you. A lot of people have been watching the legacy Allergan products, waiting for some moderation. That hasn't happened. In fact, they were really strong. And so the question that I have is, just given the difference in spending support levels on sales and marketing between the legacy Allergan and where you're at today -- and I'm just looking at Slide15. Number one, do you feel like that infrastructure is rightsized? And then secondly, just your confidence level on some of the key products in being able to continue to sustain that growth? I mean, Botox and Restasis were very strong."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think -- Randall, that's a great question. I think we are -- we have rationalized our sales force for our acquisitions and for the market as we see it over the next few years, and so we don't anticipate any additional cuts in the field. And in fact",221,"Yes, I think -- Randall, that's a great question. I think we are -- we have rationalized our sales force for our acquisitions and for the market as we see it over the next few years, and so we don't anticipate any additional cuts in the field. And in fact, we would selectively add if we thought the opportunity paid back. So as an example, with the acquisition of Kythera, we will increase our facial aesthetic sales force by roughly 75 positions, making us the strongest field force in aesthetics by a large margin. And so I think you'll see us continue to look for ways, so long as we're increasing our loin cloth-type strategy of product flow come, either through our R&D engine or through licensing and acquisition, of building and making sure we maintain leadership -- strong leadership positions, commercially in each of our therapeutic areas. 
With respect to spending on DTC and otherwise, we always look at the return on investment. And so to the extent we think we can add more money to Botox or Restasis or Linzess or even Namzaric, which will kick off in the fall DTC, we're always monitoring the situation, looking at both response and return on those investments and have no issue making them so long as we see a strong ROI."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","The other thing that we heard legacy Allergan talk a lot about was the international emerging market in Asian geographies as a big opportunity. Is that something that we should still think about for you guys that is in front of you?",42,"The other thing that we heard legacy Allergan talk a lot about was the international emerging market in Asian geographies as a big opportunity. Is that something that we should still think about for you guys that is in front of you?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think it is. It's a slower build but bigger -- big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next",115,"Yes, I think it is. It's a slower build but bigger -- big opportunity over time. I mean, look at the approvals, for example, of Juvederm in China this quarter. That gives us a great opportunity to build on Botox in that market. I'll be down in Brazil next week with our team looking at how we can continue to leverage our infrastructure in Latin America and grow. So clearly, the divestiture of the Teva business has some drawbacks in mid-markets, like Eastern Europe and Russia, in that we leveraged the old legacy Actavis infrastructure in those markets. But I think we can compensate for those and continue to grow and build in emerging markets."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of Umer Raffat with Evercore ISI.",14,"Your next question will come from the line of Umer Raffat with Evercore ISI."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Maybe the first one for David. David, what's the status of the DARPin Japanese trial that's ongoing? Should we be expecting an update soon? And what will that look like? And then second one for Brent, if I may. On transformational M&A -- the question that",94,"Maybe the first one for David. David, what's the status of the DARPin Japanese trial that's ongoing? Should we be expecting an update soon? And what will that look like? And then second one for Brent, if I may. On transformational M&A -- the question that we all keep getting from investors -- so how do you think about companies with growth profiles that might be lower than with your 10% or companies with potential biosimilar headwinds or even ex U.S. companies for that matter? Just wanted to understand how you think about this."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Sure. David, you want to take DARPin? I'll come to the transformational M&A question.",14,"Sure. David, you want to take DARPin? I'll come to the transformational M&A question."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, so sure, yes. So DARPin in Japan, we actually want Japan to join in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional small study in the United States. We're in the process",78,"Yes, so sure, yes. So DARPin in Japan, we actually want Japan to join in our global Phase III program. In order to do that, we needed to complete a small study in Japan and compare it to an additional small study in the United States. We're in the process of finalizing those studies prior to including Japanese sites in the Phase III trials sometime next year. So yes, there will be some updates on that going forward."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I think to your second point, Umer, around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth",352,"Yes, I think to your second point, Umer, around transformational M&A with companies with lower growth profiles or the like. Look, I think that in fairness, it would be very difficult for us to do a transformational deal with a company with a higher growth rate, because I think based on at least today's measure, the only one with a higher growth rate is Celgene. So that would really limit the universe. That being said, I think that the issue for us is, look, we want to be in Growth Pharma. Would we be willing to go from, let's say, roughly 10% to a 9% top line growth rate to do a highly accretive bottom line deal? The answer is absolutely. Would we be willing to go from 10% to 3% or 4% top line growth to do a highly accretive deal? I would say highly unlikely. And so we want to go out and make sure that we can acquire something that we believe has a growth orientation to it, that has longer-duration assets. And I think you should also keep in mind, we're pretty, as I use the word, bold in our thinking. So I think a lot of people look at the universe of transformational deals and say, ""Well, you can't touch this because it's got this particular product drag"" or this particular issue. We've been known to be very creative in solving for those things in the past and albeit a very deal, I would point to Furiex as just an illustration. Where they had 2 assets. They had the NDA for eluxadoline and they had a royalty stream from Takeda. We divested the royalties stream of Takeda to Royalty Pharma at the time we announced the deal. We had that prewired. And so we kept what we wanted and we sold something that was valuable to somebody else to help pay for the deal. And so to the extent we look at companies or opportunities that have things we like, and some things, perhaps, we don't like, there are always potential solutions for solving for those issues."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And your next question will come from the line of Gregg Gilbert with Deutsche Bank.",15,"And your next question will come from the line of Gregg Gilbert with Deutsche Bank."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Brent, if another party were to boldly approach you as an inversion target, other than doing what's best for shareholders, which I think you have a reputation of doing, along with Paul and the Board, are there certain elements of the model and its special",64,"Brent, if another party were to boldly approach you as an inversion target, other than doing what's best for shareholders, which I think you have a reputation of doing, along with Paul and the Board, are there certain elements of the model and its specialness and growth profile that you'd be concerned about that might play into your thinking about longer-term shareholder value creation?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, Gregg, I think you're right. It would have to be a bold offer. Second, I think Paul and I always would debate and talk to our Board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so spe",192,"Yes, Gregg, I think you're right. It would have to be a bold offer. Second, I think Paul and I always would debate and talk to our Board about the best long-term interest of our shareholders. And I think as you step back and look at what I think is so special about this company, a lot of it goes to the depth and quality of our management team. And so to the extent someone would be open to thinking about cultural change, and change and balance to leadership and talent and management, I think that would be more helpful for us. I think clearly, our commitment to R&D and the way we think about R&D is also very special. And I think our ability to be nimble and move quickly and do what we believe is always in the shareholders' best interest is also a bit unique. And so those are the types of discussions that we would have. It's not limited to that but that would be, I think, at least top of mind, for debate and I see Paul his shaking his head so I know he's in agreement."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","Your next question will come from the line of David Maris with BMO Capital.",14,"Your next question will come from the line of David Maris with BMO Capital."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","On Naurex, this looks to be like a potential billion-dollar-plus drug and I know we'll cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this. How it's differentiated in the market? But also, most im",58,"On Naurex, this looks to be like a potential billion-dollar-plus drug and I know we'll cover more of it during the R&D day. But if maybe you can talk a little bit about what's attracted you to this. How it's differentiated in the market? But also, most importantly, what are the next steps toward the path to approval?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I'll ask David to comment. I'll just give you my quick take of why I was so excited to do the deal with Naurex is that, this is an area -- a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, t",170,"Yes, I'll ask David to comment. I'll just give you my quick take of why I was so excited to do the deal with Naurex is that, this is an area -- a huge market with huge whitespace for unmet need. You can debate the numbers but very few patients, in fact, the minority of patients are adequately served by SSRI or SNRI. And then, they have to live with, in some cases, very difficult side effects from those medicines as well as a long onset of action for those with acute issues that need to be dealt with more quickly. And I think, David, you mentioned this in your earlier remarks. There's been no real novel breakthrough in depression in about 20 years. And so for us to be able to be at the forefront of potentially revolutionizing this very large and horrific disease is something that I think that's very exciting for us, given our commitment to leading in CNS and in particular, psychiatry. David, your two cents?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","I've only got time for two cents apparently, so I have to be quick. So I've been working in psychiatry in 20 years. I've taken compounds through to the market. Bill and his team have commercialized some of the biggest selling antidepressants. So I think t",192,"I've only got time for two cents apparently, so I have to be quick. So I've been working in psychiatry in 20 years. I've taken compounds through to the market. Bill and his team have commercialized some of the biggest selling antidepressants. So I think the team that we got here knows depression and the area over the last 20 decades. So when an opportunity like Naurex comes along with a novel mechanism of action over the last 2 decades, yes...
So when an new opportunity comes along with a new mechanism of action I think the team here can recognize it and seize it pretty quickly. These things are exciting: completely novel mechanism of action, showing a fast onset of action in depression, in -- and not only in depression but in depression where the patients failed to respond to SSRIs. So that's an exciting opportunity. And the next steps for us are to get into Phase III as quickly as possible with GLYX-13, the lead molecule, and to get into Phase IIb with the second compound NRX-1074. And we aim to do that as early as possible next year."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Certainly, we'd like to close a deal, but then we'll move pretty aggressively to doing it.",16,"Certainly, we'd like to close a deal, but then we'll move pretty aggressively to doing it."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Operator","And our final question for the day will come from the line of David Risinger with Morgan Stanley.",18,"And our final question for the day will come from the line of David Risinger with Morgan Stanley."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slides. Could you just tell us what the organic growth was in",62,"I guess, I have a couple of questions here. The first is with respect to the generics business that you're selling to Teva, there were some slight differences between the press release and the slides. Could you just tell us what the organic growth was in the second quarter of the generics business that you're selling? And then I have a follow-up."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, David, if I understand the question, I think the differences are between what we have and what Teva had on their slide deck, and it would be very difficult for us to comment on the differences between what we have and what another company has.",46,"Yes, David, if I understand the question, I think the differences are between what we have and what Teva had on their slide deck, and it would be very difficult for us to comment on the differences between what we have and what another company has."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the difference and, obviously, we can't comment on their 2016...",31,"So if I recall, we provided the generics business EBITDA for 2015 and they provided a number for 2016. That was the difference and, obviously, we can't comment on their 2016..."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","And just to be fair, it's their number for '16, not our number for '16. Just to be clear.",19,"And just to be fair, it's their number for '16, not our number for '16. Just to be clear."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences in the revenue reported on your [indiscernible] slide...",29,"Yes, I'm sorry, I meant the difference between Allergan's press release today and Allergan's slides today, there were some slight differences in the revenue reported on your [indiscernible] slide..."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","We can address that, yes.",5,"We can address that, yes."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","David, it's Lisa. So in the Top Global Branded Product Highlights slide, the ex U.S.-branded products from Forest, Warner Chilcott and Aptalis are not counted as generic products. They're counted in the brands total. When you look at our Global Generics s",63,"David, it's Lisa. So in the Top Global Branded Product Highlights slide, the ex U.S.-branded products from Forest, Warner Chilcott and Aptalis are not counted as generic products. They're counted in the brands total. When you look at our Global Generics segment, our Global Generics segment still counts those, as per accounting rules as part of the Global Generics business. That's the difference."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","And in terms of the organic growth of the generics business, what was that in the second quarter?",18,"And in terms of the organic growth of the generics business, what was that in the second quarter?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's what we gave you as -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter.",22,"That's what we gave you as -- well the Global Generics segment itself grew 17% on a constant currency basis quarter-over-quarter."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That's not a clean -- that's the point I was trying to make earlier about why it's so difficult to model. That's not apples-to-apples of what's being sold and what's staying. There are puts and takes in -- from the segments versus what was actually being",55,"That's not a clean -- that's the point I was trying to make earlier about why it's so difficult to model. That's not apples-to-apples of what's being sold and what's staying. There are puts and takes in -- from the segments versus what was actually being sold. And that's what makes things so complicated."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Analysts","Got it. Okay. Yes, I can follow up on that. And then separately, with respect to the Namenda switch here, obviously, it's taking you longer than expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surpr",83,"Got it. Okay. Yes, I can follow up on that. And then separately, with respect to the Namenda switch here, obviously, it's taking you longer than expected to get to your target of 60% to 65% but you're leaving that unchanged. I guess I'm a little bit surprised that you're leaving that unchanged. When you talk about 60% to 65%, is that a percentage of the total prescriptions, including the generics? Or is that just the branded Allergan franchise that you're now forecasting?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","That would be the total Namenda business, including brands and generics. And the way we think about it is we launched Namzaric only 2.5 weeks ago. A DTC campaign starts in September. We expect exceptional formulary coverage by January 1. And the increment",125,"That would be the total Namenda business, including brands and generics. And the way we think about it is we launched Namzaric only 2.5 weeks ago. A DTC campaign starts in September. We expect exceptional formulary coverage by January 1. And the incremental sales from Namzaric, by essentially taking advantage of an untapped combination market, especially in moderate Alzheimer's disease, effectively is going to get us to our target conversion rate. As I said earlier, if the formulary coverage had not developed like it has, we might have a different situation right here. But as it relates to 2016, Namzaric is going to be highly economical. XR already is and I think the majority of patients are going to have an opportunity to get it."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Okay, thanks, everybody. Brent, would you like to make some closing remarks?",12,"Okay, thanks, everybody. Brent, would you like to make some closing remarks?"
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize: I think we had a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our gro",111,"Yes, I would just like to thank everyone for joining the call today. And in closing, just summarize: I think we had a very strong and well-executed quarter. I think our plans are in motion to continue to focus on operational excellence and driving our growth agenda and are focused on our key therapeutic categories and establishing long-duration leadership in those categories. I think our leading pipeline, our reloaded capital structure and our now focus on branded pharmaceuticals and willingness to take bold and decisive actions make us the most dynamic company in Growth Pharma. I thank you for your time and look forward to updating you later again in September."
36478,305435704,851529,"Allergan plc, Q2 2015 Earnings Call, Aug 06, 2015",2015-08-06,"Earnings Calls","Allergan plc","Executives","Thanks, everyone. And I know we didn't get to quite a few people in the Q&A, so we'll follow up with you shortly. Thanks.",24,"Thanks, everyone. And I know we didn't get to quite a few people in the Q&A, so we'll follow up with you shortly. Thanks."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan third quarter earnings call. [Operator Instructions] I would now like to turn the conference over to Lisa DeFrancesc",51,"Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan third quarter earnings call. [Operator Instructions] I would now like to turn the conference over to Lisa DeFrancesco, Vice President, Investor Relations. Please go ahead."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter e",391,"Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter ended September 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We are conducting a live webcast of this call, a replay of which will be available on our website after conclusion. Please note that today's conference call is copyright material of Allergan and cannot be rebroadcast without the company's expressed written consent.
Turning to Slide 2, I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflects our current perspective of the business trends and information as of today's date.
Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Allergan business. These factors are detailed in our public periodic filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
At this time, as a result of the press release Allergan issued on October 29, 2015 confirming the company has been approached by Pfizer and is in preliminary discussions regarding a potential business combination transaction, the company will not be issuing any financial forecast that could require additional reporting under Rule 28 of the IR rule.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our third quarter continuing operations business highlight; and Tessa Hilado, our Chief Financial Officer, will then discuss the Allergan third quarter continuing operations results in more detail. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; Stephen Nicholson, Executive Vice President and President of Brands R&D; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I will turn the call over to Brent."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be here with you to review our results for the third quarter of 2015. We're obviously bee very busy on many fronts and our teams continue to be build on the momentum we have had all year. This moment",1538,"Thanks, Lisa, and good morning, everyone. It's great to be here with you to review our results for the third quarter of 2015. We're obviously bee very busy on many fronts and our teams continue to be build on the momentum we have had all year. This momentum will propel our future growth.
Turning to Slide 5. Allergan's third quarter performance illustrates the we continued to execute on the 4 pillars of our growth strategy. First, operational excellence is yielding exceptional financial performance and strong results to continuing operations, key products and key geographies.
Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive and innovative R&D engine continues to produce. Our team is looking forward to showcasing our R&D pipeline, the success we've had this year and the depth of our pipeline across all 7 therapeutic areas later today at R&D Day.
And we are executing on strategic business deals, including our Teva transaction earlier in the quarter to allow us to focus on growing our business. With the announcements of our plans to combine our Global Generics business with Teva and a deal worth approximately $40.5 billion, we are now reporting our generics business as discontinued operations. Although the business results are consolidated into a single line in the income statement, our Global Generics team continues to perform well.
I am impressed with the continued momentum in the business and proud of the performance of the steam. For example, the generics R&D team has submitted 25 new command in the U.S. this year with 16 of them potential First-to-Files. This team is a gem of the generics industry, and they are on track to submit approximately 35 outpatients by year-end.
Outside of the U.S, we filed over 1,000 marketing authorizations in critical markets. This year, we have received approval and launched over 25 products in the U.S. of these new launches are adding to our results. Internationally, the teams in the U.K, Russia and other eastern European markets continue to deliver strong performance.
The pre-integration work with Teva is going well, and we remain committed to closing this transaction during the first quarter of 2016. This plan to divest the global generics business allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapeutic areas and reward our capital structure to continue our transformation. We are confident that we are creating the most dynamic company and growth environment.
Now let me turn to the continuing operations business performance in the third quarter. Our third quarter net revenue grew 90% on a year-over-year basis to $4.1 billion as a result of the Allergan acquisition. On a pro forma basis, sales grew 10% despite the loss of exclusivity on one of our largest products, Namenda IR, which experienced generic competition in the quarter. Strong sales in key products across our business drove 65% increase and non-GAAP earnings per share to $3.48.
Meanwhile, non-GAAP EBITDA rose to $2 billion and cash flow from operations, excluding R&D asset acquisitions, restructuring and integration payments was $1.7 billion in the quarter. Our business continues to drive strong performance. More than half of our products have delivered double-digit volume driven growth. On a pro forma basis, year-over-year brand revenue increased nearly 13% excluding Namenda IR divestitures and the impact of foreign exchange.
On Slide 8. Our growth in the quarter was broad-based. Excluding the impact of foreign currency, we drove double-digit growth from leading brands across key franchises, such as Botox, Restasis, Linzess, [indiscernible] and SAPHRIS. We continue to solidify our leadership in key categories with new launches and approvals. Our recent launches include -- including advertise, relevance, Namzaric, and Kybella are all performing well supported by strong promotional activities. Looking ahead, we will continue to drive growth through new approval and upcoming launches, including Davis in a few weeks and Rigler in the first quarter of 2016.
In addition to products made in our R&D pipeline, we are also strengthening therapeutic area leadership through new acquisitions of important programs. In eye care, we continue to add shop and goal and development opportunities for dry eye disease and eye care with the acquisition of AqueSys, Lumenigene and Oculeve. Lumenigene, which we just announced this morning, brings a novel topical formulation dry eye treatment that could potentially be used alone and in combination with other dry eye therapies. This asset Phase 3 program further strengthening our dry eye pipeline, giving us the potential to launch 6 new products over the next 5 years.
In Aesthetics, we completed the acquisition of Kythera for its leading product, Kybella, adding a nonsurgical treatment for Simental Comus or double chin. We also announced this morning the acquisition of Northwood Medical Innovation, developer of innovated implant technology earfold. Earfold is a medical device for the correction of prominent years.
In CNS, we completed the acquisition of Naurex, which has potential breakthrough treatments in depression and will be discussed in detail later this morning at R&D day. And in GI, we recently completed the acquisition of commercial rights to Castella in more than 40 international markets. This acts as an important part of our commercial team internationally and helps position us for the potential to add new G.I. therapies, like eluxadoline, to our product offering for international customers.
Before I turn a call over to Tessa to review our financial performance in the third quarter, I wanted to touch in our R&D day and recent commentary on product pricing. Later this morning, David Nelson, Bill Meury, and Smith will give an update on the pipeline and the commercial it potentially contains. We believe that people we begin to take more active notice of our pipeline after today's meeting. 
With more than 70 projects in mid- to late-stage development, we have multiple programs in each of our therapeutic areas to help us sustain leadership in the areas where we choose to compete. We are building a sustainable innovation engine that power our top line performance and therapeutic area leadership well into the future. Please join us for an exciting day beginning in about an hour.
Turning to pricing. Pricing has been in the headline and featured in the presidential debates. But let's not pretend that this is a topic that has just appeared in the news. It's been a focus for many years. We know that cost is a constant concern, so as patient access to medical innovation. Allergan seeks to strike the right balance between care and cost. We operate in an open science model, developing promising products that frequently originate with smaller companies. These companies often lack the infrastructure to bring their products through expensive late stage trials or the commercial persons to recoup their R&D investments. The innovation ecosystem is full of these smaller companies who have extraordinary ideas and brilliant scientists. We want to be the magnet for their great ideas in this new innovation ecosystem.
Our models designed bring these extraordinary ideas to market. Our R&D staff is my than 2,000 people strong. They mobilize resources to help regulatory authorities around the world assess safety and efficacy of our products or providing data to payers to reflect their value.
Let's face, this effort is costly and often reflecting the cost and medicine, and it is easy to miss the significant value they represent. They reduce the need for hospitalization, surgery, followed business and more dial medical consequences. Allergan has a heritage in knowing health system economics very well, and we want to make sure patients have access to important medicines. Like many of our peers, we have patient assistance programs to ensure that patients have access to our medicines regardless of their ability to pay.
We are boiling and firing and investing in promising treatments for serious diseases, Alzheimer's, severe depression, glaucoma, debilitating gastrointestinal conditions. Our business model does not involve purchasing old products already in the marketplace and taking excessive price increases. We prefer to acquire mid- to late-stage drugs and invest extensively in their development. 
To make these decisions, to help people with unmet medical needs requires us to build bridges with physicians, academic medical centers, governments, regulators and inventors of these molecules so that they see us a partner who shares in their dedication to improve people's well-being. 
If you look at our recent development acquisitions, it's all about investing in ideas that can help change the way medicine is practiced. What makes the biopharmaceutical industry great? Inventions that change lives. We will continue to use our resources to advance treatment for unmet medical need and to tap into the world's best ideas to advance care for patients. We will do this while we will continue to strike the appropriate balance between care and cost. 
In closing, our team continues to focus on execution, and our results indicate that we are exceptionally skilled at delivering strong operating results while also doing surprising things to make our company the most dynamic and bold in health care. I'm so proud of this team for their performance, and I'm looking forward to what we can do with a strength and focus on just branded pharmaceuticals. 
With that, now I'd turn the call over to Tessa."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third qua",646,"Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third quarter was $4.1 billion, an increase of 90% versus third quarter 2014.
Non-GAAP R&D investment for the quarter was $305 million compared to $192 million in the prior year period. Non-GAAP SG&A, as a percentage of revenue was 22.4%, a decrease of 3.1 percentage points over the prior year quarter as a result of the synergies realized from recent acquisition. 
Adjusted EBITDA for the quarter was $2 billion, an increase of 168% versus the prior year, driven by strong revenues and higher gross margins across business segments. Non-GAAP earnings per diluted share for the quarter increased 65% to $3.48 compared to $2.11 per diluted share in the third quarter of 2014. Our non-GAAP tax rate was 8.4% in the quarter. This rate was below expectation, driven primarily by the allocation of the entire interest expense to continuing operations earnings. This rate could change by potentially payment of debt upon the close of the Teva transaction. 
Cash flow from operations for the third quarter was $1 billion, impacted by recent asset acquisition, excluding acquisition-related with structuring and integration payments or third quarter cash flow from operations would be $1.7 billion.
Slide 13. Turning now to our U.S. brand results on Slide 13. The business delivered strong performance year-over-year. U.S. brand's revenue was $2.4 billion for the quarter, up 60% versus the prior year period, driven by the addition of Allergan businesses and strong growth across key products including Restasis, Linzess, Women's Health products and new product launches, including letter, Namzaric and Africa. Adjusted gross margin within U.S. brands continued to be strong with margins approaching 88%. SG&A, as a percentage of revenue, decreased to 18.3% versus 22.1% in the year-ago quarter, driven by a continued synergy capture from recent acquisitions.
Turning to Slide 14 and our U.S. Medical Aesthetics business. Third quarter revenues were $457 million, an increase of 9% versus third quarter 2014 results on a pro forma basis. Sequentially, U.S. Medical Aesthetics performance was affected by seasonality related to aesthetics procedures. Third quarter gross margins were strong at 93.9%. SG&A, as a percentage of revenue, decreased 1.2 percentage points versus third quarter 2014.
Turning to Slide 15 and our International Brands results. Third quarter revenues were $661 million versus $58 million in the prior year, largely due to the Allergan acquisition. Year-over-year growth was also driven by fillers and Ozurdex in international markets. Sequential revenue performance was mostly due to seasonality. Gross margins increased 25.7 percentage points to 83% in the third quarter, due largely to the inclusion of higher margin legacy Allergan products. Segment SG&A increased 3.2 percentage points to 29.8% versus third quarter 2014 due largely to the Allergan acquisition.
Turning to our Anda business on Slide 16. Revenues increased $500 million to $576 million, up from $500 million in the prior year, an increase of 15%, driven by trends in our base business and new retail chain businesses. Results include third-party revenues and related expenses of generic product manufactured by the company and distributed through Anda.
Slide 17 details our debt capitalization. We ended the third quarter 2015 with total debt of approximately $42.7 billion and equity of $77.5 billion related to the Allergan acquisition and previous financing. In the third quarter, we paid down approximately $231 million of our debt. In October, we borrowed $800 million on our revolving credit facility to fund the Kythera acquisition.
Currently, our leverage ratio stands at 3.98x debt to pro forma adjusted EBITDA versus 3.9x in the prior quarter due to continued investments in R&D assets. We remain committed to maintaining our investment-grade ratings.
And now I will turn the call to Lisa for Q&A."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","[indiscernible] [Operator Instructions]",3,"[indiscernible] [Operator Instructions]"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range as you laid out in September? I guess, is there anything unusual or any reason to expect that r",111,"Just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range as you laid out in September? I guess, is there anything unusual or any reason to expect that ratio to move going forward because otherwise the company's going to be quickly trending to the low end of that range as top line continues to scale here. And if I can sleep in a second quick one. We've been asking this question a lot. Can you just disclose the mix of price versus volume driving your growth in the quarter?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, Tess",52,"Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, Tessa, if you want to add anything?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, we're within the range. And unfortunately, given sort of Irish results, we can't really provide guidance on a go-forward basis. But I would just say we are within the range.",31,"Yes, we're within the range. And unfortunately, given sort of Irish results, we can't really provide guidance on a go-forward basis. But I would just say we are within the range."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And then on price volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price volume, I'll say volume price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the entire",59,"And then on price volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price volume, I'll say volume price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the entire product line, it's roughly 50-50. And our price appreciation trades in the single digits."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from line of Jason Gerberry with Leerink Partners.",12,"Your next question comes from line of Jason Gerberry with Leerink Partners."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just a quick question on Namenda now that we've now a chance to see how the generic impacts come flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million peak",72,"Just a quick question on Namenda now that we've now a chance to see how the generic impacts come flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million peak sales product? Or should investors think about that peak sales target more of the combined value that XR and Namzaric could retain?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I would start and then maybe Bill can jump in. I think, as you think about where we are with Anda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both XR a",114,"Yes, I would start and then maybe Bill can jump in. I think, as you think about where we are with Anda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both XR and Namzaric. The one thing that I would caution is with respect to Namzaric, most of the formulary coverage, although it's quite good right now, kicks in January because of the Medicare Part D part of this equation. And so I think our expectations are a little higher post quarter formulate coverage that it is today. Bill, anything you want to add?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formula coverage at the end of '15 and in 2016 is high as it's been. Namzaric isn't quite a spread, a good steady job. 60% of our used today i",136,"Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formula coverage at the end of '15 and in 2016 is high as it's been. Namzaric isn't quite a spread, a good steady job. 60% of our used today is coming from our set model therapy. As Brent said, when formulary coverage converge in 2016 and after several months of direct-to-consumer advertising, I would expect over time that the overall business is going to grow and that Namzaric is going to account for a greater, greater percentage of it for one simple reason, it's a better product. If you look at the data, 2 drugs is better than 1. And I think it'll take just a little bit of time to move this category."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Amsellem with piper Jaffrey. Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",27,"Your next question comes from the line of David Amsellem with piper Jaffrey. Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. and you've got a pretty big portfolio of products that you could leverage. And I think eluxadoline the prepared com",68,"Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. and you've got a pretty big portfolio of products that you could leverage. And I think eluxadoline the prepared comments. So the question for you, what's the strategy here assuming that you remain stand-alone? And where does this rank within your business development priorities?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that's still largely is tap. We have a very strong team around the world. We have big opportunities",271,"Yes, I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that's still largely is tap. We have a very strong team around the world. We have big opportunities to continue to leverage the infrastructure that we have. I think the deal we did with Avril to buy good seller isas a proof points of the types of things we're going to do. As we're preparing to hopefully get approval for eluxadoline in Europe over time to be able to have more opportunities to leverage GI is a good move for us. Obviously, aesthetic medicine is very important. We have lots of opportunity to continue to expand the aesthetic portfolio with Asia, China, I would call out Latin America, Brazil is another market, I would call out, where we're seeing strong growth. And then, of course, eye care is very important for us around the world. And we continue to look for ways to build our portfolio of leadership in eye care. And in many markets, we are #1 in eye care outside the U.S. So we have a big heritage there and it is important for us to continue to leverage. With respect to business of element, it remains a priority. We will continue to look for ways to add scale and product flow in key international markets around the world. If we can do that ourselves by eluxadoline approval or Juvederm approval recently in China, or buying good seller or other things. It's an important growth driver for us in the future."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Should we think about this, Bill, as more of a bolt-on source of capital? I mean, everybody's can be focused on the $29 billion that you have coming from Teva in Q1, assuming that another guilt on the side doesn't happen. So should we think about internat",61,"Should we think about this, Bill, as more of a bolt-on source of capital? I mean, everybody's can be focused on the $29 billion that you have coming from Teva in Q1, assuming that another guilt on the side doesn't happen. So should we think about international as a smaller deal build-out? Or could we see more significant capital allocated there?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I think about it 3 ways. It's going to be organically driving or 70 -- most of our 70 late stage -- mid-to late-stage programs and bubble development programs took sense and makes sense to doing R&D type deals for international product flow,",84,"Yes, I mean, I think about it 3 ways. It's going to be organically driving or 70 -- most of our 70 late stage -- mid-to late-stage programs and bubble development programs took sense and makes sense to doing R&D type deals for international product flow, to buying already marketed products like, we did at Kinsella; and then perhaps from time to time where it makes strategically and financially posting on a small business in a place like Brazil or China or even Europe."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I was hoping if you could give us a little more detail on the cash made businesses as well as just Botox overall, what's going on behind-the-scenes in each of the individual areas.",33,"I was hoping if you could give us a little more detail on the cash made businesses as well as just Botox overall, what's going on behind-the-scenes in each of the individual areas."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I mean, obviously, it's a very important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. medical. That business continues to perform exceedingly well, Obviously, it was -- there was",64,"Yes, I mean, obviously, it's a very important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. medical. That business continues to perform exceedingly well, Obviously, it was -- there was some seasonality in the third quarter, as there always is. Bill, I don't know if you would want to comment on anything?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I think Kybella is really starting to get momentum, and that was [indiscernible] and the team last, I guess, 2 weeks ago. So we ended up trading roughly 1,500 top of the 800 that's been already changed from our market share standpoint, you can see -- we c",91,"I think Kybella is really starting to get momentum, and that was [indiscernible] and the team last, I guess, 2 weeks ago. So we ended up trading roughly 1,500 top of the 800 that's been already changed from our market share standpoint, you can see -- we continue to sell probably our market share especially on the [indiscernible] market. And we have a 2 million consumers part of our BD royalty program, which is an all-time high. So we're driving and we're doing extremely well and everything is in the green."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well. But the vast majority of that from the Aesthetics business within Allergan.",43,"Yes, just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well. But the vast majority of that from the Aesthetics business within Allergan."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","And what about Botox in the therapeutic areas? Like how is migraine doing over the key drivers?",17,"And what about Botox in the therapeutic areas? Like how is migraine doing over the key drivers?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you hit the right ones. Those are the main drivers for Botox therapeutically. Both indications are growing at high double-digit rate. The core indications, the regional indications are relatively stable. This income in both of those conditions, it's",79,"Yes, you hit the right ones. Those are the main drivers for Botox therapeutically. Both indications are growing at high double-digit rate. The core indications, the regional indications are relatively stable. This income in both of those conditions, it's highly effective product and it's also very economical. And the injector base today in the United States for Botox is very experienced and comfortable with the product. I expect that both indications continue to grow for the next several years."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Liav Abraham with Citi.",13,"And your next question comes from the line of Liav Abraham with Citi."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I'd be interested in your results on your outlook for Restasis given the restricted will [indiscernible]. And perhaps, at the same time, can you just remind as of your formulary coverage for Restasis.",34,"I'd be interested in your results on your outlook for Restasis given the restricted will [indiscernible]. And perhaps, at the same time, can you just remind as of your formulary coverage for Restasis."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, sure, I will let Bill answer.",7,"Yes, sure, I will let Bill answer."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a good question. I don't believe that this is going to be a fight to the death between Char and Allergan. I'd say before that the CapEx in the prevalent operation the prescription treated population is onymous. It's larger than it is in most cat",300,"Yes, it's a good question. I don't believe that this is going to be a fight to the death between Char and Allergan. I'd say before that the CapEx in the prevalent operation the prescription treated population is onymous. It's larger than it is in most categories. The importance of dry eye disease is clear, and it's getting more and more attention because of the impact it has on quality of life, the impact that it can have on vision and positive postop outcomes. When you look at the data sets between the drug, I would simply say that we'll have to see how [indiscernible] stands up in the real world. I would also point out that in the second half of 2016, we'll be launching a multi dose preservative free form of Restasis, which I believe is going to be a very popular with physicians and with patients for 2 reasons. The first is just more convenient than 60 single unit vials or droppers. And it's also easier to administer. And a big problem with all of these eyedrops is they're difficult to instill and it's often a major problem with compliance. Our promotional program in this category will continue to be at the very top. We have a large sales force that covers primary care, optometry and ophthalmology. We'll continue to run though largest direct consumer advertising program in the industry. And then, lastly, as you ask about formulary coverage, we have preferred status on 85% to 90% of health plan for formularies, and 90% of that is tier 2. And so this is a highly economical option. There's no doubt eyecare professionals are going to try something new. But I believe long-term this category has the potential of double. So there's more than enough to go around."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Gregg Gilbert with Deutsche Bank.",14,"And your next question comes from the line of Gregg Gilbert with Deutsche Bank."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a question. And if you can't answer it, I have a backup. It's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you at a business combination, these are talks are about Pfizer potentially",49,"I have a question. And if you can't answer it, I have a backup. It's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you at a business combination, these are talks are about Pfizer potentially buying Allergan or not necessarily?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I can't answer. So go to your backup question.",10,"Yes, I can't answer. So go to your backup question."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","It's more blurring. Tessa, can you share the generics sales in the gross margin and the segment margins in the quarter perhaps?",23,"It's more blurring. Tessa, can you share the generics sales in the gross margin and the segment margins in the quarter perhaps?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which we will be filed shortly. What I can say is we had solid performance for the generic business and revenues to around $4.77 billio",55,"Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which we will be filed shortly. What I can say is we had solid performance for the generic business and revenues to around $4.77 billion for the 9 months, for year-to-date 9 months."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Remember, that just to bear -- that is can discontinued operation accounted. So for those of that also, Teva is that just a simple one-to-one kind of translation, is that fair, Tessa?",32,"Remember, that just to bear -- that is can discontinued operation accounted. So for those of that also, Teva is that just a simple one-to-one kind of translation, is that fair, Tessa?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's fair. But it's performed a quarter to oats petition and good solid performance. But you'll get more detail in our 10-Q.",23,"That's fair. But it's performed a quarter to oats petition and good solid performance. But you'll get more detail in our 10-Q."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Irina Koffler with Mitsuo.",13,"And your next question comes from the line of Irina Koffler with Mitsuo."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I just wanted to see how you're thinking about your sales force going forward? Is it the right size? Are there opportunities to be a little bit more efficient or used alternative dispersion models there? Or are you [indiscernible] adding instead?",42,"I just wanted to see how you're thinking about your sales force going forward? Is it the right size? Are there opportunities to be a little bit more efficient or used alternative dispersion models there? Or are you [indiscernible] adding instead?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I was going to make bad joke. but I'll stop. Well, for me, the sales represented around the world is a very important part of our company that we tend to put them at the center of the way we think about our business and what we do is they are at the most",159,"I was going to make bad joke. but I'll stop. Well, for me, the sales represented around the world is a very important part of our company that we tend to put them at the center of the way we think about our business and what we do is they are at the most intimate with our customers. I think we look at our salesforce deployment globally very thoughtfully and strategically. For example, in facial aesthetics, which has increased our salesforce by about 75 sales reps, which was already the largest facial aesthetic sales force in the United States. And now, it's even more larger, more powerful. China, we just invested in our salesforce and added sales reps. And so we do Wolcott the Department of the sales reps very strategically and the U.S, we have the most sales reps is a very hard-working dedicated group. I think they're living more details that any other salesforce in the industry."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives. But they operate as if there was 4,500 or 5,000 just by virtue they lead the industry and activity. The most significa",187,"Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives. But they operate as if there was 4,500 or 5,000 just by virtue they lead the industry and activity. The most significant change in that we've made in the past 12 to 18 months is we'd customize the field force. So there's no longer one-size-fits-all approach. We don't have the same number of representatives in the state of Massachusetts as compared to the state of Mississippi. And so we will invest in regions and sales for space in the estimated return. But we do operate with a principle when we launch new products, and we have multiple new product launches over the next several years. We will always aim to achieve share of voice leadership. And so details and representatives on a routine basis are being reallocated across of the product line so that we can maximize the value of our business. It's a terrific group, well compensated and will change, but I don't anticipate any fundamental shifts in our salesforce model at this point."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of David Risinger with Morgan Stanley.",14,"And your next question comes from the line of David Risinger with Morgan Stanley."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have 2 primary questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go forward tax rate? And then when you give 2016 financial guidance in February for the",133,"I have 2 primary questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go forward tax rate? And then when you give 2016 financial guidance in February for the stand-alone company, how should investors think about what's are going to baked in, baked in for debt reduction. I meaning that's a huge factor model and EPS. Maybe you can just talk about it how you're thinking about it in a high-level at this point. And then, separately on Botox pricing, could you just update us on when a decision will come down on whether Allergan will be able to separate pricing for the cosmetic and therapeutic indications and more appropriately price Botox for therapeutic indications?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me take the last cushion and Tessa can take the financial one. We are continuing with our litigation with CNS around bifurcation of pricing. I really don't have an update on that today. But its something that Bob and I stayed -- very focused on. An",111,"So let me take the last cushion and Tessa can take the financial one. We are continuing with our litigation with CNS around bifurcation of pricing. I really don't have an update on that today. But its something that Bob and I stayed -- very focused on. And we'll see how that plays out as soon as we have on of that, we'll certainly, provided. But I wouldn't go any expectations around that. Second, we continue to think about therapeutic Botox as new toxins for the future. But as a longer-term strategy as well. So I think for the short term, David, I would just view those prices as being couple."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So when the 2 finance questions, David, I'll address of the second one first. We are committed to providing an update in terms of financials similar to what we've done in the pass, which should be cheering the Q1 earnings release in February. And by then,",202,"So when the 2 finance questions, David, I'll address of the second one first. We are committed to providing an update in terms of financials similar to what we've done in the pass, which should be cheering the Q1 earnings release in February. And by then, to the extent to that we have more clarity with regards to how we would deploy capital assuming the Teva transaction would have closed by then, then we will provide you guidance with regards to capital deployment, including debt repayment. One thing obviously that we're committed to is the investment grade rating. So to the extent that we don't deploy capital, we will pay down the amount necessary to maintain the rating on a go-forward basis. With regards to the tax question, based on our release, what actually occurred because of continuing operations is that the bulk of -- the entire interest expense was actually allocated to continuing operations. Hence, the low tax rate. On-the-go forward basis, that should trend upward assuming we pay down debt, but we can't really be precise at this point, given our restriction based on Irish law. But it should trend higher based on that -- if we assume debt paydown."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Aaron Gal with Bernstein.",13,"And your next question comes from the line of Aaron Gal with Bernstein."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","A couple of clarifying one than more of a strategic one. First on Botox, you reported 13% constant currency and think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. I could. Can you jus",157,"A couple of clarifying one than more of a strategic one. First on Botox, you reported 13% constant currency and think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. I could. Can you just give us a bit more color on the currencies involved? Second for Phil. Is it fair to say that [indiscernible] comes to market, the end of 2016, we should expect a weaker Restasis in '17, '18 [indiscernible] for a couple of years and growth of that product. And then may be we're not supposed to ask it. But more broadly, the equity results of this quarter you seem to be brought this up actually see getting will? Is there the revenue growth that will you multiple is much lower. It doesn't seem like a great time to engage friendly discussion with another company. Can you help us think about this a little bit?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously have -- that's Botox specifically.",26,"So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously have -- that's Botox specifically."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I think the 13% pro forma was for the entire branded business, excluding Namenda IR divestitures and the impact of foreign exchange is what I said in the prepared remarks.",31,"Yes, I think the 13% pro forma was for the entire branded business, excluding Namenda IR divestitures and the impact of foreign exchange is what I said in the prepared remarks."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","But Botox itself year-over-year grew by about 8%, 13% excluding FX.",12,"But Botox itself year-over-year grew by about 8%, 13% excluding FX."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Are you looking at a chart versus what I said, Aaron, right?",12,"Are you looking at a chart versus what I said, Aaron, right?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, I'm actually looking at your product line. Botox, could you strong growth for both [indiscernible] as medic of more than 13% excluding foreign exchange, this is  [indiscernible] 8?",29,"No, I'm actually looking at your product line. Botox, could you strong growth for both [indiscernible] as medic of more than 13% excluding foreign exchange, this is  [indiscernible] 8?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's hard to hear you, running. But a little bit of hear every second word. Yes, so you've got it.",21,"Yes, it's hard to hear you, running. But a little bit of hear every second word. Yes, so you've got it."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%.",17,"So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Okay. So [indiscernible] 13% constant currency in the third quarter?",10,"Okay. So [indiscernible] 13% constant currency in the third quarter?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Correct.",1,"Correct."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's correct, yes.",4,"That's correct, yes."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Right.",1,"Right."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Is there a reason the GAAP currency adjusted as to their couple of currencies that went particular rep this quarter?",20,"Is there a reason the GAAP currency adjusted as to their couple of currencies that went particular rep this quarter?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I mean, it's largely euro, plus we have some protection related to certain hedges that flow through.",17,"I mean, it's largely euro, plus we have some protection related to certain hedges that flow through."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Douglas Tsao with Barclays.",13,"And your next question comes from the line of Douglas Tsao with Barclays."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","And just maybe if you could also some perspective the upcoming for vers the large, especially given what you've seen from the competitive production did option of CLECs thus far? CLECs [indiscernible] and RTSE.",34,"And just maybe if you could also some perspective the upcoming for vers the large, especially given what you've seen from the competitive production did option of CLECs thus far? CLECs [indiscernible] and RTSE."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I mean, well, I just told the comments. We are very excited to be launching diversity. The sales force meeting will be out next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- were making a big inv",67,"Yes, I mean, well, I just told the comments. We are very excited to be launching diversity. The sales force meeting will be out next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- were making a big investment in these launches. That's safe to say. Bill, you want to talk about it?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a perfect complement to invest. IBS should be thought about it as a continuing constipation on one end and diary on the other. And because were able to market to products on the same condition essentially, we are able to talk about it in a more",240,"Yes, it's a perfect complement to invest. IBS should be thought about it as a continuing constipation on one end and diary on the other. And because were able to market to products on the same condition essentially, we are able to talk about it in a more complete way. I think it's a competitive advantage. As it relates to the products compared to co-packs income it's a clearly different approach to treatment. This drug works on motility and visceral pain or hypersensitivity. And is essentially an antibiotic the certainly, move in this category for more than one product. Promotionally speaking, this will be one of the largest in the industry from an investment standpoint. And I'm pretty sure it's going to be the largest launch in gas. It's going to be very nicely. We know how to do this. We did with iron with June the launch of Linzess. The DTC advertising will start not 1 year after approval, but only 3 months. And the promotional efforts, unlike any companies in the area will capture not only gastroenterologist, but primary care physicians. There's an interplay in almost every category between primary care and specialty that we can navigate that other companies can. And I would expect that this drug can do as well as Linzess does of the other side of the market and could ultimately almost double the size of our GI business over the next 5 years."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","This Ariane and I'm in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's",71,"This Ariane and I'm in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's baked into that regarding price and volume? And then, secondly, can you touch on the competitive dynamics with the potential competition to Botox from we've ANSYS product being."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I think as I was the were under some restriction under Irish law with respect to guidance. But our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominantly",319,"Yes. So I think as I was the were under some restriction under Irish law with respect to guidance. But our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominantly in a volatile situation, not a price situation. As we think about price, we tend to think about mid-to high single-digit price increases across the portfolio. And so we don't really think of any change or expect any change in our very, I think, conservative pricing policy in the way we think about price. And so we're not going to -- I don't think you're going to see us change our view are perhaps better said or commitment to the 10% growth objectives and aspirations that we have. So I think that's going to stay fairly normalized for the foreseeable future. I think with respect to refinance and competitive toxins, I'll ask David to comment as well. But I would just remind you that there are competitive toxins already the market. And more, if you talk to customers, more -- very few care about having an extra few weeks or month of duration of effect for Botox or toxins. And in fact what they mostly complain about is price. And our competitors price their toxins much -- at a much lower rate than we price Botox, and yet Botox continues to be a strong market leader. And so I would just issued to the perspective of as Bill said earlier, love to really decisions of a full range of patient aesthetics. Have a largest field force. Botox is the #1 branded pharmaceutical brand in the world. And so this is a very strong franchise with very good staying power. And so sometimes there's a hammer looking for a nail. Duration maybe just a that. But size of it, may be David can comment typical."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I'm happy to talk about that briefly. Clearly, we'll be talking about Botox during the R&D day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indica",137,"Yes, I'm happy to talk about that briefly. Clearly, we'll be talking about Botox during the R&D day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indications of Botox around the world. So extending our static reach geographically. And we will be developing Botox a new therapeutic application. I would point out, if we're talking about duration, the Botox, in some indication, has a duration for up to 9 months. But if you're talking about high to high doses solutions, Botox works for up to 9 months. So the duration of Botox depends on the use and dose that we administer. And more of this during the course of the day as we walk through our R&D pipeline."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I'll just add to this. Botox really is a [indiscernible] product. It's got a lot of indications, 10 indications. It's got great brand recognition. It has supported by the supported promotional effort, and it's got good and strong clinical science and",45,"Yes, I'll just add to this. Botox really is a [indiscernible] product. It's got a lot of indications, 10 indications. It's got great brand recognition. It has supported by the supported promotional effort, and it's got good and strong clinical science and experience behind it."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Two quick ones. First, can you tell us a bit more about the generics this quarter? When the actual sales were, the year in year trends and just some commentary there. And number two, Brent, so in an M&A scenario, is there anything legally preventing you f",55,"Two quick ones. First, can you tell us a bit more about the generics this quarter? When the actual sales were, the year in year trends and just some commentary there. And number two, Brent, so in an M&A scenario, is there anything legally preventing you from issuing more dentures that your own share account?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, so Tessa, do you want -- shoulder period he answered the question.",13,"Yes, so Tessa, do you want -- shoulder period he answered the question."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, said earlier, we have good solid performance. Performed according to our expectations. We will provide more granularity for discontinued operation in our 10-Q, which should be found in the next couple of ways. But revenue-wise, it was at $4.77 billio",46,"Yes, said earlier, we have good solid performance. Performed according to our expectations. We will provide more granularity for discontinued operation in our 10-Q, which should be found in the next couple of ways. But revenue-wise, it was at $4.77 billion for the last 9 months."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And so your other question, remember it was about share repurchase?",11,"And so your other question, remember it was about share repurchase?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, I meant, in an M&A scenario, we're issuing equity, is there anything that prevents you from issuing more than equity then your own entire share?",26,"No, I meant, in an M&A scenario, we're issuing equity, is there anything that prevents you from issuing more than equity then your own entire share?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","To be fair, I just don't know the answer. Maybe if you want to follow up, we could talk to the folks who may know the answer to that. I just don't know, Umer.",34,"To be fair, I just don't know the answer. Maybe if you want to follow up, we could talk to the folks who may know the answer to that. I just don't know, Umer."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch.",17,"And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a quick couple. First is in a relatively small part of your business that the press in France. How well is Allergan position to take advantage some of the competitive missteps there? And second, on business development, assuming your main stand-alo",64,"I have a quick couple. First is in a relatively small part of your business that the press in France. How well is Allergan position to take advantage some of the competitive missteps there? And second, on business development, assuming your main stand-alone what are the examples of some through precarious of that might excite you, we was that you are not in currently?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I'll will leave Lisa to address the resin plant situation. Sp maybe just a quick overview of what happened to those [indiscernible].",24,"Yes. So I'll will leave Lisa to address the resin plant situation. Sp maybe just a quick overview of what happened to those [indiscernible]."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So as you know, Centrale stopped selling their implant in the U.S. following what happened in Europe, where the CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of central larger account to Allergan, which i",97,"So as you know, Centrale stopped selling their implant in the U.S. following what happened in Europe, where the CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of central larger account to Allergan, which is a triple win for us because not only we're gaining market share on the first implant size but while move converting onto the breast, we're also strengthen our business for our portfolio fillers and Botox. So [indiscernible] or tripling. We get the breast implant's business, as well as the fillers and the Botox."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think it carries over to you, right, Paul?",10,"And I think it carries over to you, right, Paul?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, Joe nationally, I mean, in Europe, I think we've always had a positioning of 5.3 [ph] in France and top French service to customers. So I think an event like that on the market, we benefit from the. So we are seeing that, and we're seeing transfers c",54,"Yes, Joe nationally, I mean, in Europe, I think we've always had a positioning of 5.3 [ph] in France and top French service to customers. So I think an event like that on the market, we benefit from the. So we are seeing that, and we're seeing transfers count in the moment as well."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think with respect to potential future, therapeutic areas of interest. We're really focused on the 7 we're in. When you think about the 7 we're, we still have a lot of late space opportunity. For example, we're #1 in aesthetic medicine and a robust",199,"And I think with respect to potential future, therapeutic areas of interest. We're really focused on the 7 we're in. When you think about the 7 we're, we still have a lot of late space opportunity. For example, we're #1 in aesthetic medicine and a robust pipeline of project. But yes, mostly focused on the phase. They're still whole body to work with in aesthetic medicine and lots of opportunities. And in eye care, I'll leave seen us do a lot of things recently to support our robust development organization with dry eye and glaucoma. But there's still more things that we can do in Retina beyond DARPin and Ozurdex. And there's new opportunities of their globally as well. CNS, a strong presence in Alzheimer's and neurology and psychiatry. But we know we don't participate that say just an example, MS or Parkinson's or a variety of other conditions that could leverage CNS. And I could go down through the entire 7 therapeutic areas and point to a big white space that would allow us to leverage our infrastructure, commercially, our R&D capabilities with very little additional cost, but expand ourselves into those therapeutic areas. That's really the goal."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your final question comes from the line of Tim Chiang with the TIG.",14,"And your final question comes from the line of Tim Chiang with the TIG."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, could you talk more a little bit about your focus on GI space heading into next year? certainly, we got labor see coming online. You've got Linzess and all the filing a low-dose strength of Linzess to 72-microgram. Can you talk a little bit about h",76,"Brent, could you talk more a little bit about your focus on GI space heading into next year? certainly, we got labor see coming online. You've got Linzess and all the filing a low-dose strength of Linzess to 72-microgram. Can you talk a little bit about how that low dose might help you in the current constipation treatment market? And is Viberzi going to be the first detail in the GI space in front of Linzess?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, so I think later today, we'll talk more about the pipeline. And certainly, we have more than just low-dose. We announced our partner the colonic lease program for Linzess. And then, of course, we have very importantly moving easily through the clinic",58,"Yes, so I think later today, we'll talk more about the pipeline. And certainly, we have more than just low-dose. We announced our partner the colonic lease program for Linzess. And then, of course, we have very importantly moving easily through the clinic. So maybe Bill could just talk about how we do it from a promotional perspective."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, the reason we default of the low iron what and also the spring co-formulation, which will be introduced to accelerate our conversion over the counter market. I mean, most of the sales for Linzess today are being captured by patients overusing over-th",176,"Yes, the reason we default of the low iron what and also the spring co-formulation, which will be introduced to accelerate our conversion over the counter market. I mean, most of the sales for Linzess today are being captured by patients overusing over-the-counter medication. That will be the primary source of growth in the future, low-dose is going to give physician some optionality and for patients, it may be better tolerated. So Linzess, at 1 45 and 2 90 based on our estimation is a completely well-tolerated. The average patient is taking close to 120 days of therapy as compared to, Amities or, which we're trading at roughly 90 days a therapy. Broadly speaking, though, it's used -- it's a great space. And with Viberzi, we can pull resources to the 2 products so that each one is going to get a greater level of effort than they would have if marketed independently. And as Brent said, we'll cover more about the pipeline polymer Ellen and the other life cycle opportunities during R&D Day this afternoon."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And maybe Paul Navarre just touched on our thoughts around and perhaps later he walks out away in another G.I. opportunities around the world.",25,"And maybe Paul Navarre just touched on our thoughts around and perhaps later he walks out away in another G.I. opportunities around the world."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you mentioned, Brent, GI is a pricey for us. So internationally, we're going to send the great the [indiscernible]. And the first up was to actually buy the rights of recess in 41 markets internationally. So that's going to be the first step of creat",76,"Yes, you mentioned, Brent, GI is a pricey for us. So internationally, we're going to send the great the [indiscernible]. And the first up was to actually buy the rights of recess in 41 markets internationally. So that's going to be the first step of creating the franchise. And then we're going to wait for the approval, hopefully, with the launch of eluxadoline in 2017. So I think we have a similar ambition internationally for G.I."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Okay. I think that was our less crushing, lease up?",10,"Okay. I think that was our less crushing, lease up?"
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. I hope many of you will join us live as well as via live webcast for what I hope will be an excit",145,"So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. I hope many of you will join us live as well as via live webcast for what I hope will be an exciting, interesting and informative session with our R&D colleagues and commercial colleagues. And I would just like to invite by thanking our team around the world for a great quarter. We have quite a few things going on with integration and divestitures. And our team continues to stay focus and execution will excellence and driving results. And I think this quarter was just another long string of proof points and that we understand our business, and we're focused on execution. So thank you very much and hopefully, we'll see you all soon."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, everyone.",2,"Thanks, everyone."
36478,313170036,891491,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Ladies and gentlemen, this does conclude today's conference call. You may now disconnect.",13,"Ladies and gentlemen, this does conclude today's conference call. You may now disconnect."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan Third Quarter Earnings Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Lisa",53,"Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan Third Quarter Earnings Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Lisa DeFrancesco, Vice President, Investor Relations. Please go ahead."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter e",392,"Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter ended September 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyright material of Allergan and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflects our current perspective of business trends and information as of today's date.
Actual results may differ materially from current expectations and projections, depending on a number of factors affecting the Allergan business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
At this time, as a result of the press release Allergan issued on October 29, 2015 confirming the company has been approached by Pfizer and is in preliminary friendly discussions regarding a potential business combination transaction, the company will not be issuing any financial forecast that could require additional reporting under Rule 28 of the Irish Takeover Rules.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our third quarter continuing operations business highlights; and Tessa Hilado, our Chief Financial Officer, will then discuss the Allergan third quarter continuing operations results in more detail. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; David Nicholson, Executive Vice President and President of Global Brands R&D; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I will turn the call over to Brent."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the third quarter of 2015. We obviously have been very busy on many fronts, and our teams continue to be build on the momentum we have had all year. This momentu",1540,"Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the third quarter of 2015. We obviously have been very busy on many fronts, and our teams continue to be build on the momentum we have had all year. This momentum will propel our future growth.
Turning to Slide 5. Allergan's third quarter performance illustrates the we continue to execute on the 4 pillars of our growth strategy. First, operational excellence is yielding exceptional financial performance and strong results in continuing operations, key products and key geographies. Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive and innovative R&D engine continues to produce. Our team is looking forward to showcasing our R&D pipeline, the success we've had this year and the depth of our pipeline across all 7 therapeutic areas later today at R&D Day.
And we are executing on strategic business deals, including our Teva transaction earlier in the quarter, to allow us to focus on growing our business. With the announcements of our plans to combine our Global Generics business with Teva in a deal worth approximately $40.5 billion, we are now reporting our generics business as discontinued operations. Although the business results are consolidated into a single line in the income statement, our Global Generics team continues to perform well.
I'm impressed with the continued momentum in the business and proud of the performance of this team. For example, the generics R&D team has submitted 25 new ANDAs in the U.S. this year, with 16 of them potential First-to-Files. This team is a gem of the generics industry, and they are on track to submit approximately 35 applications by year-end.
Outside of the U.S., we filed over 1,000 marketing authorizations in critical markets. This year, we have received approval and launched over 25 products in the U.S., and these new launches are adding to our results. Internationally, the teams in the U.K., Russia and other Eastern European markets continue to deliver strong performance.
The pre-integration work with Teva is going well, and we remain committed to closing the transaction during the first quarter of 2016. This plan to divest the Global Generics business allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapeutic areas and reload our capital structure to continue our transformation. We are confident that we are creating the most dynamic company in growth pharma.
Now let me turn to the continuing operations business performance in the third quarter. Our third quarter net revenue grew 90% on a year-over-year basis to $4.1 billion as a result of the Allergan acquisition. On a pro forma basis, sales grew 10% despite the loss of exclusivity on one of our largest products, Namenda IR, which experienced generic competition in the quarter. Strong sales in key products across our business drove 65% increase in non-GAAP earnings per share to $3.48. Meanwhile, non-GAAP EBITDA rose to $2 billion, and cash flow from operations, excluding R&D asset acquisitions, restructuring and integration payments, was $1.7 billion in the quarter. 
Our business continues to drive strong performance. More than half of our products are delivering double-digit volume-driven growth. On a pro forma basis, year-over-year brand revenue increased nearly 13% excluding Namenda IR, divestitures and the impact of foreign exchange.
On Slide 8. Our growth in the quarter was broad-based. Excluding the impact of foreign currency, we drove double-digit growth from leading brands across key franchises such as Botox, Restasis, Linzess, Lo Loestrin and Saphris. We continue to solidify our leadership in key categories with new launches and approvals. Our recent launches include -- including Avycaz, Dalvance, Namzaric, Liletta and Kybella, are all performing well, supported by strong promotional activities. Looking ahead, we will continue to drive growth through new approvals and upcoming launches, including Viberzi in a few weeks and Vraylar in the first quarter of 2016.
In addition to progress made in our R&D pipeline, we are also strengthening therapeutic area leadership through new acquisitions of important programs. In eye care, we continue to add [indiscernible] and development opportunities for dry eye disease and eye care with the acquisition of AqueSys, Mimetogen and Oculeve. Mimetogen, which we just announced this morning, brings a novel topical formulation dry eye treatment that could potentially be used alone and in combination with other dry eye therapies. This adds a Phase III program, further strengthening our dry eye pipeline, giving us the potential to launch 6 new products over the next 5 years.
In aesthetics, we completed the acquisition of Kythera for its leading product, Kybella, adding a nonsurgical treatment for submental fullness or double-chin. We also announced this morning the acquisition of Northwood Medical Innovation, developer of innovative implant technology, earFold. earFold is a medical device for the correction of prominent ears.
In CNS, we completed the acquisition of Naurex, which has potential breakthrough treatments in depression and will be discussed in detail later this morning at R&D Day. 
And in GI, we recently completed the acquisition of commercial rights to Constella in more than 40 international markets. This adds an important product to our commercial team internationally and helps position us for the potential to add new GI therapies, like eluxadoline, to our product offering for international customers.
Before I turn the call over to Tessa to review our financial performance in the third quarter, I wanted to touch on our R&D Day and recent commentary on product pricing. Later this morning, David Nicholson, Bill Meury and Philippe Schaison will give an update on the pipeline and the commercial potential it contains. We believe that people will begin to take more active notice of our pipeline after today's meeting. 
With more than 70 projects in mid- to late-stage development, we have multiple programs in each of our therapeutic areas to help us sustain leadership in the areas where we choose to compete. We are building a sustainable innovation engine to power our top line performance and therapeutic area leadership well into the future. Please join us for an exciting day beginning in about an hour.
Turning to pricing. Pricing has been in the headlines and featured in the presidential debates. But let's not pretend that this is a topic that has just appeared in the news. It's been a focus for many years. We know that cost is a constant concern, so is patient access to medical innovation. Allergan seeks to strike the right balance between care and cost. We operate in an Open Science model, developing promising products that frequently originate with smaller companies. These companies often lack the infrastructure to bring their products through expensive late-stage trials or the commercial presence to recoup their R&D investments. The innovation ecosystem is full of these smaller companies who have extraordinary ideas and brilliant scientists. We want to be the magnet for their great ideas in this new innovation ecosystem. Our model is designed to bring these extraordinary ideas to market. Our R&D staff is more than 2,000 people strong. They mobilize resources to help regulatory authorities around the world assess safety and efficacy of our products while providing data to payers to reflect their value.
Let's face it. This effort is costly and often reflected in the cost of medicine, and it is easy to miss the significant value they represent. They reduce the need for hospitalization, surgery, follow-up visits and more dire medical consequences. Allergan has a heritage in knowing health system economics very well, and we want to make sure patients have access to important medicines. Like many of our peers, we have patient assistance programs to make sure that patients have access to our medicines regardless of their ability to pay.
We are [indiscernible], acquiring and investing in promising treatments for serious diseases, Alzheimer's, severe depression, glaucoma, debilitating gastrointestinal conditions. Our business model does not involve purchasing old products already in the marketplace and taking excessive price increases. We prefer to acquire mid- to late-stage drugs and invest extensively in their development. 
To make these decisions to help people with unmet medical needs requires us to build bridges with physicians, academic medical centers, government, regulators and inventors of these molecules so that they see us as a partner who shares in their dedication to improve people's well-being. 
If you look at our recent development acquisitions, it's all about investing in ideas that can help change the way medicine is practiced. What makes the biopharmaceutical industry great? Inventions that change lives. We will continue to use our resources to advance treatments for unmet medical needs and to tap into the world's best ideas to advance care for patients. We will do this while we will continue to strike the appropriate balance between care and cost. 
In closing, our team continues to focus on execution, and our results indicate that we are exceptionally skilled at delivering strong operating results while also doing surprising things to make our company the most dynamic and bold in health care. I'm so proud of this team for their performance, and I'm looking forward to what we can do with the strength and focus on just branded pharmaceuticals. 
With that, now I'd turn the call over to Tessa."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third qua",639,"Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third quarter was $4.1 billion, an increase of 90% versus third quarter 2014.
Non-GAAP R&D investment for the quarter was $305 million compared to $192 million in the prior year period. Non-GAAP SG&A as a percentage of revenue was 22.4%, a decrease of 3.1 percentage points over the prior year quarter as a result of the synergies realized from recent acquisitions. 
Adjusted EBITDA for the quarter was $2 billion, an increase of 168% versus the prior year, driven by strong revenues and higher gross margins across business segments. Non-GAAP earnings per diluted share for the quarter increased 65% to $3.48 compared to $2.11 per diluted share in the third quarter of 2014. Our non-GAAP tax rate was 8.4% in the quarter. This rate was below expectations, driven primarily by the allocation of the entire interest expense to continuing operations earnings. This rate could change by potential repayment of debt upon the close of the Teva transaction. 
Cash flow from operations for the third quarter was $1 billion, impacted by recent asset acquisitions. Excluding acquisition-related restructuring and integration payments, our third quarter cash flow from operations would be $1.7 billion.
Slide 13. Turning now to our U.S. Brand results on Slide 13. The business delivered strong performance year-over-year. U.S. Brands revenue was $2.4 billion for the quarter, up 50% versus the prior year period, driven by the addition of Allergan businesses and strong growth across key products, including Restasis, Linzess, Women's Health products, and new product launches, including Liletta, Namzaric and Avycaz. Adjusted gross margin within U.S. Brands continued to be strong with margins approaching 88%. SG&A as a percentage of revenue decreased to 18.3% versus 22.1% in the year-ago quarter, driven by continued synergy capture from recent acquisitions.
Turning to Slide 14 and our U.S. Medical Aesthetics business. Third quarter revenues were $457 million, an increase of 9% versus third quarter 2014 results on a pro forma basis. Sequentially, U.S. Medical Aesthetics performance was affected by seasonality related to aesthetics procedures. Third quarter gross margins were strong at 93.9%. SG&A as a percentage of revenue decreased 1.2 percentage points versus third quarter 2014.
Turning to Slide 15 and our International Brands results. Third quarter revenues were $661 million versus $58 million in the prior year largely due to the Allergan acquisition. Year-over-year growth was also driven by fillers and Ozurdex in international markets. Sequential revenue performance was mostly due to seasonality. Gross margins increased 25.7 percentage points to 83% in the third quarter due largely to the inclusion of higher-margin legacy Allergan products. Segment SG&A increased 3.2 percentage points to 29.8% versus third quarter 2014 due largely to the Allergan acquisition.
Turning to our Anda business on Slide 16. Revenues increased to $576 million, up from $500 million in the prior year, an increase of 15%, driven by trends in our base business and new retail chain businesses. Results include third-party revenues and related expenses of generic products manufactured by the company and distributed through Anda.
Slide 17 details our debt capitalization. We ended the third quarter 2015 with total debt of approximately $42.7 billion and equity of $77.5 billion related to the Allergan acquisition and previous financing. In the third quarter, we paid down approximately $231 million of our debt. In October, we borrowed $800 million on our revolving credit facility to fund the Kythera acquisition.  Currently, our leverage ratio stands at 3.98x debt-to-pro forma adjusted EBITDA versus 3.9x in the prior quarter due to continued investments in R&D assets. We remain committed to maintaining our investment-grade ratings.
And now I will turn the call to Lisa for Q&A."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Nan, I think we can start taking questions. [Operator Instructions]",10,"Nan, I think we can start taking questions. [Operator Instructions]"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range, I think, you laid out in September? I guess was there anything unusual or any reason to expe",116,"I just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range, I think, you laid out in September? I guess was there anything unusual or any reason to expect that ratio to move higher going forward? Because otherwise, it seems like the company's going to be quickly trending to the low end of that range as top line continues to scale here. And if I can slip in a second quick one. We've been asking this question a lot. Can you disclose the mix of price versus volume driving your growth in the quarter?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look at this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, T",53,"Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look at this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, Tessa, if you want to add anything."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, we're within the range. And unfortunately, given sort of like Irish Rules, we can't really provide guidance on a go-forward basis. I would just say that we are within the range.",32,"Yes, we're within the range. And unfortunately, given sort of like Irish Rules, we can't really provide guidance on a go-forward basis. I would just say that we are within the range."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And then on price-volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price-volume -- or I'll say volume-price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the en",59,"And then on price-volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price-volume -- or I'll say volume-price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the entire product line, it's roughly 50-50. And our price appreciation trades in the single digits."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Jason Gerberry with Leerink Partners.",13,"Your next question comes from the line of Jason Gerberry with Leerink Partners."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just a quick question on Namenda now that we've now had a chance to see how the generic impact is flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million pea",74,"Just a quick question on Namenda now that we've now had a chance to see how the generic impact is flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million peak sales product? Or should investors think about that peak sales target as more of the combined value that XR and Namzaric could retain?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I would start, and maybe then Bill can jump in. I think as you think about where we are with Namenda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both X",116,"Yes, I would start, and maybe then Bill can jump in. I think as you think about where we are with Namenda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both XR and Namzaric. The one thing that I would caution is with respect to Namzaric. Most of the formulary coverage, although it's quite good right now, kicks in in January because of the Medicare Part D part of this equation. And so I think our expectations are a little higher post broader formulary coverage than it is today. But Bill, anything you'd want to add?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formulary coverage at the end of '15 and in 2016 is as high as it's been. Next, Namzaric isn't quite a sprint, a good steady jog. 60% of our u",138,"Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formulary coverage at the end of '15 and in 2016 is as high as it's been. Next, Namzaric isn't quite a sprint, a good steady jog. 60% of our use today is coming from Aricept monotherapy. As Brent said, when formulary coverage converge in 2016 and after several months of direct-to-consumer advertising, I would expect over time that the overall business is going to grow and that Namzaric is going to account for a greater and greater percentage of it for one simple reason. It's a better product. If you look at the data, 2 drugs is better than 1, and I think it will take just a little bit of time to move this category."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Amsellem with Piper Jaffray. Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",27,"Your next question comes from the line of David Amsellem with Piper Jaffray. 
Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. And you've got a pretty big portfolio of products that you could leverage. And I think you called out eluxadoline i",72,"Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. And you've got a pretty big portfolio of products that you could leverage. And I think you called out eluxadoline in the prepared comments. So the question for you: What's the strategy here assuming that you remain stand-alone? And where does this rank within your business development priorities?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that still largely is intact. We have a very strong team around the world. We have big opportunities",268,"Yes. I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that still largely is intact. We have a very strong team around the world. We have big opportunities to continue to leverage the infrastructure that we have. I think the deal we did with Almirall to buy Constella is a proof point of the types of things we're going to do as we're preparing to hopefully get approval for eluxadoline in Europe over time. To be able to have more opportunities to leverage GI is a good move for us. Obviously, Aesthetic Medicine is very important. We have lots of opportunity to continue to expand the aesthetic portfolio in Asia, China, I would call out, Latin America. Brazil is another market I would call out where we're seeing strong growth. And then, of course, eye care is very important to us around the world. And we continue to look for ways to build our portfolio and leadership in eye care. And in many markets, we are #1 in eye care outside the U.S. So we have a big heritage there, and it is important for us to continue to leverage. With respect to business development, it remains a priority. We will continue to look for ways to add scale and product flow in key international markets around the world. And if we do that ourselves by eluxadoline approval or Juvederm approval recently in China or buying Constella or other things, it's an important growth driver for us in the future."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Should we think about this, though, as more of a bolt-on source of capital? I mean, everybody's going to be focused on the $29 billion that you have coming in from Teva in Q1, assuming that another deal on the side here doesn't happen. So should we think",64,"Should we think about this, though, as more of a bolt-on source of capital? I mean, everybody's going to be focused on the $29 billion that you have coming in from Teva in Q1, assuming that another deal on the side here doesn't happen. So should we think about international as a smaller deal build-out? Or could we see more significant capital allocated there?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. I mean, I think about it 3 ways. It's going to be organically, through driving our 70 -- most of our 70 late-stage -- mid- to late-stage programs and global development programs to the extent it makes sense; to doing R&D-type deals for international",84,"Yes. I mean, I think about it 3 ways. It's going to be organically, through driving our 70 -- most of our 70 late-stage -- mid- to late-stage programs and global development programs to the extent it makes sense; to doing R&D-type deals for international product flow; to buying already-marketed products, like we did Constella; and then, perhaps, from time to time, where it makes sense strategically and financially, bolting on a small business in a place like Brazil or China or even Europe."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I was hoping you could give us a little more detail on the cash pay businesses as well as just Botox overall, what's going on behind the scenes in each of the individual areas.",34,"I was hoping you could give us a little more detail on the cash pay businesses as well as just Botox overall, what's going on behind the scenes in each of the individual areas."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I mean, obviously, they're an important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. Medical. That business continues to perform exceedingly well. Obviously, it was -- there was some s",62,"I mean, obviously, they're an important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. Medical. That business continues to perform exceedingly well. Obviously, it was -- there was some seasonality in the third quarter, as there always is. Philippe, I don't know if you would want to comment on anything."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I think Kybella is really starting to get momentum. And I was at [indiscernible] and his team last -- I guess 2 weeks ago. So we're in the process of training roughly 1,500 top-tier reps on top of the 800 that have been already trained. From a market shar",98,"I think Kybella is really starting to get momentum. And I was at [indiscernible] and his team last -- I guess 2 weeks ago. So we're in the process of training roughly 1,500 top-tier reps on top of the 800 that have been already trained. From a market share standpoint, we -- at that point, we continue to solidify our market share, especially on the filler market. And we have 2 million consumers part of our BD loyalty program, which is an all-time high. So we're thriving, and we're doing extremely well, and everything is in the green."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well, but the vast majority of that is from the aesthetics business within Allergan Medical",44,"Just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well, but the vast majority of that is from the aesthetics business within Allergan Medical."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","And what about Botox in the therapeutic areas? Like how is migraine doing, overactive bladder, all the key drivers?",19,"And what about Botox in the therapeutic areas? Like how is migraine doing, overactive bladder, all the key drivers?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you hit the right ones. Those are the main growth drivers for Botox therapeutically. Both indications are growing at a high double-digit rate. The core indications, the regional indications are relatively stable. Listen. In both those conditions, it'",81,"Yes, you hit the right ones. Those are the main growth drivers for Botox therapeutically. Both indications are growing at a high double-digit rate. The core indications, the regional indications are relatively stable. Listen. In both those conditions, it's a highly effective product, and it's also very economical. And the injector base today in the United States for Botox is very experienced and comfortable with the product. I expect that both indications can continue to grow for the next several years."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Liav Abraham with Citi.",13,"And your next question comes from the line of Liav Abraham with Citi."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I'd be interested in your thoughts on the outlook for Restasis given the recent OPUS-3 data for Lifitegrast. And perhaps, at the same time, can you just remind us of your formulary coverage for Restasis?",36,"I'd be interested in your thoughts on the outlook for Restasis given the recent OPUS-3 data for Lifitegrast. And perhaps, at the same time, can you just remind us of your formulary coverage for Restasis?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, sure. I think Bill probably is in the best position to answer.",13,"Yes, sure. I think Bill probably is in the best position to answer."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a good question. I don't believe that this is going to be a fight to the death between Shire and Allergan. I've said before that the gap between the prevalent population and prescription-treated population is enormous. It's larger than it is in",296,"Yes, it's a good question. I don't believe that this is going to be a fight to the death between Shire and Allergan. I've said before that the gap between the prevalent population and prescription-treated population is enormous. It's larger than it is in most categories. The importance of dry eye disease is clear, and it's getting more and more attention because of the impact it has on quality of life, the impact that it can have on vision and positive post-op outcomes. When you look at the data sets between the drugs, I would simply say that we'll have to see how Lifitegrast stands up in the real world. I would also point out that in the second half of 2016, we'll be launching a multi-dose preservative-free form of Restasis, which, I believe, is going to be very popular with physicians and with patients for 2 reasons. The first, it's just more convenient than 60 single-unit vials or droppers, and it's also easier to administer. And a big problem with all of these eyedrops is they're difficult to instill, and it's often a major problem with compliance. Our promotional program in this category will continue to be at the very top. We have a large sales force that covers primary care, optometry and ophthalmology. We'll continue to run the largest direct-to-consumer advertising program in the industry. And then lastly, obviously, as you asked about formulary coverage, we have preferred status on 85% to 90% of health plan formularies, and 90% of that is Tier 2. And so this is a highly economical option. There's no doubt eye care professionals are going to try something new. But I believe, long term, this category has the potential to double, so there's more than enough to go around."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Gregg Gilbert with Deutsche Bank.",14,"And your next question comes from the line of Gregg Gilbert with Deutsche Bank."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a question, and if you can't answer it, I have a backup. But it's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you, that a business combination means that talks are about Pfizer poten",50,"I have a question, and if you can't answer it, I have a backup. But it's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you, that a business combination means that talks are about Pfizer potentially buying Allergan or not necessarily?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I can't answer. So you should go to your backup question.",12,"Yes, I can't answer. So you should go to your backup question."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","It's more boring. Tessa, can you share the generics sales and the gross margin and the segment margins in the quarter, perhaps?",23,"It's more boring. Tessa, can you share the generics sales and the gross margin and the segment margins in the quarter, perhaps?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which will be filed shortly. What I can say is we had solid performance for the generic business, and revenues are around $4.77 billion",54,"Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which will be filed shortly. What I can say is we had solid performance for the generic business, and revenues are around $4.77 billion for the 9 months, for year-to-date 9 months."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And remember, that is discontinued -- just in fairness, that is discontinued operations accounting. So for those, that also covered Teva. It's not just a simple one-to-one kind of translation. Is that fair, Tessa?",34,"And remember, that is discontinued -- just in fairness, that is discontinued operations accounting. So for those, that also covered Teva. It's not just a simple one-to-one kind of translation. Is that fair, Tessa?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's fair. But it's performed according to our expectations and good solid performance. But you'll get more detail in our 10-Q.",22,"That's fair. But it's performed according to our expectations and good solid performance. But you'll get more detail in our 10-Q."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Irina Koffler with Mizuho.",13,"And your next question comes from the line of Irina Koffler with Mizuho."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I just wanted to see how you're thinking about your sales force going forward. Is it the right size? Are there opportunities to be a little bit more efficient or use alternative distribution models there? Or are you, in fact, keep on adding in size?",46,"I just wanted to see how you're thinking about your sales force going forward. Is it the right size? Are there opportunities to be a little bit more efficient or use alternative distribution models there? Or are you, in fact, keep on adding in size?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I was going to make a bad joke, but I'll stop. Well, I mean, for me, the sales representatives around the world is a very important part of our company that we tend to put them at the center of the way we think about our business. And what they do is -- t",171,"I was going to make a bad joke, but I'll stop. Well, I mean, for me, the sales representatives around the world is a very important part of our company that we tend to put them at the center of the way we think about our business. And what they do is -- they are the most intimate with our customers. I think we look at our sales force deployment globally very thoughtfully and strategically. For example, in facial aesthetics, we just increased our sales force by about 75 sales reps, which was already the largest facial aesthetic sales force in the United States. And now it's even larger and more powerful. China, we've just invested in our sales force and added sales reps. And so we do look at it, the deployment of the sales reps, very strategically. In the U.S., Bill can comment, we have the most sales reps. It is a very hard-working, dedicated group, I think, delivering more details than any other sales force in the industry."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives, but they operate as if it was 4,500 or 5,000. Just by virtue, they lead the industry in activity. The most significant",188,"Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives, but they operate as if it was 4,500 or 5,000. Just by virtue, they lead the industry in activity. The most significant change that we've made in the past 12 to 18 months is we've customized the field force. So there's no longer a one-size-fits-all approach. We don't have the same number of representatives in the state of Massachusetts as compared to the state of Mississippi. And so we will invest in regions in sales force based on the estimated return. But we do operate with the principal when we launch new products, and we have multiple new product launches over the next several years. We will always aim to achieve share of voice leadership. And so details and representatives, on a routine basis, are being reallocated across the product line so that we can maximize the value of our business. It's a terrific group. They're well compensated and well trained, but I don't anticipate any fundamental shifts in our sales force model at this point."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of David Risinger with Morgan Stanley.",14,"And your next question comes from the line of David Risinger with Morgan Stanley."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have 2 finance questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go-forward tax rate? And then when you give 2016 financial guidance in February for the",131,"I have 2 finance questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go-forward tax rate? And then when you give 2016 financial guidance in February for the stand-alone company, how should investors think about what you're going to bake in for debt reduction? Meaning that's a huge swing factor in modeling EPS, and maybe you can just talk about how you're thinking about it at a high level at this point. And then separately, on Botox pricing, could you just update us on when the decision will come down on whether Allergan will be able to separate pricing for the cosmetic and therapeutic indications and more appropriately price Botox for therapeutic indications?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me take the last first, and then Tessa can take the financial ones. We are continuing with our litigation with CMS around bifurcation of pricing. I really don't have an update on that today. But it's something that Bob Bailey and the legal team are",118,"So let me take the last first, and then Tessa can take the financial ones. We are continuing with our litigation with CMS around bifurcation of pricing. I really don't have an update on that today. But it's something that Bob Bailey and the legal team are staying very focused on, and we'll see how that plays out. And as soon as we have an update, we'll certainly provide it. But I wouldn't build any expectations around that. Second, we continue to think about therapeutic Botox as -- with new toxins for the future. But that's a longer-term strategy as well. So I think for the short term, David, I would just view those prices as being coupled."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So on the 2 finance questions, David, I'll address the second one first. We are committed to providing an update in terms of financials similar to what we've done in the past, which should be during the Q1 earnings release in February. And by then, to the",201,"So on the 2 finance questions, David, I'll address the second one first. We are committed to providing an update in terms of financials similar to what we've done in the past, which should be during the Q1 earnings release in February. And by then, to the extent that we have more clarity with regards to how we would deploy capital, assuming the Teva transaction would have closed by then, then we will provide you guidance with regards to capital deployment, including debt repayment. One thing, obviously, that we're committed to is the investment-grade rating. So to the extent that we don't deploy capital, we will pay down the amount necessary to maintain the rating on a go-forward basis. With regards to the tax question, based on our release, what actually occurred because of continuing operations is that the bulk of -- or the entire interest expense was actually allocated to continuing operations, hence, the low tax rate. On a go-forward basis, that should trend upwards, assuming we pay down debt, but we can't really be precise at this point given our restrictions based on Irish law. But it should trend higher based on debt -- if we assume debt pay-down."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Ronny Gal with Bernstein.",13,"And your next question comes from the line of Ronny Gal with Bernstein."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","A couple of clarifying ones and then more of a strategic one. First, on Botox, you reported 13% constant currency, and I think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. Can you jus",173,"A couple of clarifying ones and then more of a strategic one. First, on Botox, you reported 13% constant currency, and I think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. Can you just give us a little bit more color on the currencies involved? Second, for Bill. Fair to say that if Lifitegrast comes to market the end of 2016, we should expect a weaker Restasis in '17, '18? [indiscernible] for a couple of years in growth of that product. And then maybe I think as a member, we're not supposed to ask it, but more broadly, the [indiscernible] results this quarter, you seem to be in the process of actually executing on what you told us you would. You got the revenue growth that will put you much above your peers. Your multiple is much lower. It doesn't seem like a great time to engage in friendly discussions with another company. Can you help us think about this a little bit?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously had -- that's Botox, specifically.",26,"So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously had -- that's Botox, specifically."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think the 13% pro forma was for the entire branded business.",13,"And I think the 13% pro forma was for the entire branded business."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Correct.",1,"Correct."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Excluding Namenda IR, divestitures and the impact of foreign exchange is what I said in the prepared remarks.",18,"Excluding Namenda IR, divestitures and the impact of foreign exchange is what I said in the prepared remarks."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","But Botox itself, year-over-year, grew by about 8%, 13% excluding FX.",11,"But Botox itself, year-over-year, grew by about 8%, 13% excluding FX."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And you're looking at the chart versus what I said, Ronny, right?",13,"And you're looking at the chart versus what I said, Ronny, right?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, I'm actually looking at the -- I'm actually looking at your products slide. Botox continued strong growth [indiscernible] of more than 13%. Excluding foreign exchange, this is just about 8%?",31,"No, I'm actually looking at the -- I'm actually looking at your products slide. Botox continued strong growth [indiscernible] of more than 13%. Excluding foreign exchange, this is just about 8%?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's right. It's hard to hear you, Ronny. That's a little bit -- we hear about every second word. Yes, so you got it.",25,"Yes, that's right. It's hard to hear you, Ronny. That's a little bit -- we hear about every second word. Yes, so you got it."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%.",17,"So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Okay. So Botox is around 13% constant currency in the third quarter.",12,"Okay. So Botox is around 13% constant currency in the third quarter."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's correct, yes.",4,"That's correct, yes."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Correct.",1,"Correct."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Is there a reason why the gap between the currency-adjusted and not currency-adjusted is so big? Is there a couple of currencies that went particularly bad this quarter?",29,"Is there a reason why the gap between the currency-adjusted and not currency-adjusted is so big? Is there a couple of currencies that went particularly bad this quarter?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I mean, it's largely euro, plus we have some protection related to certain hedges that flow through.",17,"I mean, it's largely euro, plus we have some protection related to certain hedges that flow through."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Douglas Tsao with Barclays.",13,"And your next question comes from the line of Douglas Tsao with Barclays."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just maybe if you could offer some perspective on the upcoming Viberzi launch, especially given what you've seen from the competitive adoption or the adoption of Salix thus far -- or the Salix Xifaxan so far in IBS-D, that's helpful.",40,"Just maybe if you could offer some perspective on the upcoming Viberzi launch, especially given what you've seen from the competitive adoption or the adoption of Salix thus far -- or the Salix Xifaxan so far in IBS-D, that's helpful."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I will ask Bill to comment. But we're very excited to be launching Viberzi. The sales force meeting will be next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- we're making a big investmen",67,"Yes, I mean, I will ask Bill to comment. But we're very excited to be launching Viberzi. The sales force meeting will be next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- we're making a big investment in these launches. That's safe to say. Bill, do you want to talk about it?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a perfect complement to invest. IBS should be thought about as a continuum, with constipation on one end and diarrhea on the other. And because we're able to market 2 products for the same condition essentially, we're able to talk about it in a",242,"Yes, it's a perfect complement to invest. IBS should be thought about as a continuum, with constipation on one end and diarrhea on the other. And because we're able to market 2 products for the same condition essentially, we're able to talk about it in a more complete way. I think it's a competitive advantage. As it relates to the products -- compared to Xifaxan, it's a completely different approach to treatment. This drug works on motility and visceral pain or hypersensitivity. And Xifaxan essentially is an antibiotic. There's certainly room in this category for more than one product. Promotionally speaking, this will be one of the largest launches in the industry from an investment standpoint, and I'm pretty sure it's going to be the largest launch in gastroenterology. It's going to be very noisy. We know how to do this. We did it with Ironwood during the launch of Linzess. The DTC advertising will start not 1 year after approval but only 3 months. And the promotional efforts, unlike other companies in the area, will capture not only gastroenterologists but primary care physicians. And there's an interplay in almost every category between primary care and specialty that we can navigate that other companies can't. And I would expect that this drug should do as well as Linzess does on the other side of the market and could ultimately almost double the size of our GI business over the next 5 years."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","This is Ariel Herman in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's",68,"This is Ariel Herman in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's baked into that regarding price and volume? And then secondly, can you touch on the competitive dynamics with the potential competition to Botox from Revance's product?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I think as, obviously, we're under some restriction under Irish law with respect to guidance, but our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominant",323,"Yes. So I think as, obviously, we're under some restriction under Irish law with respect to guidance, but our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominantly in a volume situation, not a price situation. As we think about price, we tend to think about mid- to high single-digit price increases across the portfolio. And so we don't really think of any change or expect any change in our very, I think, conservative pricing policy and the way we think about price. And so we're not going to -- I don't think you're going to see us change our view or, perhaps, better said, our commitment to the 10% growth objectives and aspirations that we have. So I think that's going to stay fairly normalized for the foreseeable future. I think with respect to Revance and competitive toxins, I'll ask David to comment as well. But I would just remind you that there are competitive toxins already in the market. And more -- if you talk to customers, more -- very few care about having an extra few weeks or a month of duration of effect for Botox or toxins. And in fact, what they mostly complain about is price. And our competitors price their toxins much -- at a much lower rate than we price Botox, and yet Botox continues to be a strong market leader. And so I would just urge you to keep perspective. As Philippe said earlier, we have 2 million members and brilliant distinctions. We have a full range of facial aesthetics. We have the largest field force. Botox is the #1 branded pharmaceutical brand in the world. And so this is a very strong franchise with very good staying power. And so sometimes, there's a hammer looking for a nail. Duration maybe just that. But scientifically, maybe David can comment, too."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I'm happy to talk about that briefly. Clearly, we'll be talking about Botox during R&D Day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indication",135,"Yes, I'm happy to talk about that briefly. Clearly, we'll be talking about Botox during R&D Day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indications of Botox around the world, so extending our aesthetic reach geographically. And we will be developing Botox for new therapeutic application. I would point out, if we're talking about duration, Botox, in some indications, has a duration for up to 9 months. So if we're talking about hyperhidrosis, for instance, Botox then works for up to 9 months. So the duration of Botox depends on the use and the dose that we administer. And more of this during the course of the day as we walk through our R&D pipeline."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, let me just add to this. Botox really is a [indiscernible] product. It's got a lot of indications, 10 indications. It's got great brand recognition. It is supported by the strongest promotional effort, and it's got good and strong clinical science an",46,"Yes, let me just add to this. Botox really is a [indiscernible] product. It's got a lot of indications, 10 indications. It's got great brand recognition. It is supported by the strongest promotional effort, and it's got good and strong clinical science and experience behind it."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Two quick ones. First, can you tell us a bit more about the generics this quarter, what the actual sales were, the year-on-year trends and just some commentary there? And number two, Brent, so in an M&A scenario, is there anything legally preventing you f",54,"Two quick ones. First, can you tell us a bit more about the generics this quarter, what the actual sales were, the year-on-year trends and just some commentary there? And number two, Brent, so in an M&A scenario, is there anything legally preventing you from issuing more in shares than your own share count?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So Tessa, do you want -- she already answered the generics question.",13,"Yes. So Tessa, do you want -- she already answered the generics question."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, as I said earlier, they had good solid performance, performed according to our expectations. We will provide more granularity for discontinued operations in our 10-Q, which should be filed in the next couple of days. But revenue-wise, it was at $4.77",48,"Yes, as I said earlier, they had good solid performance, performed according to our expectations. We will provide more granularity for discontinued operations in our 10-Q, which should be filed in the next couple of days. But revenue-wise, it was at $4.77 billion for the last 9 months."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And so your other question, I remember it was about share repurchase.",12,"And so your other question, I remember it was about share repurchase."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, sorry, I meant can you issue, in an M&A scenario where you're issuing equity, is there anything that prevents you from issuing more in equity than your own entire share?",31,"No, sorry, I meant can you issue, in an M&A scenario where you're issuing equity, is there anything that prevents you from issuing more in equity than your own entire share?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","To be fair, I just don't know the answer. Maybe if you want to follow up, we can talk to the folks who may know the answer to that. I just don't know, Umer.",34,"To be fair, I just don't know the answer. Maybe if you want to follow up, we can talk to the folks who may know the answer to that. I just don't know, Umer."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch.",17,"And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a quick couple. First is in a relatively small part of your business. That's the breast implants. How well is Allergan positioned to take advantage of some of the competitive missteps there? And second, on business development, assuming you remain",62,"I have a quick couple. First is in a relatively small part of your business. That's the breast implants. How well is Allergan positioned to take advantage of some of the competitive missteps there? And second, on business development, assuming you remain stand-alone, what are examples of some therapeutic areas that might excite you, among the ones that you're not in currently?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I'll let Philippe address the breast implant situation and maybe just a quick overview of what happens [indiscernible].",20,"Yes. So I'll let Philippe address the breast implant situation and maybe just a quick overview of what happens [indiscernible]."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Sure. So as you know, Sientra stopped selling their implant in the U.S. following what happened in Europe, where they lost their CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of Sientra larger account to",105,"Sure. So as you know, Sientra stopped selling their implant in the U.S. following what happened in Europe, where they lost their CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of Sientra larger account to Allergan, which is a triple win for us because not only we're gaining market share on the right implant size, but while we're converting those accounts to the breast, we also strengthen our business for our portfolio of fillers and Botox. So for us, it's a triple win. We get the breast implant business as well as the fillers and Botox."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think it carries over to Europe as well, right, Paul?",12,"And I think it carries over to Europe as well, right, Paul?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, internationally, distribution is the same in Europe. I think we've always had a positioning of high-quality implants and top French service to customers. So I think an event like that on the market, we benefit on this being the leader. So we are seei",57,"Yes, internationally, distribution is the same in Europe. I think we've always had a positioning of high-quality implants and top French service to customers. So I think an event like that on the market, we benefit on this being the leader. So we are seeing that, and we're seeing transfer of accounts in the moment as well."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think with respect to potential future therapeutic areas of interest, we're really focused on the 7 we're in. When you think about the 7 we're in, we still have a lot of white space opportunity. For example, we're #1 in aesthetic medicine and a robu",202,"And I think with respect to potential future therapeutic areas of interest, we're really focused on the 7 we're in. When you think about the 7 we're in, we still have a lot of white space opportunity. For example, we're #1 in aesthetic medicine and a robust pipeline of projects, but yes, mostly focused on the face. There's still a whole body to work with in aesthetic medicine and lots of opportunities. In eye care, obviously, you've seen us do a lot of things recently to support our robust development organization with dry eye and glaucoma. But there's still more things that we can do in Retina beyond DARPin and Ozurdex. And there's new opportunities there globally as well. CNS, a strong presence in Alzheimer's and neurology and psychiatry. But we know we don't participate, let's say, in, just as an example, MS or Parkinson's or a variety of other conditions that could leverage CNS. And I could go down through the entire 7 therapeutic areas and point to a big white space that would allow us to leverage our infrastructure commercially, our R&D capabilities with very little additional cost but expand ourselves into those therapeutic areas. So that's really the goal."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your final question comes from the line of Tim Chiang with BTIG.",13,"And your final question comes from the line of Tim Chiang with BTIG."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, could you talk a little bit more about your focus on the GI space heading into next year? Certainly, you've got Viberzi coming online. You've got Linzess. I noticed that you're filing a low-dose strength of Linzess to 72-microgram. Could you talk a",77,"Brent, could you talk a little bit more about your focus on the GI space heading into next year? Certainly, you've got Viberzi coming online. You've got Linzess. I noticed that you're filing a low-dose strength of Linzess to 72-microgram. Could you talk a little bit about how that low dose might help you in the current constipation treatment market? And is Viberzi going to be the first detail in the GI space in front of Linzess?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, so I think later today, we'll talk more about the pipeline. And certainly, we have more than just low dose. We announced, with our partner, Ironwood, the colonic release program for Linzess. And then, of course, we have, very importantly, relamorelin",62,"Yes, so I think later today, we'll talk more about the pipeline. And certainly, we have more than just low dose. We announced, with our partner, Ironwood, the colonic release program for Linzess. And then, of course, we have, very importantly, relamorelin moving easily through the clinic. So maybe Bill could just talk about how we do it from a promotional perspective."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, the reason we developed the low dose alongside Ironwood and also the sprinkle formulation, which will be introduced, is to accelerate our conversion over the over-the-counter market. I mean, most of the sales for Linzess today are being captured by p",178,"Yes, the reason we developed the low dose alongside Ironwood and also the sprinkle formulation, which will be introduced, is to accelerate our conversion over the over-the-counter market. I mean, most of the sales for Linzess today are being captured by patients who are using over-the-counter medications. And that will be the primary source of growth in the future. A low dose is going to give physicians some optionality. And for patients, it may be better tolerated. So Linzess, at that 145 and 290, based on our estimation, is extremely well tolerated. The average patient is taking close to 120 days of therapy as compared to Amitiza or Zelnorm, which were trading at roughly 90 days a therapy. Broadly speaking, though, it's a great space. And with Viberzi, we can pull resources for the 2 products so that each one is going to get a greater level of effort than they would have if marketed independently. And as Brent said, we'll cover more about the pipeline, relamorelin and the other life cycle opportunities during R&D Day this afternoon."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And maybe then Paul Navarre can just touch on our thoughts around Constella, and perhaps, later, eluxadoline and other GI opportunities around the world.",24,"And maybe then Paul Navarre can just touch on our thoughts around Constella, and perhaps, later, eluxadoline and other GI opportunities around the world."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you mentioned, Brent, GI is a priority for us. So internationally, we're going to steadily create the franchise. And the first step was to actually buy the rights of Linzess in 41 markets internationally. So that's going to be the first step of creat",75,"Yes, you mentioned, Brent, GI is a priority for us. So internationally, we're going to steadily create the franchise. And the first step was to actually buy the rights of Linzess in 41 markets internationally. So that's going to be the first step of creating the franchise. And then we're going to wait for the approval, hopefully, with the launch of eluxadoline in 2017. So I think we have a similar ambition internationally for GI."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So I think that was our last question, right, Lisa?",10,"So I think that was our last question, right, Lisa?"
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. And I hope that many of you join us live as well as via webcast for what I hope will be an exciti",146,"So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. And I hope that many of you join us live as well as via webcast for what I hope will be an exciting and interesting and informative session with our R&D colleagues and commercial colleagues. 
And I would just like to end by thanking our team around the world for a great quarter. We have quite a few things going on with integrations and divestitures. And our team continues to stay focused on executional excellence and driving results. And I think this quarter was just another in a long string of proof points that we understand our business and we're focused on execution. 
So thank you very much, and hopefully, we'll see you all soon."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, everyone.",2,"Thanks, everyone."
36478,313170036,892043,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Ladies and gentlemen, this does conclude today's conference call. You may now disconnect.",13,"Ladies and gentlemen, this does conclude today's conference call. You may now disconnect."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan Third Quarter Earnings Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Lisa",53,"Good morning. My name is Nan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Allergan Third Quarter Earnings Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Lisa DeFrancesco, Vice President, Investor Relations. Please go ahead."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter e",392,"Thank you, Nan, and good morning, everyone. I'd like to welcome you to the Allergan Third Quarter 2015 Earnings Conference Call. Earlier this morning, we issued a press release reporting Allergan earnings from continuing operations for the third quarter ended September 30, 2015. The press release and our slide deck, which we are presenting this morning, are available on our corporate website at www.allergan.com.
We're conducting a live webcast of this call, a replay of which will be available on our website after its conclusion. Please note that today's call is copyright material of Allergan and cannot be rebroadcast without the company's express written consent.
Turning to Slide 2. I'd also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking statements and reflects our current perspective of business trends and information as of today's date.
Actual results may differ materially from current expectations and projections, depending on a number of factors affecting the Allergan business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Allergan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
At this time, as a result of the press release Allergan issued on October 29, 2015 confirming the company has been approached by Pfizer and is in preliminary friendly discussions regarding a potential business combination transaction, the company will not be issuing any financial forecast that could require additional reporting under Rule 28 of the Irish Takeover Rules.
With us on today's call are Brent Saunders, our CEO and President, who will provide an overview of our third quarter continuing operations business highlights; and Tessa Hilado, our Chief Financial Officer, will then discuss the Allergan third quarter continuing operations results in more detail. Also on the call and available during the Q&A are Paul Bisaro, our Executive Chairman; Bob Stewart, President of Global Generics and Commercial Operations; Bill Meury, President of Branded Pharma; David Nicholson, Executive Vice President and President of Global Brands R&D; Paul Navarre, President of International Brands; Philippe Schaison, President of Allergan Medical; and Bob Bailey, our Chief Legal Officer.
With that, I will turn the call over to Brent."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the third quarter of 2015. We obviously have been very busy on many fronts, and our teams continue to build on the momentum we have had all year. This momentum w",1542,"Thanks, Lisa, and good morning, everyone. It's great to be with you to review our results for the third quarter of 2015. We obviously have been very busy on many fronts, and our teams continue to build on the momentum we have had all year. This momentum will propel our future growth.
Turning to Slide 5. Allergan's third quarter performance illustrates that we continue to execute on the 4 pillars of our growth strategy. First, operational excellence is yielding exceptional financial performance and strong results in continuing operations, key products and key geographies. Second, therapeutic area leadership is leading to double-digit growth among many of our franchises. Third, our productive and innovative R&D engine continues to produce. Our team is looking forward to showcasing our R&D pipeline, the success we've had this year and the depth of our pipeline across all 7 therapeutic areas later today at R&D Day.
And we are executing on strategic business deals, including our Teva transaction earlier in the quarter, to allow us to focus on growing our business. With the announcements of our plans to combine our Global Generics business with Teva in a deal worth approximately $40.5 billion, we are now reporting our generics business as discontinued operations. Although the business results are consolidated into a single line in the income statement, our Global Generics team continues to perform well.
I'm impressed with the continued momentum in the business and proud of the performance of this team. For example, the generics R&D team has submitted 25 new ANDAs in the U.S. this year, with 16 of them potential First-to-Files. This team is the gem of the generics industry, and they are on track to submit approximately 35 applications by year-end.
Outside the U.S., we filed over 1,000 marketing authorizations in critical markets. This year, we have received approval and launched over 25 products in the U.S., and these new launches are adding to our results. Internationally, the teams in the U.K., Russia and other Eastern European markets continue to deliver strong performance.
The pre-integration work with Teva is going well, and we remain committed to closing the transaction during the first quarter of 2016. This plan to divest the Global Generics business allows us to dramatically simplify our operating structure, sharpen our focus on 7 core therapeutic areas and reload our capital structures to continue our transformation. We are confident that we are creating the most dynamic company in growth pharma.
Now let me turn to the continuing operations business performance in the third quarter. Our third quarter net revenue grew 90% on a year-over-year basis to $4.1 billion as a result of the Allergan acquisition. On a pro forma basis, sales grew 10% despite the loss of exclusivity on one of our largest products, Namenda IR, which experienced generic competition in the quarter. Strong sales in key products across our business drove 65% increase in non-GAAP earnings per share to $3.48. Meanwhile, non-GAAP EBITDA rose to $2 billion, and cash flow from operations, excluding R&D asset acquisitions, restructuring and integration payments, was $1.7 billion in the quarter. 
Our business continues to drive strong performance. More than half of our products are delivering double-digit volume-driven growth. On a pro forma basis, year-over-year brand revenue increased nearly 13% excluding Namenda IR, divestitures and the impact of foreign exchange.
On Slide 8. Our growth in the quarter was broad-based. Excluding the impact of foreign currency, we drove double-digit growth from leading brands across key franchises such as Botox, Restasis, Linzess, Lo Loestrin and Saphris. We continue to solidify our leadership in key categories with new launches and approvals. Our recent launches include -- including Avycaz, Dalvance, Namzaric, Liletta and Kybella, are all performing well, supported by strong promotional activities. Looking ahead, we will continue to drive growth through new approvals and upcoming launches, including Viberzi in a few weeks and Vraylar in the first quarter of 2016.
In addition to progress made in our R&D pipeline, we are also strengthening therapeutic area leadership through new acquisitions of important programs. In eye care, we continue to add shots on goal and development opportunities for dry eye disease and eye care with the acquisition of AqueSys, Mimetogen and Oculeve. Mimetogen, which we just announced this morning, brings a novel topical formulation dry eye treatment that could potentially be used alone and in combination with other dry eye therapies. This adds a Phase III program, further strengthening our dry eye pipeline, giving us the potential to launch 6 new products over the next 5 years.
In aesthetics, we completed the acquisition of Kythera for its leading product, Kybella, adding a nonsurgical treatment for submental fullness or double-chin. We also announced this morning the acquisition of Northwood Medical Innovation, developer of an innovative implant technology, earFold. earFold is a medical device for the correction of prominent ears.
In CNS, we completed the acquisition of Naurex, which adds potential breakthrough treatments in depression and will be discussed in detail later this morning at R&D Day. 
And in GI, we recently completed the acquisition of commercial rights to Constella in more than 40 international markets. This adds an important product to our commercial team internationally and helps position us for the potential to add new GI therapies, like eluxadoline, to our product offering for international customers.
Before I turn the call over to Tessa to review our financial performance in the third quarter, I wanted to touch on our R&D Day and recent commentary on product pricing. Later this morning, David Nicholson, Bill Meury and Philippe Schaison will give an update on the pipeline and the commercial potential it contains. We believe that people will begin to take more active notice of our pipeline after today's meeting. 
With more than 70 projects in mid- to late-stage development, we have multiple programs in each of our therapeutic areas to help us sustain leadership in the areas where we choose to compete. We are building a sustainable innovation engine to power our top line performance and therapeutic area leadership well into the future. Please join us for an exciting day beginning in about an hour.
Turning to pricing. Pricing has been in the headlines and featured in the presidential debates. But let's not pretend that this is a topic that has just appeared in the news. It's been a focus for many years. We know that cost is a constant concern, so is patient access to medical innovation. Allergan seeks to strike the right balance between care and cost. We operate in an Open Science model, developing promising products that frequently originate with smaller companies. These companies often lack the infrastructure to bring their products through expensive late-stage trials or the commercial presence to recoup their R&D investments. The innovation ecosystem is full of these smaller companies who have extraordinary ideas and brilliant scientists. We want to be the magnet for their great ideas in this new innovation ecosystem. Our model is designed to bring these extraordinary ideas to market. Our R&D staff is more than 2,000 people strong. They mobilize resources to help regulatory authorities around the world assess safety and efficacy of our products while providing data to payers to reflect their value.
Let's face it. This effort is costly and often reflected in the cost of medicine, and it is easy to miss the significant value they represent. They reduce the need for hospitalization, surgery, follow-up visits and more dire medical consequences. Allergan has a heritage in knowing health system economics very well, and we want to make sure patients have access to important medicines. Like many of our peers, we have patient assistance programs to make sure that patients have access to our medicines regardless of their ability to pay.
We are bold in acquiring and investing in promising treatments for serious diseases, Alzheimer's, severe depression, glaucoma, debilitating gastrointestinal conditions. Our business model does not involve purchasing old products already in the marketplace and taking excessive price increases. We prefer to acquire mid- to late-stage drugs and invest extensively in their development. 
To make these decisions to help people with unmet medical needs requires us to build bridges with physicians, academic medical centers, government, regulators and inventors of these molecules so that they see us as a partner who shares in their dedication to improve people's well-being. 
If you look at our recent development acquisitions, it's all about investing in ideas that can help change the way medicine is practiced. What makes the biopharmaceutical industry great? Inventions that change lives. We will continue to use our resources to advance treatments for unmet medical needs and to tap into the world's best ideas to advance care for patients. We will do this while we will continue to strike the appropriate balance between care and cost. 
In closing, our team continues to focus on execution, and our results indicate that we are exceptionally skilled at delivering strong operating results while also doing surprising things to make our company the most dynamic and bold in health care. I'm so proud of this team for their performance, and I'm looking forward to what we can do with the strength and focus on just branded pharmaceuticals. 
With that, now I'd turn the call over to Tessa."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third qua",639,"Thank you, Brent. Good morning, everyone. Turning to Slide 12. Our overall results for the third quarter is on Slide 13. In the third quarter, we delivered very strong year-over-year performance. On a non-GAAP basis, consolidated revenue for the third quarter was $4.1 billion, an increase of 90% versus third quarter 2014.
Non-GAAP R&D investment for the quarter was $305 million compared to $192 million in the prior year period. Non-GAAP SG&A as a percentage of revenue was 22.4%, a decrease of 3.1 percentage points over the prior year quarter as a result of the synergies realized from recent acquisitions. 
Adjusted EBITDA for the quarter was $2 billion, an increase of 168% versus the prior year, driven by strong revenues and higher gross margins across business segments. Non-GAAP earnings per diluted share for the quarter increased 65% to $3.48 compared to $2.11 per diluted share in the third quarter of 2014. Our non-GAAP tax rate was 8.4% in the quarter. This rate was below expectations, driven primarily by the allocation of the entire interest expense to continuing operations earnings. This rate could change by potential repayment of debt upon the close of the Teva transaction. 
Cash flow from operations for the third quarter was $1 billion, impacted by recent asset acquisitions. Excluding acquisition-related restructuring and integration payments, our third quarter cash flow from operations would be $1.7 billion.
Slide 13. Turning now to our U.S. Brand results on Slide 13. The business delivered strong performance year-over-year. U.S. Brands revenue was $2.4 billion for the quarter, up 50% versus the prior year period, driven by the addition of Allergan businesses and strong growth across key products, including Restasis, Linzess, Women's Health products, and new product launches, including Liletta, Namzaric and Avycaz. Adjusted gross margin within U.S. Brands continued to be strong with margins approaching 88%. SG&A as a percentage of revenue decreased to 18.3% versus 22.1% in the year-ago quarter, driven by continued synergy capture from recent acquisitions.
Turning to Slide 14 and our U.S. Medical Aesthetics business. Third quarter revenues were $457 million, an increase of 9% versus third quarter 2014 results on a pro forma basis. Sequentially, U.S. Medical Aesthetics performance was affected by seasonality related to aesthetics procedures. Third quarter gross margins were strong at 93.9%. SG&A as a percentage of revenue decreased 1.2 percentage points versus third quarter 2014.
Turning to Slide 15 and our International Brands results. Third quarter revenues were $661 million versus $58 million in the prior year largely due to the Allergan acquisition. Year-over-year growth was also driven by fillers and Ozurdex in international markets. Sequential revenue performance was mostly due to seasonality. Gross margins increased 25.7 percentage points to 83% in the third quarter due largely to the inclusion of higher-margin legacy Allergan products. Segment SG&A increased 3.2 percentage points to 29.8% versus third quarter 2014 due largely to the Allergan acquisition.
Turning to our Anda business on Slide 16. Revenues increased to $576 million, up from $500 million in the prior year, an increase of 15%, driven by trends in our base business and new retail chain businesses. Results include third-party revenues and related expenses of generic products manufactured by the company and distributed through Anda.
Slide 17 details our debt capitalization. We ended the third quarter 2015 with total debt of approximately $42.7 billion and equity of $77.5 billion related to the Allergan acquisition and previous financing. In the third quarter, we paid down approximately $231 million of our debt. In October, we borrowed $800 million on our revolving credit facility to fund the Kythera acquisition.  Currently, our leverage ratio stands at 3.98x debt-to-pro forma adjusted EBITDA versus 3.9x in the prior quarter due to continued investments in R&D assets. We remain committed to maintaining our investment-grade ratings.
And now I will turn the call to Lisa for Q&A."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Nan, I think we can start taking questions. [Operator Instructions]",10,"Nan, I think we can start taking questions. [Operator Instructions]"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan.",14,"[Operator Instructions] Your first question comes from the line of Chris Schott with JPMorgan."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range, I think, you laid out in September? I guess was there anything unusual or any reason to expe",117,"I just had a question on SG&A. It was 22.4% of sales in the quarter. Can you help us put that number into context with your longer-term 21% to 24% guidance range, I think, you laid out in September? I guess was there anything unusual or any reason to expect that ratio to move higher going forward? Because otherwise, it seems like the company's going to be quickly trending to the low end of that range as top line continues to scale here. And if I can slip in a second quick one. We've been getting this question a lot. Can you guys disclose the mix of price versus volume driving your growth in the quarter?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look at this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, T",53,"Yes. So thanks, Chris. I think with SG&A, our previous guidance and range is still appropriate. Obviously, as you look at this quarter, I understand why you're thinking that way. But I do just put you back to the guidance we issued before. I don't know, Tessa, if you want to add anything."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, we're within the range. And unfortunately, given sort of like Irish Rules, we can't really provide guidance on a go-forward basis. I would just say that we are within the range.",32,"Yes, we're within the range. And unfortunately, given sort of like Irish Rules, we can't really provide guidance on a go-forward basis. I would just say that we are within the range."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And then on price-volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price-volume -- or I'll say volume-price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the en",59,"And then on price-volume, I'll start with the top products. If you look at Botox, Restasis and Linzess, the price-volume -- or I'll say volume-price is probably 80-20. It's largely driven by pure demand in units or prescriptions. If you look across the entire product line, it's roughly 50-50. And our price appreciation trades in the single digits."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Jason Gerberry with Leerink Partners.",13,"Your next question comes from the line of Jason Gerberry with Leerink Partners."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just a quick question on Namenda now that we've now had a chance to see how the generic impact is flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million pea",74,"Just a quick question on Namenda now that we've now had a chance to see how the generic impact is flowing through the model. Your updated thoughts on Namzaric. It's a little slow out of the box. Do you still view this as a $500 million to $750 million peak sales product? Or should investors think about that peak sales target as more of the combined value that XR and Namzaric could retain?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I would start, and maybe then Bill can jump in. I think as you think about where we are with Namenda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both X",116,"Yes, I would start, and maybe then Bill can jump in. I think as you think about where we are with Namenda XR, I think the team has worked very hard and accomplished quite a bit. We still focus a lot of our energy and time inside our organization on both XR and Namzaric. The one thing that I would caution is with respect to Namzaric. Most of the formulary coverage, although it's quite good right now, kicks in, in January because of the Medicare Part D part of this equation. And so I think our expectations are a little higher post broader formulary coverage than it is today. But Bill, anything you'd want to add?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formulary coverage at the end of '15 and into 2016 is as high as it's been. Next, Namzaric isn't quite a sprint, a good steady jog. 60% of our",138,"Yes, that's exactly right. I would make a few points. The first one is XR is very stable, and that's because the formulary coverage at the end of '15 and into 2016 is as high as it's been. Next, Namzaric isn't quite a sprint, a good steady jog. 60% of our use today is coming from Aricept monotherapy. As Brent said, when formulary coverage converts in 2016 and after several months of direct-to-consumer advertising, I would expect over time that the overall business is going to grow and that Namzaric is going to account for a greater and greater percentage of it for one simple reason. It's a better product. If you look at the data, 2 drugs is better than 1, and I think it will take just a little bit of time to move this category."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of David Amsellem with Piper Jaffray. Your next question comes from the line of Randall Stanicky with RBC Capital Markets.",27,"Your next question comes from the line of David Amsellem with Piper Jaffray. 
Your next question comes from the line of Randall Stanicky with RBC Capital Markets."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. And you've got a pretty big portfolio of products that you could leverage. And I think you called out the eluxadoli",73,"Brent, just on the international business. You're still small here, but there is clearly a lot of opportunity and growth that's at the U.S. And you've got a pretty big portfolio of products that you could leverage. And I think you called out the eluxadoline in the prepared comments. So the question for you: What's the strategy here assuming that you remain stand-alone? And where does this rank within your business development priorities?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that still largely is intact. We have a very strong team around the world. We have big opportunities",268,"Yes. I think when we did the Allergan deal, we talked about international as being one of the more important longer-term growth levers for us. And I think that still largely is intact. We have a very strong team around the world. We have big opportunities to continue to leverage the infrastructure that we have. I think the deal we did with Almirall to buy Constella is a proof point of the types of things we're going to do as we're preparing to hopefully get approval for eluxadoline in Europe over time. To be able to have more opportunities to leverage GI is a good move for us. Obviously, Aesthetic Medicine is very important. We have lots of opportunity to continue to expand the aesthetic portfolio in Asia, China, I would call out, Latin America. Brazil is another market I would call out where we're seeing strong growth. And then, of course, eye care is very important to us around the world. And we continue to look for ways to build our portfolio and leadership in eye care. And in many markets, we are #1 in eye care outside the U.S. So we have a big heritage there, and it is important for us to continue to leverage. With respect to business development, it remains a priority. We will continue to look for ways to add scale and product flow in key international markets around the world. And if we do that ourselves by eluxadoline approval or Juvederm approval recently in China or buying Constella or other things, it's an important growth driver for us in the future."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Should we think about this, though, as more of a bolt-on source of capital? I mean, everybody's going to be focused on the $29 billion that you have coming in from Teva in Q1, assuming that another deal on the side here doesn't happen. So should we think",64,"Should we think about this, though, as more of a bolt-on source of capital? I mean, everybody's going to be focused on the $29 billion that you have coming in from Teva in Q1, assuming that another deal on the side here doesn't happen. So should we think about international as a smaller deal build-out? Or could we see more significant capital allocated there?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. I mean, I think about it 3 ways. It's going to be organically, through driving our 70 -- most of our 70 late-stage -- mid- to late-stage programs and global development programs to the extent it makes sense; to doing R&D-type deals for international",85,"Yes. I mean, I think about it 3 ways. It's going to be organically, through driving our 70 -- most of our 70 late-stage -- mid- to late-stage programs and global development programs to the extent it makes sense; to doing R&D-type deals for international product flow; to buying already-marketed products, like we did with Constella; and then, perhaps, from time to time, where it makes sense strategically and financially, bolting on a small business in a place like Brazil or China or even Europe."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Marc Goodman with UBS.",12,"Your next question comes from the line of Marc Goodman with UBS."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I was hoping you could give us a little more detail on the cash pay businesses as well as just Botox overall, what's going on behind the scenes in each of the individual areas.",34,"I was hoping you could give us a little more detail on the cash pay businesses as well as just Botox overall, what's going on behind the scenes in each of the individual areas."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I mean, obviously, they're an important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. Medical. That business continues to perform exceedingly well. Obviously, it was -- there was some s",92,"I mean, obviously, they're an important part of our business. I think the biggest component of the cash pay business is the aesthetics business within U.S. Medical. That business continues to perform exceedingly well. Obviously, it was -- there was some seasonality in the third quarter, as there always is. Philippe, I don't know if you would want to comment on anything. Real quick, I think Kybella is really starting to get momentum. And I was at the sales conference with Philippe and his team last -- I guess 2 weeks ago."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So we're in the process of training roughly 1,500 top-tier reps on top of the 800 that have been already trained. From a market share standpoint, you can see at that point, we continue to solidify our market share, especially on the filler market. And we",77,"So we're in the process of training roughly 1,500 top-tier reps on top of the 800 that have been already trained. From a market share standpoint, you can see at that point, we continue to solidify our market share, especially on the filler market. And we have achieved 2 million consumers part of our BD loyalty program, which is an all-time high. So we're thriving, and we're doing extremely well, and everything is in the green."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well, but the vast majority of that is from the aesthetics business within Allergan Medical",44,"Just for directional purposes, about 20% of our sales globally come from cash pay business. Most of that is the Allergan Medical. There are some cash pay brands as well, but the vast majority of that is from the aesthetics business within Allergan Medical."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","And what about Botox in the therapeutic areas? Like how is migraine doing, overactive bladder, all the key drivers?",19,"And what about Botox in the therapeutic areas? Like how is migraine doing, overactive bladder, all the key drivers?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you hit the right ones. Those are the main growth drivers for Botox therapeutically. Both indications are growing at a high double-digit rate. The core indications, the original indications are relatively stable. Listen. In both those conditions, it'",81,"Yes, you hit the right ones. Those are the main growth drivers for Botox therapeutically. Both indications are growing at a high double-digit rate. The core indications, the original indications are relatively stable. Listen. In both those conditions, it's a highly effective product, and it's also very economical. And the injector base today in the United States for Botox is very experienced and comfortable with the product. I expect that both indications can continue to grow for the next several years."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Liav Abraham with Citi.",13,"And your next question comes from the line of Liav Abraham with Citi."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I'd be interested in your thoughts on the outlook for Restasis given the recent OPUS-3 data for Lifitegrast. And perhaps, at the same time, can you just remind us of your formulary coverage for Restasis?",36,"I'd be interested in your thoughts on the outlook for Restasis given the recent OPUS-3 data for Lifitegrast. And perhaps, at the same time, can you just remind us of your formulary coverage for Restasis?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, sure. I think Bill probably is in the best position to answer.",13,"Yes, sure. I think Bill probably is in the best position to answer."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a good question. I don't believe that this is going to be a fight to the death between Shire and Allergan. I've said before that the gap between the prevalent population and prescription-treated population is enormous. It's larger than it is in",296,"Yes, it's a good question. I don't believe that this is going to be a fight to the death between Shire and Allergan. I've said before that the gap between the prevalent population and prescription-treated population is enormous. It's larger than it is in most categories. The importance of dry eye disease is clear, and it's getting more and more attention because of the impact it has on quality of life, the impact that it can have on vision and positive post-op outcomes. When you look at the data sets between the drugs, I would simply say that we'll have to see how Lifitegrast stands up in the real world. I would also point out that in the second half of 2016, we'll be launching a multi-dose preservative-free form of Restasis, which, I believe, is going to be very popular with physicians and with patients for 2 reasons. The first, it's just more convenient than 60 single-unit vials or droppers, and it's also easier to administer. And a big problem with all of these eyedrops is they're difficult to instill, and it's often a major problem with compliance. Our promotional program in this category will continue to be at the very top. We have a large sales force that covers primary care, optometry and ophthalmology. We'll continue to run the largest direct-to-consumer advertising program in the industry. And then lastly, obviously, as you asked about formulary coverage, we have preferred status on 85% to 90% of health plan formularies, and 90% of that is Tier 2. And so this is a highly economical option. There's no doubt eye care professionals are going to try something new. But I believe, long term, this category has the potential to double, so there's more than enough to go around."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Gregg Gilbert with Deutsche Bank.",14,"And your next question comes from the line of Gregg Gilbert with Deutsche Bank."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a question, and if you can't answer it, I have a backup. But it's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you, that a business combination means that talks are about Pfizer poten",50,"I have a question, and if you can't answer it, I have a backup. But it's about a technicality, Brent, related to the prior press release. Can we assume that because Pfizer approached you, that a business combination means that talks are about Pfizer potentially buying Allergan or not necessarily?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I can't answer. So you should go to your backup question.",12,"Yes, I can't answer. So you should go to your backup question."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","It's more boring. Tessa, can you share the generics sales and the gross margin and the segment margins in the quarter, perhaps?",23,"It's more boring. Tessa, can you share the generics sales and the gross margin and the segment margins in the quarter, perhaps?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which will be filed shortly. What I can say is we had solid performance for the generic business, and revenues were around $4.77 billio",54,"Yes. So given the focus of this call is on continuing operations, what we will be providing is disclosures in our 10-Q, which will be filed shortly. What I can say is we had solid performance for the generic business, and revenues were around $4.77 billion for the 9 months, for year-to-date 9 months."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And remember, that is discontinued -- just in fairness, that is discontinued operations accounting. So for those that also covered Teva. It's not just a simple one-to-one kind of translation. Is that fair, Tessa?",34,"And remember, that is discontinued -- just in fairness, that is discontinued operations accounting. So for those that also covered Teva. It's not just a simple one-to-one kind of translation. Is that fair, Tessa?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's fair. But it's performed according to our expectations and good solid performance. But you'll get more detail in our 10-Q.",22,"That's fair. But it's performed according to our expectations and good solid performance. But you'll get more detail in our 10-Q."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Irina Koffler with Mizuho.",13,"And your next question comes from the line of Irina Koffler with Mizuho."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I just wanted to see how you're thinking about your sales force going forward. Is it the right size? Are there opportunities to be a little bit more efficient or use alternative distribution models there? Or are you, in fact, thinking about adding in size",46,"I just wanted to see how you're thinking about your sales force going forward. Is it the right size? Are there opportunities to be a little bit more efficient or use alternative distribution models there? Or are you, in fact, thinking about adding in size?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I was going to make a bad joke, but I'll stop. Look, I mean, for me, the sales representatives around the world is a very important part of our company that we tend to put them at the center of the way we think about our business. And what they do is -- t",171,"I was going to make a bad joke, but I'll stop. Look, I mean, for me, the sales representatives around the world is a very important part of our company that we tend to put them at the center of the way we think about our business. And what they do is -- they are the most intimate with our customers. I think we look at our sales force deployment globally very thoughtfully and strategically. For example, in facial aesthetics, we just increased our sales force by about 75 sales reps, which was already the largest facial aesthetic sales force in the United States. And now it's even larger and more powerful. China, we've just invested in our sales force and added sales reps. And so we do look at it, deployment of the sales reps, very strategically. In the U.S., Bill can comment, where we have the most sales reps, it is a very hard-working, dedicated group, I think, delivering more details than any other sales force in the industry."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives, but they operate as if it was 4,500 or 5,000. Just by virtue, they lead the industry in activity. The most significant",189,"Yes, that's exactly right. It's certainly the most productive when you look at calls per day. And we have roughly 4,000 representatives, but they operate as if it was 4,500 or 5,000. Just by virtue, they lead the industry in activity. The most significant change that we've made in the past 12 to 18 months is we've customized the field force. So there's no longer a one-size-fits-all approach. We don't have the same number of representatives in the state of Massachusetts as compared to the state of Mississippi. And so we will invest in regions in sales force based on the estimated return. But we do operate with a principle when we launch new products, and we have multiple new product launches over the next several years. We will always aim to achieve share of voice leadership. And so details and representatives, on a routine basis, are being reallocated across the product line so that we can maximize the value of our business. It's a terrific group. They're well compensated and well change [ph], but I don't anticipate any fundamental shifts in our sales force model at this point."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of David Risinger with Morgan Stanley.",14,"And your next question comes from the line of David Risinger with Morgan Stanley."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have 2 finance questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go-forward tax rate? And then when you give 2016 financial guidance in February for the",131,"I have 2 finance questions and then a Botox pricing question. So with respect to the tax rate, I may have missed it earlier, but how should investors think about your go-forward tax rate? And then when you give 2016 financial guidance in February for the stand-alone company, how should investors think about what you're going to bake in for debt reduction? Meaning that's a huge swing factor in modeling EPS, and maybe you can just talk about how you're thinking about it at a high level at this point. And then separately, on Botox pricing, could you just update us on when the decision will come down on whether Allergan will be able to separate pricing for the cosmetic and therapeutic indications and more appropriately price Botox for therapeutic indications?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me take the last first, and then Tessa can take the financial ones. We are continuing with our litigation with CMS around bifurcation of pricing. I really don't have an update on that today. But it's something that Bob Bailey and the legal team are",118,"So let me take the last first, and then Tessa can take the financial ones. We are continuing with our litigation with CMS around bifurcation of pricing. I really don't have an update on that today. But it's something that Bob Bailey and the legal team are staying very focused on, and we'll see how that plays out. And as soon as we have an update, we'll certainly provide it. But I wouldn't build any expectations around that. Second, we continue to think about therapeutic Botox as -- with new toxins for the future. But that's a longer-term strategy as well. So I think for the short term, David, I would just view those prices as being coupled."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So on the 2 finance questions, David, I'll address the second one first. We are committed to providing an update in terms of financials similar to what we've done in the past, which should be during the Q1 earnings release in February. And by then, to the",202,"So on the 2 finance questions, David, I'll address the second one first. We are committed to providing an update in terms of financials similar to what we've done in the past, which should be during the Q1 earnings release in February. And by then, to the extent that we have more clarity with regards to how we would deploy capital, assuming the Teva transaction would have closed by then, then we will provide you guidance with regards to capital deployment, including debt repayment. One thing, obviously, that we're committed to is the investment-grade rating. So to the extent that we don't deploy the capital, we will pay down the amount necessary to maintain the rating on a go-forward basis. With regards to the tax question, based on our release, what actually occurred because of continuing operations is that the bulk of -- or the entire interest expense was actually allocated to continuing operations, hence, the low tax rate. On a go-forward basis, that should trend upwards, assuming we pay down debt, but we can't really be precise at this point given our restrictions based on Irish law. But it should trend higher based on debt -- if we assume debt pay-down."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Ronny Gal with Bernstein.",13,"And your next question comes from the line of Ronny Gal with Bernstein."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","A couple of clarifying ones and then more of a strategic one. First, on Botox, you reported 13% constant currency, and I think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. Can you jus",180,"A couple of clarifying ones and then more of a strategic one. First, on Botox, you reported 13% constant currency, and I think about 9% actual results for Botox. It's a pretty big difference given how the product is distributed geographically. Can you just give us a little bit more color on the currencies involved? Second, for Bill. Fair to say that if Lifitegrast comes to market the end of 2016, we should expect a weaker Restasis in '17, '18? Essentially, at least not continuation for a couple of years in growth of that product. And then maybe I didn't get the memo, we're not supposed to ask it, but more broadly, Brent, you got actually good results this quarter, you seem to be in the process of successfully executing on what you told us you would. You got the revenue growth that will put you much above your peers. Your multiple is much lower. It doesn't seem like a great time to engage in friendly discussions with another company. Can you help us think about this a little bit?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously had -- that's Botox, specifically.",26,"So let me address some of the questions. Botox itself, the total Botox franchise grew year-over-year by about 7.9%. We obviously had -- that's Botox, specifically."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think the 13% pro forma was for the entire branded business.",13,"And I think the 13% pro forma was for the entire branded business."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Correct.",1,"Correct."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Excluding Namenda IR, divestitures and the impact of foreign exchange is what I said in the prepared remarks.",18,"Excluding Namenda IR, divestitures and the impact of foreign exchange is what I said in the prepared remarks."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","But Botox itself, year-over-year, grew by about 8%, 13% excluding FX.",11,"But Botox itself, year-over-year, grew by about 8%, 13% excluding FX."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And you're looking at the chart versus what I said, Ronny, right?",13,"And you're looking at the chart versus what I said, Ronny, right?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, I'm actually looking at the -- I'm actually looking at your products slide. Botox continued strong growth of both orthopedic and cosmetic of more than 13%. Excluding foreign exchange, this is at slide 8.",35,"No, I'm actually looking at the -- I'm actually looking at your products slide. Botox continued strong growth of both orthopedic and cosmetic of more than 13%. Excluding foreign exchange, this is at slide 8."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, that's right. It's hard to hear you, Ronny. But a little bit -- we hear about every second word. Yes, so you got it.",25,"Yes, that's right. It's hard to hear you, Ronny. But a little bit -- we hear about every second word. Yes, so you got it."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%.",17,"So it grew 7.9% excluding FX. Would that --  stripping out FX, it would be 13%."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Okay. So Botox is around 13% constant currency in the third quarter.",12,"Okay. So Botox is around 13% constant currency in the third quarter."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","That's correct, yes.",4,"That's correct, yes."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Correct.",1,"Correct."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Is there a reason why the gap between the currency-adjusted and not currency-adjusted is so big? Is there a couple of currencies that went particularly bad this quarter?",29,"Is there a reason why the gap between the currency-adjusted and not currency-adjusted is so big? Is there a couple of currencies that went particularly bad this quarter?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","I mean, it's largely euro, plus we have some protection related to certain hedges that flow through.",17,"I mean, it's largely euro, plus we have some protection related to certain hedges that flow through."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Douglas Tsao with Barclays.",13,"And your next question comes from the line of Douglas Tsao with Barclays."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Just maybe if you could offer some perspective on the upcoming Viberzi launch, especially given what you've seen from the competitive adoption or the adoption of Salix thus far -- or the Salix Xifaxan so far in IBS-D, that's helpful.",40,"Just maybe if you could offer some perspective on the upcoming Viberzi launch, especially given what you've seen from the competitive adoption or the adoption of Salix thus far -- or the Salix Xifaxan so far in IBS-D, that's helpful."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, I mean, I will ask Bill to comment. But we're very excited to be launching Viberzi. The sales force meeting will be next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- we're making a big investmen",67,"Yes, I mean, I will ask Bill to comment. But we're very excited to be launching Viberzi. The sales force meeting will be next week. I'll be down there for a few days to talk to the sales reps with Bill, but it's going to be -- we're making a big investment in this launch. That's safe to say. Bill, do you want to talk about it?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, it's a perfect complement to Linzess. IBS should be thought about as a continuum, with constipation on one end and diarrhea on the other. And because we're able to market 2 products for the same condition essentially, we're able to talk about it in a",242,"Yes, it's a perfect complement to Linzess. IBS should be thought about as a continuum, with constipation on one end and diarrhea on the other. And because we're able to market 2 products for the same condition essentially, we're able to talk about it in a more complete way. I think it's a competitive advantage. As it relates to the products -- compared to Xifaxan, it's a completely different approach to treatment. This drug works on motility and visceral pain or hypersensitivity. And Xifaxan essentially is an antibiotic. There's certainly room in this category for more than one product. Promotionally speaking, this will be one of the largest launches in the industry from an investment standpoint, and I'm pretty sure it's going to be the largest launch in gastroenterology. It's going to be very noisy. We know how to do this. We did it with Ironwood during the launch of Linzess. The DTC advertising will start not 1 year after approval but only 3 months. And the promotional efforts, unlike other companies in the area, will capture not only gastroenterologists but primary care physicians. And there's an interplay in almost every category between primary care and specialty that we can navigate that other companies can't. And I would expect that this drug should do as well as Linzess does on the other side of the market and could ultimately almost double the size of our GI business over the next 5 years."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Jami Rubin with Goldman Sachs.",13,"Your next question comes from the line of Jami Rubin with Goldman Sachs."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","This is Ariel Herman in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's",68,"This is Ariel Herman in for Jami. So someone already asked about pricing for the third quarter. But going forward, you've have previously provided a CAGR for your expectations for the overall branded business. Can you just provide some color around what's baked into that regarding price and volume? And then secondly, can you touch on the competitive dynamics with the potential competition to Botox from Revance's product?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I think as, obviously, we're under some restriction under Irish law with respect to guidance, but our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominant",324,"Yes. So I think as, obviously, we're under some restriction under Irish law with respect to guidance, but our pricing, as I've mentioned during my opening remarks, is always a balance. And most of our key growth drivers are, as Bill indicated, predominantly in a volume situation, not a price situation. As we think about price, we tend to think about mid- to high single-digit price increases across the portfolio. And so we don't really think of any change or expect any change in our very, I think, conservative pricing policy and the way we think about price. And so we're not going to -- I don't think you're going to see us change our view or, perhaps, better said, our commitment to the 10% growth objectives and aspirations that we have. So I think that's going to stay fairly normalized for the foreseeable future. I think with respect to Revance and competitive toxins, I'll ask David to comment as well. But I would just remind you that there are competitive toxins already in the market. And more -- if you talk to customers, more -- very few care about having an extra few weeks or a month of duration of effect for Botox or toxins. And in fact, what they mostly complain about is price. And our competitors price their toxins much -- at a much lower rate than we price Botox, and yet Botox continues to be a strong market leader. And so I would just urge you to keep perspective. As Philippe said earlier, we have 2 million members and brilliant distinctions. We have a full range of facial aesthetics. We have the largest field force. Botox is the #1 branded pharmaceutical brand in the world. And so this is a very strong franchise with very good staying power. And so sometimes, there's a hammer looking for a nail. Duration may be just that. But scientifically, maybe David can comment, too."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, happy to talk about that briefly. Clearly, we'll be talking about Botox during R&D Day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indications of",134,"Yes, happy to talk about that briefly. Clearly, we'll be talking about Botox during R&D Day later today. And Botox, of course, is a pipeline in a product, and we remain committed to continuing to build the pipeline. We will be launching new indications of Botox around the world, so extending our aesthetic reach geographically. And we will be developing Botox for new therapeutic application. I would point out, if we're talking about duration, Botox, in some indications, has a duration for up to 9 months. So if we're talking about hyperhidrosis, for instance, Botox then works for up to 9 months. So the duration of Botox depends on the use and the dose that we administer. And more of this during the course of the day as we walk through our R&D pipeline."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, let me just add to this. Botox really is a fortuitous product. It's got a lot of indications, 10 indications. It's got great brand recognition. It is supported by the strongest promotional effort, and it's got good and strong clinical science and exp",46,"Yes, let me just add to this. Botox really is a fortuitous product. It's got a lot of indications, 10 indications. It's got great brand recognition. It is supported by the strongest promotional effort, and it's got good and strong clinical science and experience behind it."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Your next question comes from the line of Umer Raffat with Evercore ISI.",13,"Your next question comes from the line of Umer Raffat with Evercore ISI."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Two quick ones. First, can you tell us a bit more about the generics this quarter, what the actual sales were, the year-on-year trends and just some commentary there? And number two, Brent, so in an M&A scenario, is there anything legally preventing you f",54,"Two quick ones. First, can you tell us a bit more about the generics this quarter, what the actual sales were, the year-on-year trends and just some commentary there? And number two, Brent, so in an M&A scenario, is there anything legally preventing you from issuing more in shares than your own share count?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So Tessa, do you want -- she already answered the generics question.",13,"Yes. So Tessa, do you want -- she already answered the generics question."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, as I said earlier was that they had good solid performance, performed according to our expectations. We will provide more granularity for discontinued operations in our 10-Q, which should be filed in the next couple of days. But revenue-wise, it was",50,"Yes, as I said earlier was that they had good solid performance, performed according to our expectations. We will provide more granularity for discontinued operations in our 10-Q, which should be filed in the next couple of days. But revenue-wise, it was at $4.77 billion for the last 9 months."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And so your other question, Umer, was about share repurchase?",10,"And so your other question, Umer, was about share repurchase?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","No, sorry, I meant can you issue, in an M&A scenario where you're issuing equity, is there anything that prevents you from issuing more in equity than your own entire share?",31,"No, sorry, I meant can you issue, in an M&A scenario where you're issuing equity, is there anything that prevents you from issuing more in equity than your own entire share?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","To be fair, I just don't know the answer. Maybe if you want to follow up, we can talk to the folks who may know the answer to that. I just don't know, Umer.",34,"To be fair, I just don't know the answer. Maybe if you want to follow up, we can talk to the folks who may know the answer to that. I just don't know, Umer."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch.",17,"And your next question comes from the line of Sumant Kulkarni with Bank of America Merrill Lynch."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","I have a quick couple. First is in a relatively small part of your business. That's the breast implants. How well is Allergan positioned to take advantage of some of the competitive missteps there? And second, on business development, assuming you remain",62,"I have a quick couple. First is in a relatively small part of your business. That's the breast implants. How well is Allergan positioned to take advantage of some of the competitive missteps there? And second, on business development, assuming you remain stand-alone, what are examples of some therapeutic areas that might excite you, among the ones that you're not in currently?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes. So I'll ask Philippe to address the breast implant situation and maybe just a quick overview of what happens for those who don't follow so closely.",27,"Yes. So I'll ask Philippe to address the breast implant situation and maybe just a quick overview of what happens for those who don't follow so closely."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Sure. So as you know, Sientra stopped selling their implant in the U.S. following what happened in Europe, where they lost their CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of Sientra larger account to",106,"Sure. So as you know, Sientra stopped selling their implant in the U.S. following what happened in Europe, where they lost their CE mark and their manufacturing plant in Brazil got on fire. So right now, we're converting most of Sientra larger account to Allergan, which is a triple win for us because not only we're gaining market share on the breast implant side, but while we're converting those accounts to the breast, we also strengthen our business for our portfolio of fillers and Botox. So for us, it's a triple win. We get the breast implant business as well as the fillers and the Botox."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think it carries over to Europe as well, right, Paul?",12,"And I think it carries over to Europe as well, right, Paul?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, internationally, distribution is the same in Europe. I think we've always had a positioning of high-quality implants and top French service to customers. So I think an event like that on the market, we benefit on it being the leader. So we are seeing",57,"Yes, internationally, distribution is the same in Europe. I think we've always had a positioning of high-quality implants and top French service to customers. So I think an event like that on the market, we benefit on it being the leader. So we are seeing that, and we're seeing transfer of accounts at the moment as well."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And I think with respect to potential future therapeutic areas of interest, we're really focused on the 7 we're in. When you think about the 7 we're in, we still have a lot of white space opportunity. For example, we're #1 in aesthetic medicine and a robu",202,"And I think with respect to potential future therapeutic areas of interest, we're really focused on the 7 we're in. When you think about the 7 we're in, we still have a lot of white space opportunity. For example, we're #1 in aesthetic medicine and a robust pipeline of projects, but yes, mostly focused on the face. There's still a whole body to work with in aesthetic medicine and lots of opportunities. In eye care, obviously, you've seen us do a lot of things recently to support our robust development organization with dry eye and glaucoma. But there's still more things that we can do in Retina beyond DARPin and Ozurdex. And there's new opportunities there globally as well. CNS, a strong presence in Alzheimer's and neurology and psychiatry. But we know we don't participate, let's say, in, just as an example, MS or Parkinson's or a variety of other conditions that could leverage CNS. And I could go down through the entire 7 therapeutic areas and point to a big white space that would allow us to leverage our infrastructure commercially, our R&D capabilities with very little additional cost but expand ourselves into those therapeutic areas. So that's really the goal."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","And your final question comes from the line of Tim Chiang with BTIG.",13,"And your final question comes from the line of Tim Chiang with BTIG."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Analysts","Brent, could you talk a little bit more about your focus on the GI space heading into next year? Certainly, you've got Viberzi coming online. You've got Linzess. I noticed that you're filing a low-dose strength of Linzess to 72-microgram. Could you talk a",77,"Brent, could you talk a little bit more about your focus on the GI space heading into next year? Certainly, you've got Viberzi coming online. You've got Linzess. I noticed that you're filing a low-dose strength of Linzess to 72-microgram. Could you talk a little bit about how that low dose might help you in the current constipation treatment market? And is Viberzi going to be the first detail in the GI space in front of Linzess?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, so again I think later today, we'll talk more about the pipeline. And certainly, we have more than just low dose. We announced, with our partner, Ironwood, the colonic release program for Linzess. And then, of course, we have, very importantly, relam",64,"Yes, so again I think later today, we'll talk more about the pipeline. And certainly, we have more than just low dose. We announced, with our partner, Ironwood, the colonic release program for Linzess. And then, of course, we have, very importantly, relamorelin moving its way through the clinic. So maybe Bill could just talk about how we do it from a promotional perspective."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, the reason we developed the low dose alongside Ironwood and also the sprinkle formulation, which will be introduced, is to accelerate our conversion over the over-the-counter market. I mean, most of the sales for Linzess today are being captured by p",178,"Yes, the reason we developed the low dose alongside Ironwood and also the sprinkle formulation, which will be introduced, is to accelerate our conversion over the over-the-counter market. I mean, most of the sales for Linzess today are being captured by patients who are using over-the-counter medications. And that will be the primary source of growth in the future. A low dose is going to give physicians some optionality. And for patients, it may be better tolerated. So Linzess, at that 145 and 290, based on our estimation, is extremely well tolerated. The average patient is taking close to 120 days of therapy as compared to Amitiza or Zelnorm, which were trading at roughly 90 days of therapy. Broadly speaking, though, it's a great space. And with Viberzi, we can pull resources for the 2 products so that each one is going to get a greater level of effort than they would have if marketed independently. And as Brent said, we'll cover more about the pipeline, relamorelin and the other life cycle opportunities during R&D Day this afternoon."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","And maybe then Paul Navarre can just touch on our thoughts around Constella, and perhaps, later, eluxadoline and other GI opportunities around the world.",24,"And maybe then Paul Navarre can just touch on our thoughts around Constella, and perhaps, later, eluxadoline and other GI opportunities around the world."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes, you mentioned, Brent, GI is a priority for us. So internationally, we're going to steadily create the franchise. And the first step was to actually buy the rights of Linzess in 41 markets internationally. So that's going to be the first step of creat",75,"Yes, you mentioned, Brent, GI is a priority for us. So internationally, we're going to steadily create the franchise. And the first step was to actually buy the rights of Linzess in 41 markets internationally. So that's going to be the first step of creating the franchise. And then we're going to wait for the approval, hopefully, with the launch of eluxadoline in 2017. So I think we have a similar ambition internationally for GI."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So I think that was our last question, right, Lisa?",10,"So I think that was our last question, right, Lisa?"
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Yes.",1,"Yes."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. And I hope that many of you join us live as well as via webcast for what I hope will be an exciti",146,"So I would just like to conclude by thanking everyone for joining us this morning. As you know, we're going to transition in just a short bit to our R&D Day. And I hope that many of you join us live as well as via webcast for what I hope will be an exciting and interesting and informative session with our R&D colleagues and commercial colleagues. 
And I would just like to end by thanking our team around the world for a great quarter. We have quite a few things going on with integrations and divestitures. And our team continues to stay focused on executional excellence and driving results. And I think this quarter was just another in a long string of proof points that we understand our business and we're focused on execution. 
So thank you very much, and hopefully, we'll see you all soon."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Executives","Thanks, everyone.",2,"Thanks, everyone."
36478,313170036,892312,"Allergan plc, Q3 2015 Earnings Call, Nov 04, 2015",2015-11-04,"Earnings Calls","Allergan plc","Operator","Ladies and gentlemen, this does conclude today's conference call. You may now disconnect.",13,"Ladies and gentlemen, this does conclude today's conference call. You may now disconnect."
